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Abstract	
Compared	to	non-diabetics,	type	2	diabetics	(T2D)	have	a	30%	increased	risk	of	colorectal	
cancer	(CRC),	which	exhibits	more	serious	histopathological	features	and	has	an	increased	
risk	 of	 recurrence.	 Cell	 stress	 following	 hyperglycaemia	 or	 hypoxia	 reduces	 fumarate	
hydratase	(FH)	activity	promoting	increased	intracellular	fumarate.	Fumarate	irreversibly	
modifies	 cysteine	 residues	 by	 succination	 to	 form	 2-succino-cysteine	 (2-SC)	which	 can	
inactivate	proteins.		
A	 significant	 increase	 in	2-SC	 staining	was	 found	 in	CRC	compared	 to	matched	normal	
tissue	and	in	tumours	from	T2D	individuals	compared	to	non-diabetics.	Tumours	positive	
for	KRAS	or	BRAF	mutation	showed	elevated	staining,	which	was	higher	in	T2D	patients.	
Adenomas	also	showed	2-SC	staining.	The	2-SC	staining	was	non-uniform	across	tumours,	
underlining	metabolic	heterogeneity	of	CRC.	
Paradoxically,	 tumours	 showed	 intense	 cytoplasmic	 FH	 staining.	 In	 a	mouse	model	 of	
polyposis	and	diabetes,	overexpression	of	cytoplasmic	FH	in	the	gut	led	to	larger	polyps.	
In	CRC	cells,	fumarate	increased	and	gene	expression	altered	after	mitochondrial	stress	
via	treatment	with	25mM	glucose	and	0.2%	oxygen:	FH	was	active	and	increased	in	cells	
cultured	without	 glucose;	 its	 activity	 inversely	 correlated	with	 fumarate.	Mitochondria	
function	was	higher	in	CRC	cells	without	glucose,	but	cells	retained	their	ability	to	utilise	
glucose	metabolism	pathways.		
Separately,	oxaliplatin	therapy	led	to	DUOX2	transcription	mediated	by	STAT1,	whereas	
cetuximab	 treatment	 inhibited	 STAT1	 activation,	 oxaliplatin-induced	 DUOX2	
upregulation,	and	ROS	generation.	This	may	explain	why	CRC	patients	on	oxaliplatin	alone	
have	 a	 better	 prognosis	 than	 those	 treated	 with	 a	 combination	 of	 oxaliplatin	 and	
cetuximab.	
This	 work	 has	 increased	 our	 understanding	 of	 CRC	 and	 aspects	 linked	 indirectly	 to	
mitochondria:	 diabetes	 mediating	 altered	 metabolism	 and	 potentially	 altered	 protein	
function.	Dysregulated	metabolism,	as	typified	by	FH	dysfunction	in	CRC	developing	in	the	
context	of	T2D,	is	significant	and	requires	further	investigation	including	identification	of	
succinated	proteins,	which	may	give	insights	into	improved	therapies.	
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Chapter	1	–	Introduction	
1.1. Colorectal	cancer	background	
Colorectal	cancer	(CRC)	is	a	malignant	epithelial	tumour	arising	from	the	large	intestine,	
which	 comprises	 the	 colon	 and	 rectum	 (Figure	 1.1).	 In	 2015,	 the	 office	 for	 national	
statistics	found	that	CRC	was	the	third	most	common	cancer	for	both	males	and	females	
in	the	UK;	there	were	34,729	cases,	with	19,178	for	males	and	15,551	for	females1.		
Worldwide,	CRC	is	the	third	most	common	cancer	and	the	fourth	most	common	cancer	
cause	of	 death2.	 In	 total,	 CRC	 accounts	 for	 9%	of	 cancer-related	deaths	worldwide,	 of	
which	90%	are	from	metastasis3.	 In	developed	countries,	almost	half	of	the	population	
will	 develop	 at	 least	 one	 benign	 intestinal	 tumour	 (adenoma)	 during	 their	 lifetime2.	
Although	CRC	survival	has	increased	year	on	year	since	the	1960's4,	survival	rates	are	still	
poor	with	no	significant	difference	 in	mortality	between	male	and	 female	cases	 (Table	
1.1).		
The	most	obvious	symptoms	of	CRC	are	blood	in	the	faeces,	a	change	in	bowel	habit	and	
abdominal	 pain5	 although	 these	 are	 often	 associated	 with	 other	 conditions,	 such	 as	
infection	and	inflammatory	bowel	disease	(IBD),	leading	to	problems	with	CRC	diagnosis.	
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Figure	1.1.	CRC	incidence	per	large	bowel	section.	Fifty	five	percent	of	CRC	tumours	are	
located	in	the	recto-sigmoid	section,	20%	in	the	caecum	and	ascending	colon,	10%	in	the	
transverse	colon	and	5%	in	the	descending	colon6,7(10%	undescribed	location).		
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Table	1.1.	Bowel	cancer	statistics.	Survival	statistics	for	patients	up	to	10	years	post	CRC	
diagnosis.	Figures	from	Cancer	Research	UK	2010-20118.		
	 Survival	(%)	
Years	post-diagnosis	 All	adults	 Men	 Women	
0	 100	 100	 100	
1	 75.7	 77.4	 73.9	
2	 67.9	 69.5	 66.3	
3	 63.2	 64.5	 61.9	
4	 60.4	 61.2	 59.5	
5	 58.7	 59.2	 58.2	
6	 57.7	 57.5	 58.0	
7	 57.1	 57.2	 57.1	
8	 56.8	 56.6	 57.0	
9	 56.6	 56.3	 57.1	
10	 56.6	 56.0	 57.2	
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1.2. Molecular	genetics	of	colorectal	cancer	
The	epithelium	of	the	large	bowel	consists	of	tens	of	millions	of	crypts	which	are	home	to	
intestinal	stem	cells	that	multiply	to	renew	the	crypt	every	three	to	six	days.	A	model	of	
CRC	progression,	which	was	initially	proposed	in	1990	by	Fearon	and	Vogelstein,	where	
CRC	results	 from	the	progressive	accumulation	of	genetic	and	epigenetic	alterations	 in	
colonic	epithelium,	remains	a	basic	paradigm	for	the	molecular	genetics	of	CRC	to	date9	
(Figure	 1.2).	 Sequential	 mutations	 in	 adenomatous	 polyposis	 coli	 (APC),	 Kirsten	 rat	
sarcoma	(KRAS)	and	smooth	mothers	against	decapentaplegic	homolog	(SMAD)	2/4	lead	
to	 transitions	 through	 early,	 intermediate	 and	 late	 adenoma,	 respectively.	 A	 loss	 of	
function	mutation	in	tumour	protein	53	(TP53)	transforms	the	adenoma	into	a	carcinoma.	
Subsequent	 genetic	 mutations	 occur	 which	 promote	 carcinogenesis	 and	 metastasis	
(Figure	1.2).	
Large	scale	sequencing	of	CRC	tissue	has	demonstrated	the	presence	of	tens	of	thousands	
of	 somatic	 mutations	 in	 intestinal	 cancer	 cells,	 although	 only	 a	 handful	 of	 these	 are	
considered	essential	or	“drivers”	for	tumourigenesis;	the	true	impact	of	the	many	genes	
identified	in	the	development	of	CRC	remains	incomplete10–12.	
APC	is	mutated	in	the	majority	(>80%)	of	sporadic	CRC13.	APC	is	a	key	protein	in	the	Wnt	
signalling	pathway	where	it	acts	as	a	negative	regulator,	controlling	β-catenin	levels	in	the	
cell	(Figure	1.3.A).	Constitutive	activation	of	Wnt	signalling	within	the	crypts	of	the	colon	
promotes	extensive	proliferation	of	the	stem	cells	and	the	subsequent	development	of	
tumours14,15.	This	is	due	to	the	actions	of	β-catenin	as	a	co-ordinator	of	cell–cell	adhesion	
and	gene	 transcription	 (Figure	1.3.B)16.	 Interestingly,	 genetic	 alterations	 in	APC	 do	not	
lead	to	a	complete	loss	of	APC	protein	function17.	Mutations	in	APC	are	usually	bi-allelic	
and	occur	at	non-random	positions	with	respect	to	each	other18.	APC	mutations	cluster	in	
codon	1282-1581	to	produce	truncated	proteins	which	retain	1-3	of	the	20	amino	acid	
repeats	 (20AARs)	 that	 are	 critical	 functional	 domains	 for	 binding	 of	 β-catenin	 (Figure	
1.3.C)19.	Proximal	CRC	tumours	show	enrichment	for	mutations	which	retain	2-3	20AARs	
whereas	 distal	 cancers	 predominantly	 have	 APC	 mutations	 which	 retain	 0-1	 20AARs	
indicating	selection	of	distinct	Wnt/β-catenin	signalling	which	 is	 favourable	 for	 tumour	
progression	dependent	on	location,	as	described	by	the	“just-right”	theory19,20.	When	APC	
is	 mutated,	 β-catenin	 is	 able	 to	 translocate	 to	 the	 nucleus	 where	 it	 binds	 to	 other	
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transcription	factors	to	form	a	complex,	which	 leads	to	the	transcription	of	Wnt	target	
genes	 involved	 in	 proliferation	 and	 differentiation	 pathways21.	Mutations	 in	 other	 key	
players	of	the	Wnt	pathway,	such	as	axis	inhibition	protein	2	(AXIN2)	and	β-catenin,	are	
also	common	in	CRC22.		
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Figure	1.2.	Fearon	and	Vogelstein	model	of	CRC	progression.	 First,	a	mutation	 in	APC	
leads	 to	 activation	 of	 the	 Wnt	 pathway,	 which	 leads	 to	 an	 early	 adenoma.	 Next,	 a	
mutation	in	KRAS	leads	to	activation	of	the	EGFR	pathway,	promoting	transformation	to	
an	 intermediate	 adenoma.	 Then,	 mutations	 in	 Smad	 2/4	 lead	 to	 TGFß	 pathway	
inactivation	and	 transformation	 to	a	 late	adenoma.	A	 loss	of	 function	mutation	 in	p53	
then	 leads	 to	 carcinoma	 formation,	with	additional	 genetic	mutations	occurring	which	
promote	metastasis23.	APC,	adenomatous	polyposis	coli;	KRAS,	Kirsten	rat	sarcoma;	EGFR,	
epidermal	 growth	 factor	 receptor;	 SMAD,	 mothers	 against	 decapentaplegic	 homolog;	
TGFß,	transforming	growth	factor	ß.		
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Figure	1.3.	The	Wnt	pathway	and	APC	mutations	in	CRC.	(A)	The	Wnt	signalling	pathway	
which	controls	β-catenin	levels	in	the	cell.	(B)	A	mutation	in	APC	leads	to	changes	in	cell	
proliferation,	cell	polarity,	cell	migration	and	cell	fate	due	to	the	actions	of	β-catenin	as	a	
co-ordinator	 of	 cell–cell	 adhesion	 and	 gene	 transcription	 (C)	APC	mutations	 cluster	 in	
codon	1282-1581	to	produce	truncated	proteins	which	retain	1-3	of	the	20AARs	that	are	
critical	 functional	domains	 for	binding	of	β-catenin,	adapted	 from	Pollard	et	al	 200915.	
APC,	 adenomatous	 polyposis	 coli;	 20AARs,	 20	 amino	 acid	 repeats;	 LRP,	 lipoprotein	
receptor;	Dvl,	dishevelled	homolog	Dvl-1;	CK1,	casein	kinase	1;	GSK,	glycogen	synthase;	
CBP,	CREB	binding	protein;	Tcf,	T-cell	factor;	Lef,	lymphoid	enhancer	factor;	myc,	v-myc	
avian	myelocytomatosis	viral	oncogene	homolog.	
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Approximately	54%	of	all	CRC	cases	harbour	mutations	in	tumour	protein	53	(TP53)	which	
is	commonly	known	as	the	“The	guardian	of	the	genome”24.	TP53	is	the	most	frequently	
mutated	tumour	suppressor	gene	(TSG)	in	all	human	cancers25.	A	TP53	mutation	is	a	late	
event	in	the	adenoma-carcinoma	sequence26.	DNA	damage	and	genotoxic	stress	results	
in	induction	of	oncogenic	TP53	which	leads	to	cell	proliferation27.	
The	third	most	frequent	mutation	in	CRC	is	the	KRAS	oncogene	which	is	mutated	in	40%	
of	CRC	tumours,	and	only	found	alongside	an	APC	mutation28.	The	RAS	protein	is	an	on/off	
switch	for	the	epidermal	growth	factor	receptor	(EGFR)	pathway.	Another	member	of	the	
EGFR	pathway,	BRAF	is	mutated	in	10%	of	CRC	tumours29.	Mutations	in	RAS	and	RAF	result	
in	a	permanent	activation	of	the	EGFR	pathway	(Figure	1.4),	resulting	in	cell	proliferation.		
Additional	genetic	alterations	are	observed	in	70%	of	CRCs23.	Some	examples	are	loss	of	
the	18q	chromosome	segment	which	harbours	a	number	of	key	genes	including	deleted	
in	colorectal	carcinoma	(DCC)30,	SMAD231	and	SMAD4	32.	Both	SMAD2	and	4	mediate	the	
transforming	growth	factor	beta	(TGF-β)	pathway,	which	in	turn	regulates	cell	growth	and	
differentiation.	 Recent	 studies	 have	 identified	 three	 genes	 encoded	 on	 the	 18q	
chromosome	which	are	lost	in	79%	of	CRC	tumours:	phosphatidylinositol	glycan	anchor	
biosynthesis	 class	 N	 (PIGN);	 mex-3	 homolog	 C	 (MEX3C);	 and	 zinc	 finger	 protein	 516	
(ZNF516)33.		
Intra-tumour	heterogeneity	 results	 in	 therapy	 resistance	as	well	 as	disease	 recurrence	
across	all	cancers34.	Although	CRCs	are	largely	a	result	of	clonally	derived	cell	populations	
from	a	smaller	number	of	 long-lived	lineages	from	the	crypt35,36	(Figure	1.2),	sub-clonal	
expansion	is	also	found37,38.		
Despite	 tumour	 heterogeneity,	 the	majority	 of	 CRCs	 (~80%)	 can	 be	 divided	 into	 three	
groups	by	their	distinctive	genetic	alterations:	chromosomal	instable	(CIN),	microsatellite	
instable	(MSI)	tumours	and	microsatellite	and	chromosomal	stable	(MACS)	tumours33,39,40.		
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Figure	1.4.	The	epidermal	growth	factor	receptor	pathway.	This	pathway	regulates	cell	
survival,	proliferation,	angiogenesis,	 invasion	and	apoptosis.	Mutations	 in	RAS	and	RAF	
lead	to	permanent	activation	of	the	pathway,	resulting	in	uncontrolled	cell	growth	and	
therefore	 tumour	 promotion41.	 EGFR,	 epidermal	 growth	 factor	 receptor;	 PLC,	
phospholipase	C;	JAK,	janus	kinase;	SRC,	cellular	Src	kinase;	PI3K,	phosphatidylinositol	3-
kinase;	PKC,	protein	kinase	C;	STAT,	signal	transducer	and	activator	of	transcription;	PTEN,	
phosphatase	 and	 tensin	 homolog;	 NF-κB,	 nuclear	 factor	 κB;	 MEF,	 myocyte	 enhancer;	
mTOR,	mammalian	target	of	 rapamycin;	MAPK,	mitogen	activated	protein	kinase;	ERK,	
extracellular	signal	related	kinase;	BIM,	Bcl-2	like	protein	11;	BCL-2,	B-cell	lymphoma	2.		
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1.2.1. Chromosomal	Instability	
CIN	 develops	 in	 the	 large	 majority	 (~60%)	 of	 CRC	 cases	 and	 is	 characterised	 by	 an	
accelerated	 rate	 of	 allelic	 gains	 or	 losses	 and	 gross	 chromosomal	 abnormalities.	 CIN	
tumours	therefore	have	an	 imbalance	 in	chromosome	number	(aneuploidy)	and	a	high	
frequency	 of	 loss	 of	 heterozygosity	 (LOH)	 where	 an	 entire	 gene	 and	 the	 surrounding	
chromosome	region	are	lost.	Frequently	mutated	genes	in	CIN	tumours	are	APC,	TP53	and	
KRAS	33.	CIN	tumours	have	recently	been	divided	into	two	groups	depending	on	telomere	
length.	 Near-tetraploid	 CIN	 tumours	 have	 significantly	 longer	 relative	 telomere	 length	
compared	to	CIN-	and	aneuploidy	tumours,	whereas	CIN	tumours	with	larger	numbers	of	
chromosome	breaks	have	significantly	shorter	relative	telomere	length42.	
1.2.2. Microsatellite	Instability	
MSI	 occurs	 in	 around	 15%	 of	 all	 CRC	 cases,	 of	 which	 3%	 are	 associated	 with	 Lynch	
syndrome	(LS,	also	known	as	Hereditary	Non-Polyposis	Colorectal	Cancer	(HNPCC))	and	
12%	are	sporadic.	MSI	 is	characterised	by	overall	genetic	hyper	mutation	as	a	result	of	
functional	loss	of	DNA	mismatch	repair	(MMR)	genes43.	The	MMR	system	consists	of	six	
genes:	 MutL	 homolog	 1	 (MLH1),	 MutS	 homolog	 (MSH)	 2,	MSH3,	MSH6,	 post-meiotic	
segregation	 (PMS)-1	 and	 PMS244.	 When	 the	 MMR	 system	 is	 impaired,	 genome-wide	
mutations	accumulate	during	DNA	replication,	usually	within	microsatellites	 (repetitive	
DNA	sequences	such	as	(A)n	or	(CA)n	repeats),	giving	rise	to	MSI	and	eventually	cancer.	
Cancers	with	high	MSI	have	better	clinical	outcome	then	low	or	non-MSI	tumours39	but	
are	also	shown	to	be	more	resistance	to	first	line	drug	treatments	such	as	5-fluorouracil	
(5-	FU)45.	
A	 subgroup	 of	 MSI	 tumours	 are	 5'—C—phosphate—G—3'	 	 (CpG)	 island	 methylator	
phenotype	positive	(CIMP+),	due	to	hyper	methylation	in	the	promoter	of	the	MMR	gene	
MLH146.	CIMP+	cancers	are	more	frequently	observed	in	the	proximal	colon	compared	to	
distal	colon	and	rectal	cancers47.		
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1.2.3. Microsatellite	and	chromosome	stable	
A	third	subgroup	of	tumours	that	are	neither	CIN	nor	MSI	was	first	described	in	1999	by	
Georgiades	 and	 colleagues48.	 MACS	 tumours	 are	 more	 likely	 to	 develop	 in	 younger	
patients49	and	are	localised	to	the	distal	colon	as	well	as	being	poorly	differentiated	and	
more	 invasive	 at	 the	 time	 of	 diagnosis40.	 This	 subgroup	 has	 stable,	 near-diploid	
chromosomes	and	stable	microsatellites.	
1.3. Cell	lines	as	a	model	for	human	CRC	
As	described	above	there	are	a	variety	of	CRC	molecular	phenotypes	observed	in	patients.	
It	 is	essential	 that	cell	 lines	 represent	 the	spectra	of	mutations	and	DNA	copy-number	
aberrations	in	primary	tumours,	and	that	these	are	known.	Whole-exome	sequencing	and	
single	nucleotide	polymorphism	(SNP)	microarray	analysis	of	70	CRC	cell	lines	established	
that	overall	cell	lines	represent	primary	tumours	at	the	genomic	level50.		
In	a	recent	paper	by	Sieber	et	al.	the	proteomes	of	CRC	cell	lines	have	also	been	found	to	
represent	primary	tumours;	proteomic	analysis	was	performed	on	44	CRC	cell	lines	and	
compared	to	95	primary	CRCs51.		
1.4. Risk	factors	for	CRC	
Countries	with	the	highest	incidence	rates	of	CRC	include	Australia,	New	Zealand,	Canada,	
the	United	States,	and	parts	of	Europe,	whereas	the	countries	with	the	lowest	risk	include	
China,	India,	and	parts	of	Africa	and	South	America52.	The	variation	in	incidence	could	be	
due	 to	 available	 diagnostic	 and	 treatment	 options2	 as	 well	 as	 several	 genetic	 and	
environmental	risk	factors	that	increase	a	person's	chance	of	developing	CRC.	These	are	
described	below.		
1.4.1. Age	
CRC	is	predominantly	a	disease	of	the	elderly	population,	with	an	average	age	at	diagnosis	
of	70	years	old.	Almost	nine	out	of	10	patients	diagnosed	in	the	UK	are	over	6053.	However,	
the	average	age	of	onset	is	decreasing	and	more	people	under	the	age	of	50	are	being	
diagnosed53.	The	United	States	National	1987-2006	Surveillance,	Epidemiology	and	End	
Results	 (SEER)	 data	 showed	 increased	 colon	 and	 rectal	 cancer	 incidence	 in	 individuals	
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between	20	and	49	years,	with	the	largest	increase	seen	in	the	40-44	years	old	bracket	
(10.7	per	100,000	population	in	1988	and	17.9	per	population	in	2006)54.	This	is	worrying	
as	currently	all	diagnostic	screening	in	the	UK	is	carried	out	in	people	55	years	and	above.			
1.4.2. Inherited	CRC	syndromes	
Around	75%	of	all	CRCs	occur	sporadically	with	no	obvious	 inherited	gene	mutation	or	
notable	 family	 history.	 The	 remaining	 CRC	 cases	 are	 hereditary	 CRC	 syndromes	 with	
specific	genetic	mutations	(2-6%)	or	familial	CRC	(~20%),	where	at	least	one	blood	relative	
has	CRC	without	a	specific	germline	mutation55.	Hereditary	CRC	syndromes	(Table	1.2)	are	
highly	penetrant	and	passed	on	to	offspring	in	a	Mendelian	manner.	The	most	common	
form	of	hereditary	CRC	is	LS,	which	is	an	autosomal	dominant	condition	where	individuals	
harbour	mutations	 in	DNA	MMR	genes,	most	 commonly	 in	MSH2,	MLH156,	MSH6	 and	
PMS257.	These	patients	have	a	cumulative	risk	of	developing	CRC	of	60-70%	in	men	and	
30-40%	in	women58,59.	LS	patients	also	have	an	increased	risk	of	developing	other	cancers	
such	as	endometrial	and	stomach	cancers60–62.	Familial	adenomatous	polyposis	(FAP)	 is	
the	second	most	common	hereditary	CRC	syndrome	and	is	well	characterised;	patients	
develop	 many	 precancerous	 colonic	 polyps	 in	 their	 mid-teens.	 FAP	 patients	 carry	 a	
mutation	 in	one	APC	allele63,64.	The	 location	of	 the	 ‘second	hit’	mutation	which	causes	
progression	 to	 FAP	 in	 linked	 to	 the	 location	 of	 the	 initial	mutation.	 FAP	 patients	with	
germline	APC	 mutations	 within	 codons	 1194-1392	 show	 allelic	 loss	 in	 their	 colorectal	
adenomas	in	contrast	to	FAP	patients	whose	‘second	hits’	occur	by	truncating	mutations	
in	the	mutation	cluster	region17.	Disease	severity	has	also	been	linked	to	the	site	of	the	
germline	APC	mutation:	patients	with	a	deletion	at	codon	1309	have	significantly	more	
colorectal	polyps	at	colectomy	than	age	and	sex	matched	FAP	controls65.	Nearly	all	FAP	
patients	 will	 go	 on	 to	 develop	 CRC	 by	 the	 time	 they	 reach	 40	 years	 of	 age.	 The	
recommended	management	for	germ-line	positive	members	of	families	with	FAP	is	early	
surveillance	with	endoscopy	and	genetic	tests	to	identify	individuals	who	have	inherited	
an	APC	germline	mutation.	Total	resection	of	the	colon	is	advised	for	patients	that	test	
positive	for	FAP	usually	during	their	late	teens66.		
Attenuated	FAP	(AFAP)	is	a	subtype	of	FAP67.	AFAP	patients	develop	polyps	after	40	years	
which	is	much	later	than	FAP	patients,	and	the	polyp	number	in	AFAP	patients	is	less	than	
100,	much	lower	than	FAP	patients	where	there	can	be	up	to	5,00067.		 	
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Table	 1.2.	 Hereditary	 and	 hamartoma	 CRC	 syndromes.	 Hereditary	 CRC	 syndrome	
features	and	associated	genetic	mutations.		
	
Syndrome	 Features	 Genetic	
mutation(s)		
References	
Lynch	syndrome	 Early	onset,	multiple	colorectal	
polyps,	~80%	penetrance		
MSH2,	 MSH6,	
MLH1,	PMS2	
57,59,62	
Familial	adenomatous	
polyposis	
100-5000	 adenomatous	
colorectal	 polyps,	 100%	
penetrance	
APC		 64,68	
MUTYH-associated	
polyposis	
Multiple	adenomatous	colonic	
polyps	(10-	100)		
MUTYH	 69,70	
Peutz-Jeghers		 Hamartomatous	 GI	 polyps	 (5-
100),	~40%	penetrance	
Serine	
threonine	
kinase	 11	
(STK11)	
71,72	
Juvenile	polyposis	 Early	onset,	Hamartomatous	GI	
polyps	 (50-200),	 10-40%	
penetrance		
SMAD4,	 bone	
morphogenetic	
protein	
receptor	 type	
1A	(BMPR1A)	
73	
Polymerase	
proofreading-
associated	polyposis	
Early	 onset,	 multiple	
adenomas,	 dominant	
inheritance	
DNA	
polymerase	
epsilon	 (POLE),	
DNA	
polymerase	
delta	 1	
(POLD1)	
74	
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Other	hereditary	CRC	syndromes	are	MUTYH-associated	polyposis	(MAP)	and	the	more	
recently	 described	 polymerase	 proofreading-associated	 polyposis.	 Hamartoma	
syndromes	 such	 as	 Peutz-Jeghers	 and	 Juvenile	 polyposis	 are	 also	 associated	 with	 an	
increased	risk	of	developing	cancer.	See	Table	1.2	for	more	details.		
	
1.4.3. Other	bowel	disorders	
There	 is	 an	 increased	 risk	 of	 CRC	 for	 those	with	 severe	 prolonged	 active	 IBD	 such	 as	
Ulcerative	Colitis	(UC)	and	Crohn’s	disease	(CD),	where	the	large	bowel	can	be	inflamed	
for	a	 long	period	of	time	and/or	where	there	are	recurrent	cycles	of	 inflammation	and	
repair75.	 Inflammation	 is	a	well-known	hallmark	of	cancer,	contributing	to	proliferation	
and	 survival	 of	 malignant	 cells76,77.	 	 One	 consequence	 of	 inflammation	 in	 the	 gut	 is	
increased	 risk	of	 field	 cancerisation	where	 the	normal	 cell	 population	 is	 replaced	by	 a	
histologically	 non-dysplastic	 but	 pro-tumourigenic	 cell	 population78,79.	 IBD	 can	 also	
directly	 result	 in	dysplasia,	an	abnormal	collection	of	cells	 in	 the	 lining	of	 the	colon	or	
rectum	 that	 can	 progress	 to	 cancer.	 As	 a	 result,	 UC	 and	 CD	 patients	 are	 screened	 for	
dysplasia	and	CRC	more	frequently	and	at	an	earlier	age.		
1.4.4. Racial	and	ethnic	background	
Incidence	rates	of	CRC	are	highest	for	black	people	and	lowest	for	American	Indian/Alaska	
Native	people80.	Mortality	rates	are	highest	for	black	people	and	lowest	for	Asian/Pacific	
Islander	persons80.	As	for	worldwide	populations,	countries	with	a	high-income	economy	
have	a	higher	incidence	of	CRC	which	suggests	a	significant	environmental	influence	on	
the	development	of	CRC.		
Jews	of	Eastern	European	descent	(Ashkenazi	Jews)	are	a	distinct	population	with	one	of	
the	highest	CRC	risks	of	any	ethnic	group	in	the	world81.	Several	gene	mutations	have	been	
found	in	this	group,	which	lead	to	an	increased	risk	of	CRC;	the	most	common	is	the	I1307K	
APC	mutation81.	
A	study	in	Tower	Hamlets,	UK	found	that	although	British	Bangladeshi	patients	have	a	low	
prevalence	of	CRC	at	27/100,000	compared	to	British	Caucasians	at	342/100,000,	61%	of	
British	Bangladeshi	patients	that	present	with	CRC	are	less	than	4082.	This	 is	defined	as	
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early	 onset	 CRC	 and	 a	 link	 to	 a	 high	 frequency	 of	 somatic	 mutations	 in	 RNA	 binding	
protein,	Fox-1	homolog	1	(RBFOX1)	has	been	made,	but	not	yet	characterised83.	
1.4.5. Diet	
A	diet	high	in	red	and	processed	meat	is	linked	to	increased	CRC	development84.	One	study	
estimated	the	risk	of	CRC	to	increase	by	29%	for	every	100	g/day	increase	in	red	meat	and	
by	21%	for	every	50	g/day	increase	in	processed	meat	consumed85.	The	heme	iron	present	
in	red	meat	generates	oxidative	stress	in	cells	and	is	a	contributor	to	CRC	progression86.	
Diets	high	in	vegetables,	fruits	and	whole	grains	are	linked	to	a	decreased	risk	of	CRC87.		
1.4.6. Intestinal	Microbiota	
Many	changes	in	the	intestinal	microbiota	have	been	reported	in	CRC	with	some	species	
of	 bacteria	 identified	 to	 have	 a	 role	 in	 CRC	 progression	 including	 Streptococcus	 bovis,	
Helicobacter	 pylori,	 Bacteroides	 fragilis,	 Enterococcus	 faecalis,	 Clostridium	 septicum,	
Fusobacterium	spp.	and	Escherichia	coli88–91.	Recent	evidence	suggests	 that	altered	gut	
microbiota	 is	 present	 in	 patients	 with	 adenomas92	 suggesting	 that	 an	 imbalance	 in	
intestinal	microbiota	promotes	 the	early	 stages	of	CRC.	More	 research	 is	necessary	 to	
determine	 correlations	 between	 changes	 in	 intestinal	 environment	 and	 microbiota	
homeostasis.	
1.4.7. Smoking	
Long-term	 smokers	 are	 2.14	 times	more	 likely	 than	 non-smokers	 to	 develop	 CRC93.	 In	
total,	 smoking	 has	 been	 attributed	 as	 the	 cause	 of	 12%	 of	 all	 CRC94	 and	 is	 associated	
dramatically	with	poorer	prognosis	after	diagnosis:	meta-analyses	yielded	random-effects	
hazard	ratio	estimates	(95%	confidence	intervals	(CI))	for	all-cause	mortality	of	1.26	(1.15–
1.37)	 for	 current	 and	 former	 smokers	 compared	 with	 1.11	 (0.93–1.33)	 for	 never	
smokers95.	Tobacco	smoke	contains	at	least	50	carcinogenic	compounds,	exposure	of	the	
bowel	epithelium	to	these	chemicals	via	the	blood	circulation	or	after	ingestion	of	saliva	
contaminated	by	tobacco	smoke	may	be	a	possible	mechanism	of	CRC	promotion96.		
1.4.8. Alcohol	intake		
A	meta-analysis	by	Fedirko	et	al.	highlighted	that	those	who	have	a	high	intake	of	alcohol	
(+4	drinks/day	or	+50g	ethanol/day)	are	more	 likely	 to	develop	CRC97.	The	relative	risk	
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(RR)	for	moderate	intake	(2-3	drinks	per	day	or	12.6-49.9g	ethanol/day)	was	1.21	(95%	CI	
1.13-1.28)	 and	 1.52	 (95%	CI	 1.27-1.81)	 for	 heavy	 alcohol	 intake.	 The	RR	 for	moderate	
alcohol	intake,	compared	with	non-/occasional	alcohol	intake,	was	stronger	for	men	(RR	
=	1.24,	95%	CI	1.13-1.37)	than	for	women	(RR	=	1.08,	95%	CI	1.03-1.13).	The	mechanism	
by	 which	 alcohol	 promotes	 CRC	 remains	 controversial.	 A	 metabolite	 of	 alcohol,	
acetaldehyde,	has	been	proven	to	be	cytotoxic	as	it	can	react	with	proteins	such	as	tubulin	
and	collagen,	to	form	stable	and	unstable	products98.		
1.4.9. Weight	
The	risk	and	incidence	of	CRC	increases	with	body	mass	index	(BMI)99.	Those	with	class	2	
obesity	(BMI	35-39.9)	are	the	most	commonly	diagnosed	and	treated	for	colorectal	as	well	
as	other	cancers.	A	study	by	Daniel	et	al.	found	that	patients	over	50	with	local	or	locally	
advanced	CRC	and	either	class	1	(BMI	30-34.9)	or	class	2	obesity	were	associated	with	a	
two-fold	to	five-fold	increased	risk	of	death	as	compared	to	overweight	patients	(BMI	25-
29.9)100.	Severe	obesity	(BMI>40)	was	also	associated	with	a	more	than	two	fold	risk	of	
death	from	CRC100.	Chronic	inflammation	is	a	phenotype	of	obesity	which	contributes	to	
the	progression	of	CRC101.	Adipose	tissue	releases	pro-inflammatory	cytokines	including	
interleukin	(IL)-8,	IL-6,	IL-2	and	tumour	necrosis	factor	alpha	(TNF-a)102.		
1.4.10. Physical	Inactivity		
Those	who	have	a	high	level	of	physical	activity	have	a	27%	reduced	risk	of	developing	
CRC103	compared	to	those	with	a	low	level	of	physical	activity.	Unfortunately,	studies	do	
not	always	report	intensity,	timing	or	domain	of	physical	intensity	so	it	is	hard	to	define	
high	 and	 low	 levels	 of	 physical	 activity.	 Biological	 mechanisms	 of	 CRC	 prevention	 by	
exercise	 include:	 increase	 in	 gut	motility	 with	 exercise,	 boosting	 the	 immune	 system,	
decreasing	insulin	and	insulin-like	growth	factor	levels,	decreasing	obesity	and	boosting	
free	radical	scavenger	systems104.	
1.4.11. Type	2	diabetes	
Type	2	diabetes	is	the	commonest	form	of	diabetes.	The	function	of	β-cells	in	the	pancreas	
is	impaired	and/or	response	to	insulin	is	compromised,	leading	to	hyperglycaemia.	Major	
risk	factors	are	excess	body	weight	and	physical	inactivity.	
	 41	
Patients	 with	 type	 2	 diabetes	 (T2D)	 have	 an	 increased	 risk	 of	 developing	 CRC	 due	 to	
confounding	risk	factors	of	obesity,	lack	of	exercise	and	smoking105–110.	Nevertheless,	even	
when	confounders	are	removed,	those	with	T2D	still	have	a	34%	increased	risk	of	CRC	as	
well	as	more	serious	histopathological	features	and	a	higher	chance	of	recurrence111.	The	
mechanisms	linking	T2D	to	CRC	remain	unknown.	
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1.5. Diagnosis	of	colorectal	cancer		
Methods	of	CRC	diagnosis	 vary	between	 countries.	 In	 the	UK,	 there	 is	 a	bowel	 cancer	
screening	service	which	uses	two	methods	used	to	detect	CRC	in	 its	earliest	stage.	The	
first	 is	 a	 one-off	 bowel	 scope	 screening	 for	 55	 year	 olds112.	 Polyps	 in	 the	 bowel	 are	
indicative	of	CRC	risk:	adenomatous	polyps	are	a	pre-cancerous	polyp	with	the	potential	
to	transform	into	cancer	whereas	hyperplastic	and	inflammatory	polyps	are	not	currently	
considered	pre-cancerous113.	 In	 the	United	States	 (US),	patients	are	screened	from	the	
earlier	age	of	50.	Screening	in	the	US	has	been	credited	as	the	main	reason	for	the	6%	
decline	in	cases,	between	2005	and	2014114.	The	second	diagnostic	test	available	in	the	
UK	 is	 a	 faecal	 occult	 blood	 test	 (FOBT)	 for	 those	between	60	 and	74.	Blood	 in	 a	 stool	
sample	is	indicative	of	CRC.	FOBT	has	a	specificity	of	95%	and	has	reduced	CRC-associated	
mortality	by	15-33%115,	but	its	usefulness	in	clinics	is	limited	due	to	poor	sensitivity	and	
false	negatives,	as	not	all	CRC	tumours	bleed116.	Quantitative	immunological	detection	of	
human	haemoglobin	(i-FOBT),	offers	a	higher	sensitivity	as	it	eliminates	contamination	of	
sample	 with	 sources	 other	 than	 human	 haemoglobin,	 like	 diet.	 Unfortunately,	 this	
technique	is	more	expensive	so	is	not	widely	used117.		
Once	a	 lesion	 is	suspected,	 the	next	step	 is	a	 flexible	sigmoidoscopy	or	a	colonoscopy.	
Both	 permit	 the	 removal	 of	 adenomas	 at	 the	 same	 time,	 reducing	 cancer	 incidence.	
Biopsy	samples	removed	during	the	procedure	are	sent	for	histopathological	assessment	
and	 genetic	 testing	 can	 be	 undertaken	 to	 provide	 further	 information.	 However,	
endoscopic	procedures	require	bowel	preparation,	carry	a	risk	of	complications,	such	as	
bowel	 perforation,	 are	 expensive	 and	 the	 results	 only	 give	 a	 snapshot	 of	 information	
about	the	tumour	at	the	biopsy	site	and	time	point.	Alongside	an	endoscopic	procedure,	
other	tests	are	completed,	such	as	blood	tests	to	detect	an	elevation	in	carcinoembryonic	
antigen	(CEA)	and	carbohydrate	antigen	(CA	19-9)	which	 is	 indicative	of	CRC,	however,	
these	can	be	unreliable	due	to	high	levels	of	false	positives	as	well	as	false	negatives118.		
Current	methods	of	diagnosis	employed	in	the	UK	often	fail	to	distinguish	between	high-	
and	low-risk	patients	because	there	are	no	current	prognostic	or	predictive	markers	for	
CRC	that	are	easy	to	use	and	accurate.	An	easy	to	perform,	non-invasive,	inexpensive	and	
accurate	test,	such	as	a	blood	test,	which	can	detect	the	disease	at	an	early	stage	is	still	
desperately	needed.	
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1.6. Staging	of	colorectal	cancer	
The	most	common	system	for	pathological	staging	of	CRC	is	called	TNM:	T	(1-4)	represents	
primary	tumour	and	how	far	 it	has	penetrated	 into	the	 lining	of	the	bowel	and	nearby	
tissues;	N	(0-2)	represents	the	spread	of	the	cancer	to	regional	lymph	nodes;	and	M	(0-2)	
represents	the	presence	of	metastases	to	other	organs	(Figure	1.5).	A	simplified	version	
is	outlined	in	Table	1.3.	There	are	also	three	grades	of	bowel	cancer	which	are	described	
in	Table	1.4.	Grade	is	based	on	how	closely	the	cancer	looks	like	normal	CRC	tissue	under	
a	microscope.		
To	determine	 the	clinical	 stage	of	 the	 tumour,	 clinicians	use	a	variety	of	 imaging	 tests	
which	help	to	identify	small	tumours.	One	imaging	technique	is	computerised	tomography	
(CT),	but	this	method	has	a	staging	accuracy	of	45-77%.	Another	imaging	technique	called	
magnetic	resonance	imaging	(MRI)	has	a	better	staging	accuracy	of	73%119	and	positron	
emission	 tomography	 (PET)	 scans	 can	 identify	 small	 metastases	 well120.	 Imaging	
techniques	 are	 combined	with	 physical	 examination,	 combined	with	 information	 from	
endoscopic	procedures,	surgical	resection	and	pathological	assessment.	
At	diagnosis,	approximately	25%	of	patients	will	have	metastatic	disease	and	almost	50%	
of	CRC	patients	will	develop	metastasis121.	The	main	sites	of	CRC	metastases	are	liver,	lung	
and	peritoneum.	Recent	evidence	suggests	that	KRAS	mutant	tumours	are	associated	with	
lung,	 brain	 and	 bone	 metastases,	 whilst	 BRAF	 mutant	 tumours	 are	 associated	 with	
peritoneal	and	distant	lymph	node	metastases122,123.	
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Figure	 1.5.	 TNM	 staging	 of	 CRC.	 T	 represents	 the	 primary	 tumour	 and	 the	 level	 of	
penetration	 into	 the	 lining	 of	 the	 bowel	 and	 nearby	 tissues	 in	 more	 severe	 cases;	 N	
represents	the	spread	of	the	cancer	cells	to	regional	lymph	nodes;	and	M	represents	the	
presence	of	 secondary	 tumour	or	metastases	 to	other	organs124.	 Each	 is	 given	a	 score	
between	0	and	4,	with	4	being	most	severe.		
	
	
	
	
	
	
	
	
	
	
	
	 45	
Table	1.3.	TNM	staging.	T	 -	primary	tumour	penetration;	N	-	spread	to	regional	 lymph	
nodes;	and	M	-	presence	of	metastases	to	other	organs	(Figure	1.5).		
Stage	 Description	
1	 T1-2,	N0,	M0:	The	cancer	has	spread	beyond	the	 layer	of	muscle	surrounding	
the	bowel	and	may	have	penetrated	the	surface	covering	the	bowel.	No	nearby	
organs,	lymph	nodes	or	distant	sites	have	been	reached.	
2a	 T3,	N0,	M0:	The	cancer	has	 spread	 into	 the	outermost	 layers	of	 the	colon	or	
rectum.	No	nearby	organs,	lymph	nodes	or	distant	sites	have	been	reached.	
2b	 T4a,	N0,	M0:	The	cancer	has	grown	through	the	wall	of	the	colon	or	rectum.	No	
nearby	organs,	lymph	nodes	or	distant	sites	have	been	reached.	
2c	 T4b,	N0,	M0:	The	cancer	has	grown	through	the	wall	of	the	colon	or	rectum	and	
is	 attached	 to	 or	 has	 penetrated	 nearby	 tissues	 or	 organs.	 No	 nearby	 lymph	
nodes	or	distant	sites	have	been	reached.	
3a	 T1-2,	N1-2a,	M0:	The	cancer	has	spread	beyond	the	mucosa	into	the	submucosa	
or	the	muscularis	propria.	No	nearby	organs	have	been	reached.	It	has	spread	to	
1-3	(N1)	or	4-6	(N2a)	nearby	lymph	nodes.	No	distant	sites	have	been	reached.	
3b	 T3-4a,	N1-2a/b,	M0:	The	cancer	has	grown	into	the	outermost	layers	or	through	
the	visceral	peritoneum.	No	nearby	organs	have	been	reached.	It	has	spread	to	
1-3	(N1)	or	4-6	(N2a)	or	7+	(N2b)	nearby	lymph	nodes.	No	distant	sites	have	been	
reached.	
3c	 T3-4a/b,	N2a/b,	M0:	The	cancer	has	grown	into	the	outermost	layers	or	through	
the	 visceral	 peritoneum.	 No	 nearby	 organs	 have	 been	 reached	 (T3/4a).	 The	
cancer	has	spread	to	nearby	organs	(T4b).	It	has	spread	to	1-3	(N1)	or	4-6	(N2a)	
or	7+	(N2b)	nearby	lymph	nodes.	No	distant	sites	have	been	reached.	
4a	 Any	T,	Any	N,	M1a:	The	cancer	may	or	may	not	have	penetrated	the	wall	of	the	
rectum	or	the	colon,	and	it	may	or	may	not	have	spread	to	nearby	lymph	nodes.	
It	has	reached	one	distant	organ	or	tissue.	
4b	 Any	T,	Any	N,	M1b:	The	cancer	may	or	may	not	have	penetrated	the	wall	of	the	
rectum	or	the	colon,	and	it	may	or	may	not	have	spread	to	nearby	lymph	nodes.	
It	has	reached	one	or	more	distant	organs	or	tissue.	
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Table	1.4.	Grades	of	CRC.	Description	of	the	grades	of	CRC.		
Grade	 Description	
1	 A	cancer	growing	slowly	with	a	low	chance	of	spreading	beyond	the	bowel.		
2	 A	cancer	growing	moderately	with	a	medium	chance	of	spreading	beyond	the	
bowel.	
3	 A	cancer	growing	rapidly	with	a	high	chance	of	spreading	beyond	the	bowel.	
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1.7. Treatment	of	colorectal	cancer		
Surgery,	 chemotherapy	 and	 radiotherapy	 all	 have	 key	 roles	 in	 the	 treatment	 of	 CRC	
dependent	on	stage.	Surgery	is	the	main	treatment	for	all	stages	of	rectal	cancer	and	the	
early	 stages	 (T1-2)	 of	 colon	 cancer,	 when	 the	 cancer	 remains	 localised,	 are	 often	
considered	curative.	During	surgery,	nearby	 lymph	nodes	are	also	 removed	 to	prevent	
recurrence.		
Chemotherapy	 remains	 the	 standard	 of	 care	 for	 the	 50%	 of	 patients	 that	 develop	
advanced	 metastatic	 disease.	 Selecting	 the	 appropriate	 therapy	 for	 patients	 with	
metastatic	CRC	is	complex	because	the	treatment	options	are	diverse.	Patients	are	usually	
treated	with	a	combination	of	cytotoxic	and	targeted	therapeutics,	dictated	by	therapy	
toxicity.	The	cytotoxic	chemotherapy	gold	standard	remains	one	of	three	options:	5-FU	
with	oxaliplatin	(FOLFOX);	capecitabine	with	oxaliplatin	(CAPOX);	or	5-FU	with	irinotecan	
(FOLFIRI).	 Newer	 targeted	 agents	 include	 antibodies	 against	 tumour	 antigens	 that	 are	
used	 depending	 on	 the	 patient’s	 mutation	 profile125–128.	 Patients	 with	 RAS	 mutant	
tumours	(mutation	in	KRAS,	usually	codon	12	and	13,	or	NRAS	exon	2,	3	and	4)	are	treated	
with	Bevacizumab	(anti-vascular	endothelial	growth	factor	(VEGF)-A	antibody)	whereas	
RAS	 wild-type	 patients	 receive	 Bevacizumab,	 Cetuximab	 or	 Panitumumab	 (anti-EGFR	
antibodies)126.	
Tumour	response	to	therapy	is	often	transient	and	many	patients	develop	resistant	cell	
populations	resulting	in	treatment	failure	or	cancer	recurrence.	Biomarkers	of	response	
to	 therapy	 are	 needed	 for	 more	 reliable	 stratification	 of	 patients	 for	 proper	 clinical	
management.	 However,	 second-line	 therapeutics	 are	 available:	 Regorafenib	 a	 non-
specific	 kinase	 inhibitor,	 is	 approved	 for	 the	 refractory	 setting;	 and	 aflibercept	 and	
ramucirumab,	which	both	target	VEGF,	are	approved	for	oxaliplatin-resistant	patients129–
131.	More	clinical	trials	are	necessary	to	determine	the	optimum	regimen	for	combining	
the	newer	biologics	and	traditional	chemotherapy.		
Recently,	 the	new	Eloxatin	Peri-Operative	Chemotherapy	 (EPOC)	 study	of	 combination	
therapy	 of	 cetuximab	with	 FOLFOX	 for	 CRC	 showed	 a	 disadvantage	 in	 overall	 survival	
combined	with	an	increase	in	tumour	burden132.	Work	by	Prof.	Daniel	Hochhauser’s	group	
at	University	College	London	in	collaboration	with	Prof.	Andrew	Silver’s	group	at	Queen	
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Mary	University	of	London	found	that	reactive	oxygen	species	(ROS)	(Chapter	1,	Section	
1.8)	 generated	 by	 dual	 oxidase	 (DUOX)-2	 as	 a	 result	 of	 cetuximab	 treatment	 reduced	
oxaliplatin	activity133	(detailed	in	Chapter	6).	DUOX2	is	a	175kDa	enzyme	which	is	part	of	
the	 nicotinamide	 adenine	 dinucleotide	 phosphate	 (NADPH)	 oxidase	 (NOX)	 family.	 The	
NADPH	 oxidase	 family	 of	 enzymes	 consists	 of	 NOX1-5	which	 produce	 superoxide	 and	
DUOX1	and	2	which	produce	the	carcinogen	hydrogen	peroxide	(H2O2)134.	DUOX2	was	first	
described	as	a	H2O2-producing	enzyme	in	the	thyroid	with	an	 important	role	 in	thyroid	
hormone	biosynthesis135.	DUOX2	is	now	also	recognised	as	an	important	part	of	the	host	
defence	 system	 of	 the	 airway	 epithelium	 and	 the	 human	 gastrointestinal	 tract136–139.	
DUOX	proteins	are	found	in	the	apical	membrane	and	in	the	enterocytes	of	the	human	
colon140.	It	is	known	that	hypoxia	increases	the	expression	of	DUOX2	in	the	gut139.		High	
levels	 of	 DUOX2	 have	 been	 observed	 in	 the	 colonic	 epithelium	of	 IBD	 patients	 and	 in	
colonic	and	pancreatic	cancers141.	Recently,	DUOX2	has	been	shown	to	be	regulated	by	a	
signal	 transducer	 and	 activator	 of	 transcription	 (STAT)-dependent	 janus	 kinase	 (JAK)	
independent	pathway142.		
Radiation	therapy	is	also	a	treatment	arm	for	rectal	cancer.	Radiation	works	by	damaging	
the	 cell’s	 DNA	 leading	 to	 cell	 death.	 Radiation	 is	 often	 given	 alongside	 chemotherapy	
before	and/or	after	surgery	to	remove	any	remaining	cancerous	cells.	This	type	of	therapy	
is	also	used	to	treat	metastases,	mainly	those	that	have	spread	to	the	bones143.		
There	 are	 a	 variety	 of	 clinical	 trials	 underway	 and	 others	 completed	 recently	 for	 CRC	
treatment.	For	primary	CRC,	 the	 focus	 is	on	 improving	screening	accuracy	and	surgical	
techniques.	For	metastatic	CRC,	there	are	a	variety	of	targeted	therapies,	which	have	been	
trialled	 in	 other	 cancers	 previously.	 These	 are	 being	 tested	 alongside	 traditional	
chemotherapy.		 	
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1.8. Hypoxia	in	colorectal	cancer	
Hypoxia	is	defined	as	a	lack	of	oxygen	in	tissues.	Healthy	tissues	in	the	body	experience	2-
9%	oxygen144	whereas	hypoxic	areas	in	solid	tumours	experience	less	than	2%	oxygen145.	
The	diffusion	limit	for	oxygen	is	~100-200μm,	therefore	for	adequate	oxygenation	cells	
must	be	within	this	radius146,147.	The	gradients	of	hypoxia	are	functional,	they	allow	for	
appropriate	 cell	 and	 tissue	 development	 and	 function.	 For	 example,	 during	 foetal	
development,	hypoxia	represents	a	positive	and	necessary	stimulus	that	is	required	for	
patterning	and	function	of	most	organs148.	However,	it	is	clear	that	the	cellular	effects	of	
exposure	to	low-oxygen	tensions	represent	a	malignant	stage	of	many	diseases	such	as	
dementia149,	cardiovascular	disease150,	diabetes151	and	cancer152.		
	
Formation	of	 vessels	 in	 tumours	 is	not	 carefully	 co-ordinated	 like	normal	physiological	
angiogenesis,	 leading	 to	 vascular	 leakiness,	 chaotic	 architecture,	 non-laminar	 blood	
flow147	and	dynamic	fluctuations	in	blood	flow	called	‘cycling	hypoxia’153.	Hypoxic	areas	in	
tumours	are	formed	as	a	consequence	of	the	metabolic	demands	of	proliferating	cancer	
cells	and/or	 functionally	 limited	vasculature154.	There	 is	often	heterogeneity	 in	 tumour	
oxygenation	 with	 hypoxic	 and	 necrotic	 areas	 characteristically	 observed	 towards	 the	
centre	of	 the	 tumour.	 Experimental	 evidence	demonstrates	 steep	 gradients	 of	 oxygen	
partial	 pressure	 that	 are	 close	 to	 zero	when	 cells	 are	 distant	 from	 vessels155,	 with	 an	
oxygen	 diffusion	 limit	 of	 235µm156.	 Poor	 vascularisation	 in	 hypoxic	 areas	 makes	 drug	
delivery	difficult	and	is	one	reason	why	hypoxic	areas	in	solid	tumours,	such	as	CRC	are	
naturally	more	resistant	to	radiation	and	chemotherapy157,158.		
	
The	cellular	response	to	hypoxia	is	mediated	by	the	O2-labile	transcription	factors	hypoxia	
inducible	 factors	 (HIF)-1	 and	 -2144.	 The	 HIFs	 consist	 of	 O2	 sensitive	 α	 subunits	 and	
constitutively	expressed	β	subunits159.	In	normoxic	conditions,	HIF-1α	has	a	half-life	of	five	
minutes	due	to	continuous	degradation	by	the	ubiquitin-proteasome	pathway	(Figure	1.6)	
where	HIF-1α	is	regulated	by	von	Hippel-Lindau	protein	(VHL)159.	As	the	oxygen	tension	
lowers,	as	is	often	seen	in	solid	tumours158,	VHL	is	downregulated,	HIF-1α	is	stabilised	and	
dimerises	with	HIF-1β	to	bind	hypoxia	response	elements	(HRE)	within	the	genome	(Figure	
1.6).	 This	 leads	 to	 transcriptional	 activation	 of	 more	 than	 30	 genes	 which	 promotes	
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aberrant	 cell	 survival	 alongside	 a	 switch	 in	 cellular	metabolism	 to	 anaerobic	 glycolysis	
enabling	disease	progression160.	These	genes	include	glucose	transporter	(GLUT)-1	which	
facilitates	cellular	glucose	uptake;	hexokinase	(HK)-2	and	lactate	dehydrogenase	(LDH)-A	
which	 regulate	 anaerobic	 metabolism;	 carbonic	 anhydrase	 (CA)-9	 helps	 to	 maintain	
intracellular	pH	in	a	hypoxic	environment;	and	VEGF	which	leads	to	vascularisation	of	the	
tumour	mass,	a	phenomenon	which	was	first	reported	in	1908161.	HIF-1α	overexpression	
is	associated	with	increased	chemoresistance,	metastasis	and	mortality	in	various	human	
cancers	 including	 bladder,	 breast,	 lung,	 ovary,	 pancreas,	 stomach	 and	 colon162.	 High	
expression	 of	HIF-1α	 in	 CRC	 correlates	with	 increased	 tumour	 invasion,	 tumour	 stage,	
lymphatic	invasion	and	liver	metastasis	and	a	poorer	prognosis163.	
	
ROS	are	thought	to	increase	in	hypoxia.	ROS	are	radicals,	ions	or	molecules	that	have	an	
unpaired	electron	in	their	outer	shell	which	makes	them	highly	reactive.	ROS	can	cause	
DNA	damage	 and	 subsequent	 genomic	 instability	 and	 result	 from	 increased	metabolic	
activity,	mitochondrial	 dysfunction	and	oncogene	activity.	 Cancer	 cells	 also	express	 an	
increased	level	of	antioxidant	proteins	to	neutralise	ROS,	suggesting	a	delicate	balance	of	
ROS	is	necessary	for	cancer	cell	function164.		
To	 maintain	 cell	 viability	 mitochondria	 quench	 ROS	 by	 generating	 glutathione	 and	
thioredoxin	redox	couples.	Under	aerobic	conditions,	cells	express	cytochrome	C	oxidase	
(COX4)	subunit	4-1-regulatory	subunit	within	the	COX	complex.	However,	in	hypoxia	HIF-
1	increases	the	expression	of	COX4-2	subunit	as	well	as	mitochondrial	lon	protease	which	
leads	to	degradation	of	the	COX4-1	subunit165,166.	This	is	hypothesised	to	aid	the	efficiency	
of	complex	IV	of	the	electron	transport	chain	under	hypoxia	and	to	prevent	generation	of	
ROS	in	hypoxia.		
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Figure	1.6.	Stabilisation	of	HIF-1α	during	hypoxia.	(A)	In	normoxic	conditions,	HIF-1α	is	
regulated	 by	 VHL	 leading	 to	 continuous	 degradation	 by	 the	 ubiquitin-proteasome	
pathway.	(B)	In	hypoxic	conditions,	VHL	is	downregulated.	HIF-1α	is	stabilised	and	free	to	
dimerise	with	HIF-1β	which	then	binds	as	a	complex	to	HRE	within	the	genome,	promoting	
transcription	 of	 genes	 involved	 in	 cancer	 cell	 survival167.	 VHL,	 von	 Hippel-Lindau;	 HIF,	
hypoxia	inducible	factor;	HRE,	hypoxia	response	elements;	PHD,	prolyl	hydroxylase;	CBP,	
CREB	binding	protein;	OAc,	acetoxy	group.		
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1.9. Metabolism	in	colorectal	cancer		
Physiologically,	 normal	 cells	 have	 a	 low	 rate	 of	 glycolysis	with	most	 energy	 efficiently	
generated	 by	 oxidative	 phosphorylation	 in	 the	 mitochondria.	 In	 general	 cancer	 cells	
mainly	use	glycolysis	to	generate	adenosine	triphosphate	(ATP).		
Glycolysis	 takes	 place	 in	 the	 cytoplasm,	 where	 glucose	 is	 broken	 down	 to	 pyruvate,	
producing	2	ATP	molecules	per	glucose	molecule	(Figure	1.7).	Pyruvate	is	then	converted	
into	acetyl-CoA	by	pyruvate	dehydrogenase	in	the	mitochondria	(Figure	1.8).	Acetyl-CoA	
enters	the	tri-carboxylic	acid	(TCA)	cycle	(also	known	as	the	citric	acid	cycle	or	the	Krebs	
cycle)	where	it	is	broken	down	via	nine	further	enzymatic	steps	to	oxaloacetate168	(Figure	
1.8).	Cells	can	also	metabolise	glutamine	using	the	TCA	cycle,	which	can	be	another	useful	
source	 of	 energy	 for	 cancer	 cells169	 (Figure	 1.8).	 During	 the	 TCA	 cycle	 nicotinamide	
adenine	dinucleotide	(NADH)	is	produced	which	then	serves	as	an	electron	donor	in	the	
electron	 transport	 chain	 (ETC),	 where	 30-36	molecules	 of	 ATP	 are	 produced	 for	 each	
glucose	molecule	via	oxidative	phosphorylation	(OXPHOS)	in	the	inter-membrane	space	
of	mitochondria168	(Figure	1.9).	Oxygen	is	used	as	an	electron	acceptor	for	OXPHOS.	In	the	
absence	 of	 oxygen	 (hypoxia)	 or	 functioning	mitochondria,	 non-malignant	 cells	 rely	 on	
glycolysis	for	ATP	generation.	It	has	also	been	recently	shown	that	cancer	cells	can	use	
intracellular	glycogen	as	a	means	of	maintaining	cell	viability	and	proliferation170	and	in	
response	to	acute	hypoxia,	cancer	cells	can	increase	glycogen	storage171.	This	is	consistent	
with	the	previously	described	glycogen	shunt	in	a	number	of	other	cell	types172.		
Interestingly,	even	when	oxygen	is	plentiful,	rapidly	growing	cancer	cells	have	glycolytic	
rates	 of	 200	 times	 that	 of	 a	 normal	 cell173.	 	 Cancer	 cells	 in	 general	 are	metabolically	
adapted	to	grow	and	proliferative	rapidly	under	conditions	of	low	pH	and	oxygen	tension	
with	 limited	 nutrients174	 where	 non-transformed	 cells	 would	 struggle	 to	 grow175.	 An	
important	study	by	Sonveaux	et	al.	 in	2008176	showed	that	normoxic	tumour	areas	can	
oxidise	 lactate	as	a	significant	carbon	source,	sparing	glucose	and	allowing	 it	to	diffuse	
further	 away	 from	 the	 tumour	 vasculature	 into	 hypoxic	 areas	 where	 anaerobic	
metabolism	was	used	to	metabolise	the	glucose	to	lactate,	which	was	then	used	by	the	
normoxic	areas.		
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Figure	 1.7.	 Glycolysis.	 The	 breakdown	 of	 glucose	 by	 enzymes	 into	 pyruvate,	 ATP	 and	
NADH	in	the	cytosol173.	ATP,	adenosine	triphosphate;	ADP,	adenosine	diphosphate;	NAD,	
nicotinamide	adenosine	dinucleotide.		
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Figure	 1.8.	 The	 tri-carboxylic	 acid	 cycle.	 Acetyl-CoA	 enters	 the	 TCA	 cycle	 in	 the	
mitochondria	where	it	is	broken	down	via	nine	further	enzymatic	steps	to	oxaloacetate168.	
Glutamine	 can	 also	 enter	 the	 TCA	 cycle.	 TCA,	 tricarboxylic	 acid	 cycle;	 PHD,	 prolyl	
hydroxylase,	NAD,	 nicotinamide	 adenosine	 dinucleotide;	GTP,	 guanosine	 triphosphate;	
FAD,	flavin	adenosine	dinucleotide.		
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Figure	1.9.	The	electron	transport	chain.	Electrons	from	the	reduced	NADH	and	succinate	
generated	 by	 the	 TCA	 cycle	 are	 transferred	 through	 a	 chain	 of	 protein	 complexes	
embedded	in	the	inner	mitochondrial	membrane177.	The	oxidation	steps	lead	to	protons	
moving	 from	 the	 inner	 matrix	 to	 the	 intermembrane	 space,	 creating	 a	 hydrogen	
concentration	gradient	which	produces	both	an	electrical	potential	and	a	pH	potential.	
This	leads	to	the	conversion	of	ADP	to	ATP	by	ATP	synthase.	These	coupled	reactions	are	
also	referred	to	as	OXPHOS.	ETC,	electron	transport	chain;	NADH,	nicotinamide	adenine	
dinucleotide;	TCA,	tricarboxylic	acid	cycle;	ADP,	adenine	di-phosphate;	ATP,	adenine	tri-
phosphate;	OXPHOS,	oxidative	phosphorylation.		 	
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The	exact	 reason	 for	 the	 switch	 in	glucose	metabolism	pathways	 in	 cancer	 cells	 is	not	
known,	although	there	are	a	number	of	theories:	1)	an	inherent	feature	of	the	malignant	
phenotype,	 called	 the	Warburg	 effect178,179;	 2)	 as	 a	 consequence	 of	 a	 hypoxic	 tumour	
microenvironment167,	or	3)	the	existence	of	a	pseudo-hypoxic	tumour	metabolic	profile173.	
	
Otto	Warburg	was	 the	scientist	who	discovered	 the	 ‘oxidative	glycolytic’	phenotype	of	
cancer	cells.	In	these	cells,	glycolysis	is	uncoupled	from	the	mitochondrial	TCA	cycle	and	
OXPHOS,	and	is	consequently	characterised	by	excess	production	of	lactate	leading	to	an	
acidic	 extracellular	 environment178.	 Warburg	 hypothesised	 that	 this	 metabolic	
reprogramming	confers	a	survival	advantage	to	cancer	cells	that	will	inevitably	reside	in	a	
hypoxic	environment	if	the	tumour	outgrows	the	vascularisation.	The	acidic	extracellular	
environment	does	favour	the	survival	of	cancer	cells,	especially	those	that	have	lost	wild	
type	TP53	function,	over	normal	cells	and	may	promote	invasion,	as	well	as	preventing	
apoptosis	upon	detachment	(anoikis)	facilitating	metastasis180.	This	is	highly	relevant	for	
the	colonic	epithelium	as	over	75%	of	human	colonic	tumours	have	lost	functional	wild	
type	TP53	activity181.	Analysis	of	CRC	patient	samples	has	identified	high	levels	of	GLUT-1,	
monocarboxylate	 transporter	 (MCT)-1	 and	 HIF-1a	 which	 indicates	 increased	 glycolytic	
metabolism	and	lactate	production182.	In	CRC,	LDHA5,	which	converts	pyruvate	to	lactate,	
is	 linked	 to	 activation	 of	 the	 HIF	 pathway	 as	 well	 as	 an	 aggressive	 phenotype183–185.	
Elevated	levels	of	lactate	also	correlate	with	poor	patient	prognosis	and	overall	survival	in	
cervical	and	ovarian	cancers186,187.		
	
Warburg	also	hypothesised	that	these	metabolic	changes	occurred	due	to	mitochondrial	
defects,	however	this	topic	remains	controversial.	Evidence	is	mounting	to	suggest	that	
damaged	mitochondria	are	not	the	cause	of	the	increased	aerobic	glycolysis	exhibited	by	
most	tumour	cells,	but	that	the	primary	functions	of	activated	oncogenes	and	inactivated	
tumour	 suppressors	 are	 to	 reprogram	 cellular	 metabolism	 (reviewed	 in188).	 Carbon	
labelling	metabolic	 studies	have	 identified	 that	 in	solid	 tumours,	where	glucose	supply	
can	 be	 low189,	 glutaminolysis,	 the	 TCA	 cycle,	 the	 pentose	 phosphate	 pathway	 and	
nucleotide	 biosynthesis	 as	 well	 as	 glycolysis	 are	 all	 enhanced	 in	 tumour	 cells190.	
Nevertheless,	the	mitochondrial	genome	is	susceptible	to	mutations	because	of	the	large	
amount	of	ROS	they	generate,	coupled	with	a	low	level	of	DNA	repair191.		
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There	 is	 some	evidence	 to	 suggest	 that	mitochondria	 are	 damaged	 in	 CRC.	One	 study	
showed	that	mitochondrial	microsatellite	instability	is	an	early	and	independent	event	in	
colorectal	precancerous	lesions	which	occurs	in	30%	of	CRC	patients	and	is	linked	to	poor	
prognosis192.	Patients	with	lower	mitochondrial	DNA	(mtDNA)	copy	number	show	higher	
TNM	stages	and	poorer	differentiation193.	CRC	cell	lines	including	DLD1,	HCT116,	SW837	
and	HT29	have	been	shown	to	have	mutations	in	mtDNA	leading	to	a	subtle	elevation	in	
ROS191;	low	levels	of	ROS	are	highly	mitogenic,	whereas	high	levels	of	ROS	are	toxic194.	It	
has	 also	 been	 shown	 that	 HCT116	 CRC	 cells	 treated	 with	 1%	 oxygen	 for	 at	 least	 20	
passages,	have	larger	mitochondrial	mass,	but	decreased	mtDNA	and	reduced	sensitivity	
to	5-FU193.	
Hypoxia	is	a	feature	of	solid	tumours	(Chapter	1,	Section	1.8)	and	can	lead	to	expression	
of	many	genes,	via	HIF-1a,	that	have	a	role	in	metabolism	such	as	GLUT-1,	HK2	and	LDHA,	
all	 which	 have	 been	 shown	 to	 be	 relevant	 in	 CRC	 tumorigenesis	 and	 linked	 to	 poor	
prognosis182,195	 (Figure	 1.10).	 HIF-1	 also	 promotes	 the	 expression	 of	 pyruvate	
dehydrogenase	kinase	(PDK)-1	expression162	which	acts	to	block	conversion	of	pyruvate	
to	 acetyl-CoA,	 effectively	 blocking	 the	 TCA	 cycle	 and	 OXPHOS,	 forcing	 the	 cell	 to	 use	
glycolysis	for	ATP	generation.	Upregulation	of	PDK1	also	protects	cells	from	ROS	damage.	
There	 is	evidence	 to	 suggest	 that	HIF-1	down	 regulates	mitochondrial	biogenesis162	by	
inducing	 microRNA	 (miRNA)-210	 transcription	 resulting	 in	 a	 reduction	 of	 iron-sulphur	
cluster	assembly	enzyme	(ISCU)	and	COX10,	two	important	elements	of	the	mitochondria	
electron	transport	chain	and	the	TCA	cycle196.		
HIF	transcription	factors	have	also	been	shown	to	affect	the	function	and	stability	of	other	
genes	which	 influence	cellular	metabolism;	 the	best	characterised	examples	are	v-myc	
avian	myelocytomatosis	viral	oncogene	homolog	(MYC)	and	p53.	MYC	binds	E-boxes	 in	
the	promoter	of	target	genes	when	associated	with	MYC-associated	protein	X	(MAX)	as	a	
heterodimer197.	 MAX	 is	 itself	 regulated	 by	 binding	 of	 MAX	 dimerisation	 protein	
(MXD1/MAD)	 and	 MAX	 interactor	 1	 (MX11/MAD2)198.	 MX11	 binding	 to	 MAX	 inhibits	
binding	 of	 MYC:MAX	 to	 E-boxes.	 HIF-1α	 can	 also	 interfere	 with	 the	 MYC:MAX	
heterodimer;	through	upregulation	of	MX11,	 increasing	competition	for	MAX199	and	by	
direct	 binding	 of	 MAX	 to	 displace	 MYC.	 Conversely,	 HIF-2α	 binds	 and	 stabilises	 the	
MYC:MAX	heterodimer	to	promote	MYC	associated	transcriptional	changes200.	HIFα	can	
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be	 outcompeted	 in	 tumours	 with	 high	 expression	 levels	 of	 MYC201,	 therefore,	 HIF-2α	
interaction	 with	 the	 MYC:MAX	 heterodimer	 is	 more	 likely	 to	 influence	 the	 hypoxia-
induced	metabolic	transformation	 in	non-MYC-amplified	tumours.	There	are	no	known	
mutations	 of	MYC	 in	 CRC.	 However,	MYC	 is	 frequently	 amplified	 in	 CRC;	 Soga	 et	 al.	
recently	implicated	amplification	of	MYC,	which	is	commonly	seen	in	CRC,		leads	a	change	
in	 expression	 of	 121	 metabolic	 genes	 and	 39	 transporter	 genes	 in	 CRC	 promoting	
metabolic	reprogramming202.		
The	relationship	between	TP53	and	hypoxia	is	controversial;	hypoxia	has	been	shown	to	
induce	TP53	 stability	 in	 some	conditions,	but	not	 in	others203,204.	 It	 appears	 that	 lower	
oxygen	 tensions	 elicit	 strong	 stabilisation	 of	 TP53,	 through	 DNA	 damage-response	
mechanisms205.	Stabilisation	of	TP53	increases	the	entry	of	glycolytic	intermediates	into	
the	pentose	phosphate	and	folate	pathway	by	modulation	of	key	enzymes206,207.	 In	this	
way,	 TP53	 can	 increase	 antioxidant	 production,	 although	 at	 the	 expense	 of	 ATP	
production.	Expression	of	TP53	is	also	important	for	the	assembly	and	function	of	COX	in	
the	ETC.	Loss	of	TP53	in	normoxia	results	in	a	similar	phenotype	observed	in	hypoxia	as	
the	malate-aspartate	shuttle	ceases	to	function	effectively208.		
Pseudo-hypoxia	 is	 the	 activation	 of	 the	 hypoxia	 response	 pathway	 under	 non-hypoxic	
conditions	which	 is	 commonly	 seen	 in	 cancers209,	 although	 this	has	not	been	 reported	
specifically	 in	 CRC	 to	 date.	 Defects	 in	 some	 TCA	 cycle	 enzymes	 lead	 to	 decreased	
hydroxylation	 of	 HIFα	 subunits	 and	 trigger	 the	 pseudo-hypoxia	 response210.	 Isocitrate	
dehydrogenase	(IDH)	is	mutated	in	glioma	and	acute	myeloid	leukaemia	(AML);	succinate	
dehydrogenase	(SDH)	and	fumarate	hydratase	(FH)	are	mutated	in	pheochromocytoma,	
para-ganglioma,	 leiomyoma,	and	renal	carcinoma188.	There	are	no	known	mutations	 in	
these	enzymes	in	CRC211.		
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Figure	1.10.	Cellular	effects	of	change	in	O2	tension.	As	a	result	of	changes	in	O2	tension	
there	are;	(A)	Changes	 in	pathways	as	a	result	of	changes	 in	O2	tension,	(B)	changes	 in	
specific	 proteins	 as	 a	 result	 of	 changes	 in	 O2	 tension	 and	 (C)	 changes	 in	 transcript	
expression152.	ROS,	reactive	oxygen	species;	PHD,	prolyl	hydroxylase	domain-containing	
protein;	OXPHOS,	oxidative	phosphorylation;	HIF,	hypoxia	inducible	factor;	LDHA,	lactose	
dehydrogenase	 A;	MCT4,	mono-carboxylate	 transporter	 4;	 HK2,	 hexokinase	 2;	 GLUT1,	
glucose	transporter	1;	PGAM,	phosphoglycerate	mutase;	TIGAR,	TP53	induced	glycolysis	
regulatory	phosphatase;	COX,	cytochrome	C	oxidase;	ALDH4,	aldehyde	dehydrogenase	4;	
PDK1,	pyruvate	dehydrogenase	kinase	1.		
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1.10. Mouse	models	of	colorectal	cancer	
Mouse	 models	 are	 often	 used	 to	 explore	 the	 influence	 of	 genetic	 changes	 on	 the	
development	of	CRC	as	well	as	effects	of	therapy.	Developing	the	ideal	mouse	model	for	
CRC	is	challenging.		
	
Despite	the	evolutionary	distance	between	mouse	and	humans,	the	genome	content	has	
largely	 been	 conserved212	 and	 most	 cancer	 pathways	 operate	 in	 both	 species213.	 The	
genomes	 of	 inbred	 laboratory	 mice	 are	 well	 characterised;	 they	 are	 considered	
homozygous	at	every	locus	and	are	housed	in	a	controlled	environment.	However,	there	
are	 some	 drawbacks.	 Inbred	 laboratory	 mice	 lack	 the	 genetic	 heterogeneity	 which	 is	
present	 in	 the	human	population;	human	tumours	are	more	heterogeneous	than	their	
mouse	 counterparts214,215.	 The	 lack	 of	 complexity	 poses	 problems	 when	 trying	 to	
recapitulate	 faithfully	 the	 human	 disease	 for	 pre-clinical	 studies	 particularly	 as	 the	
heterogeneity	 of	 human	 tumours	 results	 in	 greater	 potential	 for	 the	 development	 of	
resistance	 to	 therapy	 and	 for	 recurrence	 after	 surgical	 resection216.	 	 Humans	 also	
experience	a	more	varied	diet	and	have	a	different	microbiome	compared	to	the	mouse,	
which	 exposes	 human	 intestinal	 epithelial	 cells	 to	more	 exogenous	 genotoxins217.	 The	
difference	 in	 life	 span	 between	 man	 and	 mouse	 is	 also	 a	 problem.	 In	 man,	 the	
development	of	CRC	is	over	a	much	longer	period	compared	to	mouse,	and	mice	often	
become	anaemic	 as	 a	 consequence	of	 polyposis	 and	have	 to	be	 sacrificed	before	CRC	
develops218.	There	are	also	crucial	differences	in	telomere	maintenance	and	function219.	
Telomeres	 shorten	 with	 each	 mitotic	 cell	 division	 but	 are	 elongated	 by	 telomerase.	
Although	telomere	sequence	is	identical	in	mice	and	humans,	heterozygous	telomerase	
mutations	 in	humans	is	sufficient	to	result	 in	cancer	development,	but	 laboratory	mice	
lacking	 telomerase	 show	 no	 phenotype	 over	 several	 generations219.	 This	 is	 because	
laboratory	mice	telomeres	are	5	to	10	times	longer	than	humans	but	their	lifespan	is	30	
times	shorter.	It	is	also	well	known	that	the	immune	system	is	a	very	important	part	in	the	
development	of	cancer	and	therefore	the	use	of	a	whole	animal	system	could	be	the	key	
to	understanding	the	development	of	cancer.	However,	the	mouse	immune	system	is	not	
identical	 to	 the	 human	 immune	 system	 and	 this	 must	 be	 taken	 into	 account	 when	
interpreting	data	from	mouse	models	(reviewed	in220).	There	is	a	variety	of	mouse	models	
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commonly	used	to	investigate	polyposis	as	a	benign	precursor,	these	are	discussed	below.	
	
The	first	key	polyposis	mouse	model	was	the	multiple	intestinal	neoplasia	(Min)	mouse	
which	arose	from	a	random	ethylnitorsourea	(ENU)	mutagenesis	screen221,222.	The	ApcMin/+	
mouse	was	subsequently	recognised	as	a	paralog	for	human	FAP	syndrome	and	provided	
confirmation	of	 the	causal	gene	mutation	 in	sporadic	CRCs	with	5q21	deletions223.	The	
ApcMin/+	mouse	 is	 widely	 used	 in	 research	 today.	 More	 sophisticated	 knock-in	 and/or	
knock-out	mouse	models	enable	further	functional	study	of	genetic	mutations	involved	in	
CRC.	The	 cancer	genome	atlas	 (TCGA)	has	 identified	many	genes	which	are	 frequently	
mutated	in	many	different	types	of	malignancy,	often	referred	to	as	pan-cancer	genes,	
this	 suggests	 a	 role	 for	 these	 genes	 in	 the	 progression	 of	 cancer224.	 It	 is	 possible	 to	
introduce	genetic	mutations	 into	specific	 tissues	 in	mice;	 these	models	can	be	used	to	
determine	 if	mutations	are	passenger	or	driver	mutations225.	For	example,	 the	Apc1322T	
mouse	has	a	mutation	in	APC	specifically	in	the	bowel	(Figure	1.3).	The	use	of	Apc	mutant	
mice	 has	 increased	 our	 understanding	 of	 the	 role	 of	 Apc	 in	 the	 biology	 of	 CRC	
development,	for	example,	which	protein	domains	and	functions	of	Apc	are	responsible	
for	intestinal	tumour	initiation	and	maintenance.		Use	of	a	Cre-recombinase	driven	by	a	
specific	promoter	allows	excision	of	DNA	between	two	loxP	sites	in	a	given	tissue.		
	
Models	 which	 manipulate	 Apc	 alone	 generate	 adenomas	 in	 the	 small	 intestine,	
particularly	the	upper	part	of	the	small	intestine,	and	relatively	few	in	the	colon	or	rectum	
which	is	unfortunately	the	exact	opposite	of	the	human	disease.	The	short	lifespan	of	the	
ApcMin/+	and	the	Apc1322T	mouse	limits	the	utility	of	the	model.	A	number	of	different	Apc	
mutant	 mice	 were	 developed,	 but	 unlike	 their	 human	 counterparts	 the	 mice	 never	
develop	metastases.	 To	 try	 and	 recapitulate	metastases,	Apc	 mutant	mice	 have	 been	
crossed	to	mice	with	gene	mutations	found	in	the	later	stage	of	disease	including	TP53,	
transforming	 growth	 factor	 ß	 receptor	 2	 (TGFßR2),	 F-box	 and	 WD	 repeat	 domain	
containing	7	(FBXW7)	and	SMAD2-4,	however,	this	approach	did	not	yield	metastases.	At	
best	these	compound	mutants	displayed	more	adenocarcinomas.		However,	addition	of	
KRAS	mutation	post	APC	inactivation	can	lead	to	metastasis.	The	Apc^CKO/CKO	-LSL-KRAS	
mouse	(CKO	–	conditional	knock	out,	LSL	–	lox-stop-lox)	can	develop	distant	metastases	
to	the	liver	and	other	organs226.	The	iKAP	mouse	which	harbours	an	inducible	KRAS	allele	
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and	conditional	null	alleles	of	APC	and	TRP53	also	recapitulates	tumour	progression	to	
metastases227.		
	
Xenografts	are	another	type	of	mouse	model.	They	involve	the	injection	of	cell	 lines	or	
transplantation	of	primary	 tissue	 into	 immune-deficient	mice	 such	as	 the	nude	mouse	
(nu/nu)	to	prevent	rejection.	However,	the	results	must	be	interpreted	with	caution	due	
to	the	following	points:	xenograft	mouse	models	are	poor	representations	of	human	CRC,	
as	firstly,	the	host	is	immune	deficient	and	the	role	of	the	immune	system	is	important	in	
the	 development	 of	 CRC.	 For	 example,	 in	 CRC	 T-cell	 infiltrate	 is	 predictive	 of	 patient	
survival228	 and	 mice	 with	 deletion	 of	 SMAD4	 in	 T-cells	 excessively	 secrete	 pro-
inflammatory	cytokines	which	leads	to	the	development	of	gastrointestinal	tumours229.	
Secondly,	 few	cell	 lines	 lead	 to	 reliable	primary	 tumour	growth	and	even	 less	produce	
naturally	metastatic	CRC230.		Success	rates	are	highest	when	using	HCT116	and	HT29	cell	
lines	but	 it	 is	 not	understood	why216.	 Thirdly,	 orthotopic	 and	 subcutaneous	 xenografts	
show	differing	sensitivities	to	chemotherapeutic	agents231,232	and	site	of	injection,	mouse	
age	and	 the	 genetic	 background	of	 the	mouse	all	 dramatically	 affect	 the	 frequency	of	
lymph-node	or	 liver	metastases230,232,233.	This	suggests	that	the	microenvironment	 is	an	
important	determinant	of	therapeutic	response	and	metastatic	potential.		
	
The	 environment	 of	 a	 subcutaneous	 xenograft	 is	 very	 different	 from	 that	 of	
autochthonous	 tumours	 and	 the	 extent	 to	 which	 mismatch	 of	 tumour	 (human)	 and	
stromal	 (mouse)	 influences	 the	 growth	 of	 the	 tumour	 is	 uncertain216.	 Orthotopic	
xenografts	 introduce	 cells	 to	 a	 more	 natural	 environment,	 such	 as	 the	 serosa	 of	 the	
intestine,	and	these	models	do	result	in	more	reliable	liver	metastasis231.	Patient-derived	
orthotopic	 xenografts	 are	 another	 option.	 They	 avoid	 natural	 selection	 of	 dominant	
clones	and	epigenetic	 and	genetic	 alterations	 that	occur	during	 long-term	cell	 culture;	
however,	it	has	been	reported	that	the	host	cells	replace	the	human	stroma	which	was	
initially	transplanted	within	3	weeks234.	It	would	be	exciting	to	use	this	system	to	predict	
patient	response	to	therapy	and	development	of	resistance.	However,	this	would	require	
the	subculture	or	serial	xenografting	which	is	a	lengthy	process	and	too	long	to	benefit	
the	patient235.		The	two	major	limitations	of	xenograft	models	are	the	species	mismatch	
between	stroma	and	tumour	and	the	use	of	immune-deficient	hosts.	An	allograft	model	
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overcomes	both	of	these	issues.	Tumour	fragments	or	cell	 lines	derived	from	them	are	
grafted	to	a	genetically	identical	inbred,	immune	competent	mouse236.		
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1.11. Diabetes	
Diabetes	mellitus	 (DM)	 is	 a	 chronic	 disease	 caused	by	 dysregulated	 insulin	 production	
from	pancreatic	β-cells	leading	to	elevated	blood	glucose	(hyperglycaemia).	Insulin	works	
to	 promote	 the	 uptake	 of	 glucose	 into	 cells.	 Normal	 homeostatic	 control	maintains	 a	
blood	 glucose	 concentration	 of	 between	 4	 to	 8mM,	 with	 tissue	 levels	 of	 glucose	
commonly	 below	 2.5mM.	 In	 a	 diabetic	 individual,	 the	 pancreatic	 β-cells	 are	 either	
destroyed	culminating	in	type	1	diabetes	(T1D)	or	their	function	is	impaired	and/or	the	
body	does	not	react	to	 insulin	correctly	creating	T2D.	A	diabetic	 individual	has	a	blood	
glucose	concentration	above	and	beyond	7mmol/L.		
The	prevalence	of	 diabetes	has	been	 growing	 for	 the	past	 three	decades.	 In	 2016	 the	
World	Health	Organisation	(WHO)	published	a	global	report	on	diabetes	which	found	that	
there	were	422	million	adults	living	with	diabetes	in	2014;	in	1980	the	number	of	people	
living	with	diabetes	was	108	million237	(Table	1.5).	The	WHO	predicts	that	diabetes	will	be	
the	7th	leading	cause	of	death	by	2030238.	The	overall	risk	of	death	of	a	diabetic	person	is	
twice	 the	 risk	of	a	non-diabetic	person	due	 to	 its	association	with	a	wide	 range	of	 co-
morbidities	 and	 complications	 including	 Alzheimer’s239,	 Parkinson’s	 disease240,	
cardiovascular	disease241,	cancer242,	depression243,	kidney	problems244,	liver	failure245	and	
retinopathy246.	
A	 study	 published	 in	 the	 Lancet247	 highlighted	 the	worldwide	 burden	 of	 diabetes;	 the	
lowest	prevalence	of	diabetes	in	2014	was	in	Northwestern	Europe	(5%	for	women	and	
5.8%	for	men).	China,	India	and	USA	remained	the	top	three	countries	with	the	largest	
number	of	adults	with	diabetes	in	2014	which	is	not	surprising	as	they	have	the	largest	
populations.	The	Eastern	Mediterranean	region	had	the	highest	percentage	prevalence	of	
diabetes	in	2014.		
Diabetes	costs	the	National	Health	Service	(NHS)	in	the	UK	£14	billion	a	year,	10%	of	the	
total	budget248.	The	cost	of	drugs	and	treatments	alone	for	diabetics	in	England	has	risen	
by	56.3%	 from	£513.9	million	 in	2005/6	 to	£803.1	million	 in	2013/14249.	Prevention	of	
diabetes,	especially	T2D,	is	a	global	initiative	to	reduce	healthcare	costs250.		
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1.11.1. Type	1	diabetes	
T1D	 is	 also	 known	as	 insulin-dependent	diabetes	mellitus	 (IDMM)	or	 juvenile	diabetes	
where	 the	 pancreatic	 β-cells	 are	 destroyed	 by	 an	 autoimmune	 response251.	 T1D	often	
develops	suddenly	in	childhood	with	symptoms	of	fatigue	and	excessive	urine	excretion.	
Risk	factors	are	viral	infections	like	German	measles,	living	in	a	northern	climate,	genetics	
and	 children	 whose	 mothers	 had	 ill-functioning	 insulin	 receptors	 during	 pregnancy	
(gestational	diabetes)252.		
T1D	patients	require	 lifetime	treatment	with	exogenous	 insulin,	although	patients	with	
mutations	in	the	genes	encoding	the	sulfonylurea	receptor	(SUR)-1	and	Kir6.2	subunits	of	
the	potassium	ion	channel	that	regulates	insulin	secretion	are	given	sulfonylurea	drugs253.	
Newer	therapies	are	emerging	such	as	islet,	pancreas-kidney	and	stem	cell	transplants,	
but	these	therapies	are	a	long	way	from	general	clinical	use254.		
Sophisticated	 laboratory	 tests	 are	 required	 to	 distinguish	 between	 T1D	 and	 T2D	 it	 is	
difficult	to	find	accurate	global	prevalence	for	each.	One	study	suggests	that	T1D	is	most	
prevalent	in	Finland	(>60	per	100,000/year)	and	Sweden	(47	per	100,000/year),	whereas	
East	 Asia	 and	 native	 Americans	 have	 the	 lowest	 prevalence	 (approximately	 0.1–8	 per	
100,000/year)255.	Year	on	year,	the	average	age	of	onset	of	T1D	is	decreasing	along	with	
an	 increase	 in	 the	 numbers	 of	 patients	 diagnosed256	 suggesting	 that	 there	 are	 also	
contributing	environmental	factor(s)257.		
1.11.2. Type	2	diabetes	
Most	(90%)	diabetic	patients	have	T2D,	previously	called	non-insulin-dependent	diabetes	
mellitus	 (NIDMM)	 or	 adult-onset	 diabetes.	 T2D	was	 considered	 a	 disease	 of	 the	 adult	
population,	but	recently	many	more	cases	have	been	identified	in	children258.			
In	T2D,	 the	 function	of	 the	β-cells	 is	 impaired	and/or	 the	body’s	 response	 to	 insulin	 is	
compromised,	 resulting	 in	hyperglycaemia.	Major	 contributing	 factors	are	excess	body	
weight	and	physical	inactivity;	over	80%	of	T2D	patients	are	obese	(BMI>30).	Other	risk	
factors	 are	 high	 blood	pressure,	 having	 a	 close	 relative	with	 T2D	 and	high	 cholesterol	
levels.	A	diet	and	exercise	plan	can	offer	some	control	of	blood	glucose	in	the	short	term.	
However,	pharmacological	treatment	is	often	needed	in	the	long	term.	Metformin	is	first	
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line	 therapy	 for	 T2D,	 although	 further	 research	 is	 necessary	 to	 clarify	which	 drugs,	 or	
combinations	of	drugs,	have	the	most	durable	influence	in	modulation	of	blood	glucose	
levels.		
Detailed	prevalence	figures	for	T2D	are	hard	to	come	by.	The	majority	of	patients	with	
diabetes	 have	 T2D	 it	 can	 be	 suggested	 at	 T2D	 prevalence	 closely	matches	worldwide	
diabetes	prevalence	figures,	shown	in	Table	1.5	from	the	latest	Risk	Factor	Collaboration	
study	 in	2016247.	 This	 suggests	 that	 the	Eastern	Mediterranean	Region	has	 the	highest	
prevalence	and	the	African	Region	has	the	lowest	prevalence.		
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Table	1.5.	Estimated	prevalence	and	the	number	of	people	with	diabetes	over	18.	The	
rise	in	prevalence	is	thought	to	be	linked	to	the	worldwide	population	growing	and	ageing.	
Adapted	from247.	
	
	
	
	
	
	
	
	
	
	
	 	
	
WHO	Region	
Prevalence	(%)	 Number	(millions)	
1980	 2014	 1980	 2014	
African	Region	 3.1	 7.1	 4	 25	
Region	of	the	Americas	 5	 8.3	 18	 62	
Eastern	Mediterranean	Region	 5.9	 13.7	 6	 43	
European	Region	 5.3	 7.3	 33	 64	
South-East	Asia	Region	 4.1	 8.6	 17	 96	
Western	Pacific	Region	 4.4	 8.4	 29	 131	
Total	(includes	non-Member	States)	 4.7	 8.5	 108	 422	
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1.12. Mouse	models	of	diabetes		
Unfortunately,	there	is	no	single	animal	model	which	mirrors	the	human	T2D	condition	
fully.	The	most	 faithful	model	would	develop	 insulin	resistance,	pancreatic	dysfunction	
alongside	development	of	cardiovascular	disease.	There	are,	however,	mouse	models	that	
are	relevant	to	human	T2D.	Table	1.6	outlines	equivalent	blood	glucose	levels	needed	in	
human	and	mice	to	be	classified	as	normal,	pre-diabetic	or	diabetic.		
The	first	is	the	ob/ob	mouse	which	has	mutations	in	the	leptin	gene,	and	the	second	is	the	
db/db	mouse	which	has	mutations	in	the	leptin	receptor259,260.	Leptin	is	a	hormone	which	
is	 important	 in	 the	 control	 of	 appetite,	 it	 tells	 the	 brain	when	 enough	 food	 has	 been	
consumed	relative	to	demand261.	The	ob/ob	mouse	cannot	produce	 leptin,	 therefore	 it	
has	 an	 uncontrolled	 appetite	 and	 rapidly	 increases	 in	 weight	 compared	 to	 a	 healthy	
mouse,	developing	hyperinsulinemia,	hyperphagia	and	insulin	resistance	at	3-4	weeks262.	
Similarly	 the	db/db	mouse	 has	 an	 uncontrolled	 appetite;	 it	 becomes	 hyperinsulinemic	
within	2	weeks	of	life	and	develops	obesity	by	week	3	to	4,	followed	by	b-cell	failure	and	
hyperglycaemia	at	4-8	weeks263.	The	db/db	mouse	most	closely	mimics	human	T2D.	These	
models	are	most	commonly	used	to	assess	the	effect	of	obesity	on	the	development	of	
diabetes.		
A	 significant	 limitation	 of	 mouse	 models	 is	 the	 lack	 of	 similarity	 for	 islet	 pathology	
observed	 in	 humans	 with	 T2D.	 In	 these	 mouse	 models,	 diabetes	 manifests	 as	 a	
consequence	 of	 a	 failure	 to	 adequately	 increase	 b-cell	 mass	 in	 response	 to	 obesity-
induced	insulin	resistance264.	In	human	T2D	islet	amyloid	deposits	form	and	contribute	to	
failure	of	b-cells265.	
A	novel	model	of	diabetes	in	mice	was	recently	reported	by	Adam	et	al.	which	is	driven	
by	a	knock-out	of	Fh1	in	the	b-cells	of	the	pancreas266.	This	diabetic	model	used	a	tissue-
specific	 RipCre	 promoter	 to	 knock	 out	 Fh1	 in	 the	 β-cells	 of	 the	 pancreas	 by	
recombination267.	 Mice	 lacking	 Fh1	 in	 pancreatic	 β-cells	 exhibit	 Hif1α-independent	
glucose	 intolerance	 and	 show	 blood	 glucose	 levels	 consistent	 with	 those	 seen	 in	 an	
uncontrolled	type	2	diabetic	human268.	Interestingly,	mice	appear	normal	for	6-8	weeks,	
then	progressive	deterioration	of	b-cell	function	and	glucose	intolerance	occurs,	resulting	
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in	 severe	 diabetes	 associated	 with	 impaired	 oxidative	 metabolism,	 ATP	 production,	
intracellular	calcium	and	cytosolic	acidification.	This	work	highlighted	a	role	for	FH	in	T2D.		
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Table	1.6.	Normal,	pre-diabetic	and	diabetic	blood	glucose	values	(mmol/L)	for	human	
and	mouse269.		
Blood	glucose	 Human	(mmol/L)	 Mouse	(mmol/L)		
Normal	 5	 <8.3	
Pre-diabetic	 8	 8.3-13.9	
Diabetic	 10	 >13.9	
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1.13. The	link	between	diabetes	and	colorectal	cancer	
A	 positive	 association	 between	 diabetes	 and	 cancer	 has	 been	 noted	 since	 the	 early	
nineteen	hundreds270.	Since	then,	a	significant	amount	of	epidemiological	work	has	been	
completed,	but	 conclusions	 remain	mixed	and	 the	mechanistic	 links	between	diabetes	
and	cancer	remain	unclear.	T1D	and	T2D	should	be	considered	as	separate	diseases	with	
respect	to	risk	as	each	are	linked	to	different	types	of	cancers.		
Whilst	T1D	and	its	association	with	cancer	have	not	been	studied	in	as	much	detail	as	T2D,	
an	analysis	by	Zendenhel	et	al.	of	a	Swedish	cohort	 found	a	 two-fold	 increased	 risk	of	
stomach,	cervical	and	endometrial	cancer	in	patients	with	T1D271.	A	meta-analysis	study	
using	an	inclusion	criteria	of	<21	years	for	T1D	found	that	the	risk	of	cancer	was	higher	for	
females	than	males	and	that	patients	were	three	times	more	likely	to	get	stomach	cancer	
or	leukaemia,	and	five	times	more	likely	to	get	squamous	cell	skin	carcinomas	than	those	
without	T1D272.	By	contrast,	a	recent	review	of	all	the	available	epidemiological	evidence	
for	 T1D	 and	 cancer	 incidence	 and	 mortality273	 found	 no	 statistically	 significant	 link	
between	this	type	of	diabetes	and	any	cancer	in	case-control	studies.	Only	meta-analyses	
have	found	such	a	link,	highlighting	the	inconsistency	of	results	and	the	need	for	further	
research.		
T2D	patients	 have	 a	 greater	 risk	 of	 developing	 cancer	 compared	 to	 patients	with	 T1D	
which	is	thought	to	be	due	to	differences	in	insulin	exposure274–276.	T2D	is	most	strongly	
associated	with	an	increased	risk	of	liver	and	pancreatic	cancer276,277,	as	well	as	cancers	of	
the	digestive	tract278.	It	is	plausible	that	T2D	and	cancer	may	be	associated	without	any	
causal	link	due	to	the	overlapping	nature	of	both	environmental	and	lifestyle	risk	factors	
for	 both	 diseases279–281.	 Notably,	 Yuhara	 and	 colleagues	 suggested	 that	 T2D	 is	 an	
independent	 risk	 factor	 for	CRC	once	confounding	variables	 including	obesity,	 smoking	
and	physical	exercise	are	removed111.	
The	 increased	 risk	 of	 CRC	 for	 T2D	 patients	 has	 been	 highlighted	 by	 many	 meta-
analyses105,110,282–286.	Larsson	and	colleagues	completed	a	meta-analysis	of	15	studies	to	
include	over	2.5	million	patients	to	find	a	30%	increased	risk	of	developing	CRC	 in	T2D	
individuals	compared	to	non-diabetic	individuals282.		
	 72	
Sharma	 et	 al.	 2005	 showed	 that	 CRC	 patients	 with	 T2D	 have	 more	 serious	
histopathological	features	such	as	deeper	tumour	invasion	and	more	advanced	staging124.	
Diabetic	 patients	 are	 also	 at	 increased	 risk	 of	 CRC	 recurrence	 compared	 to	 non-
diabetics287.	Conflicting	evidence	exists	 regarding	disease	 specific	 and	overall	mortality	
with	some	studies	showing	poor	survival	in	diabetics287	and	others	showing	this	apparent	
mortality	 increase	 is	 in	 fact	 due	 to	 increased	 age	 and	 co-morbidities288.	 A	 systematic	
review	on	this	topic	concluded	that	the	current	evidence	remains	inconclusive	since	most	
studies	fail	to	account	for	raised	BMI	and	the	effect	of	co-morbidities289.		
Identification	 of	 biological	 mechanisms	 that	 link	 T2D	 to	 the	 development	 and/or	
potentiation	of	colorectal	tumours,	could	lead	to	preventative	and	therapeutic	options.	
Potential	mechanistic	links	between	T2D	and	CRC	are	discussed	below.		
1.13.1. Insulin	
Insulin	 resistance	 and	 hyperinsulinemia	 are	 both	 common	 in	 T2D	 patients.	 Insulin	
resistance	 occurs	when	 the	 body	 is	 unable	 to	 respond	 to	 insulin	 resulting	 in	 elevated	
insulin	 in	 the	 blood.	 Insulin	 resistance	 is	 the	main	 driver	 of	metabolic	 syndrome	 (the	
medical	term	for	a	combination	of	T2D,	obesity	and	high	blood	pressure),	which	is	linked	
to	CRC290.	Hyperinsulinemia	 is	 the	 release	of	 too	much	 insulin	 relative	 to	 the	 levels	of	
blood	glucose291.	This	promotes	activation	of	cellular	pathways	mediated	by	insulin	and	
the	 insulin-like	growth	 factors	 (IGF)292	 such	as	Akt,	phosphatidylinositol	3-kinase	 (PI3K)	
and	extracellular	signal-regulated	kinase	(ERK)	cascades	which	have	key	roles	in	diabetes	
and	cancer293.		
In	2006,	Tran	and	colleagues	showed	that	hyperinsulinemia	alone	is	associated	with	an	
increased	 risk	 of	 CRC;	 insulin	 dose	 dependently	 promoted	 proliferation	 of	 normal	
colorectal	 epithelial	 cells	 in	 vivo292.	 There	 is	 also	 a	 direct	 correlation	 between	
overexpression	 of	 insulin	 and	 IGF	 receptors	 with	 increased	 risk	 of	 CRC294	 as	 well	 as	
breast295,	lung,	and	prostate	cancer	and	a	polymorphism	in	the	IGF-1R	gene	is	associated	
with	advanced	CRC296.	
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1.13.2. Chronic	inflammation	
Metabolic	abnormalities	associated	with	diabetes	lead	to	an	increase	in	pro-inflammatory	
molecules	which	are	proven	to	have	cancer	promoting	roles	via	the	accumulation	of	DNA	
damage	 and	mutations297	 such	 as	 insulin,	 fatty	 acids,	 IL-6,	 and	 plasminogen	 activator	
inhibitor	(PAI)-1,	adiponectin,	leptin,	TNF-α,	free	radicals	and	ROS.		
There	are	many	 links	between	 inflammation	and	CRC.	 For	 example,	CRC	 cell	 lines	 and	
tumours	constitutively	express	nuclear	 factor	κB	(NFκB)	and	STAT-375,298,299.	Also,	 those	
that	have	severe	prolonged	active	IBD,	such	as	UC	and	CD,	have	a	greater	risk	of	CRC	than	
those	without	IBD75,	as	mentioned	in	Chapter	1,	Section	1.4.3.	
1.13.3. Reactive	oxygen	species	and	hyperglycaemia		
Cancer	 cells	 are	 known	 to	 depend	 on	 glycolysis	 for	 energy	 production	which	 requires	
glucose173.	 Therefore,	 a	 hyperglycaemic	 environment	 is	 ideal	 for	 cancer	 promotion.	
Glucose	promotes	cellular	signalling	pathways	such	as	proliferation,	migration,	invasion	
and	recurrence277,300.	Furthermore,	high	glucose	levels	can	alter	epigenetic	modulations	
of	oncogenic	pathways	and	result	in	prolonged	activation	of	cancer	cell	proliferation301.	A	
significant	association	between	high	fasting	serum	glucose	levels	and	increased	risk	of	CRC	
has	been	found	in	a	Korean	study302.	However,	when	cancer	cells	in	vitro	are	deprived	of	
glucose,	most	conventional	cytotoxic	anticancer	agents	lose	their	effectiveness303.		
Hyperglycaemia	 in	 insulin-independent	 tissues	 leads	 to	 an	 increase	 in	 substrates	 for	
glycolysis	 as	 well	 as	 the	 TCA	 cycle,	 which	 in	 turn	 increases	 the	 propensity	 for	
mitochondrial	ROS	production	(Chapter	1,	Section	1.8).	Therefore,	it	could	be	suggested	
that	ROS	generated	as	a	result	of	hyperglycaemia	could	be	linked	to	CRC	in	T2D	patients.		
1.13.4. Impaired	mitochondrial	function	
Defects	 in	 mitochondrial	 morphology,	 fission,	 fusion,	 biogenesis	 and	 oxidative	
phosphorylation	are	associated	with	T2D304.	 Studies	have	been	 completed	on	heart305,	
skeletal,	adipose	and	renal306	tissue	as	these	are	the	most	relevant	for	complications	of	
T2D.	Mitochondria	 in	 skeletal	muscle	of	 T2D	compared	 to	non-diabetic	 individuals	 are	
smaller	 in	 size,	 at	 a	 lower	 density	 and	 have	 impaired	 function307,308.	 In	 adipose	 tissue,	
mitochondrial	dysfunction	leads	to	an	increase	in	fatty	acid	release	as	well	as	increased	
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release	 of	 inflammatory	 cytokines	 both	 of	which	 are	 linked	 to	 cancer309,310.	 Adipocyte	
mitochondrial	dysfunction	in	T2D	has	been	linked	to	FH	as	well	as	succination	which	will	
both	be	explored	in	later	sections	(Section	1.13.6)	310,311.	It	is	interesting	to	note	that	in	
mice,	knocking	out	FH	in	the	b-cells	of	the	pancreas	generates	a	diabetic	phenotype266.	
Overall,	 impaired	 mitochondrial	 function	 generates	 ROS	 which	 can	 cause	 genetic	
instability.	Currently,	there	is	no	evidence	showing	mitochondrial	dysfunction	in	the	gut	
of	T2D	patients.		
1.13.5. Fumarate	hydratase	
FH	has	previously	been	linked	to	both	mitochondrial	dysfunction	and	cancer312.	FH	was	
first	discovered	by	Einbeck	in	1919313,	and	is	conserved	from	yeast	to	humans.	In	human	
cells,	the	gene	is	localised	at	1q42.1	and	expressed	as	a	homotetramer	in	mitochondrial	
and	cytosolic	compartments,	these	enzymes	are	encoded	by	the	same	transcript,	but	are	
differentially	processed314.	Protein	localisation	is	effected	by	cleavage	of	the	propeptide	
into	 two	peptides,	one	 retaining	 the	N-terminal	mitochondrial	 targeting	 sequence	and	
one	that	is	released	into	the	cytoplasm.	In	the	mitochondria	FH	participates	in	the	TCA	
cycle	 (Figure	 1.7),	 where	 it	 catalyses	 the	 stereospecific	 hydration	 across	 the	 olefinic	
double	 bond	 in	 fumarate	 to	 form	 L-malate.	 In	 the	 cytosol,	 FH	 controls	 the	 levels	 of	
fumarate	 produced	 by	 the	 urea	 cycle	 (Figure	 1.11)	 and	 amino	 acid	 catabolism,	 by	
conversion	 to	malate	which	 in	 turn	provides	 increased	 substrate	 for	 the	generation	of	
cytosolic	NADPH	though	the	malic	enzyme	reaction168.	Cytosolic	FH	also	acts	as	a	DNA	
damage	response	protein;	upon	double	strand	breaks	 in	DNA,	cytosolic	FH	 is	 recruited	
into	the	nucleus	to	aid	with	DNA	repair315.	Cytoplasmic	FH	is	present	in	all	tissues	except	
from	the	brain314.	
FH	behaves	as	a	tumour	suppressor	and,	specifically,	the	cytoplasmic	form	is	considered	
responsible	 for	 this	role315,316.	Loss	or	 inactivation	of	cytosolic	FH	causes	an	 increase	 in	
fumarate,	leading	to	genomic	instability	and	accumulation	of	HIF-1α		subunits317,318	(Figure	
1.12).	A	total	of	55	mutations	have	been	described	to	date	from	work	on	patients	with	
cutaneous	 leiomyoma,	 FH	 deficiency,	 hereditary	 leiomyomatosis	 and	 renal	 cell	 cancer	
(HLRCC),	 Leydig	 cell	 tumours,	 multiple	 cutaneous	 and	 uterine	 leiomyomas,	 ovarian	
mucinous	cyrstadenoma,	renal	cell	carcinoma,	soft	tissue	sarcoma,	uterine	leiomyomas	
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and	uterine	leiomyosarcoma319.	The	crystal	structure	of	FH	reveals	that	mutations	can	be	
grouped	 into	 two	 distinct	 classes:	 1)	 affecting	 structural	 integrity;	 or	 2)	 affecting	 the	
enzyme	active	site319.	The	most	common	mutations	in	FH	are	missense	(57%),	and	then	
frameshift	and	nonsense	(27%),	but	there	are	also	deletions,	insertions	and	duplications	
found319.		
Fh1	deficient	mice	cells	were	found	to	use	accumulated	TCA	cycle	metabolites	to	generate	
haem,	which	is	then	degraded	to	bilirubin,	creating	mitochondrial	NADH	to	generate	ATP	
by	OXPHOS.	Recently,	Adam	et	al.	have	shown	that	KO	of	Fh1	 in	pancreatic	ß-cells	can	
generate	a	diabetic	state	in	mice266.	It	has	also	been	shown	that	Fh1	deficient	cells	can	use	
glutamine	 to	 generate	 citrate	 and	malate	 by	 performing	 reductive	 carboxylation	 of	 α-
ketoglutarate	 to	 isocitrate.	 This	 process	 then	 provides	 the	 anabolic	 building	 blocks	
allowing	cell	proliferation320.	Additionally,	Fh1	deficient	mice	and	media	from	FH-deficient	
cell	 lines	 were	 found	 to	 excrete	 increased	 amounts	 of	 fumarate	 and	 arginosuccinate	
compared	 to	 their	WT	 counterparts321.	 This	 was	 found	 to	 be	 a	 result	 of	 the	 reversed	
activity	of	the	urea	cycle	enzyme	arginosucinnate	lyase	(Figure	1.11).	Concentrations	of	
fumarate	of	around	10mm	in	Fh1	deficient	cells	were	recently	found	to	inhibit	complex	II	
in	OXPHOS	by	product	inhibition322.	 	Despite	the	defects	in	the	respiratory	chain,	these	
cells	 had	 a	 high	mitochondrial	membrane	 potential	 and	 can	 resist	 conditions	 that	 are	
unfavourable	for	mitochondrial	function,	including	hypoxia,	which	suggests	that	the	loss	
of	FH	expression	could	be	selected	for	during	tumour	progression.		
HLRCC	tumours	with	FH	mutation	show	an	upregulation	of	HIF-1α	and	associated	target	
genes317,323,324.	 In	mice,	 inactivation	 of	 Fh1	 (murine	 FH)	 causes	 proliferative	 renal	 cyst	
development	and	activation	of	the	hypoxia	pathway325.	Using	HCT116	CRC	cells,	Yogev	et	
al.,	2010,	showed	that	irradiation	induced	more	cell	death	with	short	hairpin	RNA	(shRNA)	
lentiviral	 knock	down	of	 FH.	 In	mouse	embryonic	 fibroblasts	 (MEFs),	 knock	out	of	 Fh1	
leads	to	increased	lactate	production	due	to	a	shift	towards	glycolysis	driven	metabolism	
via	upregulation	of	HIF-1α	protein	levels	and	subsequent	HIF-1	target	gene	upregulation	
(HK2,	LDHA,	GLUT1),	even	though	there	is	a	reduction	of	mitochondrial	respiration	by	80%	
compared	 to	wild	 type	MEFs316.	 It	has	 recently	been	 shown	 that	FH	binding	 to	double	
strand	breaks	(DSB)	is	dependent	on	DNA-dependent	protein	kinase	(DNA-PK)-regulated	
phosphorylation	of	FH	and	the	binding	of	FH	to	histone	H2A.Z326.	One	paper	suggests	that	
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FH	acts	like	an	oncogene	with	elevated	enzymatic	activity	in	acute	monocytic	leukaemia,	
moderately	 increased	 enzymatic	 activity	 in	 acute	 granulocytic	 leukaemia,	 but	 not	
significantly	elevated	in	acute	lymphocytic	leukaemia327.	Moreover,	FH	activity	was	higher	
in	the	acute	than	the	chronic	phase	of	all	three	types	of	leukaemia.	There	are	no	known	
mutations	of	FH	in	CRC	patients328.	Although,	one	paper	found	that	mRNA	levels	of	FH	are	
reduced	in	CRC329.	
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Figure	1.11.	Urea	cycle.	A	cycle	of	biochemical	reactions	that	produce	urea	from	ammonia	
in	the	cytosol330.		
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1.13.6. Fumarate		
Dysregulated	metabolism	is	a	designated	hallmark	of	cancer331	(Chapter	1,	Section	1.9).	
Fumarate	 is	 an	 oncometabolite332,333	 and	 can	 accumulate	 to	 millimolar	 levels	 in	 FH-
deficient	 tissues334.	 Increased	 levels	 of	 fumarate	 have	 been	 found	 in	 CRC	 patient	
samples335,	 even	 though	 there	 is	 no	 evidence	 of	 FH	 mutation(s).	 Fumarate	 is	 a	 key	
component	of	the	TCA	cycle,	where	it	is	converted	to	malate	by	FH.		Elevated	fumarate	
has	multiple	cellular	consequences	(Figure	1.12).		
Fumarate	 inhibits	ten-eleven-translocation	(TET)	5-methylcytosine	(5-mC)	dioxygenases	
which	are	2-oxoglutarate	dependent	dioxygenases	(OGDD)336	.	They	convert	the	5-mC	in	
DNA	 sequentially	 to	 5-hmC	 to	 5-formylcytocine	 to	 5-carboxylcytocine,	 leading	 to	 DNA	
methylation.	 2-OGDDs	 other	 functions	 are	 oxygen	 sensing	 (via	 HIF-1α),	 collagen	
maturation	and	regulation	of	translation.	Fumarate,	succinate	and	R-2-hydroxyglutarate	
are	 2-OGDD	 analogues	 and	 competitively	 inhibit	 several	 2-OGDDs	 with	 respect	 to	 2-
oxoglutarate.	 Fumarate	 competitively	 inhibits	 the	 2-OGDDs	 that	 catalyse	 HIF	 prolyl	
hydroxylation	leading	to	stabilisation	of	HIF-1α	and	activation	of	HIF-dependent	pathways	
including	glucose	metabolism332.		
Fumarate	 can	modify	 cysteine	 residues	 in	 proteins	 via	 an	 irreversible	 process	 termed	
‘succination’333	 (Figure	 1.12).	 Alderson	 et	 al.	 2006	 first	 described	 the	 process	 of	
succination	which	is	chemical	modification	of	proteins	to	form	S-(2-succino)	cysteine	(2-
SC)	by	a	Michael	addition	reaction	that	generates	a	thioether	bond	between	fumarate	and	
the	cysteine	sulphydryl	group337.		
Succination	can	have	an	inhibitory	effect	e.g.,	inactivation	of	glyceraldehyde	3-phosphate	
dehydrogenase	 (GAPDH)	 in	 muscle	 of	 type	 1	 diabetic	 rats	 or	 preventing	 the	
polymerisation	 and	 secretion	 of	 adiponectin	 from	 type	 2	 diabetic	 mouse	 adipose	
tissue338,339.	The	proteins	which	undergo	succination	are	identified	by	mass	spectrometry.	
Some	known	examples	include	inactivation	of	the	glycolytic	enzyme	GAPDH	both	in	vivo	
and	 in	vitro338;	 impaired	enzymatic	activity	of	mitochondrial	aconitase	and	inhibition	of	
the	Kelch-like	ECH-associated	protein	(KEAP)-1	which	abrogates	 its	 interaction	with	the	
transcriptional	 factor	Nuclear	 factor	 (erythroid-derived	2)-like	2	 (NRF2)	 resulting	 in	 the	
constitutive	activation	of	the	potentially	oncogenic	NRF2-mediated	antioxidant	defence	
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pathway340.	Fumarate	can	also	succinate	glutathione	(GSH)	to	form	a	compound	which	
depletes	intracellular	NADPH	and	enhances	oxidative	stress	leading	to	cellular	senescence	
in	 non-transformed	 cells341.	 The	 overall	 effect	 of	 2-SC	 modifications	 is	 currently	 not	
understood	 fully;	 however,	 is	 likely	 to	be	 cell	 specific.	As	 succination	 is	 an	 irreversible	
process	the	effect	on	the	cell	is	dependent	on	the	half-life	and	transcription	turnover	of	
the	succinated	proteins	in	relation	to	the	level	of	fumarate,	as	well	as	how	necessary	the	
proteins	affected	are	for	cell	function.		
It	has	been	shown	that	2-SC	is	significantly	increased	in	adipocytes	treated	with	30mM	
glucose	 versus	 5mM	glucose339.	Undifferentiated	 fibroblasts	 cultured	 in	 the	 same	high	
glucose	media	did	not	exhibit	 an	 increase	 in	 succination339	whereas	differentiated	3T3	
fibroblasts	do	exhibit	increased	succination	under	30mM	glucose310.	Frizzell	et	al.	showed	
that	3T3	cells	treated	with	30mM	glucose	compared	to	5mM	showed	significant	increase	
in	 cellular	 ATP/adenosine	 diphosphate	 (ADP),	 NADH/NAD+,	 mitochondrial	 membrane	
potential,	cellular	fumarate	concentration	as	well	as	succination	of	proteins310.	This	was	
postulated	to	be	attributed	to	the	inhibition	of	NAD+-dependent	dehydrogenases	due	to	
increase	in	NADH/NAD+	ratio.	Chemical	uncouplers	which	reduce	the	NADH/NAD+	ratio	
decreased	the	cellular	fumarate	concentration	and	succination.	Addition	of	metformin	(an	
inhibitor	of	complex	I	in	the	ETC)	to	high	glucose	caused	a	further	increase	in	fumarate	
and	 succination.	 The	 conclusion	of	 the	 study	was	 that	 excess	 nutrients	 in	 the	 form	of	
glucotoxicity	creates	a	pseudo	hypoxic	environment	(high	NADH/NAD+)	which	drives	the	
increase	in	succination.		Subsequent	in	vivo	studies	indicate	that	increased	succination	in	
adipocytes	 from	 db/db	 and	 ob/ob	 mice342	 (two	 mouse	 models	 of	 human	 diabetes	
(Chapter	1,	Section	1.12))	and	in	the	skeletal	muscle	(gastrocnemius)	of	streptozotocin-
induced	diabetic	rats333	is	associated	with	glucotoxicity-driven	mitochondrial	stress310,343.	
Increased	succination	of	KEAP1	and	aconitase	2	(ACO2)	has	been	described	in	renal	cell	
carcinoma	models	which	are	derived	from	FH	mutations344,345.		
The	role	of	fumarate	in	renal	disease	has	been	well	investigated.	The	UOK262	cell	line	was	
derived	from	a	patient	with	HLRCC	and	has	an	 inactive	FH	and	therefore	high	 levels	of	
fumarate346.	These	cells	are	dependent	on	glycolysis	for	survival	and	display	undetectably	
low	mitochondrial	oxygen	consumption	and	therefore	provide	a	model	for	the	study	of	
the	Warburg	effect	in	human	cancer.	It	was	also	found	in	mice	that	the	loss	of	Fh1	in	renal	
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cells	promotes	the	formation	of	cysts	as	a	result	of	increased	succination;	specifically,	the	
modification	of	cysteine	residues	within	KEAP1,	removing	its	ability	to	repress	the	NRF2	
mediated	 antioxidant	 response	 pathway347.	 Normalisation	 of	 fumarate	 levels	 in	 the	
cytosol	by	re-expression	of	cytoplasmic-specific	Fh1	rescues	the	defects	associated	with	
renal	specific	Fh1	deletion	in	the	mice347	suggesting	that	the	addition	of	Fh1	is	enough	to	
quench	the	succination.	Other	evidence	for	the	role	of	succination	in	disease	is	found	in	a	
mouse	model	of	cardiac	disease.	Elevated	fumarate	in	Fh1	cardiac	knockout	mice	greatly	
reduced	the	amount	of	heart	tissue	damage	following	ischemic-reperfusion	injury348.	This	
is	achieved	by	diverting	amino	acids	 into	the	Krebs	cycle,	 thus,	maintaining	ATP	 levels,	
stabilising	NRF2	and	activating	the	NRF2	antioxidant	pathway.	
Fumarate	has	also	been	proven	to	have	a	role	as	an	epigenetic	modifier	in	the	context	of	
HLRCC349.	Fumarate	 inhibits	 the	Tet-mediated	demethylation	of	a	 regulatory	section	of	
the	 miRNA	 cluster	 mir-200ba429	 which	 is	 anti-metastatic,	 leading	 to	 promotion	 of	
epithelial	 to	mesenchymal	 transition	 (EMT)349.	 This	 in	 turn	 promotes	 cancer	 initiation,	
invasion	and	metastasis350.	
Interestingly,	 oral	 administration	 of	 fumarates	 such	 as	 dimethylfumarate	 (DMT)	 and	
mono-methylfumarate	 (MMF)	 improve	multiple	 sclerosis	 (MS)	 and	psoriasis351.	DMT	 is	
Food	and	Drug	Association	(FDA)	approved	for	the	treatment	on	MS	and	psoriasis352,353.	
Ghoreschi	et	al.	2011	describe	a	mechanism	which	results	in	glutathione	(GSH)	depletion	
and	 leads	 to	 induction	of	 type	 II	dendritic	cells	and	reduction	of	 IL-12	and	 IL-23354	and	
therefore	 improvement	 of	 psoriasis	 and	MS	 symptoms.	 Later	 it	 was	 found	 that	MMF	
which	 is	the	 immediate	metabolite	of	DMT	can	modify	KEAP1,	the	 inhibitor	of	NRF2	at	
cysteine	residue	151355.	DMF	treatment	has	also	been	shown	to	sensitise	cells	in	hypoxia	
to	radiation	treatment356.	Most	recently	DMF	has	been	shown	to	ameliorate	pulmonary	
arterial	 hypertension	 and	 lung	 fibrosis357.	 Grzegorzewska	 et	 al.	 2017	 suggest	 that	 the	
action	of	DMF	is	by	inhibition	of	pro-inflammatory	NFκB,	STAT3	and	cJUN	signalling	as	well	
as	reduction	if	pro-fibrogenic	mediators	specificity	protein	1	(Sp1),	tafazzin	(TAZ)	and	β-
catenin357.	However,	a	small	epidemic	of	severe	contact	dermatitis	cases	in	Finland	and	
the	UK	was	attributed	to	DMF358.	The	effects	of	DMF	in	MS,	psoriasis,	pulmonary	arterial	
hypertension	and	lung	fibrosis	are	not	confirmed	as	succination.	Nevertheless,	the	link	is	
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possible	due	to	the	wide-reaching	effects	of	the	drug.	It	has	also	been	previously	shown	
that	DMF	and	MMF	increase	succination	in	adipocytes359.	
The	key	 to	understanding	 these	 roles	of	 fumarate	as	either	an	oncometabolite	or	as	a	
protective	 agent	 may	 lie	 in	 its	 cellular	 context,	 concentration	 and	 its	
compartmentalisation	in	the	mitochondria	and	cytosol.		
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Figure	1.12.	Cellular	effects	of	fumarate.	(A)	Preventing	ubiquitination	of	2-OGDDs	such	
as	 PHDs	 leading	 to	 stabilisation	 of	 HIF-1α	 and	 activation	 of	 HIF-dependent	 pathways	
including	glucose	metabolism332.	(B)	Epigenetic	changes.	Fumarate	can	inhibit	TETs	and	
KDMs	 leading	 to	 alterations	 in	 gene	 expression360.	 (C)	 Succination.	 The	 irreversible	
generation	of	a	thioether	bond	between	fumarate	and	the	cysteine	sulphydryl	group	to	
create	2-SC337.	2-OGDD,	2-oxoglutarate-dependent	dioxygenase;	PHD,	prolyl	hydroxylase;	
HIF,	 hypoxia	 inducible	 factor;	 TET,	 ten-eleven	 translocation	 enzyme;	 KDM,	 lysine	
demethylase;	2-SC,	S-(2-succino)	cysteine.		
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1.14. Mouse	models	of	colorectal	cancer	and	diabetes	
To	study	the	interaction	between	CRC	and	T2D	in	a	whole-body	system,	it	is	necessary	to	
use	animal	models	to	complement	findings	from	human	tissues.	There	are	no	published	
models	of	polyposis,	as	a	benign	early	lesion	of	CRC,	combined	with	T2D	in	mice.	There	
are,	however,	models	of	CRC	and	obesity	which	can	further	inform	us	on	the	link	between	
T2D	and	CRC	development.	Obesity	 is	a	major	risk	factor	for	T2D,	80%	of	patients	with	
T2D	are	obese361	(Chapter	1,	Section	1.4.9).	Haha	et	al.	2011	developed	a	spontaneous	
animal	model	of	obesity	with	adenoma	formation	in	the	intestinal	tract	by	crossing	the	
db/m	mice	with	ApcMin/+	mice,	then	backcrossing	the	offspring	with	db/m	mice	to	obtain	
db/db-ApcMin/+	mice.	They	found	that	the	total	number	of	tumours	was	larger	in	db/db-
ApcMin/+	mice	than	db/m-ApcMin/+	and	m/m-ApcMin/+	mice.	Another	study362	used	a	double-
mutant	F1	offspring	obtained	by	crossing	a	mouse	model	 for	 intestinal	 tumourigenesis	
(C57BL/6J-ApcMin/+)	and	a	mouse	model	for	obesity	(C57BL/6J-Lepob/+)	that	is	heterozygous	
for	the	obese	(ob)	mutation	in	the	 leptin	(lep).	This	compound	mutant	mouse	becomes	
obese	with	a	homozygous	mutation	(ob/ob)	as	it	lacks	functional	leptin	hormone363,364	that	
regulates	 food	 intake	 and	 energy	 expenditure.	 Ob/ob	 mice	 exhibit	 a	 hyperphagia,	 a	
transient	 diabetes-like	 syndrome	 of	 hyperglycaemia	 and	 glucose	 intolerance,	 elevated	
plasma	insulin,	subfertility,	impaired	wound	healing	and	increased	hormone	production	
from	 the	 pituitary	 and	 adrenal	 glands,	 as	 well	 as	 being	 hypo	 metabolic	 and	
hypothermic365.	To	study	environmentally-induced	obesity	they	fed	the	F1	mice	either	a	
45%	 fat	 diet	 or	 a	 control	 10%	 fat	 diet	 as	 adults.	 	 They	 concluded	 that	 homozygous	
mutation	 in	 the	ob	 gene	 significantly	 increased	 the	 number	 of	 spontaneous	 intestinal	
tumours,	suggesting	an	 inherent	 link	between	food	 intake,	hyperinsulinemia	and	polyp	
formation.	A	diet	of	45%	fat	also	increased	the	number	of	tumours	in	all	mice.	Prolonged	
blood	glucose	levels	correlate	with	the	number	of	tumours.			
It	is	not	possible	to	determine	a	mechanistic	link	between	T2D	and	CRC	from	these	studies,	
as	they	do	not	mirror	the	human	situation.	An	ideal	model	would	mirror	the	progressive	
properties	 of	 diabetes	 alongside	 spontaneous	 development	 of	 CRC	 in	 the	 absence	 of	
obesity.	However,	this	is	unlikely	to	be	possible	due	to	the	inherent	short	lifespan	of	mice.	
Although,	 generating	 a	 model	 by	 crossing	 the	 Fh1flox/flox	 RipCre	 CAGFH	mice268	 (Chapter	 1,	
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Section	1.10)	with	Apc1322T+/-	mice366	(Chapter	1,	Section	1.12)	may	offer	some	insight	into	
a	possible	link	between	polyposis	and	T2D.		
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1.15. Hypothesis	and	aims	
	
My	overarching	hypothesis	was	that	patients	with	type	2	diabetes	are	more	likely	to	go	to	
develop	 CRC	 or	 have	 a	 recurrence	 of	 CRC	 due	 to	 protein	 malfunction	 as	 a	 result	 of	
succination.		
	
My	hypotheses	were:	
• Increased	levels	of	2-SC	in	normal,	adenoma	and	CRC	tissue	from	type	2	diabetic	
patients	compared	to	non-diabetic	patients	due	to	a	lack	of	or	inactive	FH	in	this	
population.		
• 2-SC	 levels	 would	 be	 higher	 in	 KRAS/BRAF	 mutant	 CRC	 tissue	 compared	 to	
KRAS/BRAF	WT	CRC.	
• Mice	with	diabetes	will	have	more	and/or	larger	polyps	compared	to	non-diabetic	
mice	and	mice	with	overexpression	of	FH	will	have	fewer	and/or	smaller	polyps.	
• Diabetes	may	alter	the	cellular	profile	of	the	gut.		
• Fumarate	concentration	will	be	highest	in	CRC	cells	held	in	hypoxia	compared	to	
normoxia	and	cultured	in	glucose	compared	to	no	glucose.		
• FH	 concentration	 will	 be	 highest	 in	 CRC	 cells	 held	 in	 normoxia	 compared	 to	
hypoxia	and	cultured	in	no	glucose	compared	to	glucose.		
• FH	activity	will	be	highest	in	CRC	cells	held	in	hypoxia	compared	to	normoxia	and	
cultured	in	glucose	compared	to	no	glucose.		
• Expression	 of	 genes	 involved	 in	 glycolysis	 will	 be	 highest	 in	 CRC	 cells	 held	 in	
hypoxia	compared	to	normoxia	and	cultured	in	glucose	compared	to	no	glucose.	
• Expression	of	genes	involved	in	mitochondrial	metabolism	will	be	highest	in	CRC	
cells	held	in	normoxia	compared	to	hypoxia	and	cultured	in	no	glucose	compared	
to	glucose.		
• The	 number	 of	 mitochondria	 will	 be	 highest	 in	 CRC	 cells	 held	 in	 normoxia	
compared	 to	 hypoxia	 and	 cultured	 in	 no	 glucose	 compared	 to	 glucose	 and	
mitochondrial	 oxygen	 consumption	 rate	 will	 be	 highest	 in	 CRC	 cells	 held	 in	
normoxia	compared	to	hypoxia	and	cultured	in	no	glucose	compared	to	glucose.		
• In	a	xenograft	model	of	CRC,	cetuximab	reduces	 the	efficacy	of	oxaliplatin	and	
that	DUOX2	and	DUOXA2	expression	is	increased	with	oxaliplatin	treatment,	and	
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reduced	 with	 cetuximab	 treatment	 and	 DUOX2	 expression	 is	 increased	 with	
oxaliplatin	treatment,	and	reduced	with	cetuximab	treatment.		
• CRC	 xenografts	 treated	 with	 cetuximab	 and	 oxaliplatin	 would	 have	 more	
proliferating	cells.		
My	aims	were:	
• To	 test	 a	 panel	 CRC,	 adenoma	 and	 normal	 tissue	 from	 non-diabetic	 and	 T2D	
individuals	for	the	presence	of	2-SC.	
• To	 test	 a	 panel	 CRC,	 adenoma	 and	 normal	 tissue	 from	 non-diabetic	 and	 T2D	
individuals	for	the	presence	of	FH.	
• To	examine	whether	KRAS/BRAF	mutation	in	CRC	is	linked	to	2-SC	staining	score.	
• Create	 and	 a	 phenotype	 a	 mouse	 model	 predisposed	 to	 both	 diabetes	 and	
intestinal	polyposis.	
• Overexpress	FH	as	a	rescue	of	diabetes	in	the	diabetic/polyposis	mouse	model.	
• To	generate	an	in	vitro	model	of	CRC	and	T2D	and	characterise:	
o Concentration	of	fumarate.	
o Amount	and	activity	of	FH.	
o Changes	in	gene	expression.		
o Amount	and	activity	of	mitochondria.		
• Generate	a	xenograft	mouse	model	using	DLD1	cells.	Treat	with	oxaliplatin	and/or	
cetuximab.		
• Analyse	DUOX2	 and	DUOXA2	 gene	 expression	 by	 RT-PCR,	 and	 DUOX2	 protein	
expression	by	IHC.		
• Assess	 the	proliferation	and	apoptotic	 status	of	 cells	within	xenograft	 tumours	
using	Ki67	and	caspase	3	staining.		
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Chapter	2	–	Materials	and	Methods	
2.1	Materials	and	Methods	for	Chapter	3	
2.1.1	Tissue	collection	
Human	 normal	 gut	 mucosa	 and	 CRC	 samples	 were	 obtained	 from	 The	 Royal	 London	
Hospital	 Pathology	Department.	 Ethical	 approval	 for	 this	 study	was	obtained	 from	 the	
local	Human	Research	Ethics	Committees	(REC	reference	13/LO/1271).		
2.1.2	Immunohistochemistry	to	detect	succination	
Immunohistochemistry	 (IHC)	 was	 carried	 out	 using	 the	 EnVision	 kit	 (Dako).	 2-SC	 was	
detected	with	an	antibody	which	is	not	commercially	available	(gift	from	Norma	Frizzell,	
University	of	South	Carolina)	and	FH	with	Autogen	Bioclear,	#NE054.	Both	were	used	at	
1:2000	following	3	minutes	of	microwaving	with	citrate	buffer	pH6	then	10	minutes	in	a	
pressure	cooker.	
2.1.3	Immunohistochemistry	scoring	after	2-SC	antibody	staining	
Following	IHC	with	2-SC	antibody	(see	2.1.2),	stained	sections	were	scored	on	a	numerical	
scale	by	Consultant	histopathologist	Professor	Roger	Feakins	(The	Royal	London	Hospital,	
Whitechapel,	 London,	UK).	RF	was	blinded	 to	 the	diabetic	 status	of	 the	patients	when	
scoring	 the	 stained	 sections.	 Scoring	 was	 based	 on	 a	 standard	 scoring	 protocol:	
percentage	 of	 epithelial	 cells	 at	 each	 of	 three	 staining	 intensity	 levels	 (1-	 3;	 low,	
immediate	and	strong)	and	a	weighted	score	generated	using	the	formula	(1x1	+	2x2	+	
3x3).	Analysis	involved	paired	matched	normal	and	tumour	values.	The	positive	controls	
were	 kidney	 samples	 from	 HLRCC	 patients	 (positive	 for	 2SC	 because	 of	 loss	 of	 FH	
activity)334.	There	was	no	non-specific	staining	observed.	Negative	controls	were	primary	
alone	and	secondary	alone.	Reproducibility	was	tested	by	conducting	repeat	2-SC	IHC	on	
10	cases	both	N	and	T	(20	sections).	No	significance	difference	was	identified	(N	versus,	
0.4122;	T	versus	T,	0.4392;	t-test)	indicating	good	reproducibility	in	2-SC	staining.	
2.1.4	DNA	extraction		
DNA	was	extracted	from	formalin	fixed	paraffin	embedded	(FFPE)	sections	using	QIAamp	
DNA	FFPE	Tissue	Kit	(Qiagen,	#56404)	according	to	manufacturer’s	protocol.	Or	DNA	was	
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extracted	from	frozen	tissue	samples	using	DNeasy	Blood	and	Tissue	Kit	(Qiagen,	#60504).	
DNA	 concentrations	 were	 determined	 using	 a	 Nanodrop	 Technologies	
spectrophotometer.		
2.1.5	PCR	for	KRAS	and	BRAF	sequencing		
	
Polymerase	 chain	 reaction	 (PCR)	 was	 completed	 using	 the	 Qiagen	 multiplex	 PCR	 kit	
(Qiagen,	#206143)	with	the	primers	in	Table	2.1.	PCR	product	was	run	out	on	a	2%	agarose	
(Sigma)	gel	and	imaged	using	a	ChemiDoc	(BioRad).		
2.1.6	Sequencing		
PCR	 product	 was	 cleaned	 up	 using	 ExoSAP-ITTM	 PCR	 product	 clean	 up	 reagent	
(ThermoFisher,	#78200.200)	and	then	sent	to	GATC	(UK)	for	sequencing.	FAST	Q	files	were	
then	scored.	
 
2.1.7	Statistics	
Unpaired	two-tailed	t-test	and	ordinary	one-way	ANOVA	with	Bonferroni	post-hoc	test	
statistics	were	performed	using	Prism	7	(GraphPad)	analysis	software.	A	P-value	of	<0.05	
was	considered	statistically	significant.		
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Table	2.1.	Primer	details	for	KRAS	codon	12	(KRAS	exon	12)	and	BRAF	V600	(BRAF	exon	
15)	mutations.		
	 Forward	Primer	(5’	to	3’)	 Reverse	Primer	(5’	to	3’)	 Annealing	
Temp	(°C)	
KRAS	 exon	
12	
TTTGATAGTGTATTAACCTTATG	 TATTAAAACAAGATTTACCTC	 50	
BRAF	 exon	
15	
TCATAATGCTTGCTCTGATAGG		 CCACTGATTAAATTTTTGGCC	 60	
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2.2	Materials	and	Methods	for	Chapter	4	
2.2.1	Breeding	
Julie	Adam	(Wellcome	Trust	Centre	 for	Genetics,	Oxford)	crossed	 female	Fh1flox/flox	RipCre	
CAGFH	mice268	with	Apc1322T	mice366	and	then	backcrossed	to	generate	Fh1flox/flox	Apc1322T+/-	
offspring	 (see	Table	2.2	 for	breeding	details).	 Female	Fh1flox/flox	RipCre	CAGFH	mice	had	 loxP	
sites	in	both	Fh1	alleles	and	were	RipCre	positive;	the	rat	insulin	II	gene	promoter	controls	
cre	 recombinase	creating	a	 conditional	 knockout	of	Fh1	 in	 the	β-cells	of	 the	pancreas.	
These	mice	were	also	globally	positive	for	CAGFH	(human	cytoplasmic	FH,	which	ensures	
that	 the	FH	 is	expressed	 in	every	cell)	 to	enable	 females	to	carry	offspring	to	 full	 term	
without	 severe	 diabetes.	 Males	 were	 heterozygous	 for	 the	 Apc	 1322	 allele	 which	
predisposes	mice	to	polyps	mostly	in	the	small	bowel366.	All	mice	generated	had	relevant	
genotypes	for	the	study	(Table	2.2).		
2.2.2	Genotyping	mice		
Tail	or	ear	clips	from	mice	were	digested	with	buffer	containing	5%	proteinase	K	overnight	
at	 55°C.	 DNA	 was	 precipitated	 using	 iso-propanol	 and	 re-suspended	 in	 nuclease	 free	
water.	 Amplification	 for	 the	 relevant	 genes	was	 completed	with	 Taq	DNA	polymerase	
(Qiagen)	and	Taq	PCR	core	kit	(Qiagen)	with	the	primers	in	Table	2.3	and	cycling	conditions	
in	Table	2.4	using	a	thermo	cycler	machine.	PCR	product	was	run	out	on	a	2%	agarose	
(Sigma)	gel	and	imaged	using	BioRad	ChemiDoc	(Figure	2.1).		
The	Mom-1	 PCR	 product	 was	 further	 digested	 using	 BamH1	 (NEB,	 #R0136S).	Mom-1s	
(susceptible	to	polyps)	will	remain	as	a	500bp	product.	Mom-1R	(resistant	to	polyps)	will	
be	cleaved	to	a	400bp	and	100bp	product367–369	(Figure	2.2).		
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Table	2.2.	Mating	scheme	for	Fh1flox/flox	Apc1322T+/-	mice.		
Round	
of	
mating	
Parents	 Possible	Offspring	
1	 ♀	Fh1flox/floxRipcre+/-
CAGFH+/-Apc1322T-/-	
♂Fh1+/+Ripcre-/-CAGFH	-/-
Apc1322T+/-	
Fh1flox/+Ripcre+/-CAGFH+/-Apc1322T+/-	
Fh1flox/+Ripcre+/-CAGFH+/-Apc1322T-/-	
Fh1flox/+Ripcre+/-CAGFH-/-Apc1322T+/-	
Fh1flox/+Ripcre+/-CAGFH-/-Apc1322T-/-	
Fh1flox/+Ripcre-/-CAGFH+/-Apc1322T-/-	
Fh1flox/+Ripcre-/-CAGFH+/-Apc1322T+/-	
Fh1flox/+Ripcre-/-CAGFH-/-Apc1322T+/-	
Fh1flox/+Ripcre-/-CAGFH-/-Apc1322T-/-	
2	 ♀	Fh1flox/floxRipcre+/-
CAGFH+/-Apc1322T-/-	
♂Fh1flox/+Ripcre-/-CAGFH	-
/-Apc1322T+/-	
Fh1flox/+Ripcre+/-CAGFH+/-Apc1322T+/-	
Fh1flox/+Ripcre+/-CAGFH+/-Apc1322T-/-	
Fh1flox/+Ripcre+/-CAGFH-/-Apc1322T+/-	
Fh1flox/+Ripcre+/-CAGFH-/-Apc1322T-/-	
Fh1flox/+Ripcre-/-CAGFH+/-Apc1322T-/-	
Fh1flox/+Ripcre-/-CAGFH+/-Apc1322T+/-	
Fh1flox/+Ripcre-/-CAGFH-/-Apc1322T+/-	
Fh1flox/+Ripcre-/-CAGFH-/-Apc1322T-/-	
Fh1flox/floxRipcre+/-CAGFH+/-Apc1322T+/-	
Fh1flox/floxRipcre+/-CAGFH+/-Apc1322T-/-	
Fh1flox/floxRipcre+/-CAGFH-/-Apc1322T+/-	
Fh1flox/floxRipcre+/-CAGFH-/-Apc1322T-/-	
Fh1flox/floxRipcre-/-CAGFH+/-Apc1322T-/-	
Fh1flox/floxRipcre-/-CAGFH+/-Apc1322T+/-	
Fh1flox/floxRipcre-/-CAGFH-/-Apc1322T+/-	
Fh1flox/floxRipcre-/-CAGFH-/-Apc1322T-/	
♀	Fh1flox/floxRipcre+/-
CAGFH+/-Apc1322T-/-	
♂Fh1flox/+Ripcre+/-CAGFH	-
/-Apc1322T+/-	
Extra	genotypes	to	the	above:	
Fh1flox/+Ripcre+/+CAGFH+/-Apc1322T+/-	
Fh1flox/+Ripcre+/+CAGFH-/-Apc1322T+/-	
Fh1flox/+Ripcre+/+CAGFH+/-Apc1322T-/-	
Fh1flox/+Ripcre+/+CAGFH-/-Apc1322T-/-	
Fh1flox/floxRipcre+/+CAGFH+/-Apc1322T+/-	
Fh1flox/floxRipcre+/+CAGFH-/-Apc1322T+/-	
Fh1flox/floxRipcre+/+CAGFH+/-Apc1322T-/-	
Fh1flox/floxRipcre+/+CAGFH-/-Apc1322T-/-	
♀	Fh1flox/floxRipcre+/-
CAGFH+/-Apc1322T-/-	
♂Fh1flox/+Ripcre+/-CAGFH	
+/-Apc1322T+/-	
Extra	genotypes	to	the	above:	
Fh1flox/+Ripcre-/-CAGFH+/+Apc1322T+/-	
Fh1flox/+Ripcre-/-CAGFH+/+Apc1322T+/-	
Fh1flox/+Ripcre-/-CAGFH+/+Apc1322T-/-	
	
Fh1flox/+Ripcre-/-CAGFH+/+Apc1322T-/-	
Fh1flox/floxRipcre-/-CAGFH+/+Apc1322T+/-	
Fh1flox/floxRipcre-/-CAGFH+/+Apc1322T+/-	
Fh1flox/floxRipcre-/-CAGFH+/+Apc1322T-/-	
Fh1flox/floxRipcre-/-CAGFH+/+Apc1322T-/-	
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Table	2.3.	Primer	details	for	genotyping	Fh1flox/flox	Apc1322T+/-	mice.		
Gene	 Primer	 Primer	Sequence	(5’	to	3’)	 Annealing	
temp.	 for	
PCR	(°C)	
Expected	 band	
size	 of	 product	
(bp)	
1322T	 Forward	
Reverse	
Reverse	
CCCTCCATCAACCAAGAAAC	
TGGGTTTGGCTCTAGCATTC	
AAGAGTGCCTCCCAAAATGA	
55	 WT	430	
Target	217	
	
FHcyt	 Forward	
Reverse	
AACATGATCGTTGGGATGCAC	
GCCTCTGCTAACCATGTTCAT	
60	 510	
Fh1	 Forward		
Reverse	
Reverse	
ACCCTGCTAGGTGTCACCAC	
CCTGGCACTGCAGACTACAA	
GCTCAGTCACCCATCCAAAT	
55	 WT	240	
Homoflox	470	
RipCre	 Forward		
Reverse	
TAGCACCAGGCAAGTGTTTG	
AGGCAAATTTTGGTGTACGG	
55	 ~890	
Mom-1	 Forward	
Reverse	
GTCCAAGGGAACATTGCG	
AGAACAGGTGATTTGGCCCC	
60	 500	
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Figure	2.1.	Reference	gel	for	genotyping	Fh1flox/flox	Apc1322T+/-	mice.	PCR	was	performed	
for	CAGFH,	Fh1flox/flox,	RipCre	and	Apc1322T	with	primers	in	Table	2.3	according	to	details	in	
Table	2.4.	PCR	product	was	then	run	on	a	2%	agarose	gel	as	shown	above.	Product	sizes	
are	confirmed	in	Table	2.3.		
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Table	2.4.	PCR	reaction	conditions.		
	
Step	 Temperature	(°C)	 Time	(mins)	
1	-	Initial	denaturation	 95	 3	
2	-	Denaturation	 3-step	 cycling	
–	 repeat	 29	
times	
95	 0.5	
3	-	Annealing	 See	Table	2.3	 0.75	
4	-	Extension	 72	 0.75	
5	-	End	 8	 For	ever	
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Figure	2.2.	Mom-1	PCR	DNA	gel	example.	PCR	was	performed	for	Mom-1	and	then	the	
product	was	digested	with	BamH1.	There	are	two	forms	of	the	Mom-1	allele367	which	form	
different	products	when	incubated	with	the	restriction	endonuclease	BamH1.	The	Mom-
1S	allele	is	not	digested	so	retains	a	500bp	length,	whereas	the	Mom-1R	allele	forms	400bp	
and	100bp	products367,370.		
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2.2.3	Tissue	collection		
Mice	 were	 sacrificed	 via	 a	 schedule	 1	 procedure	 60-90	 days	 after	 birth	 or	 when	
symptomatic	 (anaemic	 secondary	 to	 polyps	 or	 suffering	 rectal	 prolapse,	 or	 high	 blood	
sugar).	Blood	glucose	was	taken	using	ACCU-CHEK	Aviva	machine	(Roche)	at	culling.	Gut	
was	removed	and	divided	into	four	segments	in	the	following	fashion:	three	equal	lengths	
of	the	small	bowel	(SB)	to	give	proximal	(SB1),	middle	(SB2),	distal	(SB3)	and	then	the	large	
bowel	(LB).	Each	segment	was	flushed	with	phosphate	buffered	saline	(PBS)	and	opened	
longitudinally	onto	filter	paper.	Polyps	and	normal	gut	were	selected	from	each	region	of	
the	bowel	and	snap	frozen.	Guts	were	then	placed	in	10%	neutral	buffered	formalin	(NBF)	
overnight	then	stored	in	70%	ethanol	until	processing.	
2.2.4	Quantification	of	gut	length	and	polyp	number	
Fixed	 intestinal	 tissue	was	measured	using	a	ruler,	 then	submerged	 in	0.2%	methylene	
blue	(0.5g	methylene	blue	in	15mL	glacial	acetic	acid	made	up	to	500mL	with	H2O)	for	5	
seconds	and	then	placed	in	PBS.	Using	a	dissection	microscope	at	x3	magnification	and	
polyps	were	recorded	according	to	size	and	location.	See	Figure	2.3	for	an	example	of	gut	
with	polyps	visible.		
2.2.5	Tissue	processing	for	immunohistochemistry	
Each	gut	section	was	rolled	and	secured	with	a	pin	and	placed	in	a	large	cassette	(Simport,	
Macrosette,	#M512)	in	the	same	orientation.	Samples	were	processed	for	histology	using	
the	 schedule	 in	 Table	 2.5	 using	 large	 moulds	 (Simport,	 11601000	 X1000	 Base	 mould	
disposable	 37x24x5mm).	Gut	 rolls	were	 embedded	 in	wax	 so	 that	 each	 section	would	
present	in	the	same	place	in	all	blocks	(Figure	2.4).		
2.2.6	Immunohistochemistry	
H+E	stain	was	carried	out	by	The	Royal	London	Hospital	Pathology	Department	as	part	of	
the	sectioning	service.	IHC	was	carried	out	using	the	EnVision	kit	(Dako).	Paneth	cells	were	
detected	 with	 anti-lysozyme	 (Dako,	 #EC	 3.2.1.17)	 used	 at	 1:500	 after	 5	 minutes	
microwaving	 in	 citrate	 buffer	 pH6.	 Goblet	 cells	 were	 detected	 with	 alcian	 blue	 stain	
(Sigma,	#B8438).		
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Figure	2.3.	Example	polyps	in	mice.	Gut	was	extracted,	fixed,	and	stained	with	methylene	
blue.	 Polyp	 count	 was	 performed	 using	 a	 bright	 field	 microscope.	 There	 were	 five	
categories	of	polyp	size.	0-1mM	(A),	<1-2mM	(B),	<2-3mM	(C),	3+mM	(D).	
	 	
D 
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Figure	2.4.	Gut	rolls	pinned	and	placed	in	a	large	cassette	(left)	and	embedded	in	wax	
(right).	SB1	top	left,	SB2	top	right,	SB3	bottom	left	and	LB	bottom	right.	SB,	small	bowel;	
LB,	large	bowel.		
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Table	2.5.	Tissue	processing	and	embedding	details.		
Step	 Solution	 Time	(min)	
1	 70%	ethanol	 45	
2	 90%	ethanol	 30	
3	 95%	ethanol	 45	
4	 100%	ethanol	 30	
5	 100%	ethanol	 45	
6	 100%	ethanol	 45	
7	 Histoclear	 30	
8	 Histoclear	 30	
9	 Histoclear	 30	
10	 Wax	 60	
11	 Wax	 60	
12	 Embed	in	wax	 2	
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2.2.7	Scoring	of	immunohistochemistry	
Using	NDPview.2	software	(Hamamatsu)	50	villi	and	100	crypts	of	which	the	entire	length	
was	visible,	were	selected	from	each	mouse,	for	each	stain,	and	an	image	was	taken	of	
each.	All	counting	was	done	by	eye.		
2.2.8	Metabolite	analysis	
Capillary	electrophoresis	time	of	flight	mass	spectrometry	(CE-TOF/MS)	analysis	was	used	
to	determine	metabolites	levels	(nmol/g).	Samples	were	dissected	and	flash	frozen	on	dry	
ice	 then	 shipped	 to	 the	 Institute	 for	Advanced	Biosciences	 in	 Japan	 for	 CE-TOF/MS	 as	
described	previously371,372.	
2.2.9	Statistics		 	
Ordinary	 one-way	ANOVA	 and	 two-way	ANOVA	was	 performed,	 both	with	 Bonferroni	
post	hoc	test	statistics	were	performed	using	Prism	7	(GraphPad)	analysis	software.	A	P-
value	of	<0.05	was	considered	statistically	significant.		
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2.3	Materials	and	Methods	for	Chapter	5	
2.3.1	Cell	culture	
Human	CRC	cell	lines	DLD1,	HT55	and	SW387	were	a	gift	from	Professor	Ian	Tomlinson,	
(who	 also	 validated	 the	 cell	 lines)	 Wellcome	 Institute	 for	 Human	 Genetics,	 Oxford	
University,	and	were	maintained	in	Dulbecco’s	modified	Eagle’s	Medium	(DMEM)	(Gibco,	
#11966),	with	10%	fetal	bovine	serum	(FBS)	(Labtech,	#FB-1001T/500),	171μM	penicillin	
(Sigma,	 #P4333),	 172μM	 streptomycin	 (Sigma,	 #P4333),	 2mM	 L-glutamine	 (GE	
Healthcare,	 #M11-006)	 and	 either	 25mM,	 5mM	 or	 0mM	 glucose	 (Sigma,	 #G7021)	 as	
detailed	below.		
I	decided	to	reduce	[glucose]	in	the	media	slowly	over	a	period	of	3	months:	first,	from	
25mM	 to	 12.5mM;	 then	 in	 12.5mM	 glucose	 until	 their	 doubling	 time	was	 stable.	 The	
process	 was	 repeated	with	 10mM,	 7.5mM	 and	 5mM	when	 the	 cells	 were	 banked	 by	
storage	in	liquid	nitrogen.	The	glucose	was	reduced	further	to	2.5mM	and	finally	0mM	in	
the	 same	way;	 the	 cells	 which	 grew	 at	 0mM	 glucose	were	 banked.	 Once	 the	 desired	
[glucose]	was	established,	which	was	25mM,	5mM	and	0mM,	the	cells	were	cultured	for	
a	 further	 8	 passages	 before	 using	 the	 cells	 for	 experimentation	 to	 ensure	 continued	
stability	of	doubling	time.	
Fh1	 WT	 and	 KO	 MEFs	 were	 a	 gift	 from	 Dr	 Julie	 Adam,	 Oxford	 Centre	 for	 Diabetes,	
Endocrinology	 and	 Metabolism	 and	 were	 maintained	 in	 DMEM	 containing	 10%	 fetal	
bovine	serum	(FBS),	171μM	penicillin,	172μM	streptomycin,	2mM	L-glutamine	and	25mM	
glucose.	All	 cell	 lines	were	kept	at	37°C	under	a	humidified	atmosphere	containing	5%	
CO2,	 and	 20.9%	O2.	 A	 1%	 and	 0.2%	O2	atmosphere	was	 provided	 by	 an	 INVIVO2	1000	
(Baker	 Ruskinn).	 Stable	 doubling	 time	 was	 calculated	 using	 the	 following	 formula	
[h(ln2/ln(e2/e1)]	where	e1	is	cell	number	plated	and	e2	is	the	total	cell	number	harvested	
and	h	is	the	hours	between	plating	and	harvesting.	
2.3.2	Western	blotting	
Cells	were	rinsed	once	with	PBS	and	lysed	with	the	addition	of	RIPA	buffer	(Sigma).	Protein	
concentration	 was	 determined	 by	 the	 PierceTM	 BCA	 Protein	 Assay	 (ThermoFisher,	
#23225).	Equal	amounts	of	protein	were	added	to	4-12%	Bis-Tris	polyacrylamide	gels	(Life	
	 102	
Technologies).	Proteins	were	 transferred	 to	a	PVDF	membrane	using	 the	Pierce	Power	
Blotter	 (Life	Technologies).	Membranes	were	blocked	 in	5%	dry-milk	 in	PBS	containing	
0.1%	Tween-20	(Sigma)	(PBS-T)	for	1	hour	at	room	temperature.	After	washing	in	PBS-T,	
membranes	were	 incubated	with	 the	 appropriate	 primary	 antibody	 (Table	 2.6)	 at	 4°C	
overnight.	After	washing	with	PBS-T,	membranes	were	 incubated	with	the	appropriate	
horseradish	peroxidase	(HRP)-conjugated	secondary	antibody	at	room	temperature	for	1	
hour	 (see	 Table	 2.6).	 Proteins	 were	 detected	 using	 Pierce	 ECL	 Plus	 Western	 Blotting	
Substrate	(Thermo,	#32106).	
2.3.3	Viability	assay	
Cells	 were	 plated	 in	 6	 well	 plates	 and	 kept	 at	 37°C	 under	 a	 humidified	 atmosphere	
containing	 5%	 CO2	 and	 20.9%	O2.	 At	 24	 hours,	 the	 cells	were	 placed	 at	 37°C	 under	 a	
humidified	atmosphere	containing	5%	CO2,	and	either	20.9%	or	0.2%	O2.	At	72	hours,	cells	
were	washed	with	PBS	and	harvested	with	TrypLE	Express	(Invitrogen,	#12605-010).	Cells	
were	suspended	with	media	and	0.4%	trypan	blue	(Invitrogen,	#15250061).	The	number	
of	cells	were	counted	using	a	haemocytometer,	blue	cells	represented	dead	cells.		
2.3.4	Fumarate	detection	by	mass	spectrometry		
Fumarate	 (fmol/cell)	 was	 determined	 by	 CE-TOF/MS	 analysis	 by	 Professor	 Tomoyoshi	
Soga	(Keio	University,	Japan).	DLD1,	HT55	and	SW837	cell	lines	were	cultured	with	25mM	
glucose	DMEM	and	held	under	20.9%,	1%	or	0.2%	O2	for	48	hours.	Cells	were	then	washed	
two	times	 in	5%	Mannitol	 (Wako,	 Japan)	and	harvested	 in	methanol	containing	25mM	
methionine	 sulfone,	 25mM	 2-morpholinoethanesulfate	 and	 25mM	 D-camphor-10-
sulfonic	acid.		Samples	were	next	flash	frozen	on	dry	ice	and	shipped	to	the	Institute	for	
Advanced	Biosciences	in	Japan	for	CE-TOF/MS	as	described	previously371,372.		
2.3.5	Fumarate	detection	using	fluorometric	assay	
Cells	were	plated	in	flasks	and	kept	at	37°C	under	a	humidified	atmosphere	containing	5%	
CO2	 and	 20.9%	 O2.	 At	 24	 hours,	 the	 cells	 were	 placed	 at	 37°C	 under	 a	 humidified	
atmosphere	 containing	 5%	 CO2,	 and	 either	 20.9%	 or	 0.2%	O2.	 At	 72	 hours,	 cells	were	
washed	with	PBS	and	harvested	with	TrypLETM	Express	 (Invitrogen,	#12605-010).	1x106	
	 103	
cells	 were	 then	 used	 in	 a	 commercially	 available	 assay	 to	 detect	 fumarate	 (Sigma,	
MAK060).		 	
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Table	2.6.	Western	blotting	antibody	details.	
Primary	
antibody		
Company	 and	
catalogue	no.	
Dilution	
used	
Secondary	
antibody	
Company	
and	
catalogue	
no.	
Dilution	
used	
2-SC	 Not	 commercially	
available.	Gift	from	
Norma	 Frizzell,	
University	of	South	
Carolina.	
1:10,000	 HRP-linked	
anti-rabbit	
Dako,	
#P0448	
1:2,000	
HIF-1α	 BD,	#610959	 1:500	 HRP-linked	
anti-mouse	
Dako,	
#P0447	
1:2,000	
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2.3.6	Fumarate	Hydratase	activity	
Cells	were	plated	in	flasks	and	kept	at	37°C	under	a	humidified	atmosphere	containing	5%	
CO2	 and	 20.9%	 O2.	 At	 24	 hours,	 the	 cells	 were	 placed	 at	 37°C	 under	 a	 humidified	
atmosphere	 containing	 5%	 CO2,	 and	 either	 20.9%	 or	 0.2%	O2.	 At	 72	 hours,	 cells	were	
washed	with	PBS	and	the	flask	was	put	immediately	at	-80°C	for	at	least	24	hours.	Cells	
were	 thawed	 on	 ice,	 harvested	 with	 Hepes-KOH	 pH7.6	 with	 phosphatase	 inhibitors,	
sonicated	and	stored	at	 -80°C.	Samples	were	 incubated	with	a	 reaction	mix	containing	
10μM	NAD+	(Sigma,	#N7004),	1M	KH2PO4	(Sigma),	1M	MgCl2	(Sigma),	50mM	Hepes-KOH	
pH7.6	 (Sigma),	 10mM	 glutamic	 acid	 (Sigma,	 #G8415),	 malate	 dehydrogenase	 (Sigma,	
#M1567)	and	glutamic	oxaloacetate	transaminase	(Sigma,	#10105554001)	for	10	mins	at	
37°C.	30mM	fumeric	acid	(Sigma,	F8509)	was	then	added	to	the	mix.	Fluorescence	was	
measured	every	40	 seconds	at	 excitation	340nm,	emission	460nm	 for	15	minutes	 and	
corresponded	to	NADH	produced.	NADH	standards	were	made	up	fresh	(Sigma,	#N8129).		
2.3.7	Immunostaining		
Cells	 were	 plated	 in	 96-well	 plates	 and	 kept	 at	 37°C	 under	 a	 humidified	 atmosphere	
containing	 5%	 CO2	 and	 20.9%	O2.	 At	 24	 hours,	 the	 cells	were	 placed	 at	 37°C	 under	 a	
humidified	atmosphere	containing	5%	CO2,	and	either	20.9%	or	0.2%	O2.	At	72	hours,	cells	
were	washed	with	PBS	and	fixed	with	4%	paraformaldehyde,	followed	by	0.1%	Triton	X	
permeabilisation	 and	 blocking	 with	 0.25%	 bovine	 serum	 albumin	 (BSA),	 followed	 by	
antibody	incubations	(Table	2.7).		
Images	 were	 collected	 at	 10x	 using	 the	 IN	 cell	 2200	 microscope	 (GE)	 and	 the	 InCell	
Developer	Analysis	V1.9	software	(GE)	was	used	for	image	analysis.		
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Table	2.7.	Immunostaining	antibody	details.	
Primary	
antibody		
Company	 and	
catalogue	no.	
Dilution	
used	
Secondary	
antibody	
Company	
and	
catalogue	
no.	
Dilution	
used	
HIF-1α	 BD,	#610959	 1:500	 HRP-linked	
anti-mouse	
Dako,	
#P0447	
1:2,000	
FH	 Autogen	
Bioclear,	
#NE054	
1:2,000	 HRP-linked	
anti-rabbit	
Dako,	
#P0448	
1:2,000	
Mitochondrial	
protein	
Abcam,	
#ab3298	
1:2,000	 HRP-linked	
anti-mouse	
Dako,	
#P0447	
1:2,000	
Hoechst	
33342	
Invitrogen,	
#H3570	
1:5000	 -	 -	 -	
Cell	 Mask	
Deep	Red		
Invitrogen,	
#C10046	
1:100,000	 -	 -	 -	
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2.3.8	RT-qPCR	
Cells	were	plated	in	flasks	and	kept	at	37°C	under	a	humidified	atmosphere	containing	5%	
CO2	and	20.9%.	At	24	hours,	the	cells	were	placed	at	37°C	under	a	humidified	atmosphere	
containing	5%	CO2,	and	either	20.9%	or	0.2%	O2.	At	72	hours,	cells	were	washed	with	PBS	
and	RNA	was	extracted	using	miRNeasy	kit	(Qiagen)	according	to	manufacturer’s	protocol.	
RNA	 concentrations	 were	 determined	 using	 a	 Nanodrop	 Technologies	
spectrophotometer.	RNA	samples	were	reverse-transcribed	using	a	Reverse	Transcriptase	
kit	 (ABI)	and	reverse	transcription	(RT)	products	were	 incubated	with	selected	TaqMan	
assays	(Table	2.8)	and	TaqMan	Universal	MasterMix	(Applied	Biosystems)	on	a	7500	Fast	
System	 RealTime	 PCR	 cycler	 (Applied	 Biosystems),	 according	 to	 the	 manufacturer’s	
instructions.	DLD1	results	were	normalised	to	a	geomean	of	18S	and	RPLPO;	HT55	to	actin;	
SW837	to	B2M.	Data	was	analysed	by	the	∆∆^ct	method373.		
2.3.9	Seahorse	
Cells	were	plated	in	XF24	plates	(Agilent)	and	incubated	at	37°C	overnight.	The	next	day,	
medium	was	 changed	 to	 XF	 assay	medium	 (Agilent)	 containing	 25mM,	 5mM	or	 0mM	
glucose,	1mM	pyruvate,	2mM	glutamine,	and	the	cells	were	incubated	at	37°C	for	1	hour.	
Steady-state	 (baseline)	 oxygen	 consumption	 rates	 and	 extracellular	 acidification	 rates	
were	 measured	 using	 a	 XF24	 extracellular	 flux	 analyser	 (Agilent).	 Addition	 of	 1μM	
oligomycin	was	used	to	evaluate	the	amount	of	ATP	produced	by	the	mitochondria	of	the	
cells	by	inhibiting	ATP	synthase	(complex	V);	addition	of	0.6μM	FCCP	was	used	to	evaluate	
the	 maximal	 oxygen	 consumption	 rate	 by	 uncoupling	 oxygen	 consumption	 from	 ATP	
production;	addition	of	0.5μM	rotenone	and	antimycin	A	was	used	to	measure	the	spare	
respiratory	capacity	of	 the	cell	by	 inhibiting	complex	 I	and	 III	of	 the	electron	transport	
chain	respectively.		
2.3.10	Statistics		
Unpaired	 two-tailed	 t-test,	 ordinary	 one-way	 ANOVA	 and	 two-way	 ANOVA	 was	
performed,	both	with	Bonferroni	post	hoc	 test	statistics	were	performed	using	Prism	7	
(GraphPad)	analysis	software.	A	P-value	of	<0.05	was	considered	statistically	significant.		
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Table	2.8.	TaqMan	Assay	Details	(all	from	Life	Tech).		
Gene	 Probe	no.		
BAX	 Hs00180269_m1		
CA9	 Hs00154208_m1		
CASP9	 Hs00609647_m1		
COX4I2	 Hs00261747_m1		
FH	 Hs00264683_m1	
GAPDH	 Hs99999905_m1		
GLUT1	 Hs00892681_m1		
GLUT4	 Hs00168966_m1		
GPX1	 Hs00829989_gH		
HIF-1α	 Hs00153153_m1		
HIF-1ß	 Hs01121918_m1		
HIF-2α	 Hs01026149_m1		
HK2	 Hs00606086_m1		
LDHA	 Hs01378790_g1		
LONP1	 Hs00998404_m1		
PDK1	 Hs01561850_m1		
SOD2	 Hs00167309_m1		
VEGF	 Hs00900055_m1		
VHL	 Hs00184451_m1		
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2.4	Materials	and	Methods	for	Chapter	6	
	
2.4.1	Xenograft	model		
The	study	design	and	implementation	was	overseen	by	Professor	Kairbaan	Hodivala-Dilke.	
The	ethics	project	licence	for	this	work	is	PPL70/7411	(Professor	Kairbaan	Hodivala-Dilke).	
Mice	were	housed	in	a	pathogen-free	environment	and	all	procedures	were	conducted	
according	 to	 the	 requirements	of	 the	United	Kingdom	Home	Office	Animals	 (Scientific	
Procedures)	Acts,	1986.		
	
Eight-week	old	female	nude	mice	(nu/nu)	were	implanted	with	5x106	human	DLD1	CRC	
cells	 in	 200uL	 saline	 on	 a	 single	 flank.	 Once	 tumours	were	 between	 200-300mm3	 the	
dosing	 schedule	 was	 initiated.	 Mice	 were	 randomised	 into	 four	 treatment	 arms;	 1)	
oxaliplatin	 8mg/kg	 alone,	 2)	 cetuximab	 (30mg/kg),	 3)	 oxaliplatin	 8mg/kg	 +	 cetuximab	
30mg/kg,	4)	 saline	as	an	untreated	group.	Drugs	were	administered	by	 intraperitoneal	
injection.		
	
24	hours	post-drug	injection,	mice	were	killed	and	xenografts	were	harvested.	Professor	
Hodivala-Dilke’s	staff	conducted	this	work	and	I	collected	the	xenografts	for	subsequent	
analysis.	One	half	of	the	xenograft	tissue	was	submerged	in	AllProtect	(Qiagen,	#76405)	
and	kept	at	4°C.	The	other	half	of	the	tissue	was	submerged	for	12	hours	in	10%	neutral	
buffered	 formalin	 (Sigma,	 #HT501128),	 then	 moved	 to	 70%	 ethanol	 for	 12-24	 hours	
before	embedding	in	paraffin	wax.	Serial	sections	(5	µm)	were	cut	for	ISH	and	IHC.		
	
2.4.2	RT-qPCR	
	
RNA	was	extracted	using	miRNeasy	 kit	 (Qiagen)	 according	 to	manufacturer’s	 protocol.	
RNA	 concentrations	 were	 determined	 using	 a	 Nanodrop	 Technologies	
spectrophotometer.	 A	 tissue	 ruptor	 instrument	 (Qiagen)	 was	 used	 to	 assist	 with	
homogenisation	 of	 tissue.	 RNA	 samples	 were	 reverse-transcribed	 using	 a	 Reverse	
Transcriptase	 kit	 (ABI)	 and	 reverse	 transcription	 (RT)	 products	 were	 incubated	 with	
selected	 TaqMan	 assays	 and	 TaqMan	 Universal	MasterMix	 (Applied	 Biosystems)	 on	 a	
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7500	 Fast	 System	 RealTime	 PCR	 cycler	 (Applied	 Biosystems),	 according	 to	 the	
manufacturer’s	 instructions.	 Probes	used	were	DUOX2	 (Qiagen,	 #Hs01595312_g1)	 and	
DUOXA2	(Qiagen,	#Hs01595312_g1).	The	housekeeping	gene	used	was	GAPDH	(Qiagen,	
#Hs00204187_m1).	Data	was	analysed	by	the	½^ct	method373. 
	
2.4.3	Immunohistochemistry		
	
IHC	was	performed	according	to	standard	protocols.	Briefly,	serial	sections	were	dewaxed,	
rehydrated	and	immersed	in	3%	hydrogen	peroxide	for	10	minutes	to	quench	endogenous	
peroxidase	activity.	Antigen	retrieval	was	performed	by	microwaving	for	15	minutes	 in	
sodium	citrate	buffer	(pH6.0).	After	cooling,	sections	were	incubated	with	blocking	buffer	
(1:25	goat	serum	in	PBS)	for	15	mins	at	RT.	Primary	antibodies	were	applied	for	45	minutes	
at	 room	 temperature	 -	 rabbit	 anti-human	 Ki67	 at	 1:1000	 dilution	 (Abcam,	 #ab92742);	
rabbit	 anti-human	 cleaved	 caspase	 3	 at	 1:400	 (Cell	 Signaling	 #9664);	 DUOX2	 at	 1:50	
dilution	 (Millipore,	 #MABN787).	 Sections	 were	 then	 incubated	 with	 a	 biotinylated	
secondary	 antibody	 at	 room	 temperature	 for	 45	 min,	 followed	 by	 incubation	 with	
streptavidin-biotin	peroxidase	solution	at	room	temperature	for	45	min.	Visualization	of	
antibody	binding	was	carried	out	using	DAB	and	sections	were	lightly	counterstained	using	
haematoxylin.		
2.4.4	In	situ	hybridisation		
For	 in	situ	hybridisation	(ISH),	hDUOX2	expression	was	determined	using	the	RNAscope	
2.0	High	Definition	assay	(Brown,	#310035)	according	to	the	manufacturer’s	instructions	
(Advanced	Cell	Diagnostics,	Hayward,	CA).	Briefly,	samples	were	heated	at	60˚C	for	1	hour,	
dewaxed	 and	 rehydrated	 in	water	 then	 incubated	with	 Pre-treatment	 1	 buffer	 for	 10	
minutes	at	room	temperature.	Next	slides	were	boiled	in	Pre-treatment	2	buffer	for	15	
minutes,	followed	by	incubation	with	Pre-treatment	3	buffer	for	30	minutes	at	40˚C.	Then	
slides	 were	 incubated	 with	 the	 probe	 for	 2	 hours	 at	 40˚C,	 followed	 by	 successive	
incubations	with	Amp1	 to	6	 reagents.	 Staining	was	visualized	with	3,3-diaminobenzine	
(DAB)	then	 lightly	counterstained	with	haematoxylin	before	dehydrating	and	mounting	
with	distyrene	plasticiser	xylene	(DPX).		
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2.4.5	Scoring	of	immunohistochemistry	and	in	situ	hybridisation	
Slides	were	 scanned	using	 a	NanoZoomer	2.0	H-T,	 (Hamamatsu	Photonics	UK	 Limited,	
Welwyn	Garden	City,	UK).		Images	were	viewed	using	NDPview2	and	each	target	under	
investigation	was	aligned	across	serial	sections.	Seven	randomly	selected	areas	were	then	
examined	at	x20.	Total	cell	numbers	and	the	number	of	positively	stained	cells	within	a	
field	were	counted	for	IHC	and	expressed	as	percentage	positive	cells.	For	ISH	a	positive	
cell	was	scored	if	a	minimum	of	3	dots	could	be	seen	within	the	cell	boundary.		
Ki67	and	caspase	3	IHC	and	DUOX2	ISH	were	done	as	percentage	positive	cells	as	these	
are	nuclear	stains	and	easy	to	determine	which	cell	the	staining	belongs	to.	DUOX2	IHC	
was	quantified	by	the	scoring	system	outlined	in	Table	2.9.	This	method	was	used	as	the	
staining	 is	 cytoplasmic.	 Two	 independent	 individuals	 (myself	 and	 Rosemary	 Jeffery)	
blinded	to	the	experimental	group	performed	the	counts	and	scores.	
	
2.4.6	Statistics			
	
Two-tailed	 student’s	 t-test	 with	 Welch’s	 correction	 was	 performed	 using	 Prism	
(GraphPad)	analysis	software.	A	P-value	of	<0.05	was	considered	statistically	significant.		
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Table	2.9.	Scoring	method	for	DUOX2	IHC.		
Score	 Description	
0	 No	positive	staining	
1	 Less	than	5%	of	the	tissue	had	positive	staining	
2	 Less	than	10%	but	more	than	5%	of	the	tissue	had	positive	staining	
3	 Less	than	15%	but	more	than	10%	of	the	tissue	had	positive	staining	
4	 Less	than	20%	but	more	than	15%	of	the	tissue	had	positive	staining	
5	 20%	or	more	of	the	tissue	had	positive	staining	
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Chapter	3	–	Succination	is	elevated	in	CRC	tissue	from	T2D	patients		
3.1	Introduction	
Succination,	a	process	where	fumarate	causes	post-translational	modification	of	cysteine	
residues	in	proteins	to	form	2-SC	(Chapter	1,	Section	8.5,	Figure	10),	has	been	described	
in	 adipose	 and	 skeletal	 muscle	 cells	 of	 diabetic	 animal	 models341,346.	 Its	 functional	
consequences	 include	 loss	of	activity	of	 the	mitochondrial	Krebs	cycle	aconitase345	and	
the	glycolytic	enzyme	glyceraldehyde	3-phopshate	dehydrogenase	(GAPDH)338.		
To	date,	 the	only	 cancer	 in	which	protein	 succination	has	 been	described	 is	HLRCC374.	
HLRCC	patients	have	a	loss	of	function	mutation	in	FH	that	results	in	millimolar	levels	of	
fumarate,	 which	 leads	 to	 succination330.	 Fumarate	 is	 a	 member	 of	 the	 TCA	 cycle	 in	
mitochondria,	where	it	is	converted	to	malate	by	FH.	Fumarate	is	also	produced	by	the	
urea	cycle	and	amino	acid	catabolism	in	the	cytoplasm;	excess	fumarate	here	is	mopped	
up	 by	 cytoplasmic	 FH.	 Other	 known	 roles	 for	 fumarate	 are	 promotion	 of	 cancer	 cell	
survival	 by	 stabilisation	 of	 HIF-1α	 by	 competitively	 inhibiting	 2-OGDDs	 leading	 to	
activation	of	HIF-dependent	pathways	such	as	glucose	metabolism332.	Fumarate	can	also	
reduce	 DNA	 methylation	 by	 inhibiting	 TET	 5-mC	 2-OGDDs.	 Fumarate	 has	 since	 been	
described	 as	 an	 oncometabolite375.	 Fumarate	 is	 elevated	 in	 CRC	 tissue	 compared	 to	
matched	normal335	 and	 the	 functional	 consequences	of	 succination	might	 explain	why	
those	 with	 T2D	 who	 present	 with	 CRC	 have	 more	 invasive	 CRC,	 as	 well	 as	 a	 poorer	
outcome	due	to	 loss	of	activity	of	key	proteins	within	the	cell.	Moreover,	mutations	 in	
KRAS	and	BRAF	are	found	in	approximately	40%	and	10%	of	CRC	cases	respectively376,377,	
and	 these	 changes	 have	 recently	 been	 linked	 with	 alterations	 in	 cancer	 cell	
metabolism376,377.	As	fumarate	is	a	metabolite,	this	could	suggest	a	link	between	2-SC	and	
KRAS/BRAF	mutation	status.		
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3.1.1	Hypotheses	
	
I	hypothesised	increased	levels	of	2-SC	in	normal,	adenoma	and	CRC	tissue	from	type	2	
diabetic	patients	compared	to	non-diabetic	patients	due	to	a	lack	of	or	inactive	FH	in	this	
population.	 I	also	hypothesised	that	2-SC	 levels	would	be	higher	 in	KRAS/BRAF	mutant	
CRC	tissue	compared	to	KRAS/BRAF	WT	CRC.	
3.1.2	Aims	
	
• To	 test	 a	 panel	 CRC,	 adenoma	 and	 normal	 tissue	 from	 non-diabetic	 and	 T2D	
individuals	for	the	presence	of	2-SC.	
• To	 test	 a	 panel	 CRC,	 adenoma	 and	 normal	 tissue	 from	 non-diabetic	 and	 T2D	
individuals	for	the	presence	of	FH.	
• To	examine	whether	KRAS/BRAF	mutation	in	CRC	is	linked	to	2-SC	staining	score.	
	
In	this	chapter,	statistical	significance	was	determined	by	ordinary	one-way	ANOVA	with	
Bonferroni	 post-hoc	 test	 unless	 otherwise	 stated.	 Statistically	 significant	 results	 are	
denoted	with	*	in	figures,	exact	p	values	can	be	found	in	the	appendix	(Chapter	9).		
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3.2	Succination	is	present	in	normal,	adenoma	and	CRC	tissue	
IHC	for	2-SC	was	performed	on	normal,	adenoma	and	CRC	tissue	(Figure	3.1).	Evidence	of	
succination,	by	histology,	was	found	in	the	majority	of	samples,	including	normal	tissue	
(Table	3.1).	This	suggested	that	succination	is	a	normal	process	which	happens	in	the	GI	
tract.	 The	 2-SC	 staining	 was	 non-uniform	 across	 tumours,	 underlining	 metabolic	
heterogeneity	of	CRC.	
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Table	3.1.	Percentage	of	tissue	samples	with	evidence	of	succination.		
	 Tissue	
Normal	 Adenoma	 CRC	
ND	 T2D	 ND	 T2D	 ND	 T2D	
Total	no.	of	samples		 67	 26	 23	 7	 57	 25	
Percentage	(%)	of	samples	
with	succination	evidence	
85.29	 76.92	 100	 100	 98.25	 100	
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3.3	Succination	is	elevated	in	CRC		
IHC	 for	 2-SC	 was	 performed	 on	 matched	 normal	 intestinal	 mucosa	 and	 CRC	 patient	
samples;	58	from	non-diabetic	patients	and	25	from	T2D	patients	(Table	3.1,	Figure	3.1).	
I	 identified	 and	 sourced	 the	 patient	 blocks	 from	The	Royal	 London	hospital	 pathology	
archive,	 collated	 and	 analysed	 the	 data.	 IHC	 was	 carried	 out	 by	 Julie	 Adam	 using	 a	
validated	 antibody	 that	 detects	 2-SC	 motifs342	 that	 was	 gifted	 by	 Norma	 Frizzell	 (the	
antibody	 is	 not	 commercially	 available	 and	 Julie	 Adam	 holds	 the	 material	 transfer	
agreement)	 (Chapter	 2,	 Section	 2.1.2).	 The	 sections	 were	 scored	 by	 Roger	 Feakins	
(consultant	pathologist)	according	to	protocol	given	in	Chapter	2,	Section	2.1.3.		
2-SC	 was	 significantly	 elevated	 in	 CRC	 tissue	 compared	 to	 matched	 normal	 tissue	
(p<0.0001,	 unpaired	 t-test,	 Figure	 3.2.A,	 Table	 3.2).	 In	 non-diabetic	 patients,	 2-SC	was	
significantly	elevated	in	CRC	tissue	compared	to	matched	normal	tissue	(p<0.0001,	Figure	
3.2.B,	Table	3.2).	Similarly,	in	T2D	patients,	2-SC	was	significantly	elevated	in	CRC	tissue	
compared	to	matched	normal	tissue	(p<0.0001,	Figure	3.2.B,	Table	3.2).	Moreover,	2-SC	
was	 significantly	 higher	 in	 CRC	 tissue	 from	 T2D	 patients	 compared	 to	 non-diabetic	
patients	(p=0.001).		
The	2-SC	 score	difference	between	 the	normal	 and	CRC	 tissue	 is	 significantly	different	
between	non-diabetic	and	T2D	patients	(p=0.0264,	Figure	3.2.C.	Table	A.3.1,2).	There	was	
a	greater	difference	in	T2D	patients	compared	to	non-diabetic	patients.	In	non-diabetic	
patients,	the	2-SC	score	was	higher	in	the	CRC	compared	to	the	matched	normal	in	85.96%	
and	lower	in	14.03%.	In	T2D	patients	the	2-SC	score	was	higher	in	the	CRC	compared	to	
the	matched	normal	in	in	96.15%	of	patients	and	lower	in	3.85%.		
These	results	highlight	that	increased	succination	is	a	feature	of	CRC	and	bring	to	light	an	
interaction	between	succination	and	T2D	in	CRC	tissue.	The	presence	of	T2D	increases	the	
amount	 of	 2-SC.	 This	 association	 between	 cancer,	 T2D	 and	 succination	 has	 not	 been	
shown	before.		 	
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Figure	 3.1.	 Representative	 images	 of	 2-SC	 IHC	 in	 CRC	 tissue.	 IHC	 was	 performed	 on	
sections	with	a	2-SC	antibody.	(A)	Normal	tissue	from	showing	weak	or	no	2-SC	staining	
in	the	epithelium.	(B)	Normal	tissue	showing	weak	to	medium	2-SC	staining.	(C)	CRC	tissue	
showing	weak	to	medium	2-SC	staining.	(D)	CRC	tissue	showing	intense	2-SC	staining.	(E)	
Close	up	of	(A),	(F)	close	up	of	(B),	(G)	close	up	of	(C),	(H)	close	up	of	(D).	(A-D)	Scale	bar	
250µm,	(E-H)	scale	bar	100µm).		
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Figure	3.2.	2-SC	score	in	matched	normal	and	CRC	tissue	from	non-diabetics	and	T2Ds.	
IHC	was	carried	out	on	tissue	sections	with	2-SC	antibody.	Sections	were	then	scored	by	
Roger	Feakins,	a	consultant	pathologist.	(A)	2-SC	score	of	matched	normal	and	CRC	tissue	
(n=83),	unpaired	two-tailed	t-test	was	performed.	(B)	2-SC	score	of	matched	normal	and	
CRC	 tissue,	 spilt	 into	non-diabetic	 (ND)	 (n=57)	and	T2D	 (n=25)	patients.	 (C)	CRC	minus	
normal	 2-SC	 scores	 for	 matched	 normal	 and	 CRC	 tissue.	 All	 mean±SEM	 (Table	 3.2).		
*	p<0.05,	**	p<0.01,	****	p<0.0001.	Statistics	details	in	Table	A.3.1,2.		
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Table	3.2.	Summary	of	2-SC	scores	for	matched	normal	and	CRC	tissue.	Data	shown	as	
mean	±	SEM.	See	also	Figure	3.2.		
	 	 2-SC	score	
	 Number	 Normal	 CRC	 CRC	-	Normal	
Total		 83	 20.23±2.06	 84.49±5.22	 64.27±5.81	
Non-diabetic		 57	 19.45±2.39		 75.05±5.55	 55.61±6.55	
T2D		 25	 21.94±4.14	 105.19±10.66	 83.25±11.25	
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3.4	Succination	is	elevated	in	adenomas		
It	 was	 next	 hypothesised	 that	 succination	 occurs	 early	 in	 the	 progression	 of	 CRC.	
Adenomas	are	the	precursor	to	CRC.	In	the	same	way	as	described	in	Section	3.1,	IHC	for	
succination	was	performed	on	matched	normal	 intestinal	mucosa	and	adenoma	 tissue	
resected	from	patients	with	CRCs;	23	from	non-diabetic	patients	and	7	from	T2D	patients.		
It	was	difficult	to	find	adenomas	from	T2D	patients	for	this	study,	due	to	lack	of	reporting	
diabetic	 status.	 The	 results	 must	 be	 interpreted	 with	 caution	 until	 this	 study	 can	 be	
repeated	with	larger	numbers.		
The	amount	of	2-SC	was	 significantly	elevated	 (p<0.0001,	unpaired	 t-test)	 in	 adenoma	
tissue	 compared	 to	 matched	 normal	 tissue	 (Figure	 3.3.A,	 Table	 3.3,	 A.3.3,4).	 In	 non-
diabetic	patients,	2-SC	is	significantly	elevated	in	adenoma	tissue	compared	to	matched	
normal	tissue	(p<0.0001,	Figure	3.3.B,	Table	A.3.3,4).	In	T2D	patients,	2-SC	was	elevated	
in	adenoma	tissue	compared	to	matched	normal	tissue	but	was	not	significant.	There	was	
no	significant	difference	in	adenoma	2-SC	score	between	T2D	patients	and	non-diabetic	
patients.		
When	 the	2-SC	 score	of	 the	normal	 tissue	was	 taken	away	 from	the	2-SC	 score	of	 the	
adenoma	 tissue,	 there	 was	 no	 significant	 difference	 between	 non-diabetic	 and	 T2D	
patients	 (Figure	 3.3.C.	 Table	 A.3.3).	 There	 was	 a	 greater	 difference	 in	 the	 2-SC	 score	
between	adenoma	and	normal	tissue	in	the	non-diabetic	patient	group	compared	to	T2D	
patients.	In	non-diabetic	patients,	the	2-SC	score	was	higher	in	the	adenoma	compared	to	
the	matched	normal	in	91.30%	and	lower	in	8.70%.	In	T2D	patients	the	2-SC	score	was	
higher	 in	 the	adenoma	compared	to	 the	matched	normal	 in	 in	87.50%	of	patients	and	
lower	in	12.50%.	
These	results	suggest	that	succination	is	present	in	elevated	levels	at	the	early	stages	of	
CRC,	however,	 the	presence	of	T2D	 leads	 to	 lower	2-SC	scores.	This	 suggests	 that	T2D	
could	be	more	influential	on	the	level	of	2-SC	in	more	advanced	stages	of	CRC.		
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Figure	3.3.	2-SC	score	in	matched	normal	and	adenoma	tissue	from	non-diabetics	and	
T2Ds.	 IHC	 was	 carried	 out	 on	 tissue	 sections	 with	 2-SC	 antibody.	 Sections	 were	 then	
scored	by	Roger	Feakins	a	consultant	pathologist.	(A)	2-SC	score	of	matched	normal	and	
adenoma	 tissue	 (n=26).	 Unpaired	 two-tailed	 t-test	 was	 performed.	 (B)	 2-SC	 score	 of	
matched	normal	and	adenoma	tissue,	 spilt	 into	non-diabetic	 (n=19)	and	diabetic	 (n=7)	
patients.	 (C)	 Adenoma	 minus	 normal	 2-SC	 scores	 for	 matched	 tissue.	 All	 mean±SEM		
(Table	3.3).	****	p<0.0001.	Statistics	details	in	Table	A.3.3,4.	
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Table	3.3.	Summary	of	2-SC	scores	for	matched	normal	and	adenoma	tissue.	Data	shown	
as	mean	±	SEM.	See	also	Figure	3.3.		
	 	 2-SC	score	
	 Number	 Normal	 Adenoma	 Adenoma	-	Normal	
Total		 30	 16.17±2.27	 65.80±7.02	 46.63±7.41	
ND		 23	 15.76±2.84		 72.00±8.18	 56.24±8.81	
T2D		 7	 17.50±3.00	 45.43±11.23	 27.93±10.08	
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3.5	2-SC	score	is	significantly	different	between	adenoma	and	CRC		
Overall,	2-SC	score	in	normal	tissue	was	significantly	lower	than	the	2-SC	score	found	in	
both	 adenoma	 and	 CRC	 tissue	 (p<0.0001,	 one-way	 ANOVA)	 (Figure	 3.4.A,	 Table	 3.4,	
A.3.5,6).	There	was	also	a	small	 significant	difference	between	adenoma	and	CRC	2-SC	
score	(p=0.0432)	(Table	3.4).		
In	non-diabetic	patients,	2-SC	was	significantly	lower	in	normal	tissue	when	compared	to	
adenoma	 tissue	 and	 CRC	 tissue	 (p<0.0001)	 (Figure	 3.4.A,	 Table	 3.4,	 A.3.7,8)	 and	 no	
significant	difference	was	observed	between	adenoma	and	CRC	tissue.	In	T2D	patients,	2-
SC	 was	 also	 significantly	 lower	 in	 normal	 tissue	 when	 compared	 to	 adenoma	 tissue	
(p=0.001)	 and	 CRC	 tissue	 (p<0.0001)	 (Figure	 3.4.B,	 Table	 3.4,	 A.3.7,8).	 There	 was	 a	
significant	difference	between	adenoma	and	CRC	tissue	in	T2Ds	(p=0.001).		
These	data	further	confirm	a	role	for	succination	in	CRC	progression	as	well	as	a	role	for	
T2D	in	increasing	the	presence	of	succination	in	CRC	patient	samples.		
Nevertheless,	2-SC	is	consistently	found	at	an	elevated	level	compared	to	normal	tissue	
within	 adenoma	 and	 CRC	 samples,	 again	 confirming	 a	 role	 for	 succination	 in	 CRC	
progression	(Table	3.5).		
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Figure	3.4.	 2-SC	 score	 in	 total	normal,	 adenoma	and	CRC	 tissue	 in	non-diabetics	 and	
T2Ds.	 IHC	 was	 carried	 out	 on	 tissue	 sections	 with	 2-SC	 antibody.	 Sections	 were	 then	
scored	by	a	pathologist.	(A)	2-SC	score	of	normal	(n=94),	adenoma	(n=30)	and	CRC	tissue	
(n=83).	One-way	ANOVA	was	 performed.	 (B)	 2-SC	 score	 of	 normal,	 adenoma	and	CRC	
tissue,	 spilt	 into	 non-diabetic	 (normal	 n=67,	 adenoma	 n=23,	 CRC	 n=57)	 and	 diabetic	
(normal	 n=27,	 adenoma	 n=7,	 CRC	 n=26)	 patients.	 All	 mean±SEM	 in	 Table	 3.4.		
****	p<0.0001,	***	p<0.001,	**	p<0.01,	*	p<0.05.	Statistics	details	in	Table	A.3.5,6,7,8.		
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Table	3.4.	Summary	of	2-SC	score	in	total	normal,	CRC	adenoma	and	CRC	tissue.	Data	
shown	as	mean	±	SEM.	See	also	Figure	3.4.A.	
	 Number	 2-SC	score	
	 Normal	 Adenoma	 CRC	 Normal	 Adenoma	 CRC	
Total	 94	 30	 83	 19.35±1.87	 67.55±6.92	 84.49±5.22	
ND	 67	 23	 57	 18.37±2.11		 72.00±8.18	 75.05±5.55	
T2D	 27	 7	 26	 21.76±3.91	 50.50±10.98	 105.19±10.46	
	
Table	 3.5.	 Percentage	of	 2-SC	 staining	 20%	above	 the	mean	of	 2-SC	 score	of	 normal	
tissue.	T2D	normal	n=27,	adenoma	n=7,	CRC	n=26.	ND	normal	n=67,	adenoma	n=23,	CRC	
n=57.		
	 Samples	with	2-SC	staining	20%	above	the	mean	of	2-SC	
score	of	normal	tissue	
Tissue	 All	 T2D	 ND	
Adenoma		 86.67%	 71.43%	 91.30%	
CRC	 91.57%	 96.15%	 89.47%	
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3.6	FH	is	present	at	high	levels	in	CRC	tissue	
Patients	with	HLRCC	have	loss	of	expression	mutations	 in	FH	which	results	 in	fumarate	
accumulation	 and	 extremely	 elevated	 levels	 of	 2-SC.	 No	 FH	 mutations	 have	 been	
identified	in	CRC	patient	samples	to	date.	It	was	hypothesised	that	where	2-SC	staining	is	
high,	FH	staining	would	be	low.	
A	small	selection	(4)	of	normal	and	CRC	tissue	serial	sections	were	stained	for	2-SC	and	FH	
by	 Julie	 Adam.	 Some	 representative	 images	 are	 shown	 in	 Figure	 3.5.	 Interestingly,	 FH	
staining	was	consistently	present	in	normal	tissue	and	consistently	elevated	in	CRC	tissue,	
especially	those	with	high	2-SC	scores.		
This	observation	suggests	that	FH	is	present	in	CRC	tissue,	but	unable	to	control	the	level	
of	fumarate,	leading	to	elevated	levels	of	succination.	The	role	of	FH	in	CRC	tumorigenesis	
is	further	investigated	in	Chapter	4	and	5.		
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Figure	3.5.	Representative	images	of	2-SC	and	FH	IHC	on	serial	sections.	Serial	normal	
and	CRC	tissue	sections	were	stained	for	2-SC	and	FH	by	Julie	Adam.	(A)	Normal	tissue	
stained	for	2-SC,	low	score.	(B)	Serial	normal	tissue	to	(A)	stained	for	FH.	(C)	CRC	tissue	
stained	for	2-SC,	high	score.	(D)	Serial	CRC	tissue	to	(C)	stained	for	FH.	(E)	Close	up	of	(A),	
(F)	close	up	of	(B),	(G)	close	up	of	(C),	(H)	close	up	of	(D).	(A-D)	Scale	bar	250µm,	(E-H)	
scale	bar	100µm).	
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3.7	KRAS/BRAF	mutation	status	influences	succination	in	CRC	patients.		
Fumarate	 generates	 2-SC,	 therefore,	 if	 there	 is	 an	 increased	 level	 of	 2-SC,	 it	 could	 be	
assumed	that	 fumarate	 is	also	elevated.	Fumarate	 is	a	metabolite	of	the	TCA	and	urea	
cycle.	 Mutations	 in	 KRAS	 and	 BRAF	 have	 recently	 been	 postulated	 to	 be	 linked	 with	
changes	in	cancer	cell	metabolism.	KRAS	and	BRAF	mutations	are	found	in	approximately	
40%	and	10%	of	CRC	cases	respectively.	It	was	hypothesised	that	the	presence	of	KRAS	or	
BRAF	mutation	could	promote	succination	by	altering	fumarate	metabolism.		
Thirty-eight	CRC	patient	samples	in	the	cohort	examined	above	had	already	been	KRAS	
and	BRAF	genotyped	by	the	Royal	London	Hospital	Core	Pathology.	For	the	remaining	40,	
DNA	was	extracted	 from	CRC	FFPE	sections	or	 frozen	tissue.	To	ensure	CRC	tissue	was	
used	for	genotyping	it	was	first	confirmed	by	Roger	Feakins.	PCR	was	completed	for	the	
most	common	mutations	which	are	codons	12	and	13	of	KRAS378	and	the	V600E	mutation	
of	BRAF379.	First,	the	PCR	was	optimised	to	give	a	200bp	product	for	KRAS	and	a	224bp	
product	 for	 BRAF	 (Figure	 3.6.A,B).	 PCR	 product	 was	 cleaned	 and	 sent	 for	 Sanger	
sequencing	 (Chapter	 2,	 Section	 2.1.6).	 The	 single	 nucleotide	 polymorphism	 (SNP)	
mutations	shown	in	Figure	3.6.C	were	identified	from	the	traces.	The	mutations	were	then	
matched	to	the	tissue’s	corresponding	2-SC	score.	Representative	examples	of	WT	and	
mutant	Sanger	sequence	traces	for	KRAS	and	BRAF	are	shown	in	Figure	3.6.D,E.		
It	was	found	that	40.5%	of	CRC	tissue	samples	had	either	a	KRAS	or	BRAF	mutation;	31.6%	
had	a	KRAS	mutation	and	8.9%	a	BRAF	mutation.	These	results	are	in	line	with	findings	
from	previous	studies29,380–383.		
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C.	Common	mutations	found	in	KRAS	and	BRAF	genes.		
	 KRAS	 BRAF	
Location	 Codon	12	 Codon	13	 V600E	
WT	 GGT	 GGC	 GTT	
Mutation	 GGG,	GGC,	GGA	GTT,	GTC,	
GTA,	GTG,	GAT	
GAT,	 GAC,	 GGT,	
GGG,	GGA	
GAA,	 GAG,	 GTC,	
GTA,	GTG	
Figure	 3.6.	 KRAS/BRAF	 PCR	 and	 Sanger	 sequencing.	DNA	 was	 extracted	 from	 frozen	
tissue	or	paraffin	sections.	PCR	was	performed	using	Qiagen	Master	Mix	then	run	on	a	2%	
agarose	gel	and	visualised	using	a	Chemi	Doc	(Chapter	2,	Section	2.1.5).	PCR	product	was	
cleaned	 using	 ExoSAP-IT	 (Qiagen)	 and	 sent	 for	 Sanger	 sequencing	 (GATC	 biotech).	 (A)	
Product	 from	 KRAS	 PCR	 (200bp).	 (B)	 Product	 from	 BRAF	 PCR	 (200bp).	 (C)	 Common	
mutations	for	KRAS	and	BRAF.	(D)	WT	KRAS	sequence,	(E)	KRAS	codon	12	sequence	with	
a	Gà	T	mutation	(circled).		
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There	 was	 an	 elevated	 2-SC	 score	 in	 CRC	 patient	 samples	 with	 mutant	 KRAS/BRAF	
compared	to	WT	patient	samples,	but	this	was	not	significant	when	tested	by	unpaired	t-
test	(p=0.2994)	(Figure	3.7.A,	Table	3.6).	When	KRAS/BRAF	mutation	status	of	CRC	tissue	
was	matched	to	2-SC	score	as	well	as	the	patient’s	diabetic	status	it	was	found	that	the	
diabetic	 status	 had	 a	 significant	 effect	 on	 2-SC	 score	 (p=0.0034)	 (Figure	 3.7.B)	 (Table	
A.3.13,14).	 CRC	 tissue	 from	non-diabetic	WT	 KRAS/BRAF	 patients	 had	 the	 lowest	 2-SC	
score	which	was	increased	with	the	presence	of	a	KRAS/BRAF	mutation.	CRC	tissue	from	
T2D	WT	patients	showed	a	further	increase	in	2-SC	score	which	again	increased	with	the	
presence	of	a	KRAS/BRAF	mutation.	The	difference	between	the	2-SC	score	of	CRC	tissue	
from	patients	with	T2D	and	KRAS/BRAF	mutation	was	significantly	different	to	that	from	
non-diabetic	WT	patients	(p=0.05)	(Figure	3.7.B,	Table	A.3.9,10).	These	data	suggest	that	
KRAS/BRAF	mutation	is	complimentary	to	the	effect	of	T2D	on	the	process	of	succination,	
leading	to	a	further	increase	in	2-SC	score.		
When	the	2-SC	score	for	the	matched	normal	tissue	is	taken	away	from	the	CRC	tissue	2-
SC	score,	there	 is	no	significant	difference	between	groups	when	tested	by	unpaired	t-
test,	 however,	 mutant	 KRAS/BRAF	 patient	 samples	 have	 a	 higher	 average	 2-SC	 score	
compared	to	WT	patient	samples	(Figure	3.7.C).	When	this	data	is	split	into	non-diabetic	
and	T2D	patients	(Figure	3.7.D),	the	same	trend	exists	as	in	Figure	3.7.B.	Non-diabetic	WT	
KRAS/BRAF	patients	had	the	lowest	2-SC	score	difference	of	which	was	increased	with	the	
presence	of	a	KRAS/BRAF	mutation.	T2D	WT	patients	showed	a	further	increase	in	2-SC	
score	 difference	 which	 again	 increased	 with	 the	 presence	 of	 a	 KRAS/BRAF	mutation	
(Figure	3.7.D,	Table	3.6).	This	is	explained	by	similar	average	normal	tissue	2-SC	score	for	
each	group.		
Between	normal	and	CRC	tissue,	the	2-SC	score	increased	in	82.14%	of	non-diabetic	WT	
patients	and	decreased	in	17.86%.	In	T2D	WT	patients	the	2-SC	score	increased	in	94.44%	
or	patients	and	decreased	in	5.56%.	The	2-SC	score	increased	in	91.67%	of	non-diabetic	
mutant	patient	samples	and	decreased	in	8.33%.	In	T2D	mutant	patient	samples	the	2-SC	
score	 increased	 in	 100%	 and	 decreased	 in	 0%.	 These	 data	 confirm	 that	 presence	 of	 a	
KRAS/BRAF	mutation	alongside	T2D	is	more	likely	to	lead	to	an	elevation	in	2-SC	score.		 	
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Figure	3.7.	KRAS/BRAF	mutation	status,	diabetic	status	and	2-SC	score	of	CRC	samples.	
CRC	samples	from	non-diabetic	and	T2D	patients	underwent	IHC	for	2-SC,	which	was	then	
scored	by	Roger	Feakins	(consultant	pathologist).	Alongside	this	DNA	extracted	from	the	
samples	and	examined	by	PCR	for	KRAS	and	BRAF	mutation	status.	PCR	product	was	sent	
for	Sanger	sequencing	and	scored	for	mutations	in	KRAS	and	BRAF.	(A)	2-SC	score	of	CRC	
tissue	from	WT	(n=46)	and	mutant	(n=32)	patients.	(B)	2-SC	score	of	CRC	tissue	from	non-
diabetic	(ND)	WT	(n=28)	and	mutant	(n=24)	patients	and	T2D	WT	(n=18)	and	mutant	(n=8)	
patients.	(C)	CRC	minus	normal	2-SC	scores	for	matched	tissue.	(D)	2-SC	score	of	matched	
normal	 and	 CRC	 tissue	 from	 WT	 and	 mutant	 patients.	 All	 mean±SEM	 in	 Table	 3.6.	
*	p<0.05.	Statistics	details	in	Table	A.3.9,10,11.	
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Table	3.6.	Summary	of	2-SC	score	for	WT	and	KRAS/BRAF	mutant	CRC	samples	from	NDs	
and	T2Ds.	Data	shown	as	mean	±	SEM.	See	also	Figure	3.7.	
	 	 2-SC	score	
	 Number	 CRC	 CRC	-	Normal	
	 WT	 Mutant	 WT	 Mutant	 WT	 Mutant	
Total	 46	 32	 78.18±	
6.85	
91.61±	
8.69	
56.60±	
7.17	
73.45±	
10.36	
ND	 28	 24	 64.16±	
6.96	
81.15±	
9.04	
44.05±	
8.18	
64.83±	
11.09	
T2D	 18	 8	 100.00±	
12.32	
116.88±	
20.29	
76.11±	
12.08	
99.31±	
23.73	
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3.8	Discussion		
	
Metabolites	 such	as	 fumarate	are	not	widely	quantitated	 in	 tissue	due	 to	high	 cost	of	
current	methods	as	well	as	a	lack	of	effective	methodology.	Metabolites	are	often	highly	
polar,	non-volatile	and	have	poor	detectability	making	analysis	difficult.	Chan	et	al.	used	
high	 resolution	 magic	 angle	 spinning-nuclear	 magnetic	 resonance	 (NMR)	 and	 gas	
chromatography	coupled	to	mass	spectrometry	(GC-MS)	to	compare	the	metabolic	profile	
of	biopsied	CRC	tumours	and	matched	normal	tissue	from	31	patients384.	They	identified	
a	reduction	of	fumarate	in	CRC	compared	to	normal	tissue.	A	similar	result	was	found	by	
Denkert	et	al.	using	GC	time-of-flight	MS	(GC-TOFMS)	for	15	paired	CRC	and	normal	tissue	
patient	samples385.	Both	of	 these	studies	showed	a	 reduction	 in	TCA	cycle	metabolites	
which	links	well	with	Otto	Warburg’s	theory	of	reduced	mitochondrial	metabolism386.		
Hirayama	et	al.	used	capillary	electrophoresis	TOFMS	 (CE-TOFMS),	which	 they	argue	 is	
more	suited	to	metabolism	analysis	due	to	its	high	resolution	and	ability	to	simultaneously	
quantify	 charged	 low-molecular	 weight	 compounds335.	 They	 identified	 an	 increase	 in	
fumarate	in	16	CRC	tissue	samples	compared	to	matched	normal.		
My	findings	are	in	accord	with	Hirayama	and	colleagues	finding	of	elevated	fumarate	in	
CRC	tissue	compared	to	matched	normal335.	In	a	cohort	of	83	matched	normal	and	CRC	
tissue,	for	the	first	time	an	elevation	in	succination,	as	measured	by	2-SC	staining,	is	shown	
(Figure	 3.2.A).	My	work	 has	 also	 shown	elevated	 succination	 in	 the	 early	 stage	 of	 the	
cancer,	 an	 adenoma,	 compared	 to	 matched	 normal	 tissue	 (Figure	 3.3.A).	 These	 data	
suggest	that	elevated	fumarate	is	an	early	event	in	CRC	tumorigenesis	and	that	protein	
succination	could	be	a	factor	influencing	tumour	development.		
Succination	in	CRC	tissue	is	further	elevated	by	the	presence	of	T2D.	This	is	another	novel	
finding.	The	trend	of	succination	in	adenomas	is	still	to	be	confirmed.	In	this	study,	the	
number	of	adenomas	with	known	T2D	status	was	 limited.	From	the	small	cohort	used,	
succination	was	 lower	 in	 tissue	 from	T2D	patients	 compared	 to	 non-diabetic	 patients,	
however,	this	was	not	significant.		
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Interestingly,	 succination	 was	 not	 significantly	 elevated	 in	 normal	 tissue	 from	 T2D	
compared	 to	 non-diabetics,	 although	 it	 was	 raised	 in	 T2D	 compared	 to	 non-diabetic	
patients.	This	suggests	that	the	elevated	fumarate	is	a	consequence	of	an	oncogenic	event	
that	has	led	to	a	change	in	cellular	metabolism,	which	is	then	exacerbated	by	the	presence	
of	T2D	and	could	be	one	reason	why	T2D	patients	with	CRC	have	a	poorer	outcome	and	
more	invasive	cancer124.	
T2D	 is	a	metabolic	disorder	where	succination	has	already	been	confirmed	elevated	 in	
certain	 tissues.	Adipocytes	 from	db/db	and	ob/ob	mice342	which	are	mouse	models	of	
human	diabetes,	and	skeletal	muscle	from	streptozotocin-induced	diabetic	rats333	were	
found	 to	 have	 elevated	 succination	 as	well	 as	 adipocytes	 treated	with	 30mM	 glucose	
versus	5mM	glucose339	in	vitro.	Interestingly,	undifferentiated	fibroblasts	cultured	in	the	
same	 high	 glucose	 media	 did	 not	 exhibit	 an	 increase	 in	 succination339	 whereas	
differentiated	3T3	 fibroblasts	do	exhibit	 increased	succination	under	30mM	glucose310.	
Frizzell	et	al.	2012	showed	that	3T3	cells	treated	with	30mM	glucose	compared	to	5mM	
also	 showed	 significant	 increases	 in	 cellular	 ATP/adenosine	 diphosphate	 (ADP),	
NADH/NAD+,	mitochondrial	membrane	 potential	 and	 cellular	 fumarate	 concentration.	
This	 was	 postulated	 to	 an	 increase	 in	 NADH/NAD+	 ratio	 resulting	 in	 the	 inhibition	 of	
NAD+-dependent	 dehydrogenases.	 Cellular	 fumarate	 and	 succination	 was	 decreased	
upon	 addition	 of	 chemical	 uncouplers	 which	 reduce	 the	 NADH/NAD+	 ratio	 and	 upon	
addition	of	metformin	(an	inhibitor	of	complex	I	in	the	ETC)	to	high	glucose	culture	media.	
The	conclusion	of	 the	study	was	that	elevated	succination	 in	diabetic	conditions	was	a	
result	of	glucotoxicity-driven	mitochondrial	stress310,343.	
Mitochondrial	 function	 is	 known	 to	 be	 deregulated	 in	 cancer387	 and	 that	 increased	
glycolysis	is	a	feature	of	cancer.	Therefore,	it	could	be	suggested	that	glucotoxicity-driven	
mitochondrial	stress	exists	within	CRC	which	leads	to	elevated	fumarate	and,	therefore,	
elevated	 succination.	 In	 turn,	 the	 glucotoxicity-driven	 mitochondrial	 stress	 is	 further	
elevated	in	patients	with	T2D,	leading	to	higher	levels	of	succination.	Unfortunately,	I	was	
unable	 to	 determine	 the	 diabetic	 treatment	 for	 the	 majority	 of	 the	 CRC	 patients,	 as	
hospital	 records	 are	 incomplete.	 Nevertheless,	 it	 would	 be	 interesting	 to	 study	 the	
succination	 levels	 in	T2D	CRC	patients	with	and	without	metformin	treatment;	 I	would	
hypothesise	that	succination	would	be	lower	in	patients	on	metformin.		
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Surprisingly,	FH	was	elevated	in	CRC	tissue	compared	to	matched	normal	(Figure	3.5).	This	
suggests	 that	 FH	 is	 upregulated	 in	 conjunction	with,	 or	 as	 a	 consequence	 of	 elevated	
fumarate,	 but	 is	 unable	 to	 remove	 the	 excess	 fumarate.	 FH	 may	 be	 dysfunctional.	
However,	 somatic	 FH	 mutations	 are	 rare	 and	 restricted	 to	 HLRCC	 patients388;	 No	 FH	
mutations	have	been	found	in	CRC	patients388.	More	work	to	determine	FH	expression	in	
this	set	of	patients	will	be	completed	so	that	more	concrete	conclusions	can	be	made.		
FH	is	a	tetrameric	enzyme,	composed	of	four	identical	subunits	of	50kDa	each389.	There	
are	3	active	sites	(site	A)	and	one	lower	affinity	site	(site	B).	A	report	by	Mescam	et	al.	
suggests	 that	 at	 low	 fumarate	 concentrations	 (<1mM)	 the	 enzyme	 shows	 Michaelis-
Menten	kinetics;	at	0.001-0.033M	allosteric	activation	of	the	enzyme	by	binding	to	site	B	
is	observed;	at	0.1M	and	above	fumarate	actually	inhibits	FH390.	Therefore,	it	could	be	that	
fumarate	 itself	 is	 inhibiting	 the	 action	 of	 FH,	 leading	 to	 further	 increases	 in	 fumarate.	
Hirayama	et	al.	showed	that	the	fumarate	concentration	in	colon	tumour	was	around	an	
average	 of	 50nmol/g	 which	 is	 equivalent	 to	 50mM	 and,	 therefore,	 close	 to	 allosteric	
inhibition.	This	is	an	average	concentration	and	local	concentrations	maybe	much	higher	
leading	to	inhibition.		
Approximately	35-40%	of	human	CRCs	have	an	activating	missense	mutation	in	KRAS380–
383.	These	affect	hotspots	in	codons	12	and	13	which	lock	KRAS	in	an	active	GTP-bound	
conformation,	 constitutively	 presenting	 a	 docking	 surface	 for	 RAF	 kinases391.	 BRAF	
mutations	 are	 found	 in	 10%	 of	 CRCs,	 and	 are	 most	 likely	 to	 be	 a	 V600E	 amino	 acid	
substitution,	 although	 other	 mutations	 at	 codon	 600	 or	 neighbouring	 positions	 are	
documented29.	 The	 presence	 of	 these	mutations	 in	 our	 cohort	 is	 in	 accord	with	 these	
results	 and	 were	 selected	 for	 examination	 as	 they	 are	 amongst	 the	 most	 prevalent	
mutations	found.		
Although	the	use	of	KRAS	and	BRAF	mutation	status	as	a	predictive	biomarker	of	response	
to	 anti-EGFR	 therapy	 is	well	 supported,	 there	 are	 inconsistencies	within	 the	 literature	
regarding	the	association	between	KRAS	and	BRAF	mutations	and	CRC	survival.	There	are	
discrepancies	related	to	specific	mutations,	age,	stage	at	diagnosis	and	treatment.	The	
largest	 study	 to	 date,	 included	 4268	 patients	 from	 42	 centres	 in	 21	 countries	 in	 a	
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collaborative	database	called	RASCAL	(The	Kirsten	ras	in-colorectal-cancer	collaborative	
group)392.	They	identified	that	only	one	mutation	of	codon	12,	the	KRAS	p.G12V	mutation,	
found	in	8.6%	of	patients	had	a	statistically	significant	impact	on	outcome,	but	only	among	
patients	with	Dukes’	C	CRC392.	BRAF	mutation	is	associated	with	poorer	survival	of	CRC	
patients29,393.	Unfortunately,	the	specific	KRAS	or	BRAF	mutation	is	not	reported	in	patient	
notes,	therefore,	it	was	not	possible	to	distinguish	the	effect	of	specific	KRAS	and	BRAF	
mutations	on	2-SC	score	in	this	study.		
In	vitro	data	identified	that	HCT116	and	DLD1	CRC	cell	lines	with	KRAS	mutations	increase	
GLUT1	expression	after	4	days	of	culture	in	0.5mM	glucose,	leading	to	increased	glucose	
uptake	and	increased	lactate	production,	although	mitochondrial	function	and	oxidative	
respiration	were	not	 affected394.	 It	was	 also	 shown	 that	 the	WT	KRAS	CRC	 cells	which	
survived	4	days	of	culture	with	0.5mM	glucose	increased	their	mutation	rate	of	KRAS	to	
increase	 GLUT1	 expression	 and,	 therefore,	 glucose	 uptake394.	 Another	 study	 which	
involved	8	KRAS	WT	and	8	KRAS	mutant	human	colon	tumours	identified	an	association	
between	a	2-fold	 increase	 in	expression	of	glycolytic	and	glutamine	metabolic	proteins	
and	KRAS	mutation	status376.	KRAS	mutation	in	CRC	has	also	been	found	to	affect	amino	
acid	metabolism.	Human	CRC	cell	lines	and	clinical	specimens	with	KRAS	mutation	were	
found	 to	have	an	 increase	 in	asparagine	 synthetase	 (ASNS)	which	was	 induced	via	 the	
PI3K-AKT-mTOR	pathway395.	Subsequent	knock	down	of	ASNS	 in	KRAS	mutant	CRC	cell	
lines	led	to	growth	suppression.	It	was	also	found	that	asparagine	addition	prevented	cell	
death	from	glutamine	depletion.	Weinberg	et	al.	 reported	that	the	pentose	phosphate	
pathway	(PPP),	not	glycolysis	was	essential	for	KRAS	mutant	CRC	cell	growth396.	Miyo	et	
al.	reported	that	in	KRAS	mutant	CRC	cell	lines	resistance	to	glucose-deprived	conditions	
is	 associated	 with	 increased	 levels	 of	 both	 GLUD1	 and	 SLC25A13	 (a	 mitochondrial	
aspartate-glutamate	carrier)397.		
From	 the	 work	 detailed	 above	 it	 is	 clear	 that	 KRAS	 mutations	 influence	 cancer	 cell	
metabolism	in	a	cell	and	tissue	dependent	manner.	It	has	also	been	reported	that	KRAS	
driven	NSCLC	cells	 in	vitro	use	nutrients	differently	compared	to	human	 lung	tumours;	
KRAS	mutant	tumours	were	less	dependent	on	glutaminase	that	NSCLC	cells	 in	vitro398.	
This	highlights	the	importance	of	studying	cancer	metabolism	in	a	physiological	context.	
More	work	is	needed	to	determine	the	exact	role	of	KRAS	in	cancer.		
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Currently,	 there	 is	 no	 literature	 which	 link	 KRAS	 or	 BRAF	mutation	 to	 an	 increase	 in	
succination.	 This	 study	 hypothesised	 that	 presence	 of	 KRAS	 or	 BRAF	mutation	 would	
increase	succination	via	increased	use	of	the	TCA	cycle.	The	data	show	that	there	is	no	
significant	effect	of	KRAS	or	BRAF	mutation	status	on	2-SC	score.	However,	 there	 is	an	
increase	 in	2-SC	 score	 in	 samples	 from	patients	with	 T2D	and	KRAS	or	BRAF	mutation	
combined	 compared	 to	 samples	 from	 non-diabetic	 KRAS	 or	 BRAF	WT	 patients.	 This	
suggests	 an	 interaction	 between	 T2D	 and	 KRAS	 or	 BRAF	 mutation	 which	 could	 be	
attributed	to	greater	glucose	availability	and	increased	ability	to	uptake	glucose	leading	
to	more	succination.	I	would,	therefore,	hypothesise	that	KRAS	mutant	CRC	cells	would	
channel	glucose-derived	metabolites	into	the	TCA	cycle	to	a	greater	extent	than	KRAS	WT	
CRC	cells	and,	therefore,	lead	to	increased	fumarate	and	increased	succination.		
This	chapter	presented	evidence	that	fumarate	is	elevated	in	the	early	stage	of	CRC,	an	
adenoma.	There	is	increased	succination	in	both	adenoma	and	CRC	tissue	compared	to	
match	 normal	 tissue.	 Succination	 in	 CRC	 is	 further	 increased	 in	 the	 presence	 of	 T2D.	
Additionally,	 the	 2-SC	 staining	 was	 non-uniform	 across	 tumours,	 underlining	 the	
metabolic	heterogeneity	of	CRC	tissue.	T2D	patients	with	KRAS/BRAF	mutation	exhibit	a	
further	 increase	 in	 succination	 compared	 to	 T2D	 patients	 with	 WT	 KRAS/BRAF.	 The	
possibility	 of	 a	 link	 between	 2-SC	 score	 and	 patient	 prognosis	 requires	 further	
investigation	 and	would	 be	 an	 interesting	 avenue	 to	 pursue.	 The	 functional	 effects	 of	
succination	are	likely	to	be	wide-spread	and	would	take	more	time	to	investigate	through	
collaboration.	Additionally,	the	role	of	FH	in	CRC	patients	should	be	further	investigated	
(Chapter	8,	Section	8.1).	Here,	 I	 found	FH	 is	present	 in	CRC	tissue	at	an	elevated	 level,	
although	 it	 remains	 to	be	determined	 if	FH	 is	 fully	active	or	 inhibited	by	high	 levels	of	
fumarate.	 Loss	 of	 function	 at	 the	 genetic	 levels	 is	 less	 likely,	 as	 there	 are	 no	 known	
mutations	in	FH	in	CRC	patients.	
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Chapter	4	–	Influence	of	diabetes	on	intestinal	polyp	numbers	in	mice		
4.1	Introduction	
The	work	described	in	Chapter	3	raises	further	questions	about	the	role	of	diabetes	in	the	
development	of	CRC.	As	it	 is	known	that	the	presence	of	T2D	in	humans	leads	to	more	
serious	CRC	features	such	as	more	advanced	stage	at	presentation124,	it	was	hypothesised	
that	diabetes	in	mice	would	also	lead	to	enhanced	tumour	multiplicity	and	progression.	
Hence,	a	novel	mouse	model	was	generated	by	crossing	a	mouse	commonly	used	to	study	
polyps	in	the	small	intestine15	(Apc1322T)	with	a	novel	diabetic	mouse	model268	(Fh1flox/flox	
RipCre	 CAGFH);	 	 models	 were	 introduced	 in	 Chapter	 1,	 Section	 1.10	 and	 Section	 1.12,	
respectively.	 The	 breeding	 steps	 are	 outlined	 in	 Figure	 4.1	 and	 described	 below;	 for	
further	details,	refer	to	Chapter	2,	Section	2.2.1.	All	animals	used	were	backcrossed	on	a	
C57BL/6J	 background	 at	 least	 3	 times	 and	 littermate	 controls	 were	 used.	 Animal	
experiments	were	conducted	in	accordance	with	the	UK	Animals	Scientific	Procedures	Act	
(1986)	and	University	of	Oxford	local	ethical	guidelines	under	the	direction	of	Dr	J	Adam.	
The	novel	diabetic	model	 (Fh1flox/flox	RipCre	CAGFH	mice268	 (designated	Fh1βKO	mice	 for	 this	
thesis))	was	 originally	 generated	 by	 inter-crossing	 an	Fh1	 conditional	 knockout	mouse	
(Fh1tm1Pjpfl/fl)325	with	mice	expressing	Cre	recombinase	driven	by	the	rat	insulin	promoter	
(Tg(Ins2-Cre)23HerrCre	recombinase,	Rip2-Cre+/-)267.	Thus,	a	tissue-specific	RipCre	promoter	
was	used	to	knock	out	Fh1	 in	the	β-cells	of	the	pancreas	by	recombination	(Chapter	2,	
Section	2.2.1).	Mice	lacking	Fh1	in	pancreatic	β-cells	have	elevated	fumarate	that	leads	to	
fumarate	accumulation,	which	competitively	inhibits	PHDs	which	leads	to	stabilisation	of	
HIF-1α,	as	well	as	a	reduction	in	intracellular	calcium	levels.	This	leads	to	a	reduction	in	
glucose	stimulated	insulin	secretion	and	blood	glucose	levels	consistent	with	those	seen	
in	an	uncontrolled	T2D	human268.	The	mice	display	progressive	diabetes	and	are	initially	
normoglycaemic.	
Fh1βKO	 mice	 become	 very	 diabetic	 by	 approximately	 16	 weeks	 of	 age	 (with	 a	 blood	
glucose	of	>33.3mM)268	so	it	is	not	possible	to	use	female	Fh1βKO	for	breeding	purposes.	
Also,	 the	pups	of	 a	diabetic	mother	become	diabetic	much	 faster	 To	enable	breeding,	
Fh1βKO	mice	were	crossed	with	mice	stably	expressing	the	cytoplasmic	form	of	human	
FH,	 under	 the	 CAG	 promoter	 (designated	 FHcyt	 for	 this	 thesis)330	 to	 generate	
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Fh1tm1PjpGt(ROSA)26Sortm1(CAG-FH*)PjpTg(Cdh16-cre)91Igr	 (designated	 Fh1βKO	 FHcyt	 for	 this	
thesis	to	designate	that	that	the	FH	is	human	and	added	to	the	mouse).	Introduction	of	
FHcyt	as	well	as	full	length	FH	has	been	shown	to	fully	reverse	the	glucose	intolerance	of	
Fh1βKO	mice,	as	tested	in	a	glucose	tolerance	test,	and	maintains	them	with	only	a	slightly	
elevated	blood	glucose	compared	to	WT	for	>1	year268.	Female	Fh1βKO	FHcyt	mice	were	
then	 intercrossed	 with	 male	 Apc1322T	 mice	 (designated	 1322	 for	 this	 thesis).	 Female	
Apc1322T	mice	cannot	be	used	for	breeding	purposes	because	the	mice	become	sick	due	to	
the	polyp	burden	and	anaemia.	
The	addition	of	cytoplasmic	FH	allowed	 the	 role	of	FH	 in	 tumourigenesis	 to	be	 further	
scrutinised.	Cytoplasmic	FH	has	a	role	in	the	urea	cycle,	and	it	can	also	translocate	to	the	
nucleus	to	aid	repair	of	double	strand	breaks	in	DNA399.	It	is	unclear	if	the	high	levels	of	
FH	 shown	 in	 the	 human	 CRC	 samples	 are	 cytoplasmic,	 nuclear	 and/or	 mitochondrial.	
Ideally,	 a	 mouse	 model	 with	 overexpression	 of	 mitochondrial	 Fh1	 with	 and	 without	
overexpression	of	cytoplasmic	Fh1	in	the	gut	tissue	would	be	used	to	determine	the	effect	
of	FH	position	on	polyposis	in	the	mouse.	However,	these	models	were	not	available	for	
use	in	this	study.		
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4.1.1	Hypotheses	
I	hypothesised	that	mice	with	diabetes	will	have	more	and/or	larger	polyps	compared	to	
non-diabetic	mice	 and	mice	with	overexpression	of	 FH	will	 have	 fewer	 and/or	 smaller	
polyps.	I	also	hypothesised	that	diabetes	may	alter	the	cellular	profile	of	the	gut.		
4.1.2	Aims	
• Create	 and	 a	 phenotype	 a	 mouse	 model	 predisposed	 to	 both	 diabetes	 and	
intestinal	polyposis.	
• Overexpress	FH	as	a	rescue	of	diabetes	in	the	diabetic/polyposis	mouse	model.		
In	this	chapter,	statistical	significance	was	determined	by	ordinary	one-way	ANOVA	with	
Bonferroni	 post-hoc	 test	 unless	 otherwise	 stated.	 Statistically	 significant	 results	 are	
denoted	with	*	in	figures,	exact	p	values	can	be	found	in	the	appendix	(Chapter	9).	
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4.2	Genotyping	of	mice		
The	crossing	of	these	two	mouse	lines	generated	eight	genotypes	that	are	summarised	in	
Table	 4.1	 along	with	 their	 denoted	 name,	 diabetic	 and	 polyp	 phenotype	 and	 purpose	
(Figure	 4.1).	 All	 the	 genotypes	 were	 compared	 in	 the	 following	 investigations	 in	 this	
chapter.	 Of	 main	 interest	 was	 the	 Fh1βKO	 1322	 genotype,	 which	 was	 genetically	
predisposed	to	polyps	in	the	small	intestine	and	to	T2D.		
Ear	tissue	biopsies	were	used	to	check	the	genotype	of	mice	shortly	after	weaning,	(three	
weeks	of	age),	tail	tissue	was	used	to	check	recheck	genotyping	after	culling	and	was	done	
in	all	cases.	Ear	and	tail	tissue	was	digested,	DNA	extracted	and	PCR	performed	for	four	
alleles	by	PCR:	Fh1flox/flox,	RipCre,	FHcyt	and	Apc1322T.	PCR	products	were	run	on	2%	agarose	
gels	and	the	genotype	of	the	mice	determined	Chapter	2,	Section	2.2.2.			
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Figure	4.1.	Breeding	details	of	the	Fh1flox/flox	Apc1322+/-	mice	model.	Schematic	diagram	to	
show	the	breeding	steps	taken	to	create	the	experimental	mice	used	in	this	study.		
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Table	 4.1.	 Description	 of	 the	 resultant	 phenotype	 and	 purpose	 for	 each	 mouse	
genotype.	T2D	status	determined	using	parameters	explained	in	Table	1.6.		
Genotype	
name	
Genotype	explanation	 Phenotype	 Purpose	
T2D	 Polyps	 	
WT	 WT	C57BL/6J	mouse	 No		 No		 No	 polyps;	 control	 for	
1322	1322	 Apc1322T	allele	
	
No	 Yes	 Polyp	control	
FHcyt	 FH	 overexpressed	 in	 the	
cytoplasm	of	all	somatic	cells	
No	 No		 No	polyp	control	for	FHcyt	
1322	
FHcyt	1322	 FH	 overexpressed	 in	 the	
cytoplasm	 of	 all	 somatic	
cells,	Apc1322	allele	
	
No	 Yes		 To	 study	 the	 effect	 of	
overexpression	 of	 FH	 in	
gut	 epithelial	 cells	 on	
polyp	burden	
Fh1βKO	
FHcyt	
No	 Fh1	 in	 β-cells,	 FH	
overexpressed	 in	 the	
cytoplasm	of	all	somatic	cells	
	
Pre-
diabetes	
No		 No	 polyp	 control	 for	
Fh1βKO	FHcyt	1322	
Fh1βKO	
FHcyt	1322	
No	 Fh1	 in	 β-cells,	 FH	
overexpressed	 in	 the	
cytoplasm	 of	 all	 somatic	
cells,	Apc1322	allele	
	
Pre-
diabetes	
Yes	 To	 study	 the	 effect	 of	
pre-diabetic	 blood	
glucose	 coupled	 with	
overexpression	 of	 FH	 in	
gut	 epithelial	 cells	 on	
polyp	burden	
Fh1βKO	 No	Fh1	in	β-cells	
	
Yes	 No	 No	 polyp	 control	 for	
Fh1βKO	1322	
Fh1βKO	
1322	
No	 Fh1	 in	 β-cells,	 Apc1322	
allele	
	
Yes	 Yes	 To	 study	 the	 effect	 of	
diabetes	 on	 polyp	
burden		
	 	
	 145	
4.3	Genotyping	for	Mom-1	locus	shows	all	mice	are	Mom-1s	
There	are	two	forms	of	the	Mom-1	allele367	which	form	different	products	when	incubated	
with	the	restriction	endonuclease	BamH1.	The	Mom-1S	allele	is	not	digested	so	retains	a	
500bp	length,	whereas	the	Mom-1R	allele	forms	400bp	and	100bp	products367,370	(Figure	
4.2).	Mice	with	Mom-1S	allele	are	susceptible	to	higher	numbers	of	polyps.	Mice	with	the	
Mom-1R	allele	are	resistant	to	polyp	formation	and	mice	present	with	fewer	polyps367,370.	
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Figure	 4.2.	Mom-1	 genotyping.	 (A)	 Schematic	 representation	 of	 BamH1	 digestion	 of	
Mom-1	alleles.	The	Mom-1S	allele	does	not	have	a	BamH1	restriction	site	and,	therefore,	
the	PCR	product	 remains	 intact,	whereas	 the	Mom-1R	allele	PCR	product	has	a	BamH1	
restriction	site,	which	is	digested	by	BamH1	restriction	enzyme	to	give	a	400bp	and	100bp	
fragment.	 (B)	 PCR	 for	Mom-1	 was	 performed,	 product	was	 incubated	with	 BamH1	 to	
determine	if	mice	were	resistant	to	polyps	(Mom-1R)	or	susceptible	to	polyps	(Mom-1S).	
Two	gels	were	run	due	to	number	of	samples	used.		
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4.4	Fh1βKO	and	Fh1βKO	1322	mice	are	diabetic	
It	 was	 necessary	 to	 determine	 that	 the	 blood	 glucose	 of	 the	 mice	 generated	 by	 the	
crossing	Fh1βKO	FHcyt	mice	with	Apc1322T	mice	was	as	predicted.	It	was	unlikely	that	the	
Apc1322T	allele	would	interfere	with	the	diabetic	phenotype	generated	by	the	presence	of	
the	 Fh1βKO	 and/or	 FHcyt	 alleles.	 Before	 culling,	 an	 Accu-check	 monitor	 was	 used	 to	
measure	blood	glucose	level	from	tail	vein	blood.	This	was	done	within	the	same	3-hour	
time	window	of	the	day	to	reduce	variation	due	to	day/night	feeding.	Table	4.1	details	the	
diabetic	status	of	the	genotypes.	This	is	expanded	and	explained	below.		
As	 expected,	 Fh1βKO	 and	 Fh1βKO	 1322	mice	 had	 significantly	 higher	 blood	 glucose	
compared	to	all	other	genotypes	(p<0.0001)	(Figure	4.3,	Table	A.4.2,3);	Fh1βKO	mice	were	
strongly	diabetic	with	 the	maximum	read	on	the	blood	glucose	monitor	 (33.3	mmol/L)	
reached	 for	 71%	 (10	 out	 of	 14)	 of	 these	mice.	 Fh1βKO	 1322	mice	 had	 a	 lower	 blood	
glucose	 reading	 compared	 to	Fh1βKO	mice,	 as	well	 as	 a	 larger	 range	of	blood	glucose	
values	(Figure	4.3.A,	Table	4.2).	Fh1βKO	FHcyt	and	Fh1βKO	FHcyt	1322	mice	had	lower	blood	
glucose	levels	compared	to	the	Fh1βKO	and	Fh1βKO	1322	mice	respectively	(Figure	4.3.A,	
Table	A.4.1).	All	other	genotypes	had	pre-diabetic	levels	of	blood	glucose	(Figure	4.3.A,	
Table	A.4.1).	There	was	no	difference	in	blood	glucose	levels	between	male	and	female	
mice	of	the	same	genotype	(Figure	4.3.B).		
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Figure	4.3.	Blood	glucose	of	mice.	Blood	glucose	from	the	tail	vein	was	measured	with	an	
Accu-Check	monitor	 immediately	before	culling.	Blood	glucose	(mean	±	SEM,	details	 in	
Table	A.4.1)	(A)	in	the	total	cohort	and	(B)	in	males	(M)	and	females	(F).	WT	n=25,	1322	
n=12,	FHcyt	n=9,	FHcyt	1322	n=16,	Fh1βKO	FHcyt	n=16,	Fh1βKO	FHcyt	1322	n=9,	Fh1βKO	n=14	
and	Fh1βKO	1322	n=9.	*	p<0.05,	**	p<0.01,	***	p<0.001.	Statistics	details	in	Table	A.4.1,2.		
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Table	 4.2.	 Summary	 of	 blood	 glucose	 for	 each	 mouse	 genotype.	 Normal	 <8.3,	 pre-
diabetic	8.3-13.9,	diabetic	>13.9266.	Data	shown	as	mean	±	SEM.	Figure	4.3.		
Genotype	 Number	 Blood	glucose	(mmol/L)	
WT	 25	 8.6±0.2	
1322	 12	 9.1±0.3	
FHcyt	 9	 8.9±0.2	
FHcyt	1322	 16	 9.2±0.4	
Fh1βKO	FHcyt	 16	 12.4±0.4	
Fh1βKO	FHcyt	1322	 9	 11.2±0.6	
Fh1βKO	 14	 31.8±0.8	
Fh1βKO	1322	 9	 24.5±3.0	
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4.5	Glucose	metabolomics	
Polyps	 and	 adjacent	 normal	 tissue	 samples	 from	each	mouse	 genotype	with	 the	1322	
allele	were	 snap	 frozen	by	Dr	 Julie	Adam	and	glucose	concentration	was	measured	by	
Tomoyoshi	Soga	(Keio	University,	Japan)	(methods	detailed	in	Chapter	2,	Section	2.2.8).	
Data	is	presented	here	to	provide	additional	clarity	on	the	mouse	model	used	(Figure	4.4,	
Table	4.3	for	mean	±	SEM).		
Although	no	significant	difference	in	gut	tissue	[glucose]	was	found	between	genotypes,	
it	can	be	seen	that	on	average	the	[glucose]	was	lower	in	the	corresponding	polyp	tissue	
compared	to	the	normal	tissue	from	each	genotype,	suggesting	that	the	polyp	tissue	was	
utilising	the	glucose	more	for	metabolism	(Figure	4.4).		
Although	not	significantly	different,	 [glucose]	 in	 the	gut	 tissue	was	 the	highest	 in	mice	
with	the	Fh1βKO	allele.	When	the	FHcyt	allele	is	present	in	mice	it	led	to	a	reduction	in	gut	
tissue	[glucose]	by	half	when	compared	to	gut	tissue	from	mice	with	the	Fh1βKO	mice.		
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Figure	 4.4.	 Glucose	 concentration	 in	 normal	 (N)	 and	 polyp	 (P)	 tissue	 from	 each	
genotype.	Normal	and	polyp	tissue	was	flash	frozen	and	[glucose]	was	measured	by	CE-
TOF/M.	Mean	±	SEM	found	in	Table	A.4.4.		
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Table	 4.3.	 Summary	 of	 glucose	 (nmol/g)	 from	 normal	 and	 polyp	 samples	 from	 each	
genotype.	Data	shown	as	mean	±	SEM.	N=3	per	genotype.	See	also	Figure	4.4.		
	
	
	
	
	
	
	
	
	 	
Genotype	 Normal	(N)	or	polyp	(P)	tissue	 Glucose	(nmol/g)	
1322	 N	 1159.98±799.47	
P	 661.53±204.61	
FHcyt	1322	 N	 599.19±313.55	
P	 350.13±74.60	
Fh1βKO	FHcyt	1322	 N	 3149.63±1062.75	
P	 2671.35±1336.71	
Fh1βKO	1322	 N	 8020.27±4208.49	
P	 6564.43±3851.36	
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4.6	Total	gut	length	but	not	width	was	increased	in	Fhβ1KO	mice	
When	removing	the	guts	of	the	mice	for	further	analysis	it	was	noted	that	the	length	of	
the	gut	from	the	start	of	the	intestine	to	the	anus	was	longer	in	diabetic	mice	compared	
to	 non-diabetic	 animals.	 The	 gut	 is	 very	 delicate	 once	 removed	 from	 the	 body,	 so	 to	
preserve	 the	 architecture	 the	 tissue	was	 fixed	 immediately	 as	 described	 in	 Chapter	 2,	
Section	2.2.3.	Guts	were	 then	split	 into	 four	sections.	The	 large	bowel	 (LB)	and	then	3	
roughly	equal	sections	of	the	small	bowel	(SB1,	SB2	and	SB3).	A	ruler	was	used	to	measure	
the	length	and	width	of	each	gut	section	post-fixation.	Length	results	are	displayed	as	total	
length	and	then	broken	down	into	small	and	large	bowel	length	(Figure	4.5.B,C,	Table	4.5,	
A.4.3,4).	Not	all	mice	where	used	for	dissection,	 therefore,	numbers	below	differ	 from	
those	for	blood	glucose	measurement	(Figure	4.3).		
When	 comparing	 the	 length	 of	 the	 entire	 gut,	 the	Fh1βKO	mice	was	 the	 longest,	 and	
significantly	longer	than	the	guts	of	the	Fh1βKO	FHcyt	(p=0.0449),	the	Fh1βKO	FHcyt	1322	
(p=0.0391),	the	FHcyt	1322	(p=0.0025)	and	the	1322	mice	(p=0.0025)	(Figure	4.4.A,	Table	
4.5).	 The	 gut	 length	 of	 the	 Fh1βKO	 1322	 mice	 and	 the	 FHcyt	 or	 WT	 mice	 was	 not	
significantly	different	to	any	other	genotype.		
The	gut	of	 the	Fh1βKO	mice	was	 longer	 in	both	the	SB	and	LB	section	compared	to	all	
other	genotypes.	The	greatest	difference	is	seen	in	the	SB	section	where	the	gut	of	the	
Fh1βKO	mice	was	significantly	longer	than	the	gut	of	the	FHcyt	1322	(p=0.0034)	and	1322	
mice	(p=0.0020)	which	had	the	shortest	SB	section.	The	other	genotypes	had	guts	at	least	
5cm	 shorter	 than	 the	 Fh1βKO	 mice,	 but	 this	 did	 not	 reach	 significance.	 Similarly,	 the	
length	of	the	LB	of	Fh1βKO	mice	was	at	least	1cm	longer	than	all	other	genotypes,	but	this	
was	not	significant.		
Even	 though,	 on	 average	 guts	 from	 very	 diabetic	mice	 are	 longer,	when	 gut	 length	 is	
plotted	against	blood	glucose	there	is	no	trend	overall	or	per	genotype.	Table	4.2	details	
the	R2	value	overall	and	for	each	genotype.	There	are	only	two	mice	from	the	FHcyt	and	
Fh1βKO	genotypes	which	had	both	blood	glucose	and	length	measured,	therefore,	the	R2	
value	is	1,	so	they	are	not	shown	in	the	table.		
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Table	4.4.	R2	value	for	length	(cm)	vs	blood	glucose	(mmol/L)	of	mice.	FHcyt	and	Fh1βKO	
mice	not	shown	due	to	n=2	in	these	groups.		
Genotype	 Number	of	mice	 R2	values		
All	 43	 0.2748	
WT	 3	 0.1152	
1322	 7	 0.0545	
FHcyt	1322	 12	 0.0428	
Fh1βKO	FHcyt	 3	 0.0229	
Fh1βKO	FHcyt	1322	 7	 0.3198	
Fh1βKO	1322	 7	 0.2056	
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Figure	4.5.	Small	and	large	bowel	length.	Mouse	gut	was	removed	and	fixed.	Length	was	
measured	by	ruler.	(A)	Length	(mean	±	SEM	(Table	4.5))	of	total	intestine,	(B)	small	bowel	
(SB)	section,	(C)	large	bowel	(LB).	1322	n=12,	WT	n=5,	FHcyt	1322	n=16,	FHcyt	n=3,	Fh1βKO	
FHcyt	1322	n=7,	Fh1βKO	FHcyt	n=3,	Fh1βKO	1322	n=10,	Fh1βKO	n=3.	*	p<0.05,	**	p<0.01,	
***	p<0.001.	Statistics	details	in	Table	A.4.3,4.	
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Table	4.5.	Summary	of	total,	SB,	SB1,	SB2,	SB3	and	LB	gut	length	(cm)	for	each	mouse	
genotype.	Data	shown	as	mean	±	SEM.	SB,	small	bowel;	LB,	large	bowel.	See	also	Figure	
4.5.	
Genotype	 Number	 Total		 SB		 LB		
WT	 5	 40.3±1.3	 33.3±1.2	 7.0±0.3	
1322	 12	 38.2±0.8	 31.3±0.7	 6.9±0.2	
FHcyt	 3	 39.2±1.5	 32.5±1.3	 6.7±0.4	
FHcyt	1322	 16	 38.4±0.6	 31.7±0.5	 6.7±0.2	
Fh1βKO	FHcyt	 3	 38.3±0.4	 31.5±0.8	 6.8±1.2	
Fh1βKO	FHcyt	1322	 7	 39.4±0.9	 32.5±0.5	 6.9±0.5	
Fh1βKO	 3	 46.0±0.8	 37.8±1.0	 8.2±0.4	
Fh1βKO	1322	 10	 40.7±1.3	 33.6±1.0	 7.1±0.5	
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4.7	Epithelial	and	goblet	cell	numbers	remain	constant	across	genotypes	but	paneth	cell	
numbers	change	
To	establish	 if	 there	 are	 any	 fundamental	 differences	 in	 the	differentiated	 cells	 of	 the	
small	bowel	of	mice	used	in	this	study,	IHC	was	used	to	determine	percentage	of	epithelial	
goblet	and	paneth	cells	in	the	crypt	and	villi.		
Guts	were	embedded	in	paraffin	wax,	sectioned	and	used	for	IHC	procedures	(Figure	4.5).	
Next,	the	sections	were	imaged	using	the	Nanozoomer	scanner	and	visualised	using	NDP.2	
software.	 To	match	 previously	 published	 and	 similar	 studies400,	 50	 villi	 and	 100	 crypts	
were	selected	from	the	small	bowel	of	each	mouse	and	an	image	was	taken	of	each.	The	
percentage	of	positive	cells	for	each	of	cell	type	was	then	counted	by	eye.	
H+E	staining	was	completed	and	used	to	quantify	the	number	of	epithelial	cells	per	crypt	
and	villus.	Representative	example	of	an	H+E	stain	of	 the	entire	section	and	a	polyp	 is	
shown	in	Figure	4.	There	was	no	difference	in	the	number	of	epithelial	cells	in	the	villi	and	
crypts	from	the	small	bowel	of	each	genotype	(Figure	4.7,	Table	4.6,	A.5,6).		
IHC	was	next	carried	out	using	alcian	blue	stain	to	detect	goblet	cells	(Figure	4.10).	The	
number	 of	 goblet	 cells	 was	 not	 different	 between	 the	 small	 bowel	 of	 each	 genotype	
(Figure	4.8,	Table	4.6,	A.5,6).	
Anti-lysozyme	antibody	was	used	to	detect	paneth	cells	(Figure	4.9),	which	are	not	found	
in	the	villi	of	mice	and,	therefore,	only	crypt	data	is	shown.	The	number	of	paneth	cells	
was	significantly	lower	(p=0.0108)	in	the	crypts	from	Fh1βKO	FHcyt	1322	mice	compared	
to	the	Fh1βKO	FHcyt	mice	(Figure	4.9,	Table	4.6,	A.5,6).	In	general,	there	were	fewer	Paneth	
cells	in	all	mice	with	the	1322	allele	compared	to	their	specific	control,	but	this	was	not	
significant.	This	suggests	an	interaction	of	the	1322	allele	and	paneth	cell	development	
which	has	not	been	reported	in	any	previous	publication	with	mice	with	the	1322	allele.		
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Figure	4.6.	Histological	assessment	of	polyps.	(A)	An	example	H+E	section	showing	the	
entire	mouse	gut.	Top	left	SB1,	top	right	SB2,	bottom	left	SB3,	bottom	right	LB.	(B)	A	high	
power	image	of	an	H+E	of	a	polyp.	From	a	Fh1βKO	1322	mouse.		
	
A 
B 
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Figure	4.7.	 Epithelial	 cell	number	 in	 crypt	and	villi	 of	 the	 small	bowel.	Sections	were	
stained	with	H+E	and	scanned	using	a	Nanozoomer	Digital	Pathology	system	to	create	
high	quality	images	which	were	used	to	calculate	percentage	positive	cells	(n=3	mice	per	
group,	n=50	villi	and	n=100	crypts	per	mouse).	(A)	Example	H+E	images.	(B)	Percentage	
positive	 cells	 in	 crypt	 and	 (C)	 villi	 (mean	±	 SEM	 (Table	4.6)).	 There	were	no	 significant	
differences;	statistics	details	in	Table	A.4.5).	
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Figure	4.8.	Percentage	of	goblet	cells	in	crypt	and	villi	of	the	small	bowel.	Sections	were	
stained	with	alcian	blue	and	scanned	using	a	Nanozoomer	Digital	Pathology	 system	to	
create	high	quality	 images	which	were	used	to	calculate	percentage	positive	cells	 (n=3	
mice	per	group,	n=50	villi	and	n=100	crypts	per	mouse)	by	Liliane	El	Eid	a	masters	student.	
(A)	Example	alcian	blue	staining	images.	(B)	Percentage	positive	cells	in	villi	and	(C)	crypt	
(mean	±	SEM	(Table	4.6)).	There	were	no	significant	differences;	details	in	Table	A.4.5.		
	
A 
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Figure	 4.9.	 Percentage	 of	 paneth	 cells	 in	 crypt	 of	 the	 small	 bowel.	 Gut	 tissue	 was	
embedded	 in	paraffin	and	 IHC	was	performed	 for	anti-lysozyme	which	 is	a	paneth	cell	
marker.	Stained	sections	were	scanned	using	a	Nanozoomer	Digital	Pathology	system	to	
create	high	quality	 images	which	were	used	to	calculate	percentage	positive	cells	 (n=3	
mice	 per	 group,	 n=50	 villi	 and	 n=100	 crypts	 per	mouse).	 (A)	 Example	 IHC	 images.	 (B)	
Percentage	positive	cells	in	crypt	(mean	±	SEM	(Table	4.6)).	*	p<0.05.	Statistics	details	in	
Table	A.4.5,6.		
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Table	4.6.	Summary	table	of	cell	number	of	epithelial,	percentage	of	goblet	and	paneth	
cells	for	crypt	and	villi	for	each	mouse	genotype.	Data	shown	as	mean	±	SEM.	N=3	per	
genotype.	See	also	Figure	4.7,8,9.		
	 Epithelial	cells	(no.)	 Goblet	cells	(%)	 Paneth	 cells	
(%)	
Genotype	 Crypt		 Villi		 Crypt		 Villi		 Crypt	
WT	 50.5±6.7	 119.2±7.2	 31.0±3.8	 9.6±1.4	 26.2±4.1	
1322	 48.6±2.6	 114.9±2.7	 31.1±2.2	 12.3±1.6	 20.7±3.9	
FHcyt	 42.6±3.9	 114.5±2.7	 28.2±0.8	 8.1±0.3	 23.7±0.0	
FHcyt	1322	 51.0±4.9	 123.4±7.4	 31.4±2.4	 10.1±0.7	 21.3±2.9	
Fh1βKO	FHcyt	 43.1±2.4	 111.7±4.1	 28.3±0.8	 9.2±1.1	 25.2±1.2	
Fh1βKO	FHcyt	
1322	
49.5±2.6	 119.7±12.4	 31.8±1.5	 10.6±0.8	 15.1±0.3	
Fh1βKO	 51.6±4.3	 131.7±1.1	 27.2±3.4	 9.7±1.2	 23.7±2.7	
Fh1βKO	
1322	
47.7±6.2	 118.2±7.4	 28.5±2.4	 9.5±0.5	 21.1±0.2	
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4.8	Polyp	count	is	not	increased	in	mice	with	extremely	elevated	blood	glucose	
Next,	the	polyp	count	was	determined	for	each	genotype	to	allow	assessment	of	the	effect	
of	 diabetes	 on	 polyp	 burden.	 Post	 fixation,	 guts	were	 stained	with	methylene	 blue	 to	
improve	visualisation	of	polyps	under	a	dissection	microscope.	Polyp	counts	for	the	three	
SB	sections,	the	LB	and	the	total	gut	were	identified.	Polyps	were	also	categorised	by	size,	
based	on	diameter:	<1mm,	1-2mm,	2-3mm	and	>3mm;	an	example	image	of	each	of	these	
categories	is	shown	in	Chapter	2,	Section	2.2.4	and	Figure	2.3.	Mice	without	the	Apc1322T	
allele	(WT,	FHcyt,	Fh1βKO	FHcyt,	Fh1βKO,	n=22)	were	checked	for	polyps	and	as	expected	
none	were	found;	these	mice	are	not	included	in	the	data	presented	below.		
FHcyt	1322	mice	had	the	highest	total	polyp	count.	The	next	highest	total	polyp	count	was	
the	1322	mice.	Fh1βKO	FHcyt	1322	mice	and	Fh1βKO	1322	mice	had	very	similar	total	polyp	
counts	 which	 were	 much	 lower	 than	 FHcyt	 1322	 and	 1322.	 However,	 these	 were	 not	
significantly	 different	when	 analysed	 by	 (p=0.0645),	 although	 the	 p	 value	 approached	
significance	(Figure	4.10.A,	Table	4.7,	A.4.7).		
Polyp	distribution	in	the	gut	was	as	expected.	The	majority	of	polyps	were	found	in	the	
SB1	and	SB2	sections	and	the	least	number	of	polyps	were	found	in	the	LB	section	(Figure	
4.10.B+C,	Table	A.4.13).	Ninety-eight	percent	of	mice	had	one	or	more	polyps	in	the	SB1	
and	SB2	sections	(47	out	of	48).	In	the	SB3	section,	81.25%	(39	out	of	48)	of	mice	had	one	
or	more	polyps.	One	or	more	polyps	were	found	in	the	LB	of	62.5%	(30	out	of	48)	of	mice	
with	polyps.	
In	every	section	of	the	gut,	generally,	more	polyps	were	found	in	FHcyt	1322	or	1322	mice	
compared	to	Fh1βKO	1322	and	Fh1βKO	FHcyt	1322	mice	(4.10.B).	In	the	SB1	section	there	
were	significantly	more	polyps	 in	FHcyt	1322	mice	compared	 to	Fh1βKO	FHcyt	1322	 and	
Fh1βKO	1322	 (p=0.0014,	two-way	ANOVA).	FHcyt	1322	also	had	more	polyps	than	1322	
mice,	although	the	difference	was	not	significant	(Figure	4.10.B,	Table	4.8,	A.4.8,9).	
FHcyt	1322	mice	had	the	highest	percentage	of	total	polyps	in	the	SB1	section	compared	
to	Fh1βKO	FHcyt	1322,	Fh1βKO	1322	and	1322	mice	(Figure	4.10.C).	1322	mice	had	the	
highest	percentage	of	 total	polyps	 in	 the	SB2	section	compared	 to	Fh1βKO	1322,	FHcyt	
1322	 and	 Fh1βKO	 FHcyt	 1322	 mice.	 Fh1βKO	 1322	 and	 1322	 mice	 had	 very	 similar	
percentages	in	the	SB3	section,	compared	to	FHcyt	1322	and	Fh1βKO	FHcyt	1322	mice.	In	
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the	LB	section,	1322	mice	had	the	highest	percentage	of	total	polyps	compared	to	Fh1βKO	
FHcyt	1322,	Fh1βKO	1322	and	FHcyt	1322	mice	(Figure	4.10.C,	Table	4.8,	A.4.8,9).	
Overall,	FHcyt	1322	and	1322	mice	have	a	higher	polyp	burden	in	terms	of	total	number	of	
polyps	compared	to	Fh1βKO	1322	and	Fh1βKO	FHcyt	1322	mice.		
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Figure	 4.10.	 Polyp	 count	 by	 intestinal	 site.	 Guts	 were	 removed,	 fixed,	 stained	 with	
methylene	blue	and	polyps	were	counted	using	a	dissection	microscope.	Total	polyp	count	
(±	SEM	(Table	4.7))	by	(A)	genotype,	(B)	by	site,	(C)	percentage	polyps	by	site.	Two-way	
ANOVA	 was	 performed,	 with	 Bonferroni	 post	 hoc	 test	 *	 p<0.05,	 **	 p<0.01.	 Statistics	
details	in	Table	A.4.8,9.	SB,	small	bowel;	LB,	large	bowel.	
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Table	4.7.	Summary	of	total	polyp	count	per	genotype.	See	also	Figure	4.10.A.		
Genotype	 Number	 Total	polyp	count	
1322	 12	 32.64±5.85	
FHcyt	1322	 18	 31.61±3.91	
Fh1βKO	FHcyt	1322	 8	 20.61±4.24	
Fh1βKO	1322	 10	 20.60±1.45	
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Table	4.8.	Summary	of	total	and	percentage	polyp	count	for	each	mouse	genotype	by	
bowel	site.	Data	shown	as	mean	±	SEM.	SB,	small	bowel;	LB,	large	bowel.	See	also	Figure	
4.10.B,C.		
	 Total	count	
Genotype	 Total		 SB1		 SB2		 SB3	 LB		
1322	 30.58±5.32	 12.25±2.52	 9.67±1.90	 5.25±1.33	 3.42±0.94	
FHcyt	1322	 34.06±3.96	 16.44±1.66	 9.11±1.49	 5.94±1.28	 2.56±0.89	
Fh1βKO	
FHcyt	1322	
20.63±4.24	 10.50±2.08	 4.88±1.46	 2.88±1.16	 2.38±0.82	
Fh1βKO	
1322	
20.60±1.45	 9.40±1.10	 5.70±0.99	 3.90±0.74	 1.60±0.56	
	 Percentage	
Genotype	 	 SB1	 SB2	 SB3	 LB	
1322	 	 38.69±4.15	 31.88±2.73	 17.31±3.48	 12.14±3.67	
FHcyt	1322	 	 51.98±4.00	 25.63±2.65	 15.59±2.40	 6.80±2.38	
Fh1βKO	
FHcyt	1322	 	 47.38±8.48	
19.00±4.51	 10.54±3.94	 10.57±3.46	
Fh1βKO	
1322	 	 45.65±4.54	
26.96±3.70	 17.62±9.40	 9.76±4.05	
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4.9	More	>3mm	polyps	are	found	in	FHcyt	1322	mice	than	in	any	other	genotype	
To	determine	if	the	presence	of	diabetes	enhanced	polyp	growth,	polyps	were	categorised	
by	size.	In	previous	studies	using	Apc1322T	mice,	the	majority	or	polyps	are	between	1	and	
2mm	and	37%	polyps	were	>2mm	in	diameter15.	In	this	study,	over	half	of	the	polyps	in	
FHcyt	1322	mice	(53.6%)	and	Fh1βKO	FHcyt	1322	mice	(53.3%)	were	>2mm	polyps;	1322	
mice	had	37.9%	and	Fh1βKO	1322	mice	had	35.0%.	This	suggests	that	FHcyt	presence	leads	
to	 an	 increase	 in	 polyp	 size.	 Furthermore,	 this	 study	 found	 polyps	 of	 >3mm,	which	 is	
unusual.	The	majority	of	mice	had	at	least	one	polyp	>3mm,	(94.4%	(17	out	of	18)	of	FHcyt	
1322	mice,	91.7%	(11	out	of	12)	of	1322	mice,	90%	(9	out	of	10)	of	Fh1βKO	1322	and	
87.5%	(7	out	of	1)	of	Fh1βKO	FHcyt	1322	mice)	(Figure	4.10.A).	On	average	FHcyt	1322	mice	
again	had	the	highest	percentage	of	total	polyps	that	were	>3mm	(28.5%),	followed	by	
Fh1βKO	FHcyt	1322	mice	(20.5%),	Fh1βKO	1322	mice	(15.3%)	and	finally	1322	mice	(11.7%)	
(Figure	4.11.B).		
Overall	FHcyt	1322	mice	had	significantly	more	>3mm	polyps	(p<0.0001,	two-way	ANOVA)	
compared	to	Fh1βKO	FHcyt	1322,	1322	and	Fh1βKO	1322	mice.	Specifically,	FHcyt	1322	mice	
had	 significantly	more	 3mm+	polyps	 in	 the	 SB1	 segment	 (p=0.0063,	 two-way	ANOVA)	
compared	to	Fh1βKO	FHcyt	1322,	Fh1βKO	1322	and	1322	mice	(Figure	4.11.C,	Table	4.9,	
A.4.10,11).	There	were	no	significant	differences	 in	the	number	of	3+mm	polyps	 in	the	
other	bowel	sections	(Figure	4.11.D.E.F)	(Table	4.9,	A.4.10,11).		
There	were	a	similar	number	of	2-3mm	polyps	in	each	genotype	and	SB	sections	of	the	
bowel.	 In	 the	 LB	 section,	 there	 were	 significantly	 more	 2-3mm	 polyps	 in	 1322	 mice	
compared	to	FHcyt	1322	mice	(p=0.05),	although	the	overall	numbers	here	are	very	small	
compared	to	the	SB	(Table	4.9,	A.4.10,11).	
When	looking	at	1-2mm	polyps,	in	total,	there	were	more	in	the	1322	mice	and	FHcyt	1322	
mice	compared	to	Fh1βKO	1322	mice	and	Fh1βKO	FHcyt	1322	mice.	Of	note,	there	were	
significantly	more	in	the	SB3	section	of	1322	mice	(2.67±0.90)	compared	to	the	Fh1βKO	
FHcyt	1322	mice	(p=0.0424,	two-way	ANOVA)	(Table	4.9,	A.4.10,11).	In	general,	numbers	
in	SB3	tended	to	be	lower	than	in	the	other	two	SB	segments.	
Similarly,	to	1-2mm	polyps,	for	<1mm	polyps,	in	total,	there	were	more	in	the	1322	mice	
and	FHcyt	1322	mice	compared	to	Fh1βKO	1322	mice	and	Fh1βKO	FHcyt	1322	mice.	Of	note,	
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there	were	significantly	more	<1mm	polyps	in	the	SB2	section	of	1322	mice	compared	to	
Fh1βKO	 1322	 and	 Fh1βKO	 FHcyt	 1322	 mice	 (p=0.0424,	 two-way	 ANOVA)	 (Table	 4.9,	
A.4.10,11).	
Overall,	 of	 the	 high	 polyp	 count	 genotypes,	 FHcyt	 1322	 mice	 had	more	 >3mm	 polyps,	
whereas	1322	mice	had	more	<1-2mm	polyps.	The	polyp	burden	of	the	FHcyt	1322	mice	
can	perhaps	be	 classified	as	 the	highest	 suggesting	 that	 the	presence	of	FHcyt	 leads	 to	
increased	polyp	growth.		
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Figure	4.11.	Polyp	count	by	size.	Guts	were	removed,	fixed,	stained	with	methylene	blue	
and	polyps	were	counted	using	a	dissection	microscope.	Frequency	of	polyp	sizes	(mean	
±	SEM	(Table	4.9	found	in	(A)	SB1,	(B)	SB2,	(C)	SB3	and	(D)	LB.	1322	n=12,	FHcyt	1322,	n=18,	
Fh1βKO	 FHcyt	 1322,	 n=8,	 Fh1βKO	 1322	 n=10.	 Two-way	 ANOVA	 was	 performed,	 with	
Bonferroni	 post	 hoc	 test	 *	 p<0.05,	 **	 p<0.01,	 ***	 p<0.001.	 Statistics	 details	 in	 Table	
A.4.10,11.	SB,	small	bowel;	LB,	large	bowel.	
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Table	4.9.	Summary	of	frequencies	of	each	polyp	size	in	the	bowel.	Frequencies	are	given	
by	size	of	polyp	in	SB1,	SB2,	SB3	and	LB	for	each	mouse	genotype.	Data	given	as	mean	±	
SEM.	SB	small	bowel;	LB	large	bowel.	See	also	Figure	4.11.		
	 SB1	
Genotype	 <1mm		 1-2mm		 2-3mm		 3+mm		
1322	 2.50±0.54	 4.48±1.29	 3.83±1.20	 1.83±0.59	
FHcyt	1322	 2.72±0.58	 3.78±0.56	 3.78±0.72	 6.17±0.82	
Fh1βKO	FHcyt	1322	 1.38±0.71	 2.63±0.56	 3.88±1.25	 2.63±0.78	
Fh1βKO	1322	 2.90±0.50	 2.20±0.53	 2.30±0.90	 2.00±0.61	
	 SB2	
Genotype	 <1mm		 1-2mm		 2-3mm		 3+mm		
1322	 3.67±1.39	 3.33±0.87	 1.75±0.49	 1.78±0.51	
FHcyt	1322	 1.94±0.66	 2.78±0.62	 2.40±0.57	 1.78±0.49	
Fh1βKO	FHcyt	1322	 1.25±0.45	 1.00±0.57	 1.25±2.61	 1.38±0.65	
Fh1βKO	1322	 1.40±0.40	 1.60±0.27	 1.80±0.47	 0.90±0.46	
	 SB3	
Genotype	 <1mm		 1-2mm		 2-3mm		 3+mm		
1322	 1.67±0.74	 2.67±0.89	 0.75±0.25	 0.17±0.11	
FHcyt	1322	 1.61±0.59	 2.00±0.64	 1.72±0.43	 0.61±0.28	
Fh1βKO	FHcyt	1322	 1.13±0.48	 0.38±0.38	 1.00±0.46	 0.38±0.26	
Fh1βKO	1322	 0.60±0.50	 1.20±0.42	 2.00±0.63	 0.10±0.10	
	 LB	
Genotype	 <1mm		 1-2mm		 2-3mm		 3+mm		
1322	 0.50±0.42	 1.00±0.39	 1.59±0.68	 0.33±0.26	
FHcyt	1322	 0.67±0.34	 1.33±0.46	 0.22±0.15	 0.33±0.23	
Fh1βKO	FHcyt	1322	 0.50±0.50	 1.25±0.73	 0.63±0.50	 0.00±0.00	
Fh1βKO	1322	 0.00±0.00	 1.10±0.53	 0.20±0.20	 0.30±0.30	
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4.10	Discussion	
	
The	eight	genotypes	generated	by	the	breeding	of	female	Fh1βKO	FHcyt	mice	and	male	
Apc1322T	mice	allowed	the	study	of	the	effect	of	blood	glucose,	alone	or	combined	with	
overexpression	of	FH	on	polyposis.		
Mice	with	the	Fh1βKO	allele	display	greatly	elevated	blood	glucose	levels	as	matched	by	
the	original	paper268.	The	Accu-Check	blood	glucose	monitor	used	for	the	measurement	
of	blood	glucose	levels	had	a	maximum	reading	of	33.3,	which	10	out	of	14	(71.43%)	of	
Fh1βKO	and	four	out	of	nine	(44.44%)	of	Fh1βKO	1322	mice	met	indicating	the	very	high	
nature	of	the	blood	glucose	in	this	model	system.		
Metabolomics	data	for	[glucose]	(Figure	4.4)	highlight	that	polyps	from	mice	with	elevated	
blood	glucose	due	to	the	Fh1βKO	allele	do	have	additional	[glucose]	available	in	the	tissue	
for	 polyp	 growth	 compared	 to	 all	 other	 genotypes.	 Nevertheless,	 the	 polyp	 size	 data	
suggests	that	elevated	blood	glucose	alone,	is	not	sufficient	to	generate	the	largest	polyps	
in	this	model.	Interestingly,	the	presence	of	the	FHcyt	allele	also	leads	to	a	slight	reduction	
in	 [glucose]	 found	 in	 the	 tissue,	 further	 alluding	 to	 the	 role	 of	 glucose	 and	 therefore	
fumarate	in	polyposis	in	this	model.		
Presence	 of	 FH	 in	 the	 β-cells	 of	 the	 pancreas	 allows	 insulin	 secretion	 and	 glucose	
homeostasis268,	as	discussed	 in	Chapter	1,	Section	1.12.	As	seen	previously,	addition	of	
the	 FHcyt	 allele	 increased	blood	 glucose	 compared	 to	WT	mice	 and	 reduced	 the	blood	
glucose	of	mice	with	the	Fh1βKO	allele	to	pre-diabetic	levels268.		
The	total	gut	length	of	Fh1βKO	mice	was	longer	than	all	other	genotypes.	This	phenotype	
has	been	previously	noted	in	other	mouse	models	of	obesity	and	diabetes	such	as	ob/ob	
and	db/db	mice401	as	well	as	mice	with	over	nutrition402.	The	average	number	of	epithelial	
cells	per	villi	and	crypt	were	not	different	between	genotypes.	This	suggests	that	the	gut	
of	the	Fh1βKO	mice	 is	made	up	of	more	villi	and	crypts,	not	 larger	villi	and	crypts.	The	
small	intestine	is	a	critical	site	for	nutrient	absorption	and	important	for	maintenance	of	
normal	blood	glucose.	There	may	be	a	link	between	elevated	blood	glucose	and	increased	
intestinal	length,	the	causes	of	which	have	not	thus	far	been	investigated	in	the	literature.	
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There	was	no	difference	in	goblet	cell	number	between	genotypes.	However,	Paneth	cell	
content	was	variable	between	genotypes.	For	example,	the	presence	of	1322	allele	led	to	
a	 reduction	 in	 Paneth	 cells.	 There	 is	 no	 previous	 report	 in	 the	 literature	 on	 this	
observation.	Presence	of	the	Fh1βKO	or	FHcyt	allele	alone	did	not	lead	to	a	reduction	in	
Paneth	cell	number.	Whereas,	when	both	Fh1βKO	and	FHcyt	alleles	are	present	a	reduction	
in	Paneth	cell	number	is	found.	However,	the	Fh1βKO	allele	is	not	expressed	in	the	gut	
but	the	FHcyt	allele	is,	therefore,	there	is	no	logical	explanation	for	the	reduction	in	Paneth	
cell	numbers.	At	this	time,	there	is	no	obvious	phenotypic	consequence	or	explanation	as	
to	why	paneth	cell	numbers	would	change	in	this	genotype.		
Of	the	four	genotypes	with	the	1322	allele,	which	led	to	polyps,	in	terms	of	polyp	number,	
there	was	a	distinct	split	between	mice	with	and	without	the	Fh1βKO	allele,	which	leads	
to	very	high	blood	glucose.	Fh1βKO	1322	and	Fh1βKO	FHcyt	1322	mice	had	lower	polyp	
count	compared	to	1322	and	FHcyt	1322	mice.	This	is	an	opposite	result	to	hypothesized,	
rather	that	diabetes	 in	mice	as	a	consequence	of	Fh	 loss	does	not	 increase	total	polyp	
count.		
1322	mice	have	a	high	polyp	count	with	most	of	their	polyps	<1-2mm	in	size	found	in	the	
SB1	and	SB2	sections	of	the	gut.	FHcyt	1322	mice	had	the	most	polyps,	established	due	to	
high	numbers	of	polyps	in	the	SB1	section	of	the	gut	compared	to	all	other	genotypes.	
Interestingly,	the	greatest	percentage	of	polyps	from	FHcyt	1322	mice	were	in	the	>3mm	
category.	Furthermore,	FHcyt	1322	mice	had	the	most	>3mm	polyps	which	were	mainly	
found	in	the	SB1	section	of	the	gut	where	all	the	other	genotypes	had	significantly	fewer	
>3mm	polyps.	Together	this	suggests	that	over-expression	of	FH	in	the	gut	epithelial	cells	
promotes	polyposis,	both	in	number	and	size	of	polyps.	There	is	currently	no	literature	on	
cytoplasmic	 FH	 promoting	 polyposis	 in	 the	 gut;	 cytoplasmic	 FH	 is	 seen	 as	 a	 tumour	
suppressor399,403.	However,	KO	Fh1	MEFs	proliferate	much	slower	than	their	WT	Fh1	MEFs	
counterparts	(Chapter	5,	Section	5.3,	Figure	5.2).	This	could	be	due	to	the	DNA	damage	
reduction	role	of	FH,	leading	to	more	healthy	cells,	which	in	turn	proliferate.		
However,	 this	 is	not	backed	up	results	 from	Fh1βKO	FHcyt	1322	mice,	who	had	a	much	
lower	polyp	count	than	FHcyt	1322	mice,	and	a	similar	number	of	>3mm	polyps	to	1322	
and	 Fh1βKO	 1322	 mice,	 which	 is	 much	 lower	 than	 FHcyt	 1322	 again.	 This	 maybe	 a	
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consequence	of	high	blood	glucose	levels	inhibiting	the	potential	polyposis	promotion	by	
FH	in	the	gut.		
Different	again	is	the	size	distribution	of	polyps	in	Fh1βKO	FHcyt	1322	and	Fh1βKO	1322	
mice.	The	majority	of	their	polyps	are	between	1	and	3mm.	In	fact,	more	2-3mm	polyps	
are	found	when	the	Fh1βKO	allele	is	present.	Equally	there	are	slightly	more	>3mm	polyps	
in	Fh1βKO	FHcyt	1322	and	Fh1βKO	1322	mice	than	found	in	1322	mice.	This	could	suggest	
that	elevated	blood	glucose	promotes	polyposis	growth,	but	not	as	much	as	FHcyt	alone.		
This	 data	 suggests	 a	 role	 for	 cytoplasmic	 FH	 in	 tumourigenesis.	 This	 is	 in	 conflict	 to	
previous	in	vivo	studies	which	have	shown	that	overexpression	of	cytoplasmic	FH	in	renal	
cells	 ameliorates	 signs	 of	 renal	 cysts	 which	 can	 lead	 to	 the	 development	 of	 HLRCC	
suggesting	that	FH	is	a	tumour	suppressor330.	However,	it	could	suggest	that	the	role	of	
FH	is	cell	dependent.	The	main	known	role	of	mitochondrial	FH	is	to	convert	fumarate	into	
malate	in	the	TCA	cycle,	and	the	main	known	role	of	cytosolic	FH	is	to	aid	DNA	damage	
repair,	 perhaps	 in	 this	 case,	 this	 allows	 polyp	 cells	 to	 survive	 and	 grow.	 Further	
investigations	in	vitro	are	necessary	to	fully	understand	the	role	of	cytoplasmic	FH	in	CRC	
(Chapter	8,	Section	8.2).		
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Chapter	5	-	Investigating	the	link	between	T2D	and	CRC	in	vitro		
5.1.	Introduction		
My	investigations	into	the	link	between	T2D	and	CRC	in	vivo	(Chapter	3	and	4)	have	led	to	
further	questions	surrounding	the	role	of	fumarate	and	FH	in	CRC	patients	with	T2D.	There	
are	 a	 number	 of	 questions	 that	 still	 need	 answering,	 such	 as,	 does	 FH	 contribute	 to	
tumorigenesis	in	CRC?	What	is	the	role	of	fumarate	and	succination	in	CRC?		
FH	 is	 the	 enzyme	 which	 breaks	 down	 fumarate	 into	 malate	 in	 the	 TCA	 cycle.	 It	 has	
previously	been	shown	that	 lack	of	FH	and	subsequent	 increase	 in	 [fumarate]	 leads	 to	
decreased	mitochondrial	respiration,	alteration	of	the	TCA	cycle	functionality	and	reversal	
of	 the	urea321,322,332,404,405	 (Chapter	1,	Figure	1.8	and	1.10).	Fumarate	can	also	 inhibit	2-
OGDDs,	alter	gene	expression	and	generate	2-SC	by	a	process	named	succination332,406	
(Figure	1.11).	The	interplay	between	loss	of	FH,	high	[fumarate]	and	different	aspects	of	
metabolism	is	still	unclear.		
In	 vivo,	CRC	can	be	extremely	nutrient	poor	and	oxygen	 low	at	 the	 tumour	 core335,407.	
Therefore,	 it	 is	 important	 to	 understand	 the	 molecular	 events	 involved	 in	 tumour	
adaptation	to	these	conditions;	the	effect	of	different	glucose	concentrations	on	CRC	cells	
in	hypoxia	requires	investigation.	Most	in	vitro	studies	use	oxygen	tensions	in	the	region	
of	 0.8–1.0%.	However,	 there	 is	 a	marked	 lack	of	 data	 from	experiments	 that	 consider	
conditions	of	more	severe	hypoxia408.	Large	gradients	of	oxygen	tension	do	occur	in	both	
tumours	and	spheroid	models,	 including	very	low	oxygen	tension	(0.1%	O2)	and	almost	
total	anoxia154,409–412.	Additionally,	preliminary	data	in	our	lab	from	a	collaboration	with	
Tomoyoshi	 Soga	 (Keio	 University,	 Japan)	 highlighted	 a	 possible	 relationship	 between	
fumarate	and	oxygen	tension	(at	0.2%)	(further	explained	in	Section	5.2)	which	warranted	
further	investigation	with	respect	to	this	project.	
To	recapitulate	the	conditions	of	variable	nutrient	levels	and	very	low	oxygen	caused	by	
inadequate	 vascularisation,	 in	 vitro	 CRC	 cells	 were	 cultured	 in	 different	 glucose	
concentrations	and	held	 in	0.2%	O2	 to	 simulate	hypoxia.	 To	aid	 investigations	 into	 the	
possible	 relationship	 between	 fumarate	 and	 oxygen	 tension,	 mouse	 embryonic	
fibroblasts	(MEFs)	with	Fh1	(murine	FH)	completely	deleted,	named	KO	Fh1	MEFs	and	WT	
Fh1	MEFs	were	used	 in	some	experiments.	KO	Fh1	MEFs	have	previously	been	used	 in	
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studies	to	understand	the	role	of	fumarate	and	FH	further	in	HLRCC316,334,345.	KO	Fh1	MEFs	
are	known	to	have	a	different	cellular	metabolism,	previously	shown	by	Frezza	et	al.	2011	
and	Zheng	et	al.	2013321,405.	Fh1	deficient	cells	use	accumulated	TCA	cycle	metabolites	to	
generate	haem,	which	is	then	degraded	to	bilirubin.	This	process	creates	mitochondrial	
NADH	which	can	be	used	to	generate	ATP	by	OXPHOS.	It	has	also	been	shown	that	Fh1	
deficient	cells	can	generate	citrate	and	malate	from	glutamine	by	revering	parts	of	the	
TCA	cycle	to	perform	reductive	carboxylation	of	α-ketoglutarate	to	isocitrate.	This	process	
then	provides	the	anabolic	building	blocks	allowing	cell	proliferation320.	Additionally,	Fh1	
deficient	 mice	 and	 media	 from	 FH-deficient	 cell	 lines	 excrete	 increased	 amounts	 of	
fumarate	and	arginosuccinate	compared	to	their	WT	counterparts321.	This	was	found	to	
be	 a	 result	 of	 the	 reversed	 activity	 of	 the	 urea	 cycle	 enzyme	 arginosucinnate	 lyase	
(Chapter	 1,	 Figure	 1.10).	 These	 alterations	 in	 cellular	metabolism	must	 be	 considered	
throughout	the	analysis	of	the	results	of	this	chapter.		
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5.1.1 Hypotheses		
	
• Fumarate	concentration	will	be	highest	in	CRC	cells	held	in	hypoxia	compared	to	
normoxia	and	cultured	in	glucose	compared	to	no	glucose.		
• FH	 concentration	 will	 be	 highest	 in	 CRC	 cells	 held	 in	 normoxia	 compared	 to	
hypoxia	and	cultured	in	no	glucose	compared	to	glucose.		
• FH	activity	will	be	highest	in	CRC	cells	held	in	hypoxia	compared	to	normoxia	and	
cultured	in	glucose	compared	to	no	glucose.		
• Expression	 of	 genes	 involved	 in	 glycolysis	 will	 be	 highest	 in	 CRC	 cells	 held	 in	
hypoxia	compared	to	normoxia	and	cultured	in	glucose	compared	to	no	glucose.		
• Expression	of	genes	involved	in	mitochondrial	metabolism	will	be	highest	in	CRC	
cells	held	in	normoxia	compared	to	hypoxia	and	cultured	in	no	glucose	compared	
to	glucose.		
• Mitochondria	 concentration	 will	 be	 highest	 in	 CRC	 cells	 held	 in	 normoxia	
compared	to	hypoxia	and	cultured	in	no	glucose	compared	to	glucose.		
• Mitochondrial	 oxygen	 consumption	 rate	 will	 be	 highest	 in	 CRC	 cells	 held	 in	
normoxia	compared	to	hypoxia	and	cultured	in	no	glucose	compared	to	glucose.		
	
5.1.2		 Aims		
To	generate	an	in	vitro	model	of	CRC	and	T2D	and	characterise:	
• Concentration	of	fumarate.	
• Amount	and	activity	of	FH.	
• Changes	in	gene	expression.		
• Amount	and	activity	of	mitochondria.		
Statistics	 were	 performed	 with	 two-way	 ANOVA	 with	 Bonferroni	 post-hoc	 test	 unless	
otherwise	stated.		
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5.2	Preliminary	data		
Previously,	our	lab	collaborated	with	Professor	Tomoyoshi	Soga	(Keio	University,	Japan)	
to	quantify	changes	in	the	levels	of	metabolites	in	the	cell	lines	DLD1,	HT55	and	SW837	
by	CETOF-MS	after	48	hours	of	treatment	with	20.9%,	1%	or	0.2%	O2408.	Experiments	were	
performed	on	cells	which	were	cultured	 in	media	with	25mM	glucose.	The	 findings	by	
Nijhuis	et	al.	concluded	that	the	CRC	cell	lines	used	have	many	differences	in	metabolites.	
Of	particular	relevance	to	this	study	was	the	intracellular	fumarate	concentration,	which	
responded	differently	to	a	change	in	O2	tension	in	the	DLD1,	HT55	and	SW837	cell	lines	
(Figure	5.1;	Table	5.1.).	From	now	on	 [fumarate]	will	be	used	 to	denote	 ‘the	 fumarate	
concentration’.		
In	 DLD1	 cells	 [fumarate]	 was	 significantly	 higher	 at	 0.2%	 O2	 compared	 to	 20.9%	 O2	
(p=0.0011,	 one-way	 ordinary	 ANOVA;	 4.5-fold	 increase)	 (Figure	 5.1;	 Table	 A.5.1,2).	
[Fumarate]	was	also	higher	at	1%	O2	compared	to	20.9%	O2	but	the	difference	was	not	
significant	 (p=0.0897,	 one-way	 ordinary	 ANOVA;	 2.4-fold	 increase).	 The	 increase	 in	
[fumarate]	 between	 1%	 O2	 and	 0.2%	 O2	 was	 significant	 (p=0.0138,	 one-way	 ordinary	
ANOVA;	1.9-fold	increase).		
The	 HT55	 cell	 line	 followed	 the	 same	 pattern	 to	 the	 DLD1	 cell	 line.	 [Fumarate]	 was	
significantly	 higher	 at	 0.2%	 O2	 compared	 to	 20.9%	 O2	 (p<0.0001,	 one-way	 ordinary	
ANOVA;	 8.75-fold	 increase)	 (Figure	 5.1;	 Table	 A.5.2	 and	 A.5.3).	 [Fumarate]	 was	 also	
significantly	higher	at	1%	O2	compared	to	20.9%	O2	(p<0.0001,	one-way	ordinary	ANOVA;	
6.75-fold	increase).	The	increase	in	[fumarate]	between	1%	O2	and	0.2%	O2	was	significant	
(p=0.0248,	one-way	ordinary	ANOVA;	1.3-fold	increase).	
The	trend	for	the	SW837	cell	 line	was	 in	direct	contrast	to	the	trend	for	the	DLD1	and	
HT55	cell	lines.	[Fumarate]	was	significantly	decreased	at	0.2%	O2	compared	to	20.9%	O2	
(p=0.0036,	 one-way	 ordinary	 ANOVA;	 2.3-fold	 decrease)	 (Figure	 5.1;	 Table	 A.5.1,2).	
[Fumarate]	was	also	significantly	decreased	at	1%	O2		compared	to	20.9%	(p=0.0035,	one-
way	 ordinary	 ANOVA;	 2.4-fold	 decrease).	 Furthermore,	 there	 was	 minimal	 difference	
between	[fumarate]	at	1%	and	0.2%	O2.	
Interestingly,	 [fumarate]	 differs	 the	most	 at	 20.9%	O2	between	 the	 three	 cell	 lines.	At	
20.9%	O2,	SW837	cells	have	a	significantly	higher	[fumarate]	compared	to	DLD1	and	HT55	
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cells,	p=0.0004	and	p=0.0002	respectively	(one-way	ordinary	ANOVA)	(Figure	5.1;	Table	
A.5.1.).	[Fumarate]	is	very	similar	between	the	three	cell	lines	at	1%	O2.	Whereas	there	
are	differences	at	0.2%	O2,	although	non-significant	(Figure	5.1).	Overall,	these	data	show	
that	DLD1	and	HT55	cells	increased	[fumarate]	as	O2%	was	reduced,	whereas	SW837	cells	
had	the	opposite	response	and	decreased	[fumarate]	in	response	to	reduced	O2%.	
It	is	possible	that	differences	in	gene	expression	and	metabolism	between	these	cells	lines	
are	responsible	for	the	differences	in	[fumarate].	The	DLD1	and	HT55	cell	lines	originate	
from	a	colon	cancer	and	the	SW837	cell	line	originates	from	a	rectal	cancer.	It	is	possible	
cell	lines	from	these	separate	intestinal	regions	have	different	metabolisms,	however,	the	
TCGA	study	found	no	significant	differences	in	the	genetic	progression	of	colon	and	rectal	
cancers413.	HT55	cells	were	found	to	be	WT	KRAS	whereas	DLD1	and	SW837	cells	were	
mutant	KRAS,	results	confirmed	in	our	laboratory	as	part	of	cell	line	verification.	It	is	also	
important	to	note	that	extensive	mutation	analysis	by	Moudarov	and	colleagues	has	failed	
to	identify	any	FH	mutations	in	a	significant	number	of	CRC	cell	lines	and	CRC50.		
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Figure	5.1.	Fumarate	concentration	in	CRC	cell	lines	determined	by	mass	spectrometry.	
DLD1,	HT55	 and	 SW837	 cells	were	 grown	 in	media	with	 25mM	glucose,	 then	 all	 lines	
cultured	for	48	hours	under	normoxia	(20.9%	O2)	or	hypoxia	at	1%	or	0.2%	O2	conditions.	
Cell	lysates	were	harvested	and	analysed	by	capillary	electrophoresis	time	of	flight	mass	
spectrometry	and	the	concentration	of	fumarate	(fmol/cell)	determined.	Mean	±	SEM	in	
Table	5.1.	One-way	ordinary	ANOVA	was	used.	**	p<0.01,	***	p<0.001,	****	p<0.0001	
(Table	A.5.1	and	A.5.2).		
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Table	5.1.	Summary	table	of	fumarate	concentration	in	DLD1,	HT55	and	SW837	CRC	cell	
lines	maintained	in	20.9%,	1%	or	0.2%	O2	for	48	hours.	Identified	by	mass	spectrometry.	
Concentrations	are	given	in	fmol/cell	and	shown	as	mean	±	SEM.	N=3.	See	also	Figure	5.1.	
Cell	line	and	treatment	 Fumarate	(fmol/cell)	
DLD1	20.9%	O2	 0.19±0.00	
DLD1	1%	O2	 0.46±0.05	
DLD1	0.2%	O2	 0.87±0.10	
HT55	20.9%	O2	 0.08±0.01	
HT55	1%	O2		 0.54±0.20	
HT55	0.2%	O2	 0.70±0.05	
SW837	20.9%	O2	 1.40±0.17	
SW837	1%	O2	 0.59±0.00	
SW837	0.2%	O2	 0.60±0.03	
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For	 the	 further	 in	vitro	experiments	described	 in	 this	 chapter,	 I	wanted	 the	conditions	
used	to	be	similar	to	 in	vivo	T2D	CRC	conditions.	Hypoxia	 is	a	common	feature	of	solid	
tumours	like	CRC154.	To	study	the	effect	of	hypoxia	on	FH,	fumarate,	succination	and	T2D	
in	CRC	cells	I	chose	to	hold	the	cells	in	0.2%	O2	to	reflect	the	very	low	oxygen	tensions	that	
occur	 in	 both	 tumours	 and	 spheroid	 models;	 such	 low	 oxygen	 tension	 remains	
significantly	understudied409–412,414.	Moreover,	there	were	differences	in	[fumarate]	in	CRC	
cells	recorded	by	mass	spectrometry	at	0.2%	O2	and	these	observations	warrant	further	
investigation	 (Figure	 5.1).	 The	 blood	 glucose	 of	 the	 patient	 may	 influence	 how	much	
glucose	is	available	to	a	tumour	via	its	vasculature.	The	centre	of	a	CRC	is	known	to	receive	
fewer	nutrients	such	as	glucose,	compared	to	the	outer	most	margin	of	the	tumour335.	
Also,	in	Chapter	4	it	was	shown	the	intestinal	mucosa	and	polyps	of	mice	with	diabetes	
had	a	higher	glucose	content	than	non-diabetic	mice.	Therefore,	to	mirror	this	situation	
in	vitro,	it	was	necessary	to	culture	CRC	cells	in	non-diabetic	and	diabetic	concentration	
of	 glucose	 (further	 described	 in	 section	 5.2).	 However,	 another	 feature	 of	 T2D	 is	
hyperinsulinemia	which	was	not	modelled	in	this	work.	Therefore,	the	findings	must	be	
considered	in	light	of	this.		
I	 continued	 to	 use	 DLD1,	 HT55	 and	 SW837	 cell	 lines	 for	 the	 in	 vitro	 investigations	
described	in	this	chapter	as	this	also	allowed	me	to	investigate	the	influence	of	cell	line	
origin	and	mutation	profile	on	FH,	fumarate,	succination	and	T2D	in	CRC	cells.		
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5.3	Creating	CRC	cell	populations	grown	in	media	with	25mM,	5mM	or	0mM	glucose		
To	 model	 non-diabetic	 and	 T2D	 conditions	 in	 vitro	 I	 decided	 upon	 three	 final	
concentrations	of	glucose	in	the	media	of	the	cells:	25mM	which	represents	the	very	high	
blood	glucose	experienced	by	a	T2D	patient;	5mM	reflecting	a	non-diabetic	patient	blood	
glucose	or	a	very	well	controlled	T2D	patient415,416;	and	0mM	as	a	hypoglycaemic	condition	
and	because	nutrient	concentration	in	a	solid	tumour	like	CRC	can	be	extremely	low	at	
the	core335.	From	here	on	[glucose]	will	be	used	to	denote	‘the	glucose	concentration’.	
Glutamate	 is	 another	 nutrient	 found	 in	 excess	 concentration	 in	 cell	 culture	 media.	
Glutamate	can	be	used	to	generate	energy	by	a	cell	through	the	TCA	cycle	by	entry	via	α-
ketoglutarate	(Chapter	1,	Figure	1.8).	Glutamine	is	the	preferred	anaplerotic	precursor	of	
many	 cancer	 cells417.	 It	 is	 known	 that	 intestinal	 cells	 are	 particularly	 dependent	 on	
glutamine	and	depletion	leads	to	rapid	necrosis418.	Glutamine	remained	in	the	media	of	
all	cells	used	in	this	study,	to	isolate	the	effect	of	reduction	of	glucose	and	to	ensure	cells	
remained	alive.		
DLD1,	HT55	and	SW837	cells	are	usually	cultured	with	25mM	glucose	in	their	media.	To	
create	cells	comfortable	with	being	cultured	in	5mM	and	0mM	glucose	and	to	reduce	the	
stress	and	possible	death	of	the	cells,	I	decided	to	reduce	[glucose]	in	the	media	slowly	
over	a	period	of	2	months	(Chapter	2,	Section	2.3.1).	This	method	led	to	creation	of	unique	
cell	lines,	which	I	could	use	for	experimental	work.	
It	is	interesting	to	note	here	that	CRC	cells	cultured	in	higher	[glucose]	acidified	the	media	
more	rapidly	than	those	cultured	in	no	glucose.	Rapid	acidification	of	the	media	is	also	a	
feature	of	WT	Fh1	MEFs.		
It	should	be	noted	that	the	HT55	cells	were	used	by	Anthony	Xi	Tan,	an	undergraduate	
student	under	my	supervision	and	were	only	used	for	some	experiments	and,	therefore,	
do	not	appear	in	all	figure	panels.		
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5.4	Doubling	 time	of	DLD1,	HT55	and	 SW837	 cells	 grown	 increased	as	 [glucose]	was	
reduced	in	their	media		
It	 is	 generally	 accepted	 that	 doubling	 time	 is	 a	 simple	 and	 quick	 health	 check	 of	 cell	
populations.	I	measured	the	doubling	time	of	cells	to	determine	stability	at	each	reduction	
of	 media	 [glucose]	 (Figure	 5.2)	 (Table	 5.2).	 The	 equation	 (hrs*log(2))/(log(final	 cell	
number)-log(initial	cell	number))	was	used	to	calculate	doubling	time.		
[Glucose]	had	a	significant	effect	on	the	doubling	time	of	DLD1	cells	(p<0.0001,	one-way	
ANOVA)	(Figure	5.2.A).	There	was	a	significant	increase	in	the	doubling	time	of	cells	grown	
in	0mM	compared	to	those	grown	in	5mM	and	25mM	(p<0.0001	 in	both	cases).	There	
was	also	a	significant	increase	in	the	doubling	time	of	cells	grown	in	5mM	compared	to	
25mM	glucose	(p=0.0002,	one-way	ANOVA)	(Table	A.5.3).		
[Glucose]	concentration	also	had	a	significant	effect	on	the	doubling	time	of	HT55	cells	
(p=0.0365,	 one-way	 ANOVA)	 but	 post-hoc	 analysis	 revealed	 no	 significant	 difference	
between	the	groups	(Table	A.5.3,4).	The	doubling	time	of	HT55	cells	at	25mM	glucose	was	
longer	than	DLD1	and	SW837	cells.	However,	the	doubling	time	of	HT55	cells	remained	
relatively	stable	as	[glucose]	decreased	(Figure	5.2.B).		
Again,	[glucose]	had	a	significant	effect	on	the	doubling	time	of	SW837	cells	(p<0.0001,	
one-way	 ANOVA)	 (Figure	 5.2.C)	 (Table	 A.5.3).	 There	 was	 a	 significant	 increase	 in	 the	
doubling	 time	 of	 cells	 grown	 in	 0mM	 compared	 to	 those	 grown	 in	 5mM	 and	 25mM	
(p<0.0001	 in	both	cases,	one-way	ANOVA).	There	was	also	a	significant	 increase	 in	the	
doubling	time	from	cells	grown	in	5mM	compared	to	25mM	glucose	(p<0.0001,	one-way	
ANOVA)	(Table	A.5.3).		
Overall,	the	doubling	time	of	all	the	CRC	cells	increased	as	[glucose]	decreased.	Glucose	is	
the	fuel	for	glycolysis,	and	increased	glycolysis	leads	to	increased	ATP	for	the	proliferation	
of	cells.		
The	doubling	time	of	the	KO	Fh1	MEFs	was	significantly	longer	than	the	doubling	time	of	
the	WT	Fh1	MEFs	(p<0.0001	paired	t-test;	Figure	5.2.D).	The	presence	of	Fh1	increased	
doubling	 time	two-fold	 in	WT	Fh1	MEFs	compared	to	KO	Fh1	MEFs.	This	suggests	 that	
presence	of	 Fh1	has	an	 increased	proliferation	effect	on	 cells,	 likely	due	 to	 the	use	of	
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different	metabolism	pathways	used	by	KO	Fh1	MEFs	compared	to	the	full	TCA	cycle	of	
the	WT	Fh1	MEFs.	
As	all	CRC	cells	have	a	higher	doubling	time	compared	to	KO	Fh1	MEFs	this	suggests	that	
they	have	functional	FH,	which	is	allowing	generation	of	maximum	NADH	via	the	TCA	cycle	
for	use	in	ATP	generation	via	OXPHOS.		
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Figure	5.2.	Doubling	time	of	CRC	and	MEFs	cell	lines.	Doubling	time	was	calculated	using	
the	formula	(hrs*log(2))/(log(final	cell	number)	–	log(initial	cell	number)).	(A)	DLD1	cells,	
(B)	HT55	cells,	(C)	SW837	cells	were	cultured	in	25mM,	5mM	or	0mM	glucose.	Ordinary	
one-way	ANOVA	was	performed	with	Bonferroni	post	hoc	test	(D)	MEFs	were	cultured	in	
25mM	 glucose.	 Unpaired	 two-tailed	 t-test	was	 performed.	 **	 p<0.01,	 ***	 p<0.001.	 A	
summary	of	the	mean	±	SEM	is	given	in	Table	5.2	and	statistics	in	Table	A.5.3,4.		 	
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Table	5.2.	Summary	of	doubling	time	(hrs).	Data	shown	as	mean	±	SEM.	N=3.	See	also	
Figure	5.2.		
Cell	line	 Doubling	time	(hrs)	
DLD1	25mM	 25.23±0.54	
DLD1	5mM	 35.90±1.95	
DLD1	0mM	 53.29±0.72	
HT55	25mM	 36.68±1.68	
HT55	5mM	 35.85±0.40	
HT55	0mM	 44.66±2.96	
SW837	25mM	 28.06±0.34	
SW837	5mM	 41.98±0.24	
SW837	0mM	 90.43±1.06	
WT	Fh1	MEFs	 22.77±0.25	
KO	Fh1	MEFs	 44.02±0.54	
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5.5	HIF-1α	is	upregulated	in	CRC	cells	when	held	under	0.2%	O2	
For	the	following	experiments	in	this	chapter	0.2%	O2	was	used	as	a	model	of	extreme	
hypoxia.	Confirmation	of	a	hypoxic	environment	is	typically	proven	with	presence	of	HIF-
1α	protein.	Therefore,	it	was	necessary	to	determine	if	HIF-1α	was	upregulated	when	the	
CRC	cell	lines	were	held	under	0.2%	O2.		
This	was	done	via	western	blot.	Protein	lysates	were	taken	from	the	CRC	cell	lines	after	
48	hours	in	0.2%	O2.	HIF-1α	is	an	unstable	protein,	therefore,	lysates	were	taken	as	quickly	
as	possible	and	ice	was	used	to	prevent	protein	degradation.	Protein	quantification	was	
always	completed	prior	to	western	blot,	and	the	same	ng	of	protein	were	loaded	for	each	
sample	(Chapter	2,	Section	2.3.2).	To	confirm	the	loading	is	correct,	it	is	best	practice	to	
blot	for	a	protein	which	is	highly	expressed	and	stable	within	the	cell	such	as	cytoskeletal	
proteins.	Alteration	of	glucose	concentration	in	media	and	/	or	oxygen	tension	influences	
most	cytoskeletal	proteins,	therefore,	the	standard	protein	controls	for	western	blot	such	
as	actin	could	not	be	used	in	this	investigation419–422.		
It	was	decided	that	a	Ponceau	red	blot	was	the	quickest	way	to	control	for	protein	transfer	
to	membrane,	as	the	Coomasie	blue	method	does	not	take	into	account	the	transfer	step.	
This	was	not	a	perfect	solution,	however,	as	my	samples	consistently	show	a	difference	in	
protein	loading	at	different	kDa.	So,	it	was	decided	not	to	quantify	the	blots	but	use	the	
Ponceau	blot	to	determine	that	some	protein	was	present.		
DLD1	cells	have	been	previously	shown	to	produce	HIF-1α	in	hypoxia163,423,424.	The	HIF-1α	
protein	is	120kDa,	however,	the	HIF-1α	antibody	(BD	#610959)	used	for	the	Western	blot	
unfortunately	gave	multiple	bands	between	100	–	150kDa.	 It	 is	possible	that	the	other	
bands	seen	on	the	Western	blot	are	HIF-1α	conjugated	to	other	proteins	involved	in	the	
hypoxic	response	such	as	HIF-1ß	or	VHL	for	example.	A	protein	detected	at	120kDa	by	the	
HIF-1α	antibody,	which	is	assumed	to	be	HIF-1α	was	found	to	be	elevated	in	both	DLD1	
and	 SW837	 cell	 lines	 cultured	 with	 25mM,	 5mM	 and	 0mM	 glucose	 held	 in	 0.2%	 O2	
compared	to	20.9%	O2	 (Figure	5.3),	 if	 it	 is	assumed	that	all	 the	samples	do	have	equal	
loading.	The	upregulation	is	not	as	strong	when	cells	are	cultured	with	0mM	glucose.		
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Figure	5.3.	Western	blot	for	HIF-1α.	Cells	were	held	 in	20.9%	or	0.2%	O2	for	48	hours,	
then	harvested	on	ice.	Protein	was	quantified	and	equal	volumes	of	protein	were	loaded	
per	sample	onto	an	SDS-PAGE	gel.	Membranes	were	blotted	for	HIF-1α.	(A)	DLD1	cells	and	
(B)	SW837	cells.		
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5.6	Viability	of	DLD1	and	SW837	cells	cultured	with	25mM,	5MM	or	0mM	glucose	
A	viability	assay	was	performed	to	determine	if	the	[glucose]	in	the	media	affected	cell	
survival	after	the	CRC	cells	were	maintained	in	20.9%	or	0.2%	O2	for	48	hours.	The	viability	
of	the	cell	 lines	was	tested	using	trypan	blue	exclusion	assay.	The	percentage	of	viable	
cells	was	 calculated	 by	 taking	 away	 the	 dead	 cell	 count	 from	 the	 total	 cell	 count	 and	
expressing	that	number	as	a	percentage	of	total	cells	(Table	5.3).		
There	was	a	significant	effect	of	[glucose]	on	the	viability	of	DLD1	cells	(p<0.0001)	(Figure	
5.4.A)	(Table	A.5.5,6).	The	viability	of	DLD1	cells	in	20.9%	O2	did	not	change	with	[glucose].	
However,	when	DLD1	cells	were	maintained	in	0.2%	O2,	compared	to	DLD1	cells	cultured	
in	25mM	glucose,	 the	viability	significantly	decreased	as	 [glucose]	 in	media	decreased.	
There	was	also	a	significant	effect	of	oxygen	on	the	viability	of	DLD1	cells	(p<0.0001)	and	
a	 significant	 decrease	 in	 viability	when	DLD1	 cells	were	 cultured	 in	 5mM	 glucose	 and	
maintained	in	0.2%	O2	compared	to	those	in	20.9%	O2	(p<0.0001).	Similarly,	there	was	a	
significant	decrease	 in	viability	when	DLD1	cells	cultured	 in	0mM	glucose	were	held	at	
0.2%	O2	compared	to	20.9%	O2	(p<0.0001).	There	was	no	significant	difference	in	viability	
when	DLD1	cells	cultured	in	25mM	glucose	at	0.2%	O2	compared	to	20.9%	O2.	There	was	
a	 significant	 interaction	 between	 [glucose]	 and	 oxygen	 on	 the	 viability	 of	 DLD1	 cells	
(p<0.0001).	
[Glucose]	had	a	significant	effect	on	the	viability	of	SW837	cells	(p=0.0009)	(Figure	5.4.B)	
(Table	A.5.5,6).	The	viability	of	SW837	cells	 in	20.9%	O2	did	not	change	with	 [glucose].	
However,	 when	 SW837	 cells	 were	 maintained	 in	 0.2%	 O2,	 compared	 to	 SW837	 cells	
cultured	in	25mM	glucose	(99.74±0.14%),	the	viability	significantly	decreased	as	[glucose]	
in	media	decreased.	There	was	also	a	significant	effect	of	oxygen	on	the	viability	of	SW837	
cells	(p<0.0001)	and	a	significant	decrease	in	viability	when	SW837	cells	were	cultured	in	
5mM	glucose	and	held	at	0.2%	O2	compared	to	20.9%	O2	(p<0.05).	Similarly,	there	was	a	
significant	 decrease	 in	 viability	 when	 SW837	 cells	 were	 cultured	 in	 0mM	 glucose	 and	
maintained	 at	 0.2%	 O2	 compared	 to	 20.9%	 O2	 (p<0.0001).	 There	 was	 no	 significant	
difference	in	viability	when	SW837	cells	cultured	in	25mM	glucose	were	held	in	0.2%	O2	
compared	to	20.9%	O2.	There	was	a	significant	interaction	between	glucose	and	oxygen	
on	the	viability	of	SW837	cells	(p=0.0011).	
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Overall,	these	data	highlight	an	interaction	with	oxygen	tension,	glucose	availability	and	
cell	 viability	 independent	 of	 the	 differences	 in	 fumarate	 concentration	 between	DLD1	
cells	and	SW837.	Perhaps	not	surprisingly,	the	less	glucose	available	in	combination	with	
lower	oxygen,	the	lower	the	viability	of	both	DLD1	and	SW837	CRC	cells.		
The	viability	of	WT	and	KO	Fh1	MEFs	was	not	affected	by	reducing	O2	to	0.2%	compared	
to	 20.9%	 O2	 (Figure	 5.4)	 (Table	 5.3,	 A.5.5,6).	 This	 highlights	 that	 Fh1	 presence	 is	 not	
necessary	for	cell	viability	at	0.2%	O2	when	25mM	glucose	is	present	in	media,	suggesting	
elevated	fumarate	could	be	protective	in	hypoxia.		
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Figure	5.4.	Viability	of	DLD1,	SW837	and	MEFs	cells.	Viability	was	determined	by	trypan	
blue	assay	for	(A)	DLD1	cells,	(B)	SW837	cells	cultured	in	25mM,	5mM	or	0mM	glucose	for	
48	hours	with	20.9%	or	0.2%	oxygen.	(C)	MEFS	cultured	in	25mM	glucose.	Mean	±	SEM	in	
Table	5.3.	*	p<0.1,	**	p<0.01,	***	p<0.001	(Table	A.5.5,6).		
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Table	5.3.	Summary	of	viability.	Viability	is	given	as	a	percentage	of	live	cells.	Data	shown	
as	mean	±	SEM.	N=3.	See	also	Figure	5.4.	
Cell	line	and	treatment	 Viability	(%)	
DLD1	25mM	glucose;	20.9%	O2	 99.70±0.17	
DLD1	25mM	glucose;	0.2%	O2	 99.97±0.03	
DLD1	5mM	glucose;	20.9%	O2	 99.27±0.52	
DLD1	5mM	glucose;	0.2%	O2	 41.46±7.08	
DLD1	0mM	glucose;	20.9%	O2	 98.56±0.48	
DLD1	0mM	glucose;	0.2%	O2	 35.16±6.77	
SW837	25mM	glucose;	20.9%	O2	 99.77±0.12	
SW837	25mM	glucose;	0.2%	O2	 99.74±0.14	
SW837	5mM	glucose;	20.9%	O2	 99.76±0.15	
SW837	5mM	glucose;	0.2%	O2	 70.91±12.00	
SW837	0mM	glucose;	20.9%	O2	 99.31±0.36	
SW837	0mM	glucose;	0.2%	O2	 48.46±11.07	
WT	Fh1	MEFs;	20.9%	O2	 99.74±0.25	
WT	Fh1	MEFs;	0.2%	O2	 99.36±0.64	
KO	Fh1	MEFs;	20.9%	O2	 100±0.00	
KO	Fh1	MEFs;	0.2%	O2	 97.67±2.33	
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5.7	Fumarate	concentration	in	CRC	cells	was	glucose	and	oxygen	responsive		
Preliminary	 [fumarate]	 data	 identified	 by	 mass	 spectrometry	 (Figure	 5.1)	 was	 only	
completed	on	CRC	cells	grown	in	25mM	glucose.	It	was	necessary	to	identify	the	effect	on	
[fumarate]	of	growing	CRC	cells	cultured	in	25mM,	5mM	and	0mM	glucose	at	20.9%	or	
0.2%	O2	 for	48	hours.	To	keep	costs	 low	for	 this	work,	 [fumarate]	of	 the	CRC	cell	 lines	
measured	 using	 a	 fluorometric	 kit	 (Chapter	 2,	 Section	 2.3.5)	 where	 the	 final	 readout	
would	not	be	influenced	by	altered	metabolism.	Cells	were	harvested	and	assayed	three	
times	with	DLD1	and	SW837	cells,	but	only	once	with	HT55	cells	by	Anthony	Xi	Tan	under	
my	supervision	due	to	reagent	and	time	availability.	The	assay	gave	a	readout	of	fumarate	
in	ng/µL;	the	same	number	of	viable	cells	and	final	volume	were	used	for	each	sample	
(n=3)	(Figure	5.5)	(Table	5.4).		
There	was	a	significant	effect	of	[glucose]	on	[fumarate]	in	DLD1	cells	(p=0.0019,	two-way	
ANOVA;	Figure	5.5.A)	 (Table	A.5.7,8).	 [Fumarate]	 in	DLD1	cells	maintained	at	20.9%	O2	
increased	when	cells	were	cultured	with	5mM	glucose	compared	to	cells	cultured	with	
25mM	and	0mM	glucose.	When	DLD1	cells	were	held	in	0.2%	O2,	compared	to	DLD1	cells	
cultured	 in	 25mM	 glucose,	 [fumarate]	 significantly	 decreased	 as	 [glucose]	 in	 media	
decreased.	 There	 was	 also	 a	 significant	 effect	 of	 oxygen	 on	 [fumarate]	 in	 DLD1	 cells	
(p=0.0148;	Figure	5.5.A).	A	significant	increase	in	[fumarate]	between	DLD1	cells	cultured	
in	25mM	glucose	and	those	maintained	at	0.2%	O2	compared	to	20.9%	O2	was	identified	
(p<0.0001).	However,	there	was	no	difference	in	[fumarate]	between	DLD1	cells	cultured	
in	 5mM	 or	 0mM	 glucose	 at	 20.9%	 O2	 compared	 to	 0.2%	 O2.	 A	 significant	 interaction	
between	glucose	and	oxygen	concentration	on	 [fumarate]	 in	DLD1	cells	was	 identified	
(p=0.0006).		
A	possible	trend	can	only	be	described	for	HT55	due	to	n	being	only	1.	[Fumarate]	in	HT55	
cells	at	20.9%	O2	increased	when	cells	were	cultured	with	5mM	glucose	compared	to	cells	
cultured	with	25mM	and	0mM	glucose	(Figure	5.5.B).	When	HT55	cells	were	maintained	
at	 0.2%	 O2,	 compared	 to	 HT55	 cells	 cultured	 in	 25mM	 glucose,	 the	 concentration	 of	
fumarate	decreased	as	glucose	concentration	in	media	decreased.	There	was	an	increased	
[fumarate]	between	HT55	cells	cultured	in	25mM	glucose	at	0.2%	O2	compared	to	20.9%	
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O2.	However,	there	was	no	difference	in	[fumarate]	between	HT55	cells	cultured	in	5mM	
or	0mM	glucose	at	20.9%	O2	compared	to	0.2%	O2.		
[Glucose]	 had	 a	 significant	 effect	 on	 [fumarate]	 in	 SW837	 cells	 (p<0.0001,	 two-way	
ANOVA;	Figure	5.5.C)	(Table	A.5.7,8).	SW837	cells	at	20.9%	O2	and	25mM	glucose	media	
had	a	significantly	higher	[fumarate]	compared	to	SW837	cells	with	20.9%	O2	and	5mM	
glucose	(p<0.05),	and	a	higher	[fumarate]	compared	to	SW837	cells	maintained	at	20.9%	
O2	and	0mM	glucose.	SW837	cells	at	0.2%	O2,	compared	to	SW837	cells	cultured	in	25mM	
glucose,	 showed	 a	 significant	 decrease	 in	 [fumarate]	 as	 [glucose]	 in	media	 decreased	
(p<0.0001	with	two-way	ANOVA).	There	was,	therefore,	a	significant	effect	of	oxygen	on	
[fumarate]	 in	SW837	cells	 (p=0.0010)	 (Figure	5.5.C).	At	0mM	glucose,	 there	was	also	a	
significant	increase	in	[fumarate]	between	SW837	cells	cultured	at	0.2%	O2	compared	to	
20.9%	O2	(p<0.05).	However,	there	was	no	difference	in	[fumarate]	between	SW837	cells	
cultured	 in	 25mM	 or	 5mM	 glucose	 at	 20.9%	 O2	 compared	 to	 0.2%	 O2.	 A	 significant	
interaction	between	 [glucose]	 and	oxygen	 concentration	on	 [fumarate]	 in	 SW837	 cells	
was	not	found	(p=0.1106).		
These	data	showed	that	DLD1	and	HT55	had	a	similar	pattern	of	[fumarate]	in	response	
to	culture	in	25mM,	5mM	or	0mM	glucose	at	20.9%	or	0.2%	O2	for	48	hours.	SW837	cells	
showed	a	slightly	different	pattern	 to	DLD1	and	HT55	cells.	The	main	difference	 is	 the	
higher	 concentration	of	 fumarate	 found	 in	 SW837	cells	when	 they	were	 cultured	with	
25mM	glucose	and	treated	with	20.9%	O2	compared	to	DLD1	and	HT55	cells	under	the	
same	conditions.		
The	fact	that	fumarate	can	be	detected	in	DLD1,	HT55	and	SW837	cells	cultured	in	0mM	
glucose	suggests	that	alternative	substrates,	such	as	glutamine,	feed	into	the	TCA	cycle.		
There	was	a	significant	effect	of	Fh1	presence	in	MEFs	on	[fumarate]	(p=0.0034)	(Figure	
5.5.D)	(Table	A.5.7,8).	When	MEFs	were	cultured	at	20.9%	O2	and	with	25mM	glucose	in	
the	media	KO	Fh1	MEFs	had	a	significantly	higher	[fumarate]	compared	to	WT	Fh1	MEFs	
treated	with	0.2%	O2	and	25mM	glucose	(p<0.001).	When	MEFs	placed	 in	0.2%	O2	and	
25mM	glucose	media	there	was	no	difference	between	WT	Fh1	MEFs	and	KO	Fh1	MEFs.	
There	was	not	a	significant	effect	of	O2	on	[fumarate]	in	MEFs	(p=0.0613)	(Figure	5.5.D).	
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However,	when	 the	 interaction	of	 [glucose]	 and	oxygen	 concentration	was	 considered	
there	was	a	significant	effect	on	[fumarate]	(p=0.0002,	two-way	ANOVA,	Table	A.5.7,8).		
It	is	difficult	to	compare	between	techniques	due	to	the	different	methods,	the	different	
amount	of	input	and	the	different	units	used	to	measure	[fumarate].	Mass	spectrometry	
is	 a	 much	 more	 sensitive	 method	 compared	 to	 the	 fluorometric	 assay.	 Using	 mass	
spectrometry,	the	ratio	of	fumarate	between	DLD1,	HT55	and	SW837	cells	treated	with	
0.2%	O2	compared	to	20.9%	O2	is	4.58,	6.75	and	0.43	respectively.	Whereas,	when	using	
the	 fluorometric	 assay,	 the	 ratio	 of	 fumarate	 between	 DLD1,	 HT55	 and	 SW837	 cells	
treated	with	 0.2%	O2	 compared	 to	 20.9%	O2	 is	 3.3,	 2.56	 and	 1.23	 respectively.	 These	
results	 could	 suggest	 an	 influence	 of	 passage	 number	 on	 CRC	 cell	 concentration	 of	
fumarate.	The	cells	used	for	mass	spectrometry	were	earlier	in	passage	than	those	used	
for	the	fluorometric	assay.		
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Figure	5.5.	Fumarate	concentration	in	determined	by	fluorometric	assay.	(A)	DLD1,	(B)	
HT55,	 (C)	SW837	and	 (D)	MEFs	after	48	hours	20.9%	or	0.2%	oxygen.	Concentration	 is	
given	as	ng/µL	and	a	summary	of	mean	±	SEM	shown	in	Table	5.4.	*	p<0.05,	**	p<0.01,	
***	p<0.001,	****	p<0.0001.	Statistics	in	Table	A.5.7,8.		
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Table	5.4.	Summary	table	of	fumarate	concentration	from	fluorometric	assay	after	48	
hours	treatment	with	20.9%	or	0.2%	O2.	Concentration	is	given	as	ng/µL	and	data	shown	
as	mean	±	SEM.	N=3.	See	also	Figure	5.5.		
Cell	line	and	48-hour	treatment	 Fumarate	concentration	(ng/µL)		
DLD1	25mM	glucose;	20.9%	O2	 4.57±0.54	
DLD1	25mM	glucose;	0.2%	O2	 15.11±2.07	
DLD1	5mM	glucose;	20.9%	O2	 9.53±2.00	
DLD1	5mM	glucose;	0.2%	O2	 6.92±0.33	
DLD1	0mM	glucose;	20.9%	O2	 3.65±0.86	
DLD1	0mM	glucose;	0.2%	O2	 4.51±0.38	
HT55	25mM	glucose;	20.9%	O2	 8.91±0.00	
HT55	25mM	glucose;	0.2%	O2	 22.81±0.00	
HT55	5mM	glucose;	20.9%	O2	 12.21±0.00	
HT55	5mM	glucose;	0.2%	O2	 12.42±0.00	
HT55	0mM	glucose;	20.9%	O2	 9.79±0.00	
HT55	0mM	glucose;	0.2%	O2	 9.07±0.00	
SW837	25mM	glucose;	20.9%	O2	 12.23±0.20	
SW837	25mM	glucose;	0.2%	O2	 15.05±1.04	
SW837	5mM	glucose;	20.9%	O2	 7.53±0.08	
SW837	5mM	glucose;	0.2%	O2	 8.36±1.02	
SW837	0mM	glucose;	20.9%	O2	 5.96±1.10	
SW837	0mM	glucose;	0.2%	O2	 10.25±0.09	
WT	Fh1	MEFs;	20.9%	O2	 9.66±0.85	
WT	Fh1	MEFs;	0.2%	O2	 15.50±2.15	
KO	Fh1	MEFs;	20.9%	O2	 23.80±1.12	
KO	Fh1	MEFs;	0.2%	O2	 12.21±0.60	
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5.8	Succination	is	present	in	CRC	cell	lines		
Succination	is	one	action	of	fumarate	(Chapter	1,	Figure	1.11).	As	it	was	found	that	it	was	
possible	to	detect	fumarate	in	all	cell	lines,	the	next	step	was	to	ascertain	if	succination	
was	present	in	the	cell	lines.	This	was	done	by	Western	blot.	Norma	Frizzell	(University	of	
South	 Carolina)	 create	 an	 antibody,	 which	 was	 made	 available	 to	 me,	 that	 detects	
succination	(2-SC	motifs).	An	equal	amount	of	protein	was	loaded	per	cell	line	according	
to	a	protein	quantification	assay.	
However,	 this	 does	 not	 provide	 an	 adequate	 means	 of	 quantifying	 the	 levels	 of	
succination.	 This	 method	 does	 not	 allow	 determination	 of	 which	 proteins	 undergo	
succination	in	each	sample	and	to	what	extent,	therefore,	the	blots	were	primarily	used	
to	assess	if	any	succination	was	present	in	vitro.		
KO	Fh1	MEFs	were	a	positive	control	as	they	have	no	Fh1	(murine	FH),	therefore,	fumarate	
is	not	controlled	and	succination	is	elevated330	(Figure	5.6.D).		
All	the	cell	lines	have	succination	present	(Figure	5.6).	It	appears	that	generally	there	is	
more	succination	in	samples	from	cells	held	in	20.9%	O2	compared	to	their	equivalent	held	
in	0.2%	O2.	However,	it	is	not	possible	to	say	this	for	sure	as	it	is	difficult	to	quantify	the	
blot.	 This	 result	 would	 be	 opposite	 to	 predicted	 based	 on	 fumarate	 being	 generally	
elevated	at	0.2%	O2	compared	to	equivalent	samples	held	at	20.9%	O2.		
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Figure	5.6.	Western	blot	for	succination.	CRC	cells	were	held	in	20.9%	or	0.2%	O2	for	48	
hours.	 An	 equal	 amount	 of	 protein	 was	 loaded	 per	 sample	 according	 to	 a	 protein	
quantification	assay.	The	 resultant	blot	was	probed	 for	2-SC.	 (A)	DLD1,	 (B)	 SW837,	 (C)	
HT55	and	(D)	MEFs	as	controls.	
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5.9	Fumarate	hydratase	activity		
After	detecting	differences	in	[fumarate]	between	CRC	cells	held	in	20.9%	O2	compared	
to	 0.2%	O2	 it	was	necessary	 to	determine	 if	 the	 activity	 of	 FH	was	 responsible.	 It	was	
considered	that	when	[fumarate]	is	elevated,	the	activity	of	FH	is	compromised.	Also,	in	
Chapter	3	I	 identified	that	FH	was	present	at	an	unexpected	high	level	 in	CRC	samples,	
even	though	fumarate	was	also	high.	This	generated	questions,	such	as,	is	FH	functional	
in	CRC?	
I	was	 able	 to	 detect	 FH	 activity	 in	 CRC	 cells	 using	 an	 assay	 created	 by	 Jakob	 Knudsen	
(OCDEM,	University	of	Oxford)	where	the	output	measurement	was	the	fluorescence	of	
NADH	generated	by	FH	(Table	5.5).	DLD1	and	SW837	cell	lines	were	cultured	in	25mM,	
5mM	and	0mM	glucose	and	MEFs	were	cultured	in	25mM	glucose	at	20.9%	or	0.2%	O2	for	
48	 hours,	 the	 cells	 were	 then	 harvested	 and	 assayed	 (Chapter	 2,	 Section	 2.3.6).	 The	
experiment	was	done	three	times	for	each	condition.	
There	was	a	significant	effect	of	[glucose]	on	the	activity	of	FH	in	DLD1	cells	(p=0.0007,	
two-way	 ANOVA;	 Figure	 5.7.A)	 (Table	 A.5.9,10).	When	DLD1	 cells	were	maintained	 at	
20.9%	O2,	compared	to	DLD1	cells	cultured	in	25mM	glucose,	the	activity	of	FH	decreased	
when	[glucose]	in	media	was	5mM	and	was	significantly	decreased	when	DLD1	cells	were	
cultured	without	glucose.	When	DLD1	cells	were	maintained	at	0.2%	O2	the	activity	of	FH	
remained	stable	whatever	[glucose]	of	the	media.	There	was	a	significant	effect	of	oxygen	
on	the	activity	of	FH	in	DLD1	cells	(<0.0001)	(Figure	5.7.A).	There	was	a	significant	decrease	
in	FH	activity	between	DLD1	cells	cultured	in	25mM	glucose	at	20.9%	O2	compared	to	0.2%	
O2	(p<0.001)	and	between	DLD1	cells	cultured	in	5mM	glucose	and	treated	with	20.9%	O2	
compared	to	0.2%	O2	(p<0.01).	However,	there	was	no	difference	in	[fumarate]	between	
DLD1	 cells	 cultured	 in	 0mM	 glucose	 treated	 with	 20.9%	 O2	 compared	 to	 0.2%	 O2.	 A	
significant	interaction	between	[glucose]	and	oxygen	tension	on	the	activity	of	fumarate	
hydratase	in	DLD1	cells	(p=0.0131).		
There	was	a	significant	effect	of	[glucose]	on	FH	activity	in	SW837	cells	(p=0.0185)	(Figure	
5.7.B)	 (Table	 A.5.9,10).	When	 SW837	 cells	were	 treated	with	 20.9%	O2,	 there	was	 no	
significant	difference	between	the	different	[glucose].	A	slight	drop	in	activity	was	seen	
with	SW837	cells	cultured	in	0mM	glucose.	Similarly,	when	SW837	cells	at	0.2%	O2,	there	
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was	 no	 significant	 difference	 between	 the	 different	 glucose	 concentrations,	 although	
there	was	a	small	drop	in	activity	in	SW837	cells	cultured	in	0mM	glucose.	A	significant	
effect	of	oxygen	on	SW837	FH	activity	 in	SW837	cells	was	identified	(p=0.0297)	(Figure	
5.7.B).	 However,	 on	 post-hoc	 analyse	 for	 multiple	 correction	 there	 was	 no	 significant	
differences	between	cells	cultured	in	25mM,	5mM	or	0mM	at	20.9%	O2	and	0.2%	O2.	A	
significant	interaction	between	[glucose]	and	oxygen	tension	on	FH	activity	in	SW837	cells	
was	not	found	(p=0.8121).		
As	expected,	there	was	a	significant	effect	of	Fh1	presence	in	MEFs	on	the	activity	of	FH	
(p=0.0044)	(Figure	5.7.C)	(Table	A.5.9,10).	When	MEFs	were	maintained	at	20.9%	O2	and	
25mM	glucose	media	WT	Fh1	MEFs	had	a	significantly	higher	FH	activity	compared	to	KO	
Fh1	MEFs	at	0.2%	O2	and	25mM	glucose	(p<0.0001).	When	MEFs	were	held	at	0.2%	O2	in	
25mM	glucose	media	there	was	no	difference	between	the	enzyme	activity	of	WT	Fh1	
MEFs	 and	 KO	 Fh1	 MEFs.	 There	 was	 not	 a	 significant	 effect	 of	 O2	 (p=0.2980)	 or	 the	
interaction	of	cell	line	and	oxygen	(p=0.1983)	on	the	activity	of	FH	in	MEFs	(Figure	5.7.C).	
This	work	 identifies	that	FH	 is	active	 in	the	CRC	cell	 lines	used	 in	this	study.	There	are,	
however,	differences	between	the	cell	lines.	DLD1	cells	held	in	20.9%	O2	and	cultured	with	
25mM	or	5mM	glucose	in	their	media	have	a	much	higher	FH	activity	when	compared	to	
their	 SW837	 counterparts.	 SW837	 cells	 are	 not	 as	 flexible	 with	 their	 FH	 activity.	
Importantly,	 the	 FH	 activity	 data	 (Chapter	 5,	 Section	 5.11)	 corresponds	 well	 with	
[fumarate]	data	(Chapter	5,	Section	5.10).	When	[fumarate]	is	high,	fumarate	hydratase	
activity	is	lower.	
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Figure	5.7.	Fumarate	hydratase	activity.	Determined	by	fluorometric	assay	in	(A)	DLD1	
(B)	SW837	cells	and	(C)	MEFs	after	48	hours	20.9%	or	0.2%	oxygen.	Activity	 is	given	as	
µmol/min*mg	protein-1.	See	Table	5.5	for	a	summary	of	mean	±	SEM.	*	p<0.1,	**	p<0.01,	
***	p<0.001	(Table	A.5.9,10).		
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Table	5.5.	Summary	table	of	fumarate	hydratase	activity	from	fluorometric	assay	after	
48	hours	treatment	with	20.9%	or	0.2%	O2.	Activity	 is	given	as	µmol/min*mg	protein-1	
and	data	shown	as	mean	±	SEM.	N=3.	See	also	Figure	5.7.		
Cell	line	and	48-hour	treatment	 Fumarate	 hydratase	 activity	
µmol/min*mg	protein-1	
DLD1	25mM	glucose;	20.9%	O2	 1.05±0.11	
DLD1	25mM	glucose;	0.2%	O2	 0.50±0.04	
DLD1	5mM	glucose;	20.9%	O2	 0.98±0.04	
DLD1	5mM	glucose;	0.2%	O2	 0.51±0.09	
DLD1	0mM	glucose;	20.9%	O2	 0.48±0.02	
DLD1	0mM	glucose;	0.2%	O2	 0.39±0.07	
SW837	25mM	glucose;	20.9%	O2	 0.52±0.09	
SW837	25mM	glucose;	0.2%	O2	 0.35±0.04	
SW837	5mM	glucose;	20.9%	O2	 0.59±0.06	
SW837	5mM	glucose;	0.2%	O2	 0.49±0.06	
SW837	0mM	glucose;	20.9%	O2	 0.39±0.04	
SW837	0mM	glucose;	0.2%	O2	 0.29±0.07	
WT	Fh1	MEFs	20.9%	O2	 0.50±0.11	
WT	Fh1	MEFs	0.2%	O2	 0.29±0.08	
KO	Fh1	MEFs	20.9%	O2	 0.06±0.03	
KO	Fh1	MEFs	0.2%	O2	 0.08±0.08	
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5.10	Fumarate	hydratase	foci	and	area	in	cells	cultured	in	0mM	glucose	is	cell	line	and	
oxygen	dependent	
To	 further	quantify	 the	effect	of	different	 [glucose]	 in	cell	 culture	media	on	FH,	 it	was	
necessary	to	quantify	the	amount	of	FH.	Cells	were	held	in	20.9%	or	0.2%	O2	for	48	hours,	
then	 fixed	 and	 stained	with	 DAPI,	 plasma	membrane	 stain	 and	 an	 antibody	 validated	
against	 FH.	 The	 staining	 was	 imaged	 using	 an	 InCell	 2200	 microscope.	 The	 resultant	
images	were	analysed	by	InCell	Developer	V1.9.	For	further	information	on	the	method	
please	refer	to	Chapter	2,	Section	2.3.7).	This	allowed	the	quantification	of	FH	as	foci	per	
cell	as	well	as	the	area	covered	by	all	the	FH	foci	for	each	cell	(Figure	5.8)	(Table	5.6).		
For	the	purpose	of	this	work	one	focus	is	defined	as	a	discrete	area	of	staining.	It	cannot	
be	assumed	that	each	focus	is	equal	to	one	FH	protein.	Therefore,	area	covered	by	foci	is	
likely	 to	be	a	more	accurate	measurement	of	FH	quantity.	Nevertheless,	area	and	 foci	
correlate	well.		
[Glucose]	has	a	significant	effect	on	the	number	of	FH	foci	per	cell	in	DLD1	cells	(p<0.0001)	
(Figure	5.9.A)	(Table	A.5.11,12).	When	DLD1	cells	maintained	at	20.9%	O2,	the	number	of	
FH	 foci	 per	 cell	 in	 DLD1	 cells	 cultured	 in	 0mM	 glucose	 was	 significantly	 increased	
compared	 to	 DLD1	 cells	 cultured	 in	 25mM	 glucose	 (p<0.0001)	 as	 well	 as	 DLD1	 cells	
cultured	in	5mM	glucose	(p<0.0001).	When	DLD1	cells	were	at	0.2%	O2,	the	number	of	FH	
foci	per	cell	in	DLD1	cells	cultured	in	0mM	glucose	was	significantly	increased	compared	
to	DLD1	cells	cultured	in	25mM	glucose	(p<0.0001)	and	compared	to	DLD1	cells	cultured	
in	5mM	glucose	(p<0.01).	Oxygen	had	a	significant	effect	on	the	number	of	FH	foci	per	cell	
in	DLD1	cells	(p=0.0124)	(Figure	5.9.A).	There	was	a	significant	increase	in	the	number	of	
FH	foci	per	cell	between	DLD1	cells	cultured	in	0mM	glucose	and	at	0.2%	O2	compared	to	
20.9%	O2	(p<0.05).	However,	there	was	no	difference	 in	the	number	of	FH	foci	per	cell	
between	DLD1	cells	cultured	in	25mM	or	5mM	glucose	held	at	20.9%	O2	compared	to	0.2%	
O2.	A	significant	interaction	between	[glucose]	and	oxygen	tension	on	the	number	of	FH	
foci	per	cell	in	DLD1	cells	was	not	found,	although	this	approach	significance	(p=0.0746).		
[Glucose]	concentration	had	a	significant	effect	on	the	area	of	FH	per	cell	 in	DLD1	cells	
(p<0.0001)	(Figure	5.9.B)	(Table	A.5.11,12).	When	DLD1	cells	were	maintained	at	20.9%	
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O2,	 the	 area	 of	 FH	 per	 cell	 in	 DLD1	 cells	 cultured	 in	 0mM	 glucose	 was	 significantly	
increased	compared	to	DLD1	cells	cultured	in	25mM	glucose	(p<0.0001)	as	well	as	DLD1	
cells	cultured	in	5mM	glucose	(p<0.0001).	When	DLD1	cells	were	held	at	0.2%	O2,	the	area	
of	FH	per	cell	cultured	in	0mM	glucose	was	significantly	increased	compared	to	DLD1	cells	
cultured	 in	 25mM	 glucose	 (p<0.0001)	 as	 well	 as	 DLD1	 cells	 cultured	 in	 5mM	 glucose	
(p=0.001).	In	addition,	there	was	no	significant	effect	of	oxygen	tension	on	the	area	of	FH	
per	cell	in	DLD1	cells	(p=0.9407)	(Figure	5.9.B).	There	was	no	difference	in	the	area	of	FH	
per	cell	between	DLD1	cells	cultured	in	25mM,	5mM	or	0mM	glucose	and	maintained	at	
20.9%	 O2	 compared	 to	 0.2%	 O2.	 In	 line	 with	 these	 findings,	 a	 significant	 interaction	
between	[glucose]	and	oxygen	tension	on	the	area	of	FH	per	cell	 in	DLD1	cells	was	not	
identified	(p=0.	0.6619).	
[Glucose]	 had	 a	 significant	 effect	 on	 the	 number	 of	 FH	 foci	 per	 cell	 in	 SW837	 cells	
(p<0.0001)	 (Figure	 5.9.C)	 (Table	 A.5.11,12).	When	 SW837	 cells	 were	 at	 20.9%	O2,	 the	
number	 of	 FH	 foci	 per	 cell	 in	 SW837	 cells	 cultured	 in	 0mM	 glucose	 was	 significantly	
increased	 compared	 to	 SW837	 cells	 cultured	 in	 25mM	glucose	 (p<0.05)	 and	 increased	
compared	to	SW837	cells	cultured	in	5mM	glucose.	When	SW837	cells	were	held	at	0.2%	
O2,	the	number	of	FH	foci	per	cell	in	SW837	cells	cultured	in	0mM	glucose	was	significantly	
increased	compared	to	SW837	cells	cultured	in	25mM	glucose	(p<0.001)	and	compared	
to	SW837	cells	cultured	in	5mM	glucose	(p<0.001).	Oxygen	did	not	have	a	significant	effect	
on	the	number	of	FH	foci	per	cell	in	SW837	cells	(p=0.1296)	(Figure	5.9.C).	No	significant	
difference	in	the	number	of	FH	foci	per	cell	between	SW837	cells	cultured	in	0mM,	5mM	
or	25mM	glucose	and	treated	with	20.9%	O2	compared	to	0.2%	O2	was	found.	However,	a	
significant	 interaction	between	[glucose]	and	oxygen	tension	on	the	number	of	FH	foci	
per	cell	in	SW837	cells	was	found	(p=0.0423).		
[Glucose]	had	a	 significant	effect	on	 the	area	of	 FH	per	 cell	 in	 SW837	cells	 (p<0.0001)	
(Figure	5.9.D)	(Table	A.5.11,12).	When	SW837	cells	were	held	at	20.9%	O2,	the	area	of	FH	
per	cell	in	SW837	cells	cultured	in	0mM	glucose	was	not	significantly	different	compared	
to	SW837	cells	cultured	 in	25mM	glucose	or	 in	5mM	glucose.	When	SW837	cells	were	
maintained	at	0.2%	O2,	the	area	of	FH	per	cell	in	SW837	cells	cultured	in	0mM	glucose	was	
significantly	increased	compared	to	SW837	cells	cultured	in	25mM	glucose	(p<0.0001)	as	
well	as	SW837	cells	cultured	in	5mM	glucose	(p<0.0001).	Oxygen	had	a	significant	effect	
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on	the	area	of	FH	per	cell	in	SW837	cells	(p=0.0132)	(Figure	5.9.D).	There	was	a	significant	
increase	in	the	area	of	FH	per	cell	between	SW837	cells	cultured	in	0mM	glucose	and	at	
0.2%	O2	compared	to	20.9%	O2	(p<0.01).	There	was	no	difference	in	the	area	of	FH	per	cell	
between	SW837cells	cultured	in	25mM	or	5mM	glucose	and	held	at	20.9%	O2	compared	
to	0.2%	O2.	A	significant	interaction	between	[glucose]	and	oxygen	tension	on	the	area	of	
FH	per	cell	in	SW837	cells	was	not	identified	(p=0.0019).	
In	summary,	FH	foci	number	and	area	increased	when	DLD1	and	SW837	cells	are	cultured	
in	0mM	glucose	compared	to	5mM	and	25mM	glucose.	However,	FH	in	cells	cultured	in	
0mM	glucose	is	cell	 line	and	oxygen	dependent.	When	DLD1	cells	are	cultured	in	0mM	
glucose	 their	 FH	 foci	 number	 is	 1.23	 fold	 higher	 in	 20.9%	 O2	 compared	 to	 0.2%	 O2.	
However,	when	this	is	converted	to	area	there	is	no	difference	between	the	two	oxygen	
tensions.	When	SW837	cells	are	cultured	in	0mM	glucose	their	FH	foci	number	is	1.51	fold	
higher	when	maintained	at	0.2%	O2	compared	to	20.9%	O2.	When	this	is	converted	to	area,	
cells	 treated	with	0.2%	O2	have	1.97	 fold	more	FH	area	 compared	 to	 cell	 treated	with	
20.9%	O2.		
This	data	suggests	that	hypoxia	does	not	influence	FH	production	dramatically.	There	are	
minimal	 non-significant	 differences	 between	 cells	 held	 in	 20.9%	 and	 0.2%	 O2	 in	 all	
[glucose].	There	was	a	2-fold	increase	in	amount	of	area	of	FH	protein	in	cells	cultured	
with	 0mM	glucose,	 compared	 to	 cells	 cultured	with	 25mM	and	 5mM	glucose	 at	 both	
20.9%	and	0.2%	O2.	However,	there	was	at	least	a	2-fold	decrease	in	FH	activity	in	cells	
cultured	with	0mM	glucose	 compared	 to	 cells	 cultured	 in	 25mM	and	5mM	glucose	 at	
20.9%	O2.	The	FH	activity	in	DLD1	cells	was	not	different	at	0.2%	O2.	This	suggests	that	at	
0mM	 glucose	 FH	 is	 abundant	 but	 not	 active.	 This	 may	 be	 due	 to	 a	 lack	 of	 substrate	
(fumarate)	 for	 FH,	 due	 to	 no	 glucose.	 Even	 when	 fumarate	 is	 present	 at	 high	
concentrations,	such	as	in	the	FH	activity	assay,	the	FH	in	DLD1	cells	cultured	with	0mM	is	
unable	to	work	as	it	does	in	cells	cultured	with	25mM	or	5mM	glucose.		
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Figure	5.8.	 Fumarate	hydratase	 staining	analysis	process.	Cells	were	held	 in	20.9%	or	
0.2%	O2	for	48	hours,	then	fixed	and	stained	with	DAPI,	cell	mask	and	FH	antibody.	The	
staining	was	imaged	using	an	InCell	2200	microscope.	And	the	images	were	then	analysed	
by	 InCell	 Developer	 V1.9.	 (A)	 Briefly,	 cells	 are	 located	 via	 DAPI	 nuclear	 stain.	 (B)	 The	
programme	was	set	to	identify	single	nuclei	and	separate	multiple	nuclei	which	are	close	
together.	(C)	Alongside	this,	the	programme	was	set	to	identify	whole	cells	by	using	the	
cell	mask	stain.	(D)	Single	cells	are	then	defined	as	a	nucleus	(DAPI)	with	a	cell	body	(cell	
mask).	(E,	F)	FH	staining	was	generally	collected	in	foci.	(G)	Therefore,	a	FH	foci	analysis	
was	completed.	(H)	The	analysis	programme	was	then	able	to	determine	how	many	FH	
foci	there	were	per	cell.	From	these	images	it	was	possible	to	determine	the	area	covered	
by	all	the	FH	foci	for	each	cell.	Scale	bar	50µm.		 	
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Figure	 5.9.	 Fumarate	 hydratase	 foci	 and	 area	 per	 cell.	 DLD1	 and	 SW837	 cells	 were	
maintained	at	 20.9%	or	 0.2%	O2	 for	 48	hours.	 Immunofluorescence	was	performed	 to	
detect	FH	protein.	Images	were	captured	on	INCA	2200	microscope	and	analysed	using	
InCell	Developer	v1.9	software	to	determine	the	number	and	area	of	foci	for	FH	per	cell.	
(A)	Number	of	FH	foci	per	DLD1	cell.	(B)	Area	of	FH	per	DLD1	cell.	(C)	Number	of	FH	foci	
per	SW837	cell.	 (D)	Area	of	FH	per	SW837	cell.	Mean	±	SEM	 in	Table	5.6.	 	*	p<0.5,	**	
p<0.01,	***	p<0.001	(Table	A.5.11,12).		
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Table	5.6.	Summary	of	fumarate	hydratase	foci	and	area	per	cell.	Data	shown	as	mean	±	
SEM.	N=3.	See	also	Figure	5.9.		
	
Cell	line	and	48-hour	treatment	 Number	of	FH	foci	per	
cell		
FH	 area	 per	
cell	(µm2)	
DLD1	25mM	glucose;	20.9%	O2	 9.80±1.15	 5.26±0.73	
DLD1	25mM	glucose;	0.2%	O2	 8.71±0.68	 4.73±0.42	
DLD1	5mM	glucose;	20.9%	O2	 10.43±0.15	 5.63±0.12	
DLD1	5mM	glucose;	0.2%	O2	 10.03±0.78	 5.78±0.41	
DLD1	0mM	glucose;	20.9%	O2	 22.43±0.94	 12.19±0.46	
DLD1	0mM	glucose;	0.2%	O2	 18.28±0.63	 12.48±0.51	
SW837	25mM	glucose;	20.9%	O2	 3.61±0.38	 1.51±0.18	
SW837	25mM	glucose;	0.2%	O2	 3.91±0.22	 1.67±0.09	
SW837	5mM	glucose;	20.9%	O2	 5.02±1.03	 2.31±0.61	
SW837	5mM	glucose;	0.2%	O2	 4.10±0.43	 1.81±0.25	
SW837	0mM	glucose;	20.9%	O2	 9.16±2.14	 4.26±1.03	
SW837	0mM	glucose;	0.2%	O2	 13.85±0.50	 8.41±0.44	
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5.11.	Changing	the	glucose	and	oxygen	tension	significantly	changes	the	expression	of	
BAX,	CA9,	PDk1,	LDHA,	HK2,	HIF-2α and	GLUT1	
To	determine	differences	in	DLD1,	HT55,	SW837	gene	expression	induced	by	culture	in	
25mM,	5mM	or	0mM	glucose	then	held	in	20.9%	or	0.2%	O2	for	48	hours,	a	panel	of	19	
genes	was	selected	based	on	their	involvement	with	glycolysis	(Table	5.1),	mitochondrial	
function	(Table	5.2),	hypoxic	response	(Table	5.3)	and	apoptosis	(Table	5.4).		
Unfortunately,	 it	was	difficult	 to	 identify	a	housekeeping	gene	which	was	stable	 for	all	
three	cell	lines	under	the	changes	in	glucose	and	oxygen	tension	used	(Figure	5.10).	It	was	
decided	to	select	different	housekeeping	genes	for	each	CRC	cell	line:	DLD1	results	were	
normalised	 to	a	geomean	of	18S	and	RPLPO;	HT55	 to	actin;	 SW837	 to	B2M.	Data	was	
analysed	by	the	½^ct	method373.	
Normalised	 RT-PCR	 data	 of	 the	 19	 genes	 across	 the	 three	 cell	 lines	 was	 subjected	 to	
multivariate	analysis	 to	uncover	 the	relationship	between	the	expression	of	each	gene	
and	 the	 [glucose]	 and	 oxygen	 tension	 conditions	 that	 the	 cells	 were	 held	 in.	 A	 linear	
regression	model	was	used	to	determine	a	p-value	for	each	gene	in	relation	to	[glucose],	
oxygen	 tension	 and	 interaction	 of	 [glucose]	 and	 oxygen	 tension.	 The	 19	 genes	 were	
ranked	 according	 to	 the	 p-value	 for	 [glucose].	 Next	 the	 normalised	 RT-PCR	 data	 was	
expressed	as	fold	change	from	cells	cultured	in	25mM	glucose	at	20.9%	O2.	This	data	is	
shown	in	Figure	5.11	as	a	heat	map.		
The	 p-values	 for	 oxygen	 tension	 and	 interaction	 of	 [glucose]	 and	 oxygen	 tension	 are	
shown	 in	 Table	 A.5.19.	 The	 normalised	 RT-PCR	 data	 is	 shown	 in	 Table	 A.5.20-28.	 The	
normalised	RT-PCR	data	expressed	as	fold	change	from	cells	cultured	in	25mM	glucose	at	
20.9%	O2	for	each	gene	is	shown	in	Figures	A.5.1-6,	with	mean	±	SEM	and	statistical	data	
in	Table	A.5.30-37.		
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Table	5.7.	Details	of	genes	involved	in	glycolysis	for	expression	analysis	in	DLD1,	HT55	
and	SW837	cell	lines.		
Gene	 Expanded	gene	
name	
Brief	description	of	role	
GLUT1		 Glucose	
transporter	1	
Transports	glucose	into	all	cells425.	
GLUT4	 Glucose	
transporter	4	
Insulin-responsive	glucose	transporter426.		
GAPDH	 Glyceraldehyde	
3-phosphate	
dehydrogenase	
Enzyme	that	catalyses	the	sixth	step	of	glycolysis.	Emerging	
evidence	suggests	GAPDH	is	deregulated	in	cancer	cells427.	
In	diabetes	it	is	known	that	GAPDH	activity	is	reduced	and	
this	has	been	linked	to	high	levels	of	fumarate338.		
LDHA	 Lactate	
dehydrogenase	
Catalyses	 the	 conversion	 of	 pyruvate	 to	 lactate.	
Transcriptionally	 regulated	 by	 HIF-1α.	 Elevated	 in	 many	
cancers	and	linked	to	tumour	growth	and	invasion428.		
HK2	 Hexokinase	2	 Catalyses	the	first	step	of	glucose	metabolism	(glucose	to	
glucose	 6-phosphate).	 Upregulated	 in	 many	 tumours.	
Potentially	 facilitates	 autophagy	 in	 response	 to	 glucose	
deprivation429.		
PDK1	 Pyruvate	
dehydrogenase	
kinase	1	
Multi-enzyme	complex	in	the	mitochondria	that	catalyses	
the	oxidative	decarboxylation	of	pyruvate.	Can	contribute	
to	cancer	by	facilitating	invasion430.		
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Table	5.8.	Details	of	genes	involved	in	mitochondrial	function	for	expression	analysis	in	
DLD1,	HT55	and	SW837	cell	lines.		
Gene	 Expanded	gene	
name	
Brief	description	of	role	
BAX	 BCL2	
associated	X		
Cell	 death	 regulator	 whose	 activation	 induces	
mitochondrial	membrane	permeabilisation	leading	to	the	
release	of	apoptotic	factor	cytochrome	c	and	consequently	
cell	death431.		
FH	 Fumarate	
hydratase	
Enzyme	 that	 catalyses	 the	 conversion	 of	 fumarate	 to	
malate.	 There	 are	 two	 forms,	 mitochondrial	 and	
cytosolic209	(both	detected	by	the	probe	used	in	this	study).	
LONP1	 Mitochondrial	
protease	
Mitochondrial	matrix	protein	which	mediates	the	selective	
degradation	 of	 misfolded,	 unassembled	 or	 oxidatively	
damaged	polypeptides432.		
SOD2	 Mitochondrial	
manganese	
superoxide	
dismutase	
Mitochondria	 antioxidant	 enzyme.	Many	 human	 cancers	
have	reduced	SOD2	activity433.		
COX4I2	 Cytochrome	 c	
oxidase	subunit	
4	isoform	2	
	The	 terminal	 enzyme	 of	 the	 mitochondrial	 respiratory	
chain.	 Subunit	 4	 is	 the	 largest	 nuclear	 encoded	 subunit	
which	plays	a	pivotal	role	in	COX	regulation165434.		
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Table	5.9.	Details	of	genes	involved	in	hypoxia	for	expression	analysis	in	DLD1,	HT55	and	
SW837	cell	lines.		
Gene	 Expanded	gene	
name	
Brief	description	of	role	
HIF-1α	 Hypoxia	
inducible	factor	
1	alpha	
A	 transcription	 factor	 that	 has	 a	 major	 role	 in	 tumour	
response	to	hypoxia407.	Leads	to	upregulation	of	glycolysis	
and	 survival	 genes	 (Chapter	 1,	 Section	 1.8).	 HIF-1	 is	
stabilised	by	hypoxia	and	fumarate435.		
HIF-1ß	 Hypoxia	
inducible	factor	
1	ß	
Also	 known	 as	 aryl	 hydrocarbon	 receptor	 nuclear	
translocator	 (ARNT).	 Forms	 a	 transcription	 factor	 when	
bound	to	HIF-1α436.		
HIF-2α	 Hypoxia	
inducible	factor	
2	alpha	
Also	known	as	endothelial	PAS	domain	protein	1	(EPAS1).	
A	 transcription	 factor	 involved	 in	 the	 induction	of	 genes	
when	oxygen	concentration	falls437.	
VHL	 Von	 Hippel-
Lindau		
Key	role	in	oxygen	sensing	within	the	cell.	Targets	hypoxia-
inducible	 factors	 for	 ubiquitination	 and	 proteasomal	
degradation438.		
CA9	 Carbonic	
anhydrase	9	
Catalyses	 carbon	 dioxide	 hydration	 to	 bicarbonate	 and	
proton439.	Role	in	pH	maintenance	of	the	cell.	
VEGF	 Vascular	
endothelial	
growth	factor	
Key	 regulator	 of	 blood	 vessel	 development	 and	network	
patterning.	Upregulated	in	hypoxia440.		
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Table	5.10.	Details	of	genes	involved	in	apoptosis	for	expression	analysis	in	DLD1,	HT55	
and	SW837	cell	lines.		
Gene	 Expanded	gene	
name	
Brief	description	of	role	
BAX	 BCL2	
associated	X		
Cell	 death	 regulator	 whose	 activation	 induces	
mitochondrial	membrane	permeabilisation	leading	to	the	
release	of	apoptotic	factor	cytochrome	c	and	consequently	
cell	death431.		
CASP9		 Caspase-9	 Initiates	the	mitochondrial	apoptotic	pathway441.	
GPX1	 Glutathione	
peroxidase	
Protects	cells	from	oxidative	stress.	This	 isoform	exists	 in	
the	cytoplasm442.		
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Figure	5.10.	House-keeping	gene	choice	for	qPCR	panel.	DLD1,	HT55,	SW837	cells	were	
cultured	in	25mM,	5mM	or	0mM	glucose	then	held	in	20.9%	or	0.2%	O2	for	48	hours.	RNA	
was	extracted	and	analysed	via	qPCR.	DLD1	results	were	normalised	to	a	geomean	of	18S	
and	RPLPO;	HT55	to	actin;	SW837	to	B2M.	
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When	all	cell	 lines	are	considered	in	analysis	[glucose]	at	which	the	cells	were	cultured	
significantly	 altered	 the	 expression	 of	 BAX	 (p=0.01370),	 CA9	 (p=0.01723),	 PDK1	
(p=0.01900)	 and	 LDHA	 (p=0.02906).	 The	 oxygen	 tension	 significantly	 altered	 the	
expression	of	CA9	(p=0.00958),	PDK1	(p=0.00864),	LDHA	(p=0.00836),	HK2	(p=0.00221),	
HIF-2α	(p=0.03318)	and	GLUT1	(p=0.00125).	When	oxygen	tension	and	[glucose]	are	both	
taken	 into	 account	 in	 analysis,	 only	 CA9	 gene	 expression	 is	 significantly	 changed	
(p=0.0172).		
BAX	is	involved	in	the	process	of	apoptosis	as	well	as	mitochondrial	function.	This	analysis	
proves	there	is	a	relationship	between	[glucose],	apoptosis	and	mitochondrial	function.	
BAX	mRNA	expression	is	reduced	when	oxygen	tension	is	lowered	to	0.2%	O2	and	when	
[glucose]	 is	 lowered.	 This	 suggests	 that	 apoptosis	 is	 triggered	 less	via	mitochondria	 in	
these	 conditions	 to	 allow	 generation	 of	 ATP	when	 [glucose]	 is	 lower	 or	when	 oxygen	
tension	is	reduced.	However,	it	would	be	necessary	to	study	the	mitochondrial	membrane	
potential	and	the	structure	of	the	mitochondria	to	determine	if	the	mitochondria	are	fully	
functional	(Chapter	8,	Section	8.3).		
Interestingly,	BAX	protein	has	been	shown	to	be	prognostic	 in	human	CRC,	with	higher	
amounts	linked	to	more	severe	disease443.	It	is	necessary	to	study	the	level	of	BAX	protein	
in	the	CRC	cell	line	studied	in	this	thesis	to	determine	if	BAX	protein	levels	are	altered	by	
[glucose]	and	O2	tension.		
CA9	 and	 HIF-2α are	 involved	 in	 the	 cells	 response	 to	 hypoxia	 suggesting	 there	 is	 a	
relationship	between	hypoxia	and	[glucose],	as	already	widely	reported	in	literature444,445.	
PDK1,	 LDHA,	 HK2	 and	 GLUT-1	 are	 all	 involved	 in	 glycolysis	 (Chapter	 1,	 Figure	 1.7),	
suggesting	 that	 glycolysis	 is	 affected	by	both	 [glucose]	 and	oxygen	 tension,	 as	 already	
corroborated	by	the	literature446.		
One	surprising	result	was	the	very	low	quantities	of	COX4I2	 in	most	samples.	COX4I2	 is	
the	terminal	enzyme	of	the	mitochondrial	respiratory	chain.	COX4I2	has	been	shown	to	
have	a	HRE,	and,	therefore,	be	upregulated	in	hypoxia165.	However,	this	was	not	seen	in	
my	results.	Further	analysis	of	this	mRNA	and	protein	is	necessary.		
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To	validate	these	results,	 it	would	be	necessary	to	do	a	western	blot	for	all	the	protein	
products	of	the	genes	analysed	by	qPCR	as	mRNA	and	protein	results	can	be	different.	
Unfortunately,	there	was	not	enough	time	to	do	this	as	part	of	this	study.		
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Figure	 5.11.	Altered	 CRC	 cell	 gene	 expression	 profile	 after	 48	 hours	 treatment	 with	
20.9%	or	0.2%	oxygen.	A	heat	map	of	log	transformed	fold	changes	between	the	different	
oxygen	tensions	normalised	to	25mM	and	20.9%	treatment	is	shown.	Genes	are	ranked	
by	 significance	 of	 glucose	 concentration	 identified	 by	 linear	 regression	 multivariate	
analysis.		
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5.12	Mitochondrial	foci	number	and	area	are	increased	in	cells	cultured	in	0mM	glucose	
FH	 protein	 can	 be	 found	 throughout	 the	 cell,	 however,	 it	 is	 mainly	 found	 within	 the	
mitochondria	 where	 it	 participates	 in	 the	 TCA	 cycle.	 To	 understand	 if	 changes	 in	 the	
amount	 of	 FH	 protein	 and,	 therefore,	 in	 [fumarate]	 and	 FH	 activity	 are	 linked	 to	 the	
number	of	mitochondria	within	the	CRC	cells	it	was	necessary	to	quantify	mitochondria	
(Figure	5.13,	Table	5.11).		
Cells	were	treated	to	20.9%	or	0.2%	O2	for	48	hours,	then	fixed	and	stained	with	DAPI	for	
nucleus	identification,	plasma	membrane	stain	and	with	an	antibody	validated	against	a	
non-disclosed	protein	found	in	mitochondria	(Chapter	2,	Section	2.3.7,	Table	2.7).	From	
this	mitochondria	foci	and	area	could	be	determined.	Staining	was	imaged	by	InCell	2200	
microscope	and	the	resultant	images	were	analysed	by	InCell	Developer	V1.9	as	described	
in	Figure	5.12.		
It	 cannot	 be	 assumed	 that	 each	 focus	 is	 equal	 to	 one	 mitochondria.	 Therefore,	 area	
covered	by	focus	is	likely	to	be	a	more	accurate	measurement	of	mitochondria	quantity.	
Nevertheless,	area	and	foci	correlate	well.		
[Glucose]	had	a	significant	effect	on	the	number	of	mitochondrial	 foci	per	cell	 in	DLD1	
cells	 (p<0.0001)	 (Figure	 5.13.A).	 When	 DLD1	 cells	 were	 at	 20.9%	 O2,	 the	 number	 of	
mitochondrial	 foci	 per	 cell	 in	 DLD1	 cells	 cultured	 in	 0mM	 glucose	 was	 significantly	
increased	compared	to	DLD1	cells	cultured	in	25mM	glucose	(p<0.0001)	as	well	as	DLD1	
cells	cultured	in	5mM	glucose	(p<0.0001).	When	DLD1	cells	maintained	at	0.2%	O2,	the	
number	 of	 mitochondrial	 foci	 per	 cell	 in	 DLD1	 cells	 cultured	 in	 0mM	 glucose	 was	
significantly	 increased	compared	 to	DLD1	cells	 cultured	 in	25mM	glucose	 (p<0.01)	and	
increased	 compared	 to	 DLD1	 cells	 cultured	 in	 5mM	 glucose.	 Oxygen	 had	 a	 significant	
effect	 on	 the	 number	 of	 mitochondrial	 foci	 per	 cell	 in	 DLD1	 cells	 (p=0.0140)	 (Figure	
5.13.A).	 There	was	 a	 significant	 increase	 in	 the	 number	 of	mitochondrial	 foci	 per	 cell	
between	 DLD1	 cells	 cultured	 in	 0mM	 glucose	 held	 at	 0.2%	O2	 compared	 to	 20.9%	O2	
(p<0.001).	However,	there	was	no	difference	in	the	number	of	mitochondrial	foci	per	cell	
between	DLD1	cells	cultured	in	25mM	or	5mM	glucose	maintained	at	20.9%	O2	compared	
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to	those	at	0.2%	O2.	A	significant	interaction	between	[glucose]	and	oxygen	tension	on	
the	number	of	mitochondrial	foci	per	cell	in	DLD1	cells	was	identified	(p=0.0002).	
[Glucose]	 had	 a	 significant	 effect	 on	 the	 area	 of	 mitochondria	 per	 cell	 in	 DLD1	 cells	
(p<0.0001)	 (Figure	 5.13.B).	 When	 DLD1	 cells	 were	 held	 at	 20.9%	 O2,	 the	 area	 of	
mitochondria	per	cell	in	DLD1	cells	cultured	in	0mM	glucose	was	significantly	increased	
compared	 to	 DLD1	 cells	 cultured	 in	 25mM	 glucose	 (p<0.0001)	 as	 well	 as	 DLD1	 cells	
cultured	 in	 5mM	 glucose	 (p<0.0001).	 When	 DLD1	 cells	 were	 at	 0.2%	 O2,	 the	 area	 of	
mitochondria	per	cell	in	DLD1	cells	cultured	in	0mM	glucose	was	significantly	increased	
compared	to	DLD1	cells	cultured	in	25mM	glucose	(p<0.05)	as	well	as	DLD1	cells	cultured	
in	 5mM	 glucose	 (p<0.01).	 There	 was	 no	 significant	 effect	 of	 oxygen	 on	 the	 area	 of	
mitochondria	 per	 cell	 in	 DLD1	 cells	 (p=0.0564)	 (Figure	 5.13.B).	 However,	 there	 was	 a	
significant	increase	in	the	area	of	mitochondria	per	cell	between	DLD1	cells	cultured	in	
0mM	glucose	held	at	0.2%	O2	compared	 to	 those	cells	at	20.9%	O2	(p<0.05).	However,	
there	was	no	difference	in	the	area	of	mitochondria	per	cell	between	DLD1	cells	cultured	
in	 25mM	or	 5mM	glucose	 at	 20.9%	O2	compared	 to	 0.2%	O2.	 A	 significant	 interaction	
between	[glucose]	and	oxygen	tension	on	the	area	of	mitochondria	per	cell	in	DLD1	cells	
was	found	(p=0.0082).		
[Glucose]	had	a	significant	effect	on	the	number	of	mitochondrial	foci	per	cell	in	SW837	
cells	 (p=0.0003)	 (Figure	 5.13.C).	When	 SW837	 cells	were	maintained	 at	 20.9%	O2,	 the	
number	 of	 mitochondrial	 foci	 per	 cell	 in	 SW837	 cells	 cultured	 in	 0mM	 glucose	 was	
increased	 compared	 to	 SW837	 cells	 cultured	 in	 25mM	glucose	 as	well	 as	 SW837	 cells	
cultured	in	5mM	glucose.	When	SW837	cells	at	0.2%	O2,	the	number	of	mitochondrial	foci	
per	cell	in	SW837	cells	cultured	in	0mM	glucose	was	increased	compared	to	SW837	cells	
cultured	 in	 25mM	 glucose	 and	 was	 significantly	 increased	 compared	 to	 SW837	 cells	
cultured	in	5mM	glucose	(p<0.001).	Oxygen	had	a	significant	effect	of	on	the	number	of	
mitochondrial	 foci	 per	 cell	 in	 SW837	 cells	 (p=0.9646)	 (Figure	 5.13.C).	 There	 was	 a	 no	
difference	in	the	number	of	mitochondrial	foci	per	cell	between	SW837	cells	cultured	in	
0mM,	 5mM	 or	 25mM	 glucose	 and	 at	 20.9%	 O2	 compared	 to	 0.2%	 O2.	 A	 significant	
interaction	between	[glucose]	and	oxygen	tension	on	the	number	of	mitochondrial	foci	
per	cell	in	SW837	cells	(p=0.6084).		
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[Glucose]	 had	 a	 significant	 effect	 on	 the	 area	 of	mitochondria	 per	 cell	 in	 SW837	 cells	
(p<0.0001)	(Figure	5.13.D).	When	SW837	cells	were	maintained	at	20.9%	O2,	the	area	of	
mitochondria	 per	 cell	 in	 SW837	 cells	 cultured	 in	 0mM	 glucose	 was	 not	 significantly	
different	compared	to	SW837	cells	cultured	in	25mM	glucose	or	in	5mM	glucose.	When	
SW837	 cells	 were	 held	 at	 0.2%	 O2,	 the	 area	 of	 mitochondria	 per	 cell	 in	 SW837	 cells	
cultured	in	0mM	glucose	was	significantly	increased	compared	to	SW837	cells	cultured	in	
25mM	glucose	(p<0.01)	as	well	as	SW837	cells	cultured	in	5mM	glucose	(p<0.001).	Oxygen	
tension	did	not	have	a	significant	effect	on	the	area	of	mitochondria	per	cell	 in	SW837	
cells	(p=0.2712)	(Figure	5.13.D).	There	was	no	difference	in	the	area	of	mitochondria	per	
cell	 between	SW837cells	 cultured	 in	25mM,	5mM	or	0MM	glucose	and	maintained	at	
20.9%	O2	compared	to	0.2%	O2.	A	significant	 interaction	between	[glucose]	and	oxygen	
tension	on	the	area	of	mitochondria	per	cell	in	SW837	cells	was	not	found	(p=0.0706).	
The	readings	for	both	mitochondrial	foci	number	and	area	per	cell	are	similar	when	DLD1	
and	SW837	cells	were	cultured	 in	25mM	and	5mM	at	both	20.9%	and	0.2%	O2.	When	
DLD1	 cells	 were	 cultured	 in	 0mM	 glucose	 their	 mitochondrial	 foci	 number	 and	 area	
increase,	more	so	when	held	at	20.9%	O2	compared	to	0.2%	O2.	When	SW837	cells	were	
cultured	 in	 0mM	glucose	 their	mitochondrial	 foci	 number	 and	 area	 increase,	more	 so	
when	treated	with	0.2%	O2	compared	to	20.9%	O2,	but	not	as	much	as	DLD1	cells.	
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Figure	5.12.	Mitochondrial	staining	analysis	process.	Cells	were	held	in	20.9%	or	0.2%	O2	
for	48	hours,	then	fixed	and	stained	with	DAPI,	cell	mask	and	mitochondrial	antibody.	The	
staining	was	imaged	using	an	InCell	2200	microscope.	And	the	images	were	then	analysed	
by	 InCell	 Developer	 V1.9.	 Briefly,	 (A)	 cells	 are	 located	 via	 DAPI	 nuclear	 stain.	 (B)	 The	
programme	was	set	to	identify	single	nuclei	and	separate	multiple	nuclei	which	are	close	
together.	(C)	Alongside	this,	the	programme	was	set	to	identify	whole	cells	by	using	the	
cell	mask	stain.	(D)	Single	cells	are	then	defined	as	a	nucleus	(DAPI)	with	a	cell	body	(cell	
mask).	 (E,	 F)	 Mitochondrial	 staining	 was	 generally	 collected	 in	 foci.	 (G)	 Therefore,	 a	
mitochondrial	foci	analysis	was	completed.	(H)	The	analysis	programme	was	then	able	to	
determine	how	many	mitochondrial	foci	there	were	per	cell.	From	these	images	it	was	
possible	to	determine	the	area	covered	by	all	the	mitochondrial	foci	for	each	cell.	Scale	
bar	50µm.		
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Figure	5.13.	Mitochondrial	foci	and	area	per	cell.	DLD1	and	SW837	cells	were	maintained	
at	 20.9%	 or	 0.2%	 O2	 for	 48	 hours.	 Immunofluorescence	 was	 performed	 to	 detect	
mitochondrial.	Images	were	captured	on	INCA	2200	microscope	and	analysed	using	InCell	
Developer	v1.9	software	to	determine	the	number	and	area	of	foci	for	mitochondria	per	
cell.	(A)	Number	of	mitochondrial	foci	per	DLD1	cell.	(B)	Area	of	mitochondria	per	DLD1	
cell.	(C)	Number	of	mitochondrial	foci	per	SW837	cell.	(D)	Area	of	mitochondria	per	SW837	
cell.	Mean	±	SEM	in	Table	5.11.	*	p<0.1,	**	p<0.01,	***	p<0.001	(Table	A.5.32,33).		
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Table	5.11.	Summary	table	of	mitochondrial	foci	and	area	per	cell.	Data	shown	as	mean	
±	SEM.	N=3.	See	also	Figure	5.14.	
Cell	line	and	48-hour	treatment	 Number	 of	
mitochondrial	foci	per	
cell		
Mitochondrial	
area	 per	 cell	
(µm2)	
DLD1	25mM	glucose;	20.9%	O2	 17.31±0.99	 19.36±1.85	
DLD1	25mM	glucose;	0.2%	O2	 18.09±1.02	 19.74±0.78	
DLD1	5mM	glucose;	20.9%	O2	 17.76±0.13	 17.49±0.41	
DLD1	5mM	glucose;	0.2%	O2	 20.22±0.64	 18.84±0.82	
DLD1	0mM	glucose;	20.9%	O2	 39.15±2.71	 41.38±3.56	
DLD1	0mM	glucose;	0.2%	O2	 26.83±0.46	 30.44±1.21	
SW837	25mM	glucose;	20.9%	O2	 16.23±1.70	 12.25±1.25	
SW837	25mM	glucose;	0.2%	O2	 16.55±0.84	 13.00±0.60	
SW837	5mM	glucose;	20.9%	O2	 15.56±1.17	 12.74±1.41	
SW837	5mM	glucose;	0.2%	O2	 13.74±0.98	 10.46±0.66	
SW837	0mM	glucose;	20.9%	O2	 22.77±2.96	 19.94±3.51	
SW837	0mM	glucose;	0.2%	O2	 24.10±0.56	 26.23±0.58	
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5.13	FH	is	mainly	found	in	mitochondria		
FH	is	 largely	present	 in	mitochondria,	but	can	also	be	found	in	the	cytoplasm,	where	it	
participates	in	the	urea	cycle	(Chapter	1,	Figure	1.10).	To	determine	the	distribution	of	FH	
in	the	cell	when	cultured	in	25mM,	5mM	or	0mM	glucose	and	held	in	20.9%	or	0.2%	O2,	
the	amount	of	coinciding	staining	for	mitochondria	and	FH	was	quantified.	Data	shown	in	
Figure	5.9	for	FH	staining	and	Figure	5.13	for	mitochondrial	staining	was	analysed	again	
to	 identify	 FH	 staining	which	was	 present	 in	 the	 same	 area	 as	mitochondrial	 staining	
(Figure	15,	Table	5.12).	The	remaining	FH	staining	was	then	classified	as	cytoplasmic	or	
nuclear	 (abbreviated	 to	 cytoplasmic	 in	 explanation	 and	 figures	 for	 ease).	 Figure	 5.14	
displays	some	fusion	images	from	each	condition.		
[Glucose]	had	a	significant	effect	on	the	mitochondrial	vs.	cytoplasmic	ratio	of	FH	in	DLD1	
cells	(p=0.0002)	(Figure	5.15.A).	When	DLD1	cells	were	held	at	20.9%	O2	the	location	of	
FH	was	significantly	different	at	25mM	glucose	compared	to	DLD1	cells	cultured	in	5mM	
glucose	(p<0.005).	DLD1	cells	cultured	in	0mM	glucose	had	a	ratio	of.	When	DLD1	cells	
were	 held	 at	 0.2%	 O2	 the	 location	 of	 FH	 was	 significantly	 different	 at	 5mM	 glucose	
compared	to	cells	cultured	in	25mM	glucose	(p<0.001)	and	0mM	glucose	(p<0.001).	There	
was	a	significant	effect	of	oxygen	on	the	location	of	FH	in	DLD1	cells	(p=0.0254),	but	no	
significant	interaction	between	[glucose]	and	oxygen	was	found	(p=0.253).		
There	was	no	significant	effect	of	[glucose]	on	the	location	of	FH	in	SW837	cells	(p=0.2218)	
or	oxygen	(p=0.1029)	(Figure	5.15.B).	There	was	very	little	change	in	the	distribution	of	
FH.	The	amount	of	FH	was	between	83	and	90%	in	the	mitochondria	and	10	and	17%	in	
the	cytoplasm.		
In	all	 [glucose]	and	oxygen	tensions	the	cells	were	cultured	 in,	FH	was	overwhelmingly	
present	in	the	mitochondria,	with	less	than	a	quarter	in	the	cytoplasm	and	nucleus	(Figure	
5.15)	(Table	5.12).	Unfortunately,	no	non-cancerous	cells	were	used	in	this	experiment.		
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Figure	5.14.	Representative	fusion	images	of	FH	and	mitochondria	staining.	Cells	were	
treated	to	20.9%	or	0.2%	O2	for	48	hours,	then	fixed	and	stained	for	mitochondria	(green)	
and	FH	(orange),	nucleus	is	blue.		
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Figure	 5.15.	 Distribution	 of	 FH	 within	 CRC	 cells.	 (A)	 DLD1	 and	 (B)	 SW837	 cells	 were	
maintained	at	 20.9%	or	0.2%	O2	 for	 48	hours.	 Immunofluorescence	was	performed	 to	
detect	a	FH	and	a	mitochondrial	protein.	Images	were	captured	on	INCA	2200	microscope	
and	analysed	using	InCell	Developer	v1.9	software	to	determine	the	location	of	FH.	Mean	
±	SEM	in	Table	5.12.	*	p<0.1,	**	p<0.01,	***	p<0.001	(Table	A.5.34,35).	
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Table	5.12.	Summary	table	of	percentage	of	total	FH	 in	mitochondria	and	cytoplasm.	
Data	shown	as	mean	±	SEM.		N=3.	See	also	Figure	5.16.	
Cell	line	and	48-hour	treatment	 %	FH	in	mitochondria	 %	FH	in	cytoplasm	
DLD1	25mM	glucose;	20.9%	O2	 88.76±0.88		 11.24±0.88	
DLD1	25mM	glucose;	0.2%	O2	 85.02±4.90	 14.98±4.90	
DLD1	5mM	glucose;	20.9%	O2	 80.50±2.54	 19.50±2.54	
DLD1	5mM	glucose;	0.2%	O2	 75.06±3.41	 24.94±3.41	
DLD1	0mM	glucose;	20.9%	O2	 85.97±1.94	 14.03±1.95	
DLD1	0mM	glucose;	0.2%	O2	 85.10±0.78	 14.90±0.78	
SW837	25mM	glucose;	20.9%	O2	 84.86±2.17	 15.15±2.17	
SW837	25mM	glucose;	0.2%	O2	 89.09±0.78	 10.91±0.78	
SW837	5mM	glucose;	20.9%	O2	 84.98±1.46	 15.01±1.46	
SW837	5mM	glucose;	0.2%	O2	 83.97±5.22	 16.03±5.22	
SW837	0mM	glucose;	20.9%	O2	 86.30±1.60	 13.70±1.60	
SW837	0mM	glucose;	0.2%	O2	 89.64±0.70	 10.36±0.70	
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5.14	Mitochondria	are	less	functional	when	cells	are	cultured	in	25mM	glucose	
As	 it	 has	 been	 found	 previously	 that	 there	 was	 more	 mitochondrial	 staining	 in	 cells	
cultured	in	0mM	glucose	compared	to	25mM	and	5mM	glucose	(Chapter	5,	Section	5.9),	
the	 next	 step	 was	 to	 determine	 if	 these	 mitochondria	 were	 functional.	 A	 functional	
mitochondrion	will	provide	energy	to	the	cell	via	the	TCA	cycle,	which	involves	fumarate	
and	FH.		
To	 determine	 differences	 in	mitochondrion	 function	 the	 Seahorse	 XF	 Cell	Mito	 Stress	
Test447	 was	 used	 (Chapter	 2,	 Section	 2.3.9).	 The	 test	 uses	 compounds	 which	 target	
components	of	the	electron	transport	chain	(ETC)	of	the	mitochondria.	The	Seahorse	XF	
machine	can	determine	key	parameters	of	mitochondria	metabolic	function	interpreted	
from	the	oxygen	consumption	rate	(OCR)	and	extracellular	acidification	rate	(ECAR)	of	the	
cells.	 The	 compounds	 oligomycin,	 carbonyl	 cyanide-4	 (trifluoromethoxy)	
phenylhydrazone	(FCCP),	rotenone	and	antimycin	A	(described	in	Table	5.5)	are	serially	
injected	to	measure	ATP	production,	maximal	respiration,	non-mitochondrial	respiration,	
proton	 leak	 and	 spare	 capacity	 (defined	 in	 Table	 5.6).	 A	model	 OCR	 output	 from	 the	
Seahorse	Mito	Stress	test	is	shown	in	Figure	5.16.		
DLD1	and	SW837	cells	cultured	in	25mM,	5mM	or	0mM	glucose	were	used	in	this	assay.	
Cell	response	to	different	oxygen	tensions	could	not	be	determined	as	the	Seahorse	XF	
machine	was	not	in	the	hypoxic	chamber.	The	experiment	was	done	in	two	ways.	First,	
the	compounds	were	dissolved	in	media	with	the	same	concentration	of	glucose	as	the	
cells	were	cultured	in.	Second,	all	cells	were	pre-treated	with	25mM	glucose	media	for	1	
hour	and	all	compounds	were	dissolved	in	25mM	glucose	media.	Data	was	normalised	to	
the	numbers	of	 cells	 (100,000	 cells).	 Figure	 5.17	 and	5.18	 show	 the	 same	data	with	 a	
different	layout:	Figure	5.17	illustrates	the	data	as	a	real	time	OCR	trace	whereas	Figure	
5.18	shows	the	data	separated	into	the	parameters	that	can	be	measured	from	the	Mito	
Stress	test.	MEFs	were	also	used,	but	only	 in	the	first	way,	where	they	were	used	with	
25mM	glucose	in	their	media.		
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Table	5.13.	Summary	of	mode	of	action	of	compounds	used	in	Seahorse	Mito	Stress	test.	
Oxygen	Consumption	Rate	(OCR).	
Compound	 Mode	of	action		 Effect	on	OCR	
Oligomycin	 ATP	synthase	(complex	V)	inhibitor		 Decrease	
Carbonyl	 cyanide-4	
(trifluoromehtoxy)	
phenylhydrazone	
(FCCP)	
Disrupts	 the	 mitochondrial	 membrane	
potential.	An	uncoupling	agent	that	collapses	
the	 proton	 gradient	 resulting	 in	 an	
uninhibited	 flow	 of	 electrons	 through	 the	
electron	 transport	 chain	 (ETC)	 and	maximal	
oxygen	consumption	by	complex	IV.	
Increase	
Rotenone	 Complex	I	inhibitor	 Decrease	
Antimycin	A	 Complex	III	inhibitor	 Decrease	
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Table	5.14.	Description	of	metabolic	parameters	measured	by	Seahorse	Mito	Stress	test.		
Term	 Explanation		
Basal	
respiration	
Oxygen	consumption	used	to	meet	energetic	demand	of	the	cell	in	
baseline	conditions;	as	a	result	of	cellular	ATP	demand	and	natural	
mitochondrial	proton	leak.		
ATP	production	 ATP	 produced	 by	 the	 mitochondria.	 The	 decrease	 in	 OCR	 upon	
oligomycin	 administration	 represents	 the	 proportion	 of	 basal	
respiration	that	was	being	used	for	ATP	production.		
Proton	leak	 Basal	respiration	which	is	not	coupled	to	ATP	production.	Can	be	a	
sign	 of	 mitochondrial	 damage	 or	 a	 mechanism	 to	 regulate	 the	
mitochondrial	ATP	production.		
Maximal	
respiration	
The	maximum	rate	of	respiration.	Administration	of	FCCP	mimics	a	
physiological	energy	demand.	This	stimulates	the	respiratory	chain	
to	operate	at	maximum	capacity	 leading	to	the	rapid	oxidation	of	
substrates	such	as	sugars,	fats	and	amino	acids.		
Spare	capacity	 The	capability	of	the	cell	to	respond	to	an	energetic	demand.	Also,	
a	measurement	of	how	close	a	cell	is	to	respiring	to	its	theoretical	
maximum.	An	indicator	of	cell	fitness	and	flexibility.		
Non-
mitochondrial	
respiration	
Measurement	 of	 OCR	 created	 by	 a	 subset	 of	 cellular	 enzymes	
produce	oxygen.		
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Figure	5.16.	Representation	of	the	Seahorse	XF	Cell	Mito	Stress	Test	which	measures	
mitochondrial	 function	 by	 directly	measuring	 the	 oxygen	 consumption	 rate	 of	 cells.	
Sequential	injections	of	oligomycin,	FCCP,	and	a	mix	of	rotenone	and	antimycin	A	enable	
measurement	of	ATP	production,	maximal	respiration	and	non-mitochondrial	respiration.	
Proton	 leak	 and	 spare	 capacity	 can	 then	 be	 calculated	 from	 these	 measurements447.	
Image	from	Agilent447.		
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There	was	an	effect	of	 [glucose]	on	mitochondrial	metabolic	parameters	measured	by	
OCR	using	the	Seahorse	machine	(Figure	5.17	and	5.18).	In	general,	the	lower	[glucose]	of	
the	media	 in	 which	 the	 cells	 were	 cultured,	 the	 higher	 the	 OCR	measurement	 of	 the	
mitochondrial	 metabolic	 parameter.	 DLD1	 cells	 had	 lower	 OCR	 measurements	 of	 all	
parameters	when	compared	 to	SW837	cells	 cultured	 in	equivalent/identical	 conditions	
(see	Table	5.15	for	mean	±	SEM).		
Within	the	cell	lines,	the	metabolic	parameter	most	often	significantly	different	between	
[glucose]	is	the	spare	capacity.	Interestingly,	this	is	often	reduced	when	cells	have	more	
glucose	available	suggesting	that	cells	rely	on	the	continuous	glucose	supply,	instead	of	
storing	energy	in	other	ways.		
When	CRC	cells	cultured	in	0mM	glucose	were	treated	with	25mM	glucose	for	1	hour	prior	
to	the	Mito	Stress	Test	this	reduced	the	OCR	measurements	for	all	parameters	suggesting	
that	cells	had	not	 lost	the	ability	to	utilise	glucose.	This	may	be	aided	by	the	increased	
expression	of	glycolysis	related	mRNA	such	as	GLUT-1,	HK2	and	PDK1	in	cells	cultured	in	
0mM	 glucose.	 This	 suggests	 that	 the	 cells	 are	 still	 flexible	 in	 their	 energy	 creating	
pathways.	
Overall	 it	 was	 found	 that	 cells	 cultured	 with	 0mM	 glucose	 have	 the	 highest	 basal	
mitochondrial	respiration	rate,	produce	the	most	ATP	via	mitochondria,	have	the	highest	
maximal	capacity	in	their	mitochondria	as	well	as	the	greatest	spare	capacity.	When	cells	
cultured	 in	 0mM	 glucose	 are	 treated	 with	 25mM	 glucose	 for	 one	 hour,	 all	 of	 these	
measurements	are	reduced	and	significance	is	lost	when	compared	to	5mM	and	25mM	
glucose	cells.	They	have	potentially	upregulated	glycolysis	within	1	hour.		
KO	 Fh1	MEFs	 have	 reduced	mitochondrial	 function	 compared	 to	WT	 Fh1	MEFs	 on	 all	
parameters	confirming	that	FH	has	a	critical	role	in	mitochondrial	metabolism.	It	can	be	
concluded	 from	 this	 data	 that	 glucose	 presence	 prevents	 cells	 from	 using	 their	
mitochondria	to	full	capacity.		
Measuring	other	mitochondrial	parameters	such	as	membrane	permeability,	fusion	and	
fission	would	 allow	 further	 insight	 into	 the	 functionality	 in	 the	 cells	 used	 in	 this	 study	
(Chapter	8,	Section	8.3).	
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Figure	5.17.	Seahorse	Mito	Stress	test	output.	Cells	were	 incubated	within	a	Seahorse	
machine	which	injected	the	denoted	drugs	(arrowed)	at	the	time	points	indicated	to	test	
the	 mitochondrial	 metabolism	 of	 (A)	 DLD1	 cells	 in	 media	 at	 their	 denoted	 glucose	
concentration,	(B)	DLD1	cells	all	treated	with	25mM	glucose	for	1	hour	prior	to	the	assay,	
(C)	 SW837	 cells	 in	 media	 at	 their	 denoted	 glucose	 concentration,	 (D)	 SW837	 cells	 all	
treated	with	25mM	glucose	for	1	hour	prior	to	the	assay,	(E)	MEFs	in	25mM	glucose	media.	
Oxygen	consumption	rate	(OCR).		 	
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Figure	 5.18.	 Mitochondrial	 respiration	 parameters.	 (A)	 DLD1	 cells	 in	 media	 at	 their	
denoted	glucose	concentration,	(B)	DLD1	cells	all	treated	with	25mM	glucose	for	1	hour	
prior	to	the	assay,	(C)	SW837	cells	in	media	at	their	denoted	glucose	concentration,	(D)	
SW837	cells	all	treated	with	25mM	glucose	for	1	hour	prior	to	the	assay,	(E)	MEFs	in	25mM	
glucose	media.	Oxygen	consumption	rate	(OCR).	Mean	±	SEM	(Table	5.15).	Un-paired	t-
test	was	performed	*	p<0.5,	**	p<0.01,	***	p<0.001,	****	p<0.0001	(Table	A.5.36).	
	 237	
	
Figure	5.18b.	Mitochondrial	respiration	parameters,	A-D	fold	change	from	cells	cultured	
in	25mM	glucose,	E	fold	change	from	WT	MEFs.	(A)	DLD1	cells	in	media	at	their	denoted	
glucose	concentration,	(B)	DLD1	cells	all	treated	with	25mM	glucose	for	1	hour	prior	to	
the	assay,	(C)	SW837	cells	 in	media	at	their	denoted	glucose	concentration,	(D)	SW837	
cells	 all	 treated	with	 25mM	 glucose	 for	 1	 hour	 prior	 to	 the	 assay,	 (E)	MEFs	 in	 25mM	
glucose	 media.	 Oxygen	 consumption	 rate	 (OCR).	Mean	 ±	 SEM	 (Table	 5.15).	 Two-way	
ANOVA	with	Bonferroni	post	hoc,	*	p<0.5,	**	p<0.01,	***	p<0.001,	****	p<0.0001	(Table	
A.5.36b).	
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Table	5.15.	Oxygen	consumption	rate	for	CRC	cell	 lines	determined	by	Seahorse	Mito	
Stress	test.	Oxygen	consumption	rate	(OCR)	was	obtained	when	cells	were	assayed	with	
the	 glucose	 concentration	 they	 were	 cultured	 in	 (25mM,	 5mM	 or	 0mM	 glucose;	 un-
shaded	rows)	or	after	they	were	 incubated	with	25mM	glucose	for	1	hour	prior	to	the	
assay	(shaded	rows).	Data	shown	as	mean	±	SEM.	N=3.	See	also	Figure	5.18.	
Cell	
line	
Basal	
resp.	
ATP	
production	
Proton	
leak	
Maximal	
resp.	
Spare	
capacity	
Non-mito.		
resp.	
DLD1	
25mM	
35.88±	
8.94	
10.82±	
2.77	
2.26±	
1.59	
22.90±	
4.23	
9.82±	
1.27	
22.80±	
10.89	
DLD1	
5mM	
35.57±	
4.70	
13.49±	
5.96	
4.25±	
1.75	
28.33±	
11.55	
10.50±	
3.93	
17.83±	
6.61	
DLD1	
0mM	
57.06±	
10.48	
33.18±	
9.90	
5.86±	
0.37	
93.33±	
15.04	
54.29±	
5.93	
18.01±	
1.16	
DLD1	
25mM	
45.74±	
3.61	
24.10±	
3.00	
14.92±	
1.24	
23.45±	
2.70	
-15.57±	
1.89	
6.72±	
1.80	
DLD1	
5mM	
77.96±	
5.99	
42.88±	
3.03	
25.37±	
9.18	
47.99±	
2.55	
-20.25±	
5.15	
9.71±	
1.24	
DLD1	
0mM	
80.62±	
3.96	
33.13±	
5.73	
35.13±	
3.82	
70.96±	
11.93	
2.70±	
8.50	
12.36±	
2.16	
SW837	
25mM	
52.86±	
8.25	
12.88±	
7.22	
23.90±	
17.29	
58.67±	
21.02	
21.89±	
10.32	
16.08±	
7.04	
SW837	
5mM	
76.39±	
9.78	
38.62±	
8.62	
8.09±	
2.87	
101.79±	
22.44	
55.09±	
13.51	
29.69±	
17.60	
SW837	
0mM	
229.85±	
37.07	
143.80±	
21.36	
29.59±	
9.99	
325.00±	
31.19	
151.61±	
6.54	
56.46±	
11.97	
SW837	
25mM	
76.93±	
9.01	
46.84±	
2.95	
19.14±	
2.62	
43.15±	
4.67	
-22.82±	
2.46	
10.96±	
3.75	
SW837	
5mM	
110.57±	
16.08	
70.80±	
10.45	
17.69±	
1.95	
83.26±	
12.01	
-5.24±	
4.56	
22.08±	
10.06	
SW837	
0mM	
158.55±	
31.05	
103.21±	
17.47	
30.67±	
8.70	
158.73±	
26.70	
24.85±	
1.02	
24.66±	
5.36	
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When	 baseline	 values	 for	 OCR	 and	 ECAR	 are	 plotted	 it	 is	 possible	 to	 determine	 the	
metabolic	phenotype	of	the	cells	 (Figure	5.19).	Both	DLD1	and	SW837	cells	cultured	 in	
5mM	and	25mM	glucose	are	similar.	In	comparison	with	MEFs	the	CRC	cells	are	much	less	
glycolytic.	It	 is	difficult	to	directly	compare	murine	and	human	cells.	Plus,	KO	Fh1	MEFs	
use	 different	 metabolic	 pathways	 as	 described	 in	 Chapter	 5,	 Section	 5.1.	 DLD1	 cells	
cultured	in	0mM	glucose	are	much	more	quiescent	than	DLD1	cells	cultured	in	5mM	and	
25mM	glucose,	suggesting	that	they	do	not	generate	as	much	energy.	In	contrast,	SW837	
cells	cultured	in	0mM	glucose	are	much	more	aerobic	than	SW837	cells	cultured	in	5mM	
and	25mM	glucose,	suggesting	that	they	are	able	to	generate	energy	well.	Post	incubation	
with	 25mM	 glucose	 cells	 are	 grouped	 together	 suggesting	 that	 their	 glycolysis	 and	
mitochondrial	metabolism	pathways	 are	 functioning	 in	 a	 similar	way.	 Cells	 cultured	 in	
5mM	and	25mM	glucose	do	not	change	their	metabolic	phenotype	on	 incubation	with	
25mM	glucose.		
However,	this	data	is	hard	to	interpret.	The	results	are	relative	to	samples	tested	at	the	
same	 time.	Each	graph	 represents	an	experiment.	Unfortunately,	 the	Agilent	Seahorse	
machine	available	only	took	24-well	plates	so	it	was	not	possible	to	test	every	condition	
on	the	same	plate.		
	 	
	 240	
	
	
Figure	5.19.	Metabolic	phenotype	of	CRC	cells.	The	metabolic	phenotype	of	cells	can	be	
determined	from	baseline	oxygen	consumption	rate	(OCR)	and	extracellular	acidification	
rate	(ECAR).	Cells	with	high	OCR	and	ECAR	are	determined	energetic,	those	with	low	OCR	
and	ECAR	are	quiescent.	Cells	with	high	OCR	and	low	ECAR	are	aerobic,	whereas	cells	with	
low	OCR	and	high	ECAR	are	glycolytic.	(A)	DLD1	cells	in	media	at	their	denoted	glucose	
concentration,	(B)	DLD1	cells	all	treated	with	25mM	glucose	for	1	hour	prior	to	the	assay,	
(C)	 SW837	 cells	 in	 media	 at	 their	 denoted	 glucose	 concentration,	 (D)	 SW837	 cells	 all	
treated	with	25mM	glucose	for	1	hour	prior	to	the	assay,	(E)	MEFs	in	25mM	glucose	media.	
OCR,	Oxygen	consumption	rate;	ECAR,	extracellular	acidification	rate.		
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5.15	Discussion	
The	physiology	of	normal	and	tumour	tissues	is	different	in	many	aspects,	the	majority	of	
which	 are	 as	 a	 result	 of	 differences	 in	 vasculature.	 Solid	 tumours,	 such	 as	 CRC,	 have	
deficient	vascular	systems	due	to	excessive	and	unregulated	cancer	cell	growth	alongside	
insufficient	 angiogenesis.	 As	 a	 result,	 perfusion	 within	 solid	 tumours	 is	 inadequate,	
leading	to	tumour	regions	which	are	transiently	and	chronically	exposed	to	nutrient	and	
oxygen	 starvation448.	 Cancer	 cells	 respond	 to	 these	 conditions	 by	 adapting	 their	
metabolism	 to	 enable	 survival	 and	 proliferation.	 Several	 reports	 have	 indicated	 that	
changes	 in	cancer	cell	metabolism	are	 induced	by	oncogenes	and	mutations	 in	tumour	
suppressor	genes.	Some	examples	relating	to	CRC	are	MYC,	HIF1α	and	p53	which	lead	to	
increased	expression	of	genes	with	a	 role	 in	glycolysis	such	as	GLUT-1,	HK2,	LDHA	and	
PDK1195,413,449–452.	It	has	also	been	found	that	glucose	deprivation	promotes	development	
of	KRAS	mutations	in	cancer	cells453.	Overall	these	genetic	changes	lead	to	high	rates	of	
glucose	 consumption	and	 lactate	production	 in	 cancer	 cells,	 despite	 low	availability	of	
oxygen	for	complete	oxidation	of	glucose,	known	as	the	Warburg	effect446.		
The	 interruption	of	 glycolysis	by	 inhibition	of	GLUT-1,	HK2	and	LDH	 for	example,	 is	 an	
attractive	method	for	cancer	treatment454–456.	However,	targeting	glycolysis	has	not	yet	
translated	 into	 the	 clinic.	 The	 precise	 effects	 of	 oncogenes	 and	 mutations	 in	 tumour	
suppressor	genes	on	CRC	cell	metabolism	are	 still	disputed.	Tumours	are	known	to	be	
heterogeneous	so,	it	is	likely	that	cancer	cells	in	different	tumour	regions	have	different	
adaptions	 according	 to	 their	 microenvironment	 pressures457.	 Cells	 further	 from	 blood	
vessels	 will	 have	 selection	 pressure	 for	 those	 that	 survive	 low	 oxygen	 and	 nutrient	
conditions.	 This	 heterogeneity	 contributes	 to	 therapy	 resistance	 and	 poses	 a	 major	
challenge	for	personalised	therapy.		
In	 vitro	 studies	 to	 determine	 effect	 of	 oxygen	 deprivation	 or	 hypoxia	 on	 cancer	 cells	
predominantly	 use	 oxygen	 concentrations	 below	 2%144.	 Healthy	 tissues	 experience	
between	2	and	9%	oxygen144.	Experimentally	such	oxygen	tensions	are	achieved	through	
use	of	a	heated	humidified	chamber	where	the	oxygen	concentration	can	be	controlled.	
Cells	 are	 plated	 in	 atmospheric	 oxygen	 (20.9%)	 and	 then	 transferred	 to	 the	 hypoxic	
treatment	 for	 24-72	 hours.	 A	 concentration	 of	 0.2%	O2	 for	 48	 hours	was	 used	 as	 the	
hypoxic	treatment	for	this	thesis.	CO2	content	remained	at	5%	to	maintain	the	pH	of	the	
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media.	These	conditions	were	chosen	based	on	previous	work	in	the	lab	which	identified	
stronger	changes	in	microRNAs	in	CRC	cell	lines	when	treated	with	0.2%	O2	compared	to	
1%	O2408–412,414.		
Traditionally,	most	cancer	cell	lines	are	cultured	in	media	with	25mM	glucose.	However,	
normal	 blood	 glucose	 in	 humans	 is	 equivalent	 to	 5mM	 glucose415,416.	 And	 the	 glucose	
concentration	that	solid	tissues	experience	is	lower	than	5mM335.	Culturing	of	cancer	cells	
in	vitro	with	25mM	glucose	does	not	accurately	represent	physiological	conditions	and	
could	be	one	reason	why	glycolysis	inhibitors	developed	 in	vitro	do	not	translate	to	the	
clinic.	 And,	 in	 vitro	 studies	 to	 determine	 effect	 of	 glucose	 deprivation	 on	 cancer	 cells	
typically	remove	glucose	from	the	media	for	24-72	hours	and	then	test	for	observations.	
The	removal	of	glucose	from	the	media	in	this	short	time	frame	often	leads	to	cancer	cell	
death	 via	 caspase	 activation	 and	 ROS458–460.	 In	 my	 opinion,	 this	 is	 not	 an	 accurate	
representation	of	tumours	in	vivo.	The	time-frame	over	which	tumours	grow	and	adapt	
to	low	glucose	concentrations	in	vivo	is	much	longer	than	72	hours.	To	enable	me	to	study	
the	effect	of	glucose	concentration	on	CRC	cells	in	a	way	that	represents	in	vivo	conditions	
I	 gradually	 reduced	 the	 concentration	of	 glucose	 in	 CRC	 cell	media	 over	 a	 period	of	 3	
months	instead	of	dropping	the	glucose	concentration	dramatically.	Over	this	prolonged	
time	period,	glucose	would	not	be	totally	removed	from	the	cells,	so	those	cultured	 in	
0mM	glucose	were	 truly	glucose	 free.	This	approach	has	not	been	 taken	before	 to	my	
knowledge.	 Originally,	 I	 was	 interested	 in	 25mM	 and	 5mM	 glucose	 to	 simulate	 blood	
glucose	concentrations	of	an	uncontrolled	diabetic	and	a	normal	individual,	respectively.	
However,	CRC	cells	were	able	to	survive	without	any	glucose	in	their	media	which	I	found	
interesting	and,	therefore,	decided	to	include	this	condition	in	my	study.		
The	first	part	of	work	I	did	was	to	phenotype	the	CRC	cells	that	I	had	created	to	understand	
baseline	 differences.	 As	 expected,	 reducing	 the	 glucose	 concentration	 increased	 the	
doubling	time	of	all	CRC	cell	lines	(Figure	5.1).	Glycolysis	is	a	major	producer	of	ATP	for	
the	cancer	cell,	 therefore,	 if	 less	glucose	 is	entering	the	pathway	then	 less	ATP	will	be	
made	 for	 processes	 like	 proliferation.	 However,	 there	 is	 more	 than	 one	 metabolic	
pathway	 that	 can	 generate	 ATP.	 It	 is	 known	 that	 glutamine	 is	 metabolised	 more	
abundantly	 than	 other	 non-essential	 amino	 acids	 in	 cancer	 cells461,462.	 Glutamine	
remained	in	the	CRC	cell	media	at	2mM	regardless	of	glucose	concentration.	This	allowed	
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for	 only	 the	 effects	 of	 changing	 glucose	 concentration	 to	 be	 studied.	 Glutamine	 is,	
therefore,	 likely	 to	be	contributing	to	cell	 survival	under	glucose	 free	conditions.	DLD1	
cells	have	previously	been	shown	to	have	increased	levels	of	glutamate	dehydrogenase	1	
(GLUD1)	which	metabolises	glutamine	and	feeds	it	into	the	TCA	cycle	via	α-ketoglutarate	
to	 generate	 ATP397.	 And	 knock-down	 of	 GLUT1	 in	 DLD1	 cells	 in	 glucose-deprived	
conditions	(removal	of	glucose	for	72	hours)	led	to	decreased	growth397.		
Doubling	time	of	KO	Fh1	MEFs	was	higher	than	WT	Fh1	MEFs	(Figure	5.2).	This	is	 likely	
due	 to	 the	alteration	 in	 the	TCA	cycle	of	KO	Fh1	MEFs,	 leading	 to	 lower	generation	of	
energy	for	cell	proliferation.	Tyrakis	et	al.	2017	recently	reported	that	Fh1	deficient	cells	
are	unable	to	grow	in	glucose-free	medium322.	It	was	reported	that	cells	were	unable	to	
further	increase	the	function	of	their	mitochondria	to	meet	energy	demands.	However,	it	
was	not	reported	in	the	methods	how	the	reduction	of	glucose	was	accomplished.	This	
evidence	suggests	that	the	CRC	cells	have	functional	FH	as	they	are	able	to	cope	without	
glucose.		
It	was	also	necessary	to	confirm	HIF-1α	upregulation	during	the	0.2%	O2	treatment	(Figure	
5.6).	Upregulation	of	HIF-1α	was	identified	strongly	in	cells	cultured	in	25mM	and	5mM	
glucose.	The	presence	of	HIF-1α	is	not	as	strong	in	CRC	cells	cultured	with	0mM	glucose.	
The	dependence	of	HIF-1α	stability	on	glucose	has	previously	been	described	in	human	
pancreatic	 cancer	 cells463,	 human	 prostate	 cancer	 cells463,	 human	 pharyngeal	 cancer	
cells464	 and	 human	 glioma	 cells185.	 It	 is	 suggested	 that	 pyruvate,	 the	 end	 product	 of	
glycolysis,	has	a	role	in	preventing	the	degradation	of	HIF-1α	protein185.	Despite	this	fact,	
gene	expression	data	in	Figure	5.11	shows	that	in	CRC	cells	cultured	with	0mM	glucose	
there	was	upregulation	of	genes	controlled	by	HIF-1α,	which	implies	there	must	be	some	
stabilisation	 of	 HIF-1α.	 Alternatively,	 the	 genes	 could	 be	 upregulated	 via	 a	 different	
mechanism.		
Cancer	cells	are	known	to	survive	 in	a	hypoxic	environment	by	 increasing	their	glucose	
uptake	facilitated	by	increased	expression	of	HIF-1α465.	However,	when	both	glucose	and	
oxygen	 are	 in	 low	 supply	 and	 cell	 energy	 demand	 is	 high,	 cell	 survival	 can	 be	
compromised.	The	in	vitro	cell	viability	results	(Figure	5.5)	corroborate	this	observation:	
viability	was	 decreased	 at	 0.2%	O2	 in	 CRC	 cells	 cultured	with	 5mM	 and	 0mM	 glucose	
compared	to	those	cultured	with	25mM	glucose.	Viability	of	MEFs	(Figure	5.5)	with	both	
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WT	and	KO	Fh1	was	equal	in	hypoxia	and	normoxia	likely	due	to	their	culture	in	25mM	
glucose.	This	suggests	that	CRCs	in	T2D	patients	may	be	able	to	survive	hypoxia	better	if	
blood	[glucose]	is	increased.		
Next,	 it	was	 important	 to	understand	 the	changes	 in	 fumarate	and	how	they	 relate	 to	
[glucose]	 and	 oxygen	 tension.	 It	 has	 previously	 been	 shown	 that	 [fumarate]	 can	 be	
elevated	200-300	times	in	HLRCC	samples	compared	to	normal	fibroblast	cell	samples324.	
Stomach	 and	 colon	 cancer	 samples	 have	 also	 been	 shown	 to	 have	 elevated	 fumarate	
compared	 to	 normal	 tissue,	which	 is	 attributed	 the	 oncogenic	 changes	within	 the	 cell	
leading	to	increased	demand	for	ATP	leading	to	an	increase	in	metabolism	and,	therefore,	
more	 fumarate	 and	 other	metabolites335.	 Fumarate	 impairs	 HIF-1	 prolyl	 hydroxylation	
leading	 to	 stabilisation	 of	 HIF-1α316.	 High	 levels	 of	 intrinsic	 fumarate	 in	 a	 cell	 can,	
therefore,	promote	pseudohypoxia	and	the	Warburg	effect,	both	survival	mechanisms	for	
cancer	cells.	Fumarate	is	also	generated	during	a	DNA	damage	repair	carried	out	by	FH330.	
FH	travels	to	sites	of	DNA	damage,	which	are	more	likely	in	hypoxia466,	to	promote	repair	
of	double	strand	breaks	in	DNA;	fumarate	is	generated	in	this	process467.		
In	line	with	the	above	evidence,	[fumarate]	was	found	to	generally	increase	in	CRC	cells	
held	in	0.2%	O2.	Recently,	treatment	with	increasing	[fumarate]	has	been	shown	to	reduce	
the	viability	of	HepG2	cells,	due	to	extensive	DNA	damage	and	activation	of	an	apoptotic	
pathway468.	A	[fumarate]	of	2.5mM	reduced	HepG2	cell	viability	to	around	20%.	Although,	
viability	of	cells	in	this	study	is	reduced	at	0.2%	O2,	it	appears	that	the	intrinsic	[fumarate]	
in	this	study	is	not	sufficient	to	affect	cell	viability.	The	highest	[fumarate]	found	in	this	
study	was	in	KO	Fh1	MEFs	of	around	23	ng/uL	which	equates	to	198µM	and	is,	therefore,	
not	high	enough	to	potentially	effect	cell	viability.	Interestingly,	DLD1	cells	held	in	0.2%	
O2	more	FH	was	found	in	the	nucleus	or	the	cytoplasm	(Figure	5.9)	suggesting	that	the	
increase	in	[fumarate]	could	be	due	to	the	role	of	FH	in	DNA	repair,	which	protects	cells	
from	 DNA	 damage.	 Increasing	 [fumarate]	 and	 measuring	 cell	 viability	 would	 be	 an	
interesting	experiment	to	complete	with	the	CRC	cells	generated	for	this	work	(Chapter	
8,	Section	8.3).	
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Although,	fumarate	concentration	was	dependent	on	cell	type,	oxygen	and	[glucose].	The	
effect	 of	 [glucose]	 on	 [fumarate]	was	more	 closely	 related	 to	 cell	 line.	 In	 SW837	 cells	
[fumarate]	was	highest	in	cells	cultured	with	25mM	glucose,	but	in	DLD1	and	HT55	cells,	
[fumarate]	 was	 highest	 when	 cells	 were	 cultured	 in	 5mM	 glucose,	 and	 this	 was	
comparable	to	the	[fumarate]	of	SW837	cells	cultured	in	25mM	glucose.	DLD1	and	HT55	
cell	lines	are	both	derived	from	colon	cancer	patients	whereas	SW837	cell	line	is	derived	
from	a	rectal	cancer	patient.	It	is	interesting	that	the	DLD1	and	HT55	cell	lines	have	similar	
[fumarate]	under	the	same	treatment	and	that	these	are	different	to	the	SW837	cell	line.	
The	 same	 grouping	 of	 cell	 lines	 occurred	 in	 the	 [fumarate]	mass	 spectrometry	 results	
(Figure	5.1).	I	can	find	no	literature	which	suggests	that	cells	from	the	colon	and	rectum	
have	intrinsically	different	fumarate	or	glucose	levels.	However,	it	is	known	that	there	is	
less	 blood	 supply	 to	 the	 rectum.	 This	 work	 highlights	 a	 potential	 novel	 finding	 in	 the	
relationship	between	[fumarate]	and	[glucose]	in	cells	from	different	tissue	origins,	and	
should	be	followed	up	(Chapter	8,	Section	8.3).		
KO	Fh1	MEFs	had	the	highest	[fumarate],	as	expected	due	to	no	Fh1	converting	fumarate	
into	 malate.	 However,	 this	 decreased	 upon	 treatment	 with	 0.2%	 O2,	 which	 was	 the	
opposite	result	to	all	other	cell	lines.	This	is	an	interesting	result,	which	suggests	that	when	
Fh1	is	not	present	another	mechanism	could	be	operating	which	is	regulating	fumarate	
concentration	under	hypoxia.	The	[fumarate]	found	in	KO	Fh1	MEFs	was	almost	matched	
by	HT55	cells	cultured	in	25mM	glucose	and	held	at	0.2%	O2	which	suggests	that	FH	could	
be	inhibited	by	lack	of	oxygen	alongside	high	[glucose]	in	HT55	cells.		
The	NADH-fumarate	reductase	system	is	an	anaerobic	form	of	respiration	that	exists	in	
anaerobic	organisms.	This	system	results	in	the	formation	of	succinate	from	the	reverse	
reaction	of	complex	II	in	the	mitochondria	but	has	not	been	widely	studied	in	human	cells.	
Paddenburg	et	al.	describe	the	use	of	this	system	in	hypoxic	pulmonary	vasculature	where	
they	suggest	that	complex	II	switches	its	catalytic	activity	from	succinate	dehydrogenase	
to	fumarate	reductase	at	reduced	oxygen	tension469.	It	could	be	speculated	that	this	is	a	
mechanism	 to	 generate	 extra	 energy	 under	 hypoxic	 conditions	 in	 CRC	 cells,	 where	
fumarate	levels	rise.		
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As	I	had	been	able	to	detect	fumarate	it	was	next	necessary	to	determine	if	it	was	possible	
to	 identify	 succination	 in	 the	 CRC	 cell	 lines.	 This	 was	 crudely	 done	 by	 western	 blot.	
Succination	was	present	in	all	cell	lines.	However,	it	would	be	better	to	identify	2-SC	motifs	
on	proteins	by	mass	spectrometry,	which	would	enable	 identification	of	exact	proteins	
that	have	been	succinated.		
Differences	in	[fumarate]	in	CRC	lines	found	by	fluorometric	assay	can	be	explained	by	FH	
activity.	As	predicted,	when	[fumarate]	is	high,	FH	activity	is	low.	Differences	in	FH	activity	
are	more	pronounced	in	the	DLD1	cell	line,	with	activity	much	higher	in	cells	cultured	in	
25mM	and	5mM	glucose	and/or	treated	with	20.9%	O2	compared	to	cells	cultured	in	0mM	
glucose	 and/or	 0.2%	 O2.	 This	 suggests	 that	 in	 the	 DLD1	 cell	 line,	 FH	 activity	 is	 more	
dependent	on	[glucose]	and	oxygen	availability	relative	to	the	SW837	cell	line	where	FH	
activity	 is	 only	 slightly	 increased	 at	 each	 glucose	 concentration	 when	 cells	 were	
maintained	in	20.9%	O2	over	0.2%	O2.	FH	activity	has	been	linked	to	cell	growth	rate	and	
carbon	 source	 utilisation	 independently	 by	 a	 study	 done	 in	 Escherichia	 coli470.	 The	
researchers	found	that	FH	activity	increased	under	aerobic	conditions	and	when	acetate	
was	 used	 instead	 of	 glucose	 as	 the	 sole	 carbon	 source.	 It	 has	 also	 been	 shown	 that	
inhibition	 of	 FH	 activity	 at	 low	 glucose	 concentrations	 is	 cytotoxic471,	 therefore,	 there	
must	be	a	relatively	precise	window	of	FH	activity	that	is	advantageous	to	the	cell.		
As	expected	in	WT	Fh1	MEFs	FH	activity	is	higher	in	20.9%	O2	compared	to	0.2%	O2.	Some	
minimal	activity	is	observed	in	KO	Fh1	MEFs	which	suggests	that	the	assay	is	not	perfect,	
as	there	should	be	no	read	out	if	Fh1	is	not	present.	However,	the	readout	is	cellular	NADH	
which	is	made	elsewhere	in	the	cell.	Therefore,	the	value	for	KO	Fh1	MEFs	was	used	as	a	
background	value,	 and	 substituted	 from	all	 final	 readouts.	As	CRC	 cell	 lines	produce	a	
readout	from	this	assay,	this	suggests	that	FH	activity	is	not	fully	compromised	in	CRC	like	
HLRCC.	Further	critical	work	needs	 to	be	completed	 to	ascertain	 the	 full	potential	and	
changes	in	FH	activity	relating	to	[glucose]	and	O2	tension	in	CRC.	
As	detailed	in	the	Chapter	3	discussion,	at	concentrations	above	0.1M	fumarate	can	inhibit	
FH	and	at	0.001-0.033M	allosteric	activation	of	the	enzyme	by	binding	to	site	B	is	observed	
390.	Both	the	mass	spectrometry	and	fluorometric	assay	readouts	for	CRC	cell	[fumarate]	
were	lower	than	0.001M	so	FH	was	not	inhibited	by	fumarate	in	the	cell	conditions	used	
for	this	study.		
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It	 was	 thought	 that	 FH	 activity	 could	 be	 linked	 to	 amount	 of	 FH	 protein	 in	 the	 cells.	
Therefore,	it	was	necessary	to	determine	the	area	of	FH	in	the	cell.	DLD1	cells	had	more	
FH	than	SW837	cells	at	each	[glucose].	For	both	cell	lines,	the	area	of	FH	did	not	change	
in	cells	cultured	in	25mM	and	5mM	glucose	when	held	in	0.2%	O2.	As	the	FH	activity	data	
suggest	that	FH	is	more	active	in	DLD1	cells	held	in	20.9%	O2	this	suggests	that	FH	area	
does	not	correlate	with	FH	activity.		
FH	 staining	 did	 not	 correlate	 with	 [fumarate],	 suggesting	 that	 presence	 of	 FH	 is	 not	
influenced	by	fumarate.	Furthermore,	in	both	DLD1	and	SW837	cells	the	area	of	FH	was	
greater	upon	culture	in	0mM	glucose	compared	to	culture	in	25mM	and	5mM	(Figure	5.9).	
This	suggests	that	the	cell	is	able	to	up-regulate	FH	when	glucose	is	not	present.	However,	
FH	mRNA	expression	was	not	increased	in	0mM	glucose,	suggesting	a	post-translational	
control	over	FH.	Rossignol	et	al.,	studied	HeLa	cells	grown	in	no	glucose	for	3	weeks472.	
They	 identified	 that	 in	 HeLa	 cells	 grown	 in	 glucose,	 80%	 of	 glucose	 is	metabolised	 by	
glycolysis	and	only	4-5%	of	glucose	carbon	entered	the	TCA	cycle.	Whereas,	when	HeLa	
cells	are	grown	in	galactose	medium,	glutamine	provided	98%	of	the	ATP	used	for	growth	
via	the	TCA	cycle.	They	also	found	by	Western	blot	that	cells	synthesis	more	respiratory	
chain	protein	when	grown	without	glucose	which	matches	with	the	upregulation	of	FH	
shown	in	cells	grown	in	0mM	glucose	in	this	study.	I	could	find	no	similar	studies	in	tumour	
cells.	Even	though	more	FH	is	present	in	cells	cultured	in	0mM	glucose,	the	activity	of	FH	
is	lowest	in	this	condition	which	suggests	that	FH	is	inhibited	in	some	way	by	culture	in	
0mM	glucose.		
One	other	point	of	note	is	that	the	number	of	FH	foci	 in	DLD1	cells	 is	 lower	in	0.2%	O2	
compared	to	20.9%	O2,	however,	the	FH	area	is	similar.	This	could	suggest	that	the	hypoxic	
stress	 generates	 a	 clumping	 of	 FH	 protein.	 Because	 the	 majority	 of	 FH	 is	 within	 the	
mitochondria	(Figure	5.16)	this	could	suggest	that	mitochondrial	fission	is	occurring.	The	
opposite	is	true	for	SW837	cells;	there	are	more	foci	and	a	greater	area	in	SW837	cells	
cultured	in	0mM	glucose	when	they	are	treated	with	0.2%	O2	compared	to	20.9%	O2	which	
suggests	a	stimulus	in	production	of	FH.	To	determine	these	ideas,	further	experiments	
with	higher	 resolution	 imagery	should	be	completed,	 such	as	confocal	and/or	electron	
microscopy	(Chapter	8,	Section	8.3).		
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Gene	expression	between	DLD1,	HT55,	SW837	cells	after	culture	in	25mM,	5mM	or	0mM	
glucose	and	treatment	with	20.9%	O2	or	0.2%	O2	is	different.	No	similar	gene	expression	
studies	 have	 been	 published	 that	 I	 can	 find.	 When	 multivariate	 linear	 regression	 is	
completed	 with	 the	 data	 for	 all	 three	 cell	 lines,	 glucose	 concentration	 significantly	
influenced	BAX,	CA9,	PDK1	and	LDHA	which,	have	all	been	previously	implicated	as	having	
a	role	in	metabolism428,430,473,474.	Oxygen	concentration	significantly	influenced	CA9,	PDK1,	
LDHA,	HK2	and	GLUT1	gene	expression	which,	are	known	to	be	regulated	by	HIF	and	have	
been	reported	upregulated	in	hypoxia	previously475.	This	suggests	that	in	this	study	HIF	is	
activated	with	0.2%	O2	treatment.	 Interestingly,	 the	mRNA	for	HIF	and	FH	genes	 is	not	
increased	suggesting	post-translational	effects	on	protein	abundance.	To	validate	these	
results,	it	would	be	necessary	to	do	a	western	blot	for	all	the	protein	products	of	the	genes	
analysed	by	qPCR	as	mRNA	and	protein	results	can	be	different.	Unfortunately,	there	was	
not	enough	time	to	do	this	as	part	of	this	study.		
There	was	less	BAX	when	[glucose]	is	reduced	and	oxygen	tension	is	0.2%	O2.	BAX	deletion	
or	 inactivation	 is	 rare	 in	 cancers,	 but	 has	 been	 reported	 in	 CRC476.	 Interestingly,	 BAX	
protein	has	also	been	shown	to	be	prognostic	in	human	CRC,	with	higher	amounts	linked	
to	more	 severe	disease443.	 A	 paper	 studying	 the	 effect	 of	 loss	 of	BAX	 in	HCT116	 cells,	
suggests	that	loss	of	BAX	expression	leads	to	a	defect	in	mitochondrial	oxidative	capacity	
and	 favouring	 of	 the	 glycolysis	 pathway	 by	 the	 cell473.	 In	 my	 work,	 a	 reduction	 in	
mitochondrial	 oxidative	 capacity	 is	 not	 seen	 when	 [glucose]	 and	 BAX	 expression	 is	
reduced.	 In	healthy	cells	BAX	has	been	shown	to	be	required	 for	normal	mitochondria	
fusion477.	To	investigate	if	CRC	cells	used	in	this	study	had	differences	in	mitochondria,	it	
would	be	necessary	to	use	confocal	or	electron	microscopy	to	get	high	power	images	of	
mitochondria	(Chapter	8,	Section	8.3).	
CA9	 and	 HIF-2α are	 involved	 in	 the	 cells	 response	 to	 hypoxia	 suggesting	 there	 is	 a	
relationship	between	hypoxia	and	[glucose],	as	already	widely	reported	in	literature444,445.	
PDK1,	LDHA,	HK2	and	GLUT-1	are	all	 involved	 in	glycolysis,	suggesting	that	glycolysis	 is	
affected	 by	 both	 [glucose]	 and	 oxygen	 tension,	 as	 already	 corroborated	 by	 the	
literature446.		
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One	surprising	result	was	the	very	low	quantities	of	COX4I2	 in	most	samples.	COX4I2	 is	
the	terminal	enzyme	of	the	mitochondrial	respiratory	chain.	COX4I2	has	been	shown	to	
have	a	HRE,	and	can	thereby	be	upregulated	in	hypoxia165.	However,	this	wasn’t	seen	in	
my	results.	Further	analysis	of	this	mRNA	and	protein	is	necessary.		
To	further	understand	if	[glucose],	[fumarate]	and	FH	levels	and	activity	are	in	any	way	
linked	to	mitochondria,	it	was	necessary	to	determine	the	number	of	mitochondria	within	
the	cells.	Mitochondria	are	important	organelles	within	the	cell,	hosting	the	TCA	cycle	and	
OXPHOS.		
Area	of	mitochondria	was	stable	in	DLD1	and	SW837	cells	cultured	in	25mM	and	5mM	
glucose,	with	no	difference	between	oxygen	tension	treatment.	When	cells	are	cultured	
in	 0mM	 glucose	 the	 area	 of	 mitochondria	 increases.	 This	 could	 be	 explained	 by	
mitochondrial	fusion	and	fission,	processes	which	respond	to	changes	in	metabolism478.	
Fusion	is	a	result	of	energy	demand	and	stress.	New	mitochondria	are	generated	by	fission	
which	is	essential	for	growing	cells.	When	cells	have	to	rely	on	OXPHOS	due	to	withdrawal	
of	 glucose,	mitochondria	 become	more	 fused479.	 This	 suggests	 that	 the	 larger	 area	 of	
mitochondria	 found	 in	 cells	 cultured	 in	 0mM	 glucose	 is	 due	 to	 mitochondrial	 fusion.	
However,	the	number	of	mitochondrial	foci	is	not	reduced	when	DLD1	and	SW837	cells	
are	cultured	in	0mM	glucose,	suggesting	there	is	a	similar	number	of	mitochondria	which	
are	 larger.	 Further	 work	 using	 confocal	 and	 electron	 microscopy	 would	 confirm	
differences	in	area	as	well	as	determining	mitochondria	morphology	in	the	CRC	cells	used	
in	this	study.	This	also	correlates	with	the	increased	OCR	in	cells	cultured	in	0mM	glucose	
shown	by	the	Seahorse	Mito	Stress	Test	(Figure	5.18).	Suggesting	that	larger	mitochondria	
are	able	to	generate	a	higher	OCR.		
There	 is	 a	 correlation	 between	 FH	 and	 mitochondria	 area	 per	 cell,	 the	 greater	 the	
mitochondrial	area,	the	greater	the	FH	area.	As	FH	has	a	role	within	the	mitochondria,	this	
was	expected.	FH	also	has	a	cytoplasmic	role	in	the	urea	cycle	and	in	the	nucleus	in	the	
DNA	damage	response399.	It	was	possible	to	calculate	the	percentage	of	total	FH	within	
the	mitochondria	 and	 outside	 the	mitochondria.	 FH	was	 overwhelmingly	 found	 in	 the	
mitochondria	in	the	DLD1	and	SW837	cells	in	all	conditions.	In	SW837	cells	the	ratio	of	FH	
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in	the	mitochondria	to	FH	in	the	cytoplasm	and	nucleus	was	very	similar	in	all	conditions.	
Whereas,	in	DLD1	cells,	more	FH	was	found	in	the	cytoplasm	and	the	nucleus	when	cells	
were	 held	 in	 0.2%	O2,	which	 could	 be	 due	 to	 the	 participation	 of	 FH	 in	 DNA	 damage	
response	as	suggested	earlier.		
Fibroblast	 cell	 lines	 have	 previously	 been	 shown	 to	 have	 an	 equal	 or	 more	 balanced	
distribution	of	FH	between	mitochondria	and	cytoplasm	via	Western	blot314,	when	these	
are	 compared	 to	 samples	 from	 HLRCC	 patient	 the	 amount	 cytoplasmic	 FH	 in	 greatly	
reduced,	similar	to	the	distribution	of	FH	seen	in	the	CRC	cell	 lines	 in	this	study314.	The	
difference	between	HLRCC	patients	and	CRC	cells	lines	is	that	HLRCC	patient	samples	have	
a	mutation	in	FH	which	renders	FH	inactive,	whereas	CRC	cell	lines	have	no	mutation211,480.	
This	 suggests	 that	 the	 FH	 in	 CRC	 cell	 lines	 is	 dysfunctional	 in	 some	 way.	 It	 would	 be	
interesting	to	do	this	experiment	with	matched	normal	and	CRC	tissue	samples	(Chapter	
8,	Section	8.3).	
To	test	the	influence	of	[glucose]	on	the	function	of	mitochondria	I	chose	to	do	a	Seahorse	
Mito	Stress	Test.	The	data	 identified	that	CRC	cells	cultured	 in	0mM	and	5mM	glucose	
have	 enhanced	 basal	 OCR	 compared	 to	 cells	 cultured	 in	 25mM	 glucose	 and	 have,	
therefore,	adapted	their	metabolism	to	use	more	mitochondrial	metabolism.	Almost	all	
measurements	were	highest	in	cells	cultured	in	0mM	glucose,	including	proton	leak.	This	
suggests	that	although	cells	are	able	to	adapt	and	use	their	mitochondria	more,	they	could	
be	damaged	too.	To	confirm	damaged	mitochondria	mitochondrial	membrane	potential	
should	be	measured	(Chapter	8,	Section	8.3).	
Cancer	cells	are	known	to	generate	the	majority	of	their	energy	through	glycolysis	and	
preferring	to	use	the	end	product	of	glycolysis	pyruvate	to	make	lactate	instead	of	acetyl-
CoA	for	the	TCA	cycle481.	This	data	suggests	that	CRC	cells	are	able	to	function	without	
glucose,	so	aerobic	glycolysis	is	not	necessary	for	their	survival.		
In	both	cell	lines	spare	capacity	is	significantly	lower	in	cells	cultured	in	25mM	and	5mM	
glucose	compared	to	0mM	glucose.	This	correlates	with	the	area	of	mitochondria	results.	
When	more	mitochondria	are	present,	 the	cell	has	a	greater	 spare	capacity.	 For	other	
measurements,	 there	 was	 no	 significant	 difference	 in	 DLD1	 cells.	 In	 SW837	 cells	 ATP	
production	and	maximal	respiration	is	significantly	higher	in	cells	cultured	in	0mM	glucose	
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compared	 to	 25mM	 glucose.	 Even	 though	 it	 is	 known	 that	 mitochondrial	 respiration	
generates	more	ATP	than	glycolysis	I	was	still	surprised	by	the	huge	difference	seen.	This	
may	again	be	due	to	the	increase	in	number	of	mitochondria	in	SW837	cells	cultured	with	
0mM	glucose.	 To	 confirm	 the	 change	 in	mitochondria	 area	 and	number,	 further	work	
measuring	mitochondrial	DNA	would	add	to	the	evidence	(Chapter	8,	Section	8.3).	
There	was	a	great	difference	between	OCR	for	DLD1	and	SW837	cells.	As	SW837	cells	had	
a	 lower	mitochondrial	 area	when	cultured	 in	0mM	glucose,	 I	 predicted	 that	 their	OCR	
would	be	lower	than	DLD1	cells.	However,	the	exact	opposite	was	found.	SW837	cells	had	
higher	values	than	DLD1	cells	 for	all	conditions	and	measurements.	DLD1	cell	 readouts	
were	similar	to	WT	Fh1	MEFs.	Whereas	KO	Fh1	MEFs	had	almost	no	hint	of	mitochondrial	
respiration.	This	suggests	 that	SW837	cells	have	more	active	or	efficient	mitochondria,	
which	could	potentially	be	fuelled	by	greater	input	into	the	TCA	cycle,	but	this	was	not	
measured	 in	 this	 study.	 Perhaps	 DLD1	 cells	 are	 using	 an	 alternative	 form	 of	 energy	
generation.	SW837	cells	cultured	in	0mM	glucose	also	have	a	longer	doubling	time	than	
DLD1	 cells	 cultured	 in	 0mM	 glucose,	which	 suggests	 that	 the	 energy	 generation	 from	
mitochondria	isn’t	being	used	for	proliferation.		
The	mitochondrial	metabolism	of	DLD1	cells	was	not	affected	by	the	addition	of	25mM	
glucose,	suggesting	that	their	metabolism	is	not	as	flexible	as	SW837	cells.	Perhaps	the	
long	 period	 of	 culture	 in	 25mM,	 5mM	or	 0mM	glucose	 has	 permanently	 altered	 their	
make-up.	To	test	this,	cells	would	be	incubated	with	25mM	glucose	for	longer	periods	of	
time	before	testing	again.		
In	SW837,	addition	of	25mM	glucose	for	one	hour	before	the	Seahorse	Mito	Stress	Test	
led	to	a	reduction	in	OCR	for	cells	cultured	in	0mM	glucose	for	all	mitochondrial	metabolic	
parameters.	 This	 suggests	 that	 these	 cells	 are	 not	 permanently	 changed	 from	 being	
cultured	 in	 0mM	 glucose;	 they	 still	 have	 plasticity	 to	 up-regulate	 glycolysis	 again.	
Interestingly,	the	cells	with	the	least	spare	capacity	are	those	cultured	in	25mM	glucose	
which	suggests	that	the	cells	are	used	to	a	continuous	supply	of	glucose	and	do	not	hold	
much	reserve	for	stress	situations.		
These	 results	 are	 further	 highlighted	with	 the	metabolic	 phenotype	 plot.	 SW837	 cells	
cultured	 in	 0mM	 glucose	 are	 much	 more	 energetic	 than	 any	 other	 cell	 type	 tested.	
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Unfortunately,	the	Seahorse	Mito	Stress	Test	could	not	be	done	with	cells	held	in	0.2%	O2	
as	the	Seahorse	machine	 is	not	within	the	 INVIVO	chamber	 I	used	for	reducing	oxygen	
tension.	 I	would,	 however,	 expect	mitochondrial	 respiration	 to	be	 reduced	 in	 0.2%	O2	
compared	to	20.9%	O2.			
There	are	no	similar	Seahorse	studies	on	cancer	cell	 lines	where	 the	glucose	has	been	
reduced	over	a	prolonged	period	of	time.	However,	 it	 is	widely	known	that	a	glycolytic	
phenotype	 is	 linked	 to	 cancer	 progression	 and	 aggressiveness.	 There	 was	 not	 much	
difference	in	OCR	measured	by	Seahorse	of	cells	cultured	in	25mM	and	5mM	glucose	at	
20.9%	O2,	which	 suggests	 that	 cancer	cells	 can	generate	energy	well	 via	glycolysis	and	
mitochondrial	metabolism	with	a	wide	range	of	[glucose].	Nevertheless,	I	was	surprised	
to	 see	 SW837	 cells	 cultured	with	 0mM	 glucose	 generating	 such	 high	 OCR	 reads.	 This	
suggests	 that	 as	 expected	 tumour	 cells	 are	 able	 to	 adapt	 to	 different	 tumour	
microenvironments	by	using	different	substrates	 for	metabolism.	 It	would	be	useful	 to	
repeat	the	Seahorse	Mito	Stress	Test	with	cells	held	in	0.2%	O2	which	is	more	similar	to	
an	in	vivo	tumour	microenvironment.		
Unfortunately,	the	Seahorse	Mito	Stress	Test	could	not	be	done	with	cells	held	in	0.2%	O2	
as	the	Seahorse	machine	 is	not	within	the	 INVIVO	chamber	 I	used	for	reducing	oxygen	
tension.	 I	would,	 however,	 expect	mitochondrial	 respiration	 to	be	 reduced	 in	 0.2%	O2	
compared	to	20.9%	O2.	It	is	known	that	hypoxia	impairs	mitochondrial	fusion	which	leads	
to	mitochondrial	depolarisation,	loss	of	mtDNA	and	impaired	distribution	of	mitochondria	
within	the	cells	can	be	accompanied	by	altered	respiration	rate482.		
The	 work	 in	 this	 chapter	 has	 confirmed	 that	 CRC	 cell	 lines	 are	 very	 different,	 which	
matches	the	findings	of	Nijhuis	et	al.	2017408.	These	differences	should	be	considered	in	
the	implications	of	this	work	as	well	as	across	the	wider	scientific	field.	Overall	the	work	
has	shown	that	[fumarate]	in	CRC	cells	is	responsive	to	[glucose]	and	O2	tension.	It	was	
identified	that	2-SC	is	present	 in	vitro	 in	CRC	cells.	The	work	has	additionally	confirmed	
that	FH	in	CRC	cells	is	active	to	some	extent	in	vitro,	although,	the	amount	of	FH	and	FH	
activity	do	not	correlate.	CRC	cells	were	also	found	to	have	functional	mitochondria	and	
are	 plastic	 in	 their	 use	 of	 glycolysis	 and	OXPHOS.	 Further	 questions	 have	 been	 raised	
about	the	control	of	FH	and	its	activity	in	different	compartments	of	the	cell.		
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These	data	suggest	that	T2D	patients	with	CRC,	which	is	likely	to	be	hypoxic	at	the	core,	
could	experience	elevated	fumarate	in	their	tumour	compared	to	non-diabetic	patients,	
leading	to	changes	in	succination,	metabolism	and	gene	expression.		
	 	
	 254	
Chapter	6	–	DUOX2	activity	is	increased	by	cetuximab	
	
6.1	Introduction	
	
This	 work	 is	 focused	 on	 examining	 DUOX	 expression	 in	 xenografts	 of	 DLD1	 cells	 in	
response	to	exposure	to	the	oxaliplatin	and	cetuximab.	The	motivation	for	this	work	was	
the	 surprising	 results	 from	 the	 New	 Eloxatin	 Peri-Operative	 Chemotherapy	 (EPOC)	
study132.	 Patients	 who	 received	 oxaliplatin	 and	 5-FU	 combined	 with	 cetuximab	
demonstrated	reduced	progression-free	survival	than	those	who	received	oxaliplatin	or	
5-FU	alone132.	In	collaboration	with	Prof.	Daniel	Hochhauser’s	group	at	University	College	
London,	the	presented	data	within	this	chapter	formed	part	of	a	publication	in	the	JNCI	
journal	 that	 describes	 the	 role	 of	 ROS	 as	 generated	 by	 DUOX	 in	 the	 abrogation	 of	
oxaliplatin	activity	by	cetuximab	in	CRC	cells133.	
	
Oxaliplatin	is	a	chemotherapy	for	CRC	patients	given	in	combination	with	5-FU	(FOLFOX)	
or	capecitabine	(CAPOX).	Unfortunately,	this	therapy	does	not	work	for	every	patient	and	
cancer	cell	populations	that	are	resistant	to	oxaliplatin	can	develop,	leading	to	treatment	
failure129–131.	 Newer	 biologic	 treatments,	 such	 as	 cetuximab,	 are	 being	 developed	 and	
trialled	 in	 combination	 with	 drugs	 like	 oxaliplatin	 to	 try	 to	 prevent	 resistant	 cell	
populations	from	developing	and	thereby	improving	patient	outcome483,484.		
	
Cetuximab	is	a	monoclonal	antibody	to	EGFR	that	benefits	CRC	patients	without	a	KRAS	
mutation485.	Promising	 in	vitro	 studies	showed	positive	effects	of	combining	oxaliplatin	
and	cetuximab486,487.	Phase	 II	data	showed	promise	 for	combination	of	cetuximab	with	
oxaliplatin	as	a	first	line	therapy	for	patients	with	metastatic	CRC488.	The	addition	of	EGFR	
targeted	antibodies	cetuximab	or	panitumumab	to	chemotherapy	was	further	tested	and	
found	to	show	benefit,	especially	when	patients	had	a	cancer	without	a	KRAS	mutation489–
493.	However,	the	COIN	trial,	which	investigated	addition	of	cetuximab	to	oxaliplatin	and	
5-FU	 chemotherapy	 in	 first-line	 treatment	 of	 advanced	 CRC,	 did	 not	 confirm	 the	
synergistic	 benefit	 of	 cetuximab494.	 The	NORDIC	 trial	was	 another	 study	 including	 566	
patients	which	also	investigated	addition	of	cetuximab	to	oxaliplatin	and	5-FU/folinic	acid	
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chemotherapy	in	previously	untreated	advanced	CRC495,	but	again	showed	no	benefit	to	
patients.	The	New	EPOC	trial	was	carried	out	as	an	extension	to	the	COIN	and	EPOC496	
studies	 and	 used	 very	 similar	 investigational	 strategies	 to	 assess	 any	 improvement	 of	
patient	outcome	with	the	addition	of	cetuximab	to	oxaliplatin	and	5-FU	therapy132.		
Antagonism	between	platinum	drugs	and	cetuximab	has	been	reported	previously	in	KRAS	
wild-type	 CRCs497.	 ROS	 have	 been	 shown	 to	mediate	 resistance	 to	 chemotherapy.	 For	
example,	 preclinical	 studies	 have	 shown	 that	 treatment	 with	 platinum	 drugs	 and	
cetuximab	 in	 combination	 with	 gefitinib	 in	 colon	 and	 lung	 cancer	 cells	 resulted	 in	
antagonistic	 effects	 because	 of	 inhibition	 of	 chemotherapy-induced	 ROS	 by	 EGFR-
targeted	agents497,498.	By	contrast,	others	have	shown	that	EGFR	 inhibition	by	erlotinib	
resulted	in	ROS	production	via	NOX4	overexpression499.	
	
ROS	 includes	 superoxide	and	hydrogen	peroxide.	 In	 the	 cell,	ROS	are	produced	by	 the	
membrane	 bound	 enzymatic	 family	 of	 NADPH	 oxidases	 (NOX	 1-5	 and	 dual	 oxidases	
DUOX1/2)500,	 the	 mitochondrial	 electron	 transport	 chain,	 xanthine	 oxidase	 as	 well	 as	
other	 systems501–503.	ROS	 formation	 can	 lead	 to	 tumour	 initiation	and	 /	or	progression	
(Chapter	1,	Section	1.8).	Therefore,	ROS	is	an	important	signalling	molecule	which	controls	
the	 balance	 between	 proliferation	 and	 anti-proliferative	 signalling	 pathways	 in	 vivo,	
especially	 in	 tumours	and	their	microenvironment504.	 Inflammatory	cells	 in	 the	tumour	
microenvironment	stimulate	NOX-mediated	ROS	production	by	tumour	cells	 leading	to	
enhanced	angiogenesis	and	altered	DNA	integrity	promoting	genomic	instability505.		
	
The	work	 in	this	chapter	specifically	 involves	DUOX2	and	 its	obligate	maturation	factor	
DUOXA2	(Chapter	1,	Section	1.15).	In	summary,	DUOX2	was	initially	described	as	a	H2O2-
producing	 enzyme	 in	 the	 thyroid	 and	 does	 indeed	 have	 an	 important	 role	 in	 thyroid	
hormone	biosynthesis135.	DUOX2	has	since	been	 identified	as	an	 important	part	of	 the	
host	defence	system	in	the	airway	epithelium	and	our	lab.	has	shown	recently	that	DUOX2	
and	DUOXA2	form	the	predominant	H2O2-producing	enzyme	system	in	the	mucosa	of	the	
human	gastrointestinal	tract136–139.	As	a	consequence	of	this	work	our	lab	has	developed	
and	 used	DUOX2/DUOXA2	 qPCR	 and	 in	 situ	 hybridisation	 (ISH)	 to	 identify	 and	 locate	
mRNA	in	the	intestinal	mucosa	of	patients	with	UC	and	CRC139.	High	levels	of	DUOX2	have	
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been	observed	 in	 the	 colonic	epithelium	of	 IBD	patients	and	 in	 colonic	and	pancreatic	
cancers141.	Recently,	DUOX2	has	been	shown	to	be	regulated	by	a	STAT-dependent	JAK-
independent	pathway142.		
	
In	vitro	 lab.	work	by	Daniel	Hochhauser	and	colleagues	found	that	cetuximab	 inhibited	
STAT1	activation	and	DUOX2-mediated	ROS	generation	which	opposed	p38-dependent	
apoptosis	by	oxaliplatin133,	an	observation	which	required	additional	supportive	 in	vivo	
data.	However,	patient	biopsies	before	and	after	treatment	were	not	available	from	the	
New	EPOC	study	and,	therefore,	a	xenograft	model	was	deemed	necessary.		
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6.1.1	Hypotheses	
• Cetuximab	reduces	the	efficacy	of	oxaliplatin.		
• DUOX2	 and	 DUOXA2	 expression	 is	 increased	 with	 oxaliplatin	 treatment,	 and	
reduced	with	cetuximab	treatment.		
• DUOX2	 expression	 is	 increased	 with	 oxaliplatin	 treatment,	 and	 reduced	 with	
cetuximab	treatment.	
• Xenografts	treated	with	cetuximab	and	oxaliplatin	have	more	proliferating	cells.		
	
6.1.2	Aims	
• Generate	a	xenograft	mouse	model	using	DLD1	cells.	Treat	with	oxaliplatin	and/or	
cetuximab.		
• Analyse	DUOX2	 and	DUOXA2	 gene	 expression	 by	 RT-PCR,	 and	 DUOX2	 protein	
expression	by	IHC.		
• Assess	 the	proliferation	and	apoptotic	 status	of	 cells	within	xenograft	 tumours	
using	Ki67	and	caspase	3	staining.		
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6.2	Effect	of	cetuximab	on	ROS	production	by	oxaliplatin	
	
A	 mouse	 xenograft	 model	 was	 available	 via	 collaboration	 with	 Professor	 Kairbaan	
Hodivala-Dilke	at	the	Barts	Cancer	Institute,	QMUL.	This	involved	nude	(nu/nu)	mice	and	
their	injection	with	DLD1	CRC	cells	in	one	flank	and	subsequent	treatment	with	oxaliplatin	
and	cetuximab	alone	and	in	combination.	This	portion	of	the	work	was	performed	within	
the	animal	unit	at	the	St	George’s	Hospital	unit	by	Valeria	Santoro	and	Ruochen	Jia	from	
Daniel	Hochhauser’s	 lab	and	Bruce	Williams	at	 the	animal	unit.	At	 the	endpoint	of	 the	
study,	 I	 collected	 the	xenograft	 tissue,	 split	 the	 xenograft	 tissue	 into	 two	 sections	and	
fixed	one	piece	of	 tissue	with	neutral	buffered	 formalin,	which	was	 then	embedded	 in	
paraffin	wax	by	Rebecca	Carroll	from	the	pathology	service	at	The	Royal	London	Hospital.	
The	 second	 piece	 of	 tissue	 was	 submerged	 in	 Tissue	 Protect	 solution	 and	 then	 RNA	
extracted	from	these	samples.				
	
Proven	 techniques	were	 used	 to	 determine	 levels	 of	 DUOX2	mRNA	 in	 the	 embedded	
xenograft	 tissue139.	 Gene	 expression	 of	 DUOX2	 and	 DUOXA2	 in	 the	 xenografts	 was	
measured	by	RT-PCR	and	expressed	relative	to	control	(GAPDH)	(Figure	6.1.A	and	B)	(Table	
A.6.1).	DUOX2	mRNA	expression	was	also	confirmed	using	ISH	(Figure	6.1.C).	The	RT-PCR	
data	showed	that	dosing	with	oxaliplatin	alone	increased	DUOX2	mRNA	levels	(p=0.11),	
whereas	 combination	 with	 cetuximab	 greatly	 attenuated	 this	 response	 to	 5.3-fold	
(p=0.16)	 (Figure	 6.1A	 and	B).	 Analysis	 of	DUOXA2	mRNA	 revealed	 a	 similar	 pattern	 to	
DUOX2	results;	oxaliplatin	alone	significantly	upregulated	expression	of	DUOXA2	mRNA	
(p=0.02),	while	combination	with	cetuximab	only	increased	DUOXA2	mRNA	by	4.77-fold	
(p=0.02).	 DUOX2	 gene	 expression	 determined	 by	 ISH	 (Figure	 1C),	 identified	 the	 same	
pattern,	however,	fold	changes	were	not	as	striking.		
Results	from	DUOX2	IHC	were	in	agreement	with	mRNA	expression	findings	(Figure	6.2).	
Treatment	with	oxaliplatin	alone	 increased	DUOX2	protein	expression	of	DUOX2	more	
than	 treatment	 with	 cetuximab	 or	 treatment	 with	 a	 combination	 of	 oxaliplatin	 and	
cetuximab,	 although	 differences	 between	 treatments	were	 not	 statistically	 significant.	
DUOX2	mRNA	and	protein	expression	was	shown	to	co-localise	(Figure	6.3).	Serial	sections	
were	used	for	ISH	and	IHC	and	positive	staining	was	found	in	similar	areas	in	each	section.	
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Figure	6.1.	Effect	of	oxaliplatin	and	cetuximab	treatment	of	DLD1	xenografts	on	DUOX2	
and	DUOXA2	mRNA.	(A)	Relative	gene	expression	for	mRNA	for	DUOX2	and	(B)	DUOXA2	
determined	 by	 RT-PCR,	 (C)	DUOX2	mRNA	 determined	 by	 ISH	 using	 xenograft	 sections	
(5μM);	 all	 results	 expressed	 as	 a	 fold-change	 (mean	 ±	 SEM)	 (Table	 6.1)	 normalised	 to	
untreated	control.	N=3.	Statistics	was	performed	using	two-tailed	Student’s	t	test	with	
Welch’s	correction	*p<0.05.	
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Figure	6.2.	Effect	of	oxaliplatin	and	cetuximab	treatment	of	DLD1	xenografts	on	DUOX2	
protein	 expression.	 Xenograft	 sections	 (5	 μM)	 were	 prepared	 and	 DUOX2	
immunohistochemistry	 (IHC)	was	 conducted	 and	 scored	 (mean	±	 SEM)	 (Table	 6.1).	No	
statistically	significant	observations	were	made.	N=3.		
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Figure	6.3.	Effect	of	oxaliplatin	and	cetuximab	treatment	of	DLD1	xenografts	on	DUOX2	
mRNA	and	protein	expression	on	serial	xenograft	sections.	Representative	images	(40x	
magnification)	of	serial	sections	of	xenograft,	stained	for	DUOX2	mRNA	by	ISH	and	DUOX2	
protein	expression	by	IHC	is	presented	for	each	treatment	arm	(scale	bars	=	100μm).		
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Table	6.1.	 Summary	of	DUOX2	mRNA	 fold	 change	 from	control,	DUOXA2	mRNA	 fold	
change	from	control,	DUOX2	ISH	and	DUOX2	IHC.	Data	shown	as	mean	±	SEM.	See	Figure	
6.1,2,3.	
Treatment	 DUOX2	 mRNA	
fold	change	from	
control	
DUOXA2	 mRNA	
from	change	from	
control	
DUOX2	
ISH	score	
DUOX2	
IHC	log	10	
score	
Control	 1.00±0.00	 1.00±0.00	 15.02±0.00	 0.58±0.00	
Cetuximab	 1.25±0.10	 1.06±0.05	 13.61±3.73	 0.88±0.26	
Oxaliplatin	 21.11±7.53	 6.64±0.99	 22.03±2.07	 1.60±0.09	
Oxaliplatin	
+	
cetuximab	
5.35±2.03	 1.87±0.88	 11.40±3.04	 0.81±0.46	
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Ki67	 IHC	was	used	 to	determine	proliferating	 cells	within	 the	 xenografts	 (Figure	6.4.A,	
Figure	6.5)	(Table	6.2).	There	were	more	Ki67	positive	cells	in	xenografts	treated	with	a	
combination	 of	 oxaliplatin	 and	 cetuximab	 compared	 to	 those	 treated	 with	 oxaliplatin	
alone.	Caspase	3	IHC	was	used	to	determine	apoptotic	cells	within	the	xenografts	(Figure	
6.4.B,	Figure	6.6).	The	most	apoptotic	cells	were	found	in	mice	treated	with	oxaliplatin	
alone,	whereas	the	least	apoptotic	cells	were	found	in	the	xenografts	from	mice	treated	
with	oxaliplatin	and	cetuximab,	however,	there	was	no	significant	difference.	
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Figure	 6.4.	 Effect	 of	 oxaliplatin	 and	 cetuximab	 treatment	 of	 DLD1	 xenografts	 on	
proliferation	 and	 apoptosis.	 Proliferation	 and	 apoptosis	 of	 DLD-1	 xenografts	 (n=3)	
treated	with	cetuximab,	oxaliplatin	alone	or	in	combination	were	assessed	using	Ki67	(A)	
and	 cleaved	 caspase	3	 (B)	with	 results	 expressed	as	percentage	positive	 cells	 (mean	±	
SEM)	(Table	6.2).	Statistics	was	performed	using	two-tailed,	Student’s	t-test	with	Welch’s	
correction	*p<0.05.	
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Table	6.2.	Summary	of	Ki67	and	caspase	3	IHC.	Data	shown	as	mean	±	SEM.	Figure	6.4.		
Treatment	 Ki67	IHC	score	 Caspase	3	IHC	score	
Control	 20.18±0.00	 1.80±0.00	
Cetuximab	 31.20±6.77	 3.05±1.04	
Oxaliplatin	 23.34±3.52	 5.99±1.91	
Oxaliplatin	 +	
cetuximab	
38.28±0.57	 1.27±0.72	
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Figure	6.5.	Representative	images	from	Ki67	IHC.	(A)	Control,	(B)	Cetuximab	treated,	(C)	
Oxaliplatin	treated	and	(D)	Oxaliplatin	and	Cetuximab	combined	treated.	Images	taken	
at	20x	from	Nanozoomer	scanner	files.		
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Figure	6.6.	Representative	images	from	Caspase	3	IHC.	(A)	Control,	(B)	Cetuximab	
treated,	(C)	Oxaliplatin	treated	and	(D)	Oxaliplatin	and	Cetuximab	combined	treated.	
Images	taken	at	20x	from	Nanozoomer	scanner	files.		
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6.3.	Discussion		
Both	the	in	vitro	data	from	Professor	Hochhauser’s	group	and	my	ex	vivo	data	indicated	
that	DUOX2/DUOXA2	induction	by	oxaliplatin	is	a	dynamic	process	which	occurs	within	
24	 hours.	 In	 support	 of	 the	 in	 vitro	 data,	 treatment	 of	 xenograft	 animals	 with	 a	
combination	of	cetuximab	and	oxaliplatin	showed	higher	tumour	proliferation	compared	
with	 oxaliplatin	 alone	 as	 highlighted	 by	 elevated	 Ki67	 staining	 and	 reduced	 cleaved	
caspase	3	staining.	DUOX2/DUOXA2	mRNA	expression	was	also	in	accordance	with	the	in	
vitro	 findings:	expression	was	 increased	by	oxaliplatin	treatment	alone	and	reduced	by	
combination	 with	 cetuximab,	 although	 statistical	 significance	 was	 only	 reached	 by	
DUOXA2.	The	same	pattern	was	observed	with	DUOX2	protein	levels133.	
In	response	to	oxaliplatin	therapy	alone,	the	increase	in	DUOX2	mRNA	and	protein	led	to	
subsequent	 elevation	 in	 ROS.	 Elevated	 ROS	 induced	 by	 oxaliplatin	 therapy	 resulted	 in	
activation	of	p38	and	subsequent	cell	death.	Cetuximab	has	inhibitory	effects	on	EGFR	as	
well	 as	ROS	production.	Combination	of	 cetuximab	with	oxaliplatin	 results	 in	 impaired	
activation	 of	 ROS-dependent	 cell	 death	 mechanisms	 induced	 by	 oxaliplatin	 via	
phosphorylation	of	p38.	ROS	is	known	to	modulate	response	to	chemotherapy	and	other	
studies	have	 shown	 involvement	of	different	NADPH	oxidases	 (NOX)	 in	producing	ROS	
following	chemotherapy497,506.		
The	 combined	 work	 identified	 that	 STAT1	 mediates	 DUOX2	 transcription	 by	 direct	
promoter	binding	following	treatment	with	oxaliplatin	whereas	cetuximab	inhibits	STAT1	
activation,	oxaliplatin-induced	DUOX2	upregulation,	and	ROS	generation133.		
It	is	likely	that	regulation	of	DUOX2/DUOXA2	expression	in	mouse	xenografts	and	human	
tumours	 in	 response	 to	oxaliplatin	 and	 cetuximab	 treatment	 is	 complex.	 For	 example,	
modulation	of	DUOX2	expression	could	be	a	direct	effect	of	drugs,	mouse/human	immune	
response	to	the	tumour	cells	influenced	directly	or	indirectly	by	drug	exposure,	and	/	or	a	
response	to	tumour	cell	death	caused	by	the	drugs.		
It	is	important	to	note	that	our	study	has	limitations.	In	the	future,	the	effects	described	
need	 to	be	examined	 in	clinical	 samples	 from	patients	 receiving	oxaliplatin	alone	or	 in	
combination	with	cetuximab;	unfortunately,	these	specimens	were	not	available133.	The	
effects	 of	 combination	 treatment	 on	 ROS	 production	 demonstrated	 here	 needs	 to	 be	
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balanced	against	 the	contribution	made	by	EGFR	 inhibition	of	DNA	repair	and	 immune	
response,	which	would	potentially	favour	this	combination507,508.	This	could	explain	why	
the	 interaction	 of	 EGFR-inhibitory	 antibodies	 and	 chemotherapy	 is	 beneficial	 in	 some	
studies491,509.	It	is,	therefore,	critical	to	assess	the	effects	of	combining	drugs	for	therapy	
by	additional	approaches,	including	patient-derived	xenografts	and	analysis	of	circulating	
tumour	 cells.	 However,	 we	 have	 described	 an	 important	 mechanism	 of	 undesirable	
interaction	between	oxaliplatin	and	cetuximab	that	might	explain	why	a	subset	of	CRC	
patients	 does	 not	 respond	 to	 this	 combination.	 The	 study	 also	 provides	 a	 novel	
explanation	for	unexpected	trial	results	and	could	be	used	for	optimisation	of	studies	for	
future	combination	therapies.	
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Chapter	7	–	Conclusion		
Fumarate	 has	 been	 identified	 previously	 as	 a	 oncometabolite332,510.	 It	 is	 known	 that	
fumarate	is	a	competitive	inhibitor	of	2-OGDDs	which	includes	the	HIF	hydroxylases	and	
TET	dioxygenases,	leading	to	activation	of	oncogenic	pathways403.	Another	mechanism	of	
fumarate	action	is	the	non-enzymatic	alteration	of	cysteine	residues	by	succination	which	
can	 disrupt	 protein	 function	 and,	 therefore,	 lead	 to	 dysfunctional	 cell	 signalling	 and	
metabolism406.	 Previous	 studies	 of	 succination	 have	 shown	 it	 is	 increased	 in	 diabetic	
tissue343	and	in	HLRCC	where	one	copy	of	FH	is	not	mutated374.	
The	literature	has	previously	identified	an	increase	in	[fumarate]	in	CRC	tissue	compared	
to	 normal	 tissue335.	 The	mechanism	 for	 the	 increase	 in	 [fumarate]	 in	 CRC	 is	 not	 clear,	
however,	it	is	likely	due	to	an	increased	use	of	glycolysis	and	the	TCA	cycle	which	helps	
the	cancerous	tissue	to	proliferate.	 In	Chapter	3,	this	study	provided	the	first	report	of	
increased	succination	in	adenomatous	and	CRC	tissue	and	significantly	higher	amounts	of	
succination	 in	 tumour	 tissue	 compared	 to	 the	 normal	 bowel.	 There	 is	 an	 additional	
increase	 in	 succination	 if	 the	 CRC	 sample	 is	 from	 a	 T2D	 compared	 to	 a	 non-diabetic	
patient.	 The	 2-SC	 staining	 was	 non-uniform	 across	 tumour	 tissue,	 underlining	 the	
metabolic	 heterogeneity	 of	 CRC.	 This	 is	 reinforced	 by	 evidence	 from	 in	 vitro	work	 in	
Chapter	 5	 which	 identified	 [fumarate]	 was	 dependent	 on	 cell	 line,	 but	 was	 generally	
higher	when	cells	are	cultured	with	25mM	glucose	and	held	in	0.2%	O2.	Suggesting	that	
increased	[fumarate]	in	cell	lines	could	be	a	result	of	external	stress	in	the	form	of	hypoxia	
or	high	glucose.		
Upon	 further	 study,	 in	 Chapter	 3,	 it	 was	 noted	 that	 T2D	 patients	 with	 KRAS/BRAF	
mutations	 in	 cancers	 had	 more	 succination	 compared	 to	 T2D	 patients	 with	 WT	
KRAS/BRAF.	 This	 is	 a	 further	 novel	 link;	 the	 influence	 of	 KRAS/BRAF	 mutation	 on	
succination	should	be	pursued.	It	could	be	speculated	that	succination	is	one	reason	why	
CRC	in	T2D	individuals	is	more	invasive	and	more	likely	to	relapse.		
Succination	was	not	studied	in	the	Fh1βKO	mouse	model	in	Chapter	4,	but	is	planned	for	
future	work	(Chapter	8,	Section	8.2).	Based	on	our	findings	to	date,	of	a	small	difference	
in	succination	in	a	small	number	of	human	adenomas,	I	would	hypothesise	that	all	polyps	
would	 show	 some	 evidence	 of	 succination,	 but	 that	 there	 would	 be	 no	 significant	
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difference	 in	 2-SC	 staining	 intensity	 in	 polyps	 from	 diabetic	 and	 non-diabetic	 mice.	
Evidence	of	succination	was	found	in	DLD1	and	SW837	cell	lines,	however,	it	could	not	be	
linked	to	[glucose]	at	this	point.	I	would	hypothesise	that	CRC	cells	cultured	in	hypoxia	and	
high	 glucose	 would	 have	 increased	 succination	 compared	 to	 CRC	 cells	 cultured	 in	
normoxia	and	low	glucose.	Unfortunately,	the	identify	of	proteins	that	are	succinated	in	
CRC	remains	unknown	at	this	point	of	writing	and	will	require	further	investigation	using,	
for	example,	micro-dissection	of	succinated	areas	and	mass	spectroscopy.	
Interestingly,	despite	high	levels	of	succination	in	CRC	tissue,	there	was	also	an	increase	
in	FH	in	CRC	tissue	compared	to	adjacent	normal	tissue,	which	was	opposite	to	what	was	
predicted.	In	Chapter	3,	FH	staining	in	CRC	samples	was	overwhelmingly	cytoplasmic,	but	
it	was	unclear	 if	 FH	 staining	was	also	high	 in	mitochondria.	 Evidence	 from	 the	Human	
Protein	Atlas	suggests	that	FH	staining	is	intense	for	a	large	number	of	cancers	including	
CRC,	breast,	prostate,	liver	and	lung511.	It	is	possible	that	as	fumarate	levels	rise,	due	to	
increased	 glycolysis	 and	 TCA	 cycle	metabolism	 use,	 so	 do	 FH	 levels,	 then	 as	 levels	 of	
fumarate	increase	further	FH	can	be	inhibited,	as	shown	by	Mescam	et	al.390.	Additionally,	
in	Chapter	4,	when	FH	was	overexpressed	in	the	cytoplasm	of	all	cells	in	a	mouse	model	
of	intestinal	polyposis	and	diabetes,	larger	polyps	were	found.	This	suggests	a	potential	
role	 for	 cytoplasmic	 FH	 in	 tumourigenesis.	 Coupled	 with	 the	 fact	 that	 there	 are	 no	
indications	of	FH	mutation	in	human	CRC,	this	suggests	that	FH	remains	active	but	cannot	
control	 levels	 of	 fumarate.	 Studies	 involving	measurement	 of	 both	 [fumarate]	 and	 FH	
activity	in	CRC	tissue	would	bring	evidence	to	support	or	disprove	this	theory.			
In	Chapter	5	the	abundance	of	FH	in	vitro	did	not	correlate	with	levels	of	fumarate	in	CRC	
cells.	 It	 is	 necessary	 to	 quantify	 the	 level	 of	 FH	 in	 normal	 epithelial	 bowel	 cells	 to	
determine	 the	 difference	 between	 normal	 and	 cancer	 cells.	 However,	 FH	 activity	was	
lower	 where	 [fumarate]	 was	 increased,	 suggesting	 that	 FH	 activity	 is	 influenced	 by	
[fumarate]	or	vice	versa.	However,	[fumarate]	recorded	in	CRC	cells	in	this	study	was	not	
high	 enough	 to	 inhibit	 FH	 according	 to	 Mescam	 et	 al.390.	 Nevertheless,	 this	 warrants	
further	study.	Additionally,	the	readings	for	FH	activity	were	established	using	whole	cell	
extract.	The	majority	of	FH	was	found	in	the	mitochondria	and	not	in	the	cytoplasm	or	
nucleus	of	CRC	cells.	This	mimics	what	is	seen	in	HLRCC	patients	which	suggests	some	sort	
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of	default	 in	FH325.	 It	would	be	 interesting	 to	see	 if	 there	are	differences	 in	FH	activity	
between	the	cytoplasm	and	the	mitochondria.		
In	Chapter	3	it	was	found	that	the	addition	of	FHcyt	reduced	the	available	glucose	found	in	
the	 gut	 tissue,	 suggesting	 that	more	 glucose	 was	 used	 in	metabolism	 and	 potentially	
polyposis.	Perhaps	the	increase	in	FH	in	human	CRC	tissue	is	to	increase	the	use	of	glucose	
and	fumarate	through	the	glycolysis	and	TCA	cycle	pathways,	to	generate	more	energy	
for	tumorigenesis.		
The	finding	in	Chapter	5,	that	all	CRC	cells	 in	this	study	have	quantifiable	OCR	suggests	
that	CRC	cells	are	using	the	TCA	cycle	to	generate	NADH	for	ATP	production	via	OXPHOS.	
Notably	it	was	also	found	that	OCR	decreased	when	glucose	was	added	to	the	media	of	
cells	 cultured	 in	 0mM	 glucose.	 This	 suggests	 that	 CRC	 cells	 are	 flexible	 with	 regards	
metabolism	pathways,	which	is,	of	course,	a	desirable	trait	for	cancer	cells.	Further	study	
into	 the	 functionality	 of	 mitochondria	 would	 allow	 further	 links	 to	 [glucose]	 and	
[fumarate]	to	be	made.		
Overall,	there	remains	a	lot	to	be	identified	about	the	specific	role	of	FH,	fumarate	and	
succination	in	CRC	and	T2D.	An	initial	mechanism	can	be	suggested.	Once	CRC	starts	to	
progress,	fumarate	increases	and	more	succination	occurs.	This	means	that	more	of	the	
proteins	in	the	cell	are	unable	to	work	properly,	which	can	promote	the	cancer.	On	top	of	
this,	there	is	a	further	increase	in	succination	in	CRC	samples	from	T2D	patients	suggesting	
that	additional	glucose	can	further	promote	succination.	This	could	be	one	reason	why	
CRC	in	T2D	patients	is	more	aggressive	and	had	a	poorer	outcome.		
The	additional	finding	that	overexpression	of	FH	 in	 intestinal	cells	 in	a	mouse	model	of	
CRC	leads	to	larger	polyps	was	also	novel.	It	is	yet	to	be	shown	if	more	intense	FH	staining	
in	CRC	leads	to	a	poorer	outcome	or	the	opposite.		
It	 is	 important	 to	 highlight	 this	work	 to	 clinicians	working	with	 T2D	 and	CRC	patients.	
Clinicians	could	encourage	T2D	patients	to	control	their	blood	glucose	by	emphasising	the	
possible	risk	of	cancer	associated	with	uncontrolled	blood	glucose.		
It	is	important	to	educate	the	wider	population	so	they	fully	understand	the	risks	of	T2D,	
which	would	hopefully	lead	to	a	reduction	in	T2D	and	CRC	cases.	My	public	engagement	
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work,	 listed	below,	has	attempted	to	highlight	the	risks	of	T2D	and	CRC	to	the	general	
public.		
-	Pint	of	Science,	2016	
-	QMUL	Festival	of	Ideas,	2017	
-	Science	Showoff,	2017-2018	
-	FameLab	London	Finals	2017,	FameLab	Cambridge	Finals	2018	
In	 a	 separate	 piece	 of	 work,	 in	 Chapter	 6,	 I	 was	 able	 to	 help	 identify	 that	 following	
treatment	 with	 oxaliplatin,	 DUOX2	 transcription	 is	 mediated	 by	 STAT1,	 whereas	
cetuximab	treatment	inhibits	STAT1	activation,	oxaliplatin-induced	DUOX2	upregulation,	
and	ROS	generation133.	This	mechanism	may	explain	why	CRC	patients	on	oxaliplatin	alone	
have	 a	 better	 prognosis	 than	 those	 treated	 with	 a	 combination	 of	 oxaliplatin	 and	
cetuximab.	
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Chapter	8	–	Future	Work	
The	work	 in	 this	 thesis	on	 the	 link	between	T2D	and	CRC	 leads	 to	 the	 future	 research	
questions.	These	are	given	below	along	with	potential	experimental	procedures.	
8.1	Future	work	based	on	findings	presented	in	Chapter	3	
Findings	presented	in	Chapter	3	indicate	that	a	large	patient	study,	possibly	as	a	multi-
centre	trial,	would	be	appropriate.	The	main	questions	would	be:	
1) Can	 the	 management	 of	 T2D	 and	 /	 or	 CRC	 be	 improved	 using	 a	 2-SC	 score?	
Experiments	would	aim	to	answer	the	following:	
a. In	CRC,	is	succination	higher	the	longer	the	patient	has	been	diagnosed	as	
a	T2D?	
b. Is	a	high	2-SC	score	indicative	of	poor	prognosis?		
c. Can	succination	levels	be	measured	meaningfully	in	blood	as	well	as	the	
tumour	and	can	the	output	score	be	used	as	a	prognostic	biomarker?		
d. Is	there	a	CRC	preventative	or	pre-operative	therapy	that	will	lower	2-SC,	
reduce	risk	and	improving	outcome,	respectively?	Is	metformin	useful	in	
this	regard512,513?	
e. If	T2D	 is	well	 controlled,	 is	2-SC	 lower	and	does	 this	 reduce	 the	risk	of	
CRC?		
2) What	is	the	role	of	FH	in	human	CRC?		
a. Which	 cellular	 compartment(s)	 is	 FH	 increased	 in	 CRC	 compared	 to	
normal	tissue?		
b. Is	FH	active	in	human	CRC?	
c. Does	FH	expression	correlate	with	the	presence	of	2-SC?	
d. Is	FH	expression	determined	by	fumarate	levels	in	the	tumours	and	is	the	
ability	 of	 FH	 to	 reduce	 succination	 by	 fumarate	 limited,	 e.g.	 by	
compartmentalisation,	such	that	2-SC	still	occurs	at	high	levels?	
e. Can	FH	act	as	an	oncogene	in	particular	context	in	CRC?		
3) Which	proteins	are	succinated	in	patients	with	T2D	and	CRC	and	how	does	this	
chemical	process	alter	the	activity	of	key	proteins?		
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4) Do	pre-adenoma	dysplastic	regions	in	the	gut	show	2-SC	and,	if	so,	which	proteins	
are	altered?		
	
To	answer	 these	questions,	 the	 following	would	be	necessary	 to	support	experimental	
protocols:		
The	study	would	have	two	independent	cohorts	and	include	the	following	types	of	patients:	
- Patients	±	T2D	and	±	CRC;	and	
- Patients	±	T2D	and	±	CRC	adenoma	and	/	or	dysplasia.	
	
The	following	information	would	be	recorded	from	the	appropriate	patients:	
- Age;	
- Sex;	
- Ethnicity;	
- Stage	of	CRC;	
- Type	of	T2D	therapy;	
- Type	of	CRC	therapy;	
- Any	other	medications,	particularly	metformin;	
- Time	diagnosed	with	T2D;	
- Time	diagnosed	with	CRC;	and		
- Control	of	T2D	–	preferably	monitor	blood	glucose	levels	daily	/	weekly.	
	
A	biopsy	of	normal	and	CRC	tissue	would	be	taken	to	determine:	
- Mutation	profile	of	CRC	determined	by	array	or	PCR;	
- 2-SC	 IHC	 of	 normal	 and	 CRC/adenoma/dysplastic	 tissue,	 scored	 by	 a	 trained	
pathologist;	
- FH	 IHC	 of	 normal	 and	 CRC/adenoma/dysplastic	 tissue,	 scored	 by	 a	 trained	
pathologist;		
- Detection	of	succinated	proteins	by	mass	spectrometry;	and	
- FH	activity.	
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A	blood	sample	would	also	be	taken	to	attempt	to	detect	succinated	proteins	in	blood;	if	
this	correlates	with	2-SC	in	tumours	and	could	be	used	to	monitor	CRC	in	patients	more	
easily	as	a	non-invasive	biomarker.		
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8.2	Future	work	based	on	findings	presented	in	Chapter	4	
To	complement	the	human	work,	 it	 is	necessary	 to	 further	 investigate	the	relationship	
between	T2D	and	CRC	in	a	whole	animal	system,	of	which	the	mouse	remains	the	best	
model	currently	available	for	the	earlier	polyp	stage.		
Some	questions	remain	regarding	the	mouse	model	developed	in	Chapter	4	of	this	thesis.	
These	are:	
1) Does	knocking	out	FH	in	the	cytoplasm	of	bowel	epithelial	cells	lead	to	smaller	or	
fewer	polyps?	
Create	1322	mice	with	genetic	conditional	KO	of	Fh1	in	bowel	epithelial	cells	with	
mice	and	breed	with	mice	with	KO	Fh1	in	the	ß-cells	of	the	pancreas.	Count	and	
size	the	resultant	polyps.		
2) What	is	the	mRNA	expression	profile	of	the	polyps	from	different	genotypes?		
Extract	RNA	 from	 frozen	polyps,	 send	 for	array,	analyse	 the	data.	Test	any	key	
findings	in	cell	models	to	validate	their	tumorigenic	potential.		
3) What	is	the	2-SC,	FH,	HIF-1α,	Ki67,	caspase	3	score	of	the	polyps	and	normal	tissue	
from	the	different	genotypes?		
Perform	immunohistochemistry	to	identify	differences	in	levels	of	the	markers.		
4) Do	succination	targets	differ	across	the	different	genotypes?	
Use	frozen	polyps	for	mass	spectrometry	analysis	to	identify	succinated	proteins.	
Link	differences	to	genotypes	or	blood	glucose.	Cross	reference	finding	with	mass	
spectrometry	findings	from	Chapter	8,	Section	8.2.		
5) What	is	the	effect	of	metformin	therapy	in	the	model?	
Re-measure	all	the	parameters	in	this	thesis	and	mentioned	above.		
The	Fh1βKO	mouse	is	a	valuable	new	model	for	T2DM	where	glucose	intolerance	develops	
progressively	and	the	mice	are	not	obese	and	the	model	does	not	require	alterations	in	
diet.	However,	there	are	many	challenges	in	developing	the	ideal	model	of	T2D	and	CRC	
in	the	mouse.	Currently,	the	mouse	models	for	T2D	and	CRC	have	limitations	(Chapter	1,	
Section	 1.14).	 Ideally,	 the	 ‘perfect’	 model	 would	 have	 features	 similar	 to	 the	 human	
tumour	pathologies,	 such	 as	 polyps	which	progress	 to	 adenomas,	 cancers	 in	 the	 large	
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bowel	and	development	of	T2D	as	part	of	the	ageing	process	through	insulin	resistance	
and	hyperinsulinemia.	Any	new	CRC	model	 could	 then	be	used	 to	 repeat	many	of	 the	
measurements	taken	in	this	thesis.		
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8.3	Future	work	based	on	findings	presented	in	Chapter	5	
To	 further	 complement	 the	 mouse	 and	 human	 work	 it	 is	 important	 to	 do	 further	
mechanistic	work	in	vitro.	Following	on	from	the	work	in	Chapter	5,	the	possible	questions	
and	experimental	work	are	outlined	below:	
1) Continue	investigating	the	differences	of	DLD1	and	SW837	cells	grown	in	25mM,	
5mM	or	0mM	after	 treatment	with	20.9%	and	0.2%	oxygen.	Culture	cells	with	
insulin	 to	 make	 a	 model	 closer	 to	 physiological	 diabetic	 conditions	 in	 vivo.	
Measure	the	following:	
- FH	activity	in	mitochondria,	cytoplasm	and	nuclear	fractions	of	cells;		
- Glucose	uptake	by	colourimetric	/	fluorometric	assay	pre-	and	post-treatment	with	
glucose	over	a	time	course;	
- Determine	ratio	of	cells	in	cell	cycle	phases	by	flow	cytometry;		
- NAD/NADH	ratio	by	colourimetric	/	fluorometric	assay;	
- ROS	by	immunofluorescence;		
- Survival	after	drugs	–	cell	count	post	drug	treatment;	
- Western	blots	to	parallel	the	qPCR	panel;	
- Measure	the	mitochondrial	membrane	potential;		
- Image	mitochondria	using	electron	microscopy	to	analyse	structure	changes;	
- Cell	migration	by	scratch	assay;	
- Overexpress	and	knock	out	FH	and	see	if	there	is	an	effect	on	all	the	parameters	
measured	in	this	thesis;	
- Identify	succinated	proteins	by	mass	spectrometry;	and	
- Attempt	 to	 build	 a	 spheroid	 and/or	 3D	 organotypic	 model	 from	 intestinal	
epithelial	cells.	Which	cells,	CRC	lines	or	primary	cells	from	surgical	resection,	can	
create	the	most	useful	spheroids	and	organotypics?	What	influence	does	hypoxia	
play	in	proliferation	and	survival?		
2) Artificially	 alter	 fumarate	 levels	 in	 the	 cell	model	 to	 test	what	 happens	 to	 cell	
viability,	gene	expression	and	succination.		
3) Culture	intestinal	organoids	in	different	concentrations	of	glucose	and	measure	
the	parameters	used	in	this	thesis	to	identify	any	changes.		
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4) What	are	the	functional	consequences	of	succination?	Does	it	affect	protein	half-
life?	Is	a	succinated	protein	targeted	for	degradation?		
It	may	 eventually	 be	 possible	 to	 identify	 an	 appropriate	 cell	 where	 the	 known	
succinated	protein	is	present.	Then,	over-express	said	protein,	dose	with	fumarate	
to	increase	succination	and	measure	the	effects	(proliferation,	protein	turnover,	
protein	localisation	and	drug-resistance).		
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8.4	Future	work	based	on	findings	presented	in	Chapter	6	
Additional	 further	 work	 questions	 based	 on	 the	 findings	 of	 the	 DUOX2	 chapter	 are	
outlined	below:		
1) What	is	the	optimum	level	of	DUOX2	and	production	of	hydrogen	peroxide	
for	 CRC	 tumorigenesis?	 Is	 increased	 hydrogen	 peroxide	 production	 over	 a	
prolonged	period	of	time	sufficient	to	transform	cells.			
Overexpress	DUOX2	in	CRC	cells	and	measure:	
- Proliferation	rate;	
- Viability;		
- Response	to	drug	challenge;	and		
- Ability	to	form	xenograft	tumours.		
2) Would	cyclic	therapy	of	cetuximab	and	oxaliplatin	be	beneficial?		
Test	a	cyclic	regime	of	cetuximab	and	then	oxaliplatin	therapy	in	an	animal	
model	of	CRC.	Measure	tumour	size	and	survival	of	animals.		
3) Do	 all	 EGFR	 inhibitors	 reduce	 phosphorylation	 of	 STAT1?	 And,	 therefore,	
should	be	avoided	in	combination	with	oxaliplatin?		
Test	 if	 STAT1	 phosphorylation	 is	 inhibited	 in	 response	 to	 EGFR	 inhibitor	
therapy	in	CRC	cells.	Determine	if	DUOX2	mRNA	and	protein	levels	are	reduced	
after	EGFR	therapy	in	CRC	cells.	
4) Conditionally	 overexpress	 DUOX2/DUOXA2	 in	 the	 mouse	 intestinal	
epithelium	and	assess	resultant	pathology.		
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Taken	together	this	work	would	uncover	more	details	surrounding	the	role	of	fumarate,	
FH	and	succination	in	the	progression	of	CRC,	as	well	as	the	link	to	T2D.	It	is	also	important	
to	use	the	same	approach	as	outlined	in	this	thesis	to	look	at	other	cancers,	such	as	breast	
cancer,	which	are	also	linked	to	T2D281,514.		
Additionally,	the	role	of	DUOX2	in	CRC	progression	would	also	be	clearer,	particularly	in	
the	context	of	IBD.	And	the	optimum	therapy	for	combined	drug	regimen	where	DUOX2	
expression	 is	 important	 can	 be	 investigated.	 The	 mouse	 model	 of	 increased	
DUOX2/DUOXA2	will	be	important	here.	
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Chapter	9	-	Appendix	
9.1	Chapter	3			
Table	A.3.1.	Summary	of	two-way	ANOVA	of	2-SC	score	for	matched	normal	and	CRC	
tissue.	See	also	Figure	3.2.	
	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(1,	162)	=	5.983	 0.0194	 *	
Non-diabetic	vs	T2D	 F	(1,	162)	=	75.33	 0.0059	 **	
Normal	vs	CRC	 F	(1,	1620)	=	6.074	 <0.0001	 ****	
	
Table	A.3.2.	Summary	of	Bonferroni	post	hoc	test	of	2-SC	score	for	matched	normal	and	
CRC	 tissue.	 Only	 significant	 values	 shown.	 See	 also	 Figure	 3.2.	
	
	 Summary	
ND:Normal	vs	ND:CRC	 ****	
ND:Normal	vs	T2D:CRC	 ****	
ND:CRC	vs	T2D:Normal	 ****	
ND:CRC	vs	T2D:CRC	 **	
T2D:Normal	vs	T2D:CRC	 ****	
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	Table	 A.3.3.	 Summary	 of	 two-way	 ANOVA	 of	 2-SC	 scores	 for	 matched	 normal	 and	
adenoma	tissue.	See	also	Figure	3.3.	
	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(1,	56)	=	2.762	 0.1021	 ns	
ND	vs	T2D	 F	(1,	56)	=	2.125	 0.1505	 ns	
Normal	vs	CRC	 F	(1,	56)	=	24.41	 <0.0001	 ****	
	
Table	A.3.4.	Summary	of	Bonferroni	post	hoc	test	of	2-SC	scores	for	matched	normal	and	
adenoma	tissue.	See	also	Figure	3.3.		
	 Summary	
ND:Normal	vs	ND:Adenoma	 ****	
ND:Adenoma	vs	T2D:Normal	 ***	
	
Table	A.3.5.	Summary	of	one-way	ANOVA	of	2-SC	score	in	total	normal,	CRC	adenoma	
and	CRC	tissue.	See	also	Figure	3.4.A.	
p	value	 Summary	
<0.0001	 ****	
	
Table	A.3.6.	 Summary	of	Bonferroni	post	hoc	 test	of	2-SC	 score	 in	 total	normal,	CRC	
adenoma	and	CRC	tissue.	See	also	Figure	3.4.A.	
	 Adjusted	p	value	 p	value	summary	
Normal	vs.	Adenoma	 <0.0001	 ****	
Normal	vs.	CRC	 <0.0001	 ****	
Adenoma	vs.	CRC	 0.0432	 *	
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Table	A.3.7.	Summary	of	two-way	ANOVA	of	2-SC	score	in	total	normal,	CRC	adenoma	
and	CRC	tissue.	See	also	Figure	3.4.B.	
	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(2,	291)	=	7.454	 0.0008	 ***	
ND	vs	T2D	 F	(1,	201)	=	0.4049	 0.5253	 ns	
Normal	vs	CRC	 F	(2,	201)	=	78.08	 <0.0001	 ****	
	
Table	A.3.8.	Summary	of	Bonferroni	post	hoc	 test	of	2-SC	 score	 in	 total	normal,	CRC	
adenoma	and	CRC	tissue.	Only	significant	values	shown.	See	also	Figure	3.4.B.	
	 Summary	
ND:Normal	vs	ND:Adenoma	 ****	
ND:Normal	vs	ND:CRC	 ****	
ND:Normal	vs	TD2:CRC	 ****	
ND:Adenoma	vs	T2D:Normal	 ****	
ND:Adenoma	vs	T2D:CRC	 **	
ND:CRC	vs	T2D:Normal	 ****	
ND:CRC	vs	T2D:CRC	 ***	
T2D:Normal	vs	T2D:CRC	 ****	
T2D:Adenoma	vs	T2D:CRC	 ***	
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Table	A.3.9.	Summary	of	two-way	ANOVA	of	2-SC	score	for	WT	and	KRAS/BRAF	mutant	
CRC	samples	from	NDs	and	T2Ds.	See	also	Figure	3.7.B.	
	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(1,	74)	=	0.008782	 0.9256	 ns	
WT	vs	Mutant	 F	(1,	74)	=	2.445	 0.01222	 ns	
Non-diabetic	vs	T2D	 F	(1,	74)	=	9.169	 0.0034	 **	
	
Table	A.3.10.	Summary	of	Bonferroni	post	hoc	test	of	2-SC	score	for	WT	and	KRAS/BRAF	
mutant	CRC	samples	from	NDs	and	T2Ds.	See	also	Figure	3.7.B.		
	 Summary	
WT:NB	vs.	Mutant:T2D	 *	
	
Table	A.3.11.	Summary	of	two-way	ANOVA	of	2-SC	score	for	WT	and	KRAS/BRAF	mutant	
CRC	samples	from	NDs	and	T2Ds.	See	also	Figure	3.7.D.		
	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(1,	74)	=	0.008642	 0.9262	 ns	
WT	vs	Mutant	 F	(1,	74)	=	2.851	 0.0956	 ns	
Non-diabetic	vs	T2D	 F	(1,	74)	=	6.524	 0.0127	 *	
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9.2	Chapter	4			
Table	A.4.1.	Summary	of	one-way	ordinary	ANOVA	for	blood	glucose.	See	also	Figure	
4.3.	
	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Blood	glucose	 F	(7,	102)	=	114.9	 P<0.0001	 ****	
	
	
Table	A.4.2.	Summary	of	one-way	ordinary	ANOVA	Bonferroni	post	hoc	test	for	blood	
glucose.	See	also	Figure	4.3,	Table	A.4.1.	Only	significant	values	shown.	
	 p	value	 p	value	summary	
WT	vs.	Fh1βKO	FHcyt	
	
0.0032	
	
**	
WT	vs.	Fh1βKO	 <0.0001	 ****	
WT	vs.	Fh1βKO	1322	 <0.0001	 ****	
1322	vs.	Fh1βKO	 <0.0001	 ****	
1322	vs.	Fh1βKO	1322	 <0.0001	 ****	
FHcyt	vs.	Fh1βKO	 <0.0001	 ****	
FHcyt	vs.	Fh1βKO	1322	 <0.0001	 ****	
FHcyt	1322	vs.	Fh1βKO	 <0.0001	 ****	
FHcyt	1322	vs.	Fh1βKO	1322	 <0.0001	 ****	
Fh1βKO	FHcyt	vs.	Fh1βKO	 <0.0001	 ****	
Fh1βKO	FHcyt	vs.	Fh1βKO	1322	 <0.0001	 ****	
Fh1βKO	FHcyt	1332	vs.	Fh1βKO	 <0.0001	 ****	
Fh1βKO	FHcyt	1332	vs.	Fh1βKO	1322	 <0.0001	 ****	
Fh1βKO	vs.	Fh1βKO	1322	 <0.0001	 ****	
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Table	A.4.3.	Summary	of	one-way	ordinary	ANOVA	of	gut	length.	See	also	Figure	4.5.	
		 F	(DFn,	DFd)	 p	value	 p	value	summary	
Total	 F	(7,	51)	=	3.332	 0.0053	 **	
	SB	 F	(7,	51)	=	3.432	 0.0044	 **	
LB	 F	(7,	51)	=	0.7037	 0.6687	 ns	
	
Table	 A.4.4.	 Summary	 of	 one-way	 ordinary	 ANOVA	 Bonferroni	 post	 hoc	 test	 of	 gut	
length.	See	also	Figure	4.5,	Table	A.4.6.	Only	significant	values	shown.	
		 	 p	value	 p	value	summary	
Total	 1322	vs.	Fh1βKO		
	
0.0025	
	
**	
FHcyt	1322	vs.	Fh1βKO	
	
0.0025	
	
**	
Fh1βKO	FHcyt	vs.	Fh1βKO	
	
0.0499	
	
*	
Fh1βKO	FHcyt	1332	vs.	Fh1βKO	
	
0.0391	
	
*	
SB	 1322	vs.	Fh1βKO	
	
0.0020	
	
**	
FHcyt	1322	vs.	Fh1βKO	
	
0.0034	
	
**	
	
Table	A.4.5.	Summary	of	one-way	ordinary	ANOVA	of	cell	type	count.	See	also	Figure	
4.11,12,13.	
	Cell	type		 Location		 F	(DFn,	DFd)	 p	value	 p	value	summary	
Epithelial			 Crypt	 F	(7,	16)	=	0.5894	
	
0.7553	
	
ns	
Villi		 F	(7,	16)	=	0.8975	
	
0.5315	
	
ns	
Goblet		 Crypt	 F	(7,	16)	=	0.5574	 0.7792	 ns	
Villi		 F	(7,	16)	=	1.338	
	
0.2957	
	
ns	
Paneth		 Crypt	 F	(7,	16)	=	1.941	
	
0.1289	
	
ns	
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Table	A.4.6.	Summary	of	one-way	ordinary	ANOVA	Bonferroni	post	hoc	test	of	paneth	
cell	counts.	See	also	Figure	4.13.	
Stain	 Cell	 Condition	 p	value	 p	value	summary	
Paneth	 Crypt	 Fh1βKO	FHcyt	vs.	Fh1βKO	FHcyt	1322	
	
0.0108	
	
*	
	
Table	A.4.7.	Summary	of	one-way	ordinary	ANOVA	for	polyp	count	by	genotype.	See	
also	Figure	4.8.A.	
		 F	(DFn,	DFd)	 p	value	 p	value	summary	
Genotype	 F	(3,	44)	=	2.593	 0.0645	 ns	
	
	
Table	A.4.8.	Summary	of	two-way	ANOVA	for	polyps	by	site.	See	also	Figure	4.10.B,	C.		
		 	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Site	 Interaction	 F	(9,	176)	=	0.9883	 0.4514	 ns	
Polyp	site	 F	(3,	176)	=	29.05	 <0.0001	 ****	
Genotype	 F	(3,	176)	=	5.397	 0.0014	 **	
Site	(%)	
Interaction	 F	(9,	176)	=	1.565	 0.1290	 ns	
Polyp	site	 F	(3,	176)	=	67.14	 <0.0001	 ****	
Genotype	 F	(3,	176)	=	0.5222	 0.6676	 ns	
	
Table	A.4.9.	Summary	of	two-way	ANOVA	Bonferroni	post	hoc	test	for	polyps	by	site.	
See	also	Figure	4.9.B,	C,	Table	A.4.12.	Only	significant	values	shown.	
		 Condition	 p	value	summary	
Site	 SB1	Fh1βKO	1322	vs.	FHcyt	1322	
	
**	
SB1	Fh1βKO	FHcyt	1322	vs.	FHcyt	1322	
	
*	
Site	(%)	 SB1	FHcyt	1322	vs.	1322	
	
*	
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Table	A.4.10.	Summary	of	two-way	ANOVA	for	polyps	by	size	results.	See	also	Figure	4.9.	
		 	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Size	 Interaction	 F	(9,	176)	=	1.135	 0.3402	 ns	
Polyp	size	 F	(3,	176)	=	2.883	 0.0373	 *	
Genotype	 F	(3,	176)	=	4.977	 0.0024	 **	
Size	(%)	 Interaction	 F	(9,	176)	=	2.169	 0.0263	 *	
Polyp	size	 F	(3,	176)	=	6.98	 0.0002	 ***	
Genotype	 F	(3,	176)	=	0.4521	 0.7161	 Ns	
SB1	 Interaction	 F	(9,	176)	=	2.089	 0.0328	 *	
Polyp	site	 F	(3,	176)	=	1.196	 0.3128	 ns	
Genotype	 F	(3,	176)	=	4.252	 0.0063	 **	
SB2	 Interaction	 F	(9,	176)	=	0.9839	 0.4550	 ns	
Polyp	site	 F	(3,	176)	=	1.38	 0.2506	 ns	
Genotype	 F	(3,	176)	=	2.783	 0.0424	 *	
SB3	 Interaction	 F	(9,	176)	=	1.15	 0.3303	 ns	
Polyp	size	 F	(3,	176)	=	3.899	 0.0099	 **	
Genotype	 F	(3,	176)	=	1.529	 0.2086	 ns	
LB	 Interaction	 F	(9,	176)	=	0.9324	 0.4984	 ns	
Polyp	size	 F	(3,	176)	=	3.829	 0.0109	 *	
Genotype	 F	(3,	176)	=	0.8133	 0.4881	 ns	
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Table	A.4.11.	Summary	of	two-way	ANOVA	Bonferroni	post	hoc	test	for	polyps	by	size.	
See	also	Figure	4.9.A,	B,	Table	A.4.14.	Only	significant	values	shown.	
		 Condition	 p	value	summary	
Size	 3+	FHcyt	1322	vs.	1322	
	
*	
Size	(%)	 3+	FHcyt	1322	vs.	1322	
	
**	
	SB1	 3+mm	Fh1βKO	1322	vs.	FH
cyt	1322	
	
**	
3+mm	Fh1βKO	FHcyt	1322	vs.	FHcyt	1322	
	
*	
3+mm	FHcyt	1322	vs.	1322	
	
***	
SB3	 1-2mm	Fh1βKO	FHcyt	1322	vs.	1322	
	
*	
LB	 2-3mm	FHcyt	1322	vs.	1322	
	
*	
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9.3	Chapter	5	
Table	A.5.1.	Summary	of	one-way	ANOVA	statistics	for	fumarate	concentration	in	CRC	
cell	lines	determined	by	mass	spectrometry.	See	also	Figure	5.1.	
Cell	line	 F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	(Figure	5.1.A)	 F	(2,6)	=	26.49	 0.0011	 **	
HT55	(Figure	5.1.B)	 F	(2,6)	=	121.3	 <0.0001	 ****	
SW837	(Figure	5.1.C)	 F	(2,6)	=	22.21	 0.0017	 **	
	
Table	A.5.2.	Summary	of	Bonferroni	post	hoc	test	values	for	fumarate	concentrations	in	
CRC	cell	lines	determined	by	mass	spectroscopy.	See	also	Figure	5.1.	
			 Condition	 p	value	 p	value	summary	
DLD1		
(Figure	5.1)	
20.9%	O2	vs.	1%	O2	 0.0897	 ns	
20.9%	O2	vs.	0.2%	O2	 0.0011	 **	
1%	O2vs.	0.2%	O2	 0.0138	 *	
HT55		
(Figure	5.1)	
20.9%	O2	vs.	1%	O2	 <0.0001	 ****	
20.9%	O2	vs.	0.2%	O2	 <0.0001	 ****	
1%	O2vs.	0.2%	O2	 0.0248	 *	
SW837	
(Figure	5.1)	
20.9%	O2	vs.	1%	O2	 0.0035	 **	
20.9%	O2	vs.	0.2%	O2	 0.0036	 **	
1%	O2vs.	0.2%	O2	 >0.9999	 ns	
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Table	A.5.3.	Summary	of	one-way	ANOVA	statistics	for	doubling	time.	See	also	Figure	
5.2.	
Cell	line	 F	(DFn,	DFd)	 p	value	 p	 value	
summary	DLD1	(Figure	5.2.A)	 F	(2,6)	=	128.9	 <0.0001	 ****	
HT55	(Figure	5.2.B)	 F	(2,6)	=	6.043	 0.0365	 *	
SW837	 (Figure	
5.2.C)	
F	(2,6)	=	2469	 <0.0001	 ****	
	
Table	A.5.4.	 Summary	of	Bonferroni	post	hoc	 test	 values	 for	doubling	 time.	 See	 also	
Figure	5.2.	
		 Conditions	 p	value	 p	 value	
summary	DLD1	(Figure	5.2.A)	 25mM	vs.	5mM	 0.0002	 ***	
25mM	vs.	0mM	
	
<0.0001	 ****	
5mM	vs.	0mM	 <0.0001	 ****	
HT55	(Figure	5.2.B)	 25mM	vs.	5mM	 <0.999	 ns	
25mM	vs.	0mM	
	
0.0874	 ns	
5mM	vs.	0mM	 0.0596	 ns	
SW837	 (Figure	
5.2.C)	
25mM	vs.	5mM	 <0.0001	 ****	
25mM	vs.	0mM	
	
<0.0001	 ****	
5mM	vs.	0mM	 <0.0001	 ****	
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Table	A.5.5.	Summary	of	two-way	ANOVA	statistics	for	viability.	See	also	Figure	5.4.		
		 ANOVA	table	 F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	
(Figure	
5.4.A)	
Interaction	 F	(2,	24)	=	37.86	 <0.0001	 ****	
Glucose	 F	(2,	24)	=	39.95	 <0.0001	 ****	
Oxygen	 F	(1,	24)	=	148.4	 <0.0001	 ****	
SW837	
(Figure	
5.4.B)	
Interaction	 F	(2,	24)	=	9.151	 0.0011	 **	
Glucose	 F	(2,	24)	=	9.467	 0.0009	 ***	
Oxygen	 F	(1,	24)	=	29.85	 <0.0001	 ****	
MEFs	
(Figure	
5.4.C)	
Interaction	 F	(1,	8)	=	0.6403	 0.4467	 ns	
Cell	line	 F	(1,	8)	=	0.3504	 0.5702	 ns	
Oxygen	 F	(1,	8)	=	1.25	 0.2960	 ns	
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Table	A.5.6.	Summary	of	Bonferroni	post	hoc	test	values	for	viability.	See	also	Figure	5.4.	
Only	significant	values	shown.		
	 Condition	 Bonferroni	 post	 hoc	 test	 value	
summary	
DLD1	
(Figure	
5.4.A)	
25mM	20.90%	vs.	5mM	0.20%	 ****	
25mM	20.90%	vs.	0mM	0.20%	 ****	
25mM	0.20%	vs.	5mM	0.20%	 ****	
25mM	0.20%	vs.	0mM	0.20%	 ****	
5mM	20.90%	vs.	5mM	0.20%	 ****	
5mM	20.90%	vs.	0mM	0.20%	 ****	
5mM	0.20%	vs.	0mM	20.90%	 ****	
0mM	20.90%	vs.	0mM	0.20%	 ****	
SW837	
(Figure	
5.5.B)	
25mM	20.90%	vs.	5mM	0.20%	 *	
25mM	20.90%	vs.	0mM	0.20%	 ****	
25mM	0.20%	vs.	5mM	0.20%	 *	
25mM	0.20%	vs.	0mM	0.20%	 ****	
5mM	20.90%	vs.	5mM	0.20%	 *	
5mM	20.90%	vs.	0mM	0.20%	 ****	
5mM	0.20%	vs.	0mM	20.90%	 *	
0mM	20.90%	vs.	0mM	0.20%	 ****	
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Table	A.5.7.	Summary	of	two-way	ANOVA	statistics	for	fumarate	concentration.	See	also	
Figure	5.5.		
		 ANOVA	table	 F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	
(Figure	
5.5.A)	
Interaction	 F	(2,	12)	=	14.56	 0.0006	 ***	
Glucose	 F	(2,	12)	=	11.08	 0.0019	 **	
Oxygen	 F	(1,	12)	=	8.090	 0.0148	 *	
SW837	
(Figure	
5.5.C)	
Interaction	 F	(2,	12)	=	2.660	 0.1106	 ns	
Glucose	 F	(2,	12)	=	37.15	 0.0001	 ****	
Oxygen	 F	(1,	12)	=	18.47	 0.0010	 **	
MEFs	
(Figure	
5.5.D)	
Interaction	 F	(1,	8)	=	43.66	 0.0002	 ***	
Cell	line	 F	(1,	8)	=	16.91	 0.0034	 **	
Oxygen	 F	(1,	8)	=	4.733	 0.0613	 ns	
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Table	A.5.8.	Summary	of	Bonferroni	post	hoc	 test	values	for	fumarate	concentration.	
See	also	Figure	5.5.	Only	significant	values	shown.		
	 Conditions		 Bonferroni	 post	 hoc	 test	
values	summary	
DLD1	
(Figure	
5.5.A)	
25mM	20.9%	O2	vs.	25mM	0.2%	O2	
	
**	
25mM	0.2%	O2	vs.	5mM	0.2%	O2	 **	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 ***	
25mM	0.2%	O2	vs.	0mM	0.2%	O2	 **	
SW837	
(Figure	
5.5.C)	
25mM	20.9%	O2	vs.	5mM	20.9%	O2	
	
*	
25mM	20.9%	O2	vs.	0mM	20.9%	O2	 **	
25mM	0.2%	O2	vs.	5mM	20.9%	O2	 ***	
25mM	0.2%	O2	vs.	5mM	0.2%	O2	 ***	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 ****	
25mM	0.2%	O2	vs.	0mM	0.2%	O2	 *	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
*	
MEFs	
(Figure	
5.5.D)	
	
WT	Fh1	20.9%	O2	vs.	KO	Fh1	20.9%	O2	
	
***	
	
WT	Fh1	0.2%	O2	vs.	KO	Fh1	20.9%	O2	
	
*	
	
KO	Fh1	20.9%	O2	vs.	KO	Fh1	0.2%	O2	
	
**	
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Table	A.5.9.	Summary	of	two-way	ANOVA	statistics	for	fumarate	hydratase	activity.	See	
also	Figure	5.7.		
	 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	(Figure	5.7.A)	 Interaction	 F	(2,	12)	=	6.366	 0.0131	 *	
Glucose	 F	(2,	12)	=	14.06	 0.0007	 ***	
Oxygen	 F	(1,	12)	=	42.30	 <	0.0001	 ****	
SW837	(Figure	5.7.B)	Interaction	 F	(2,	12)	=	0.2118	 0.8121	 ns	
Glucose	 F	(2,	12)	=	5.672	 0.0185	 *	
Oxygen	 F	(1,	12)	=	6.084	 0.0297	 *	
MEFs	(Figure	5.7.C)	 Interaction	 F	(1,	8)	=	1.968	 0.1983	 ns	
Cell	line	 F	(1,	8)	=	15.34	 0.0044	 **	
Oxygen	 F	(1,	8)	=	1.239	 0.2980	 ns	
	
Table	 A.5.10.	 Summary	 of	 Bonferroni	 post	 hoc	 test	 values	 for	 fumarate	 hydratase	
activity.	Only	significant	values	shown.	See	also	Figure	5.7.		
	 Conditions		 Bonferroni	post	hoc	 test	
values	summary	
DLD1	
(Figure	
5.7.A)	
25mM	20.9%	O2	vs.	25mM	0.2%	O2	 **	
25mM	20.9%	O2	vs.	5mM	0.2%	O2	 **	
25mM	20.9%	O2	vs.	0mM	20.9%	O2	 **	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 ***	
25mM	0.2%	O2	vs.	5mM	20.9%	O2	 **	
5mM	20.9%	O2	vs.	5mM	0.2%	O2	 **	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	 **	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 **	
MEFs	
(Figure	
5.7.C)	
WT	Fh1	20.9%	O2	vs.	KO	Fh1	20.9%	
O2	
*	
WT	Fh1	20.9%	O2	vs.	KO	Fh1	0.2%	O2	 *	
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Table	A.5.11.	Summary	of	two-way	ANOVA	data	for	fumarate	hydratase	foci	and	area	
per	cell.	See	also	Figure	5.9.		
Measurement		 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	 value	
summary	
DLD1	 FH	 foci	 per	 cell	
(Figure	5.9.A)	
Interaction	 F	(2,	12)	=	3.248	 0.0746	 ns	
Glucose	 F	(2,	12)	=	123.1	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	8.643	 0.0124	 *	
DLD1	 FH	 area	 per	 cell	
(Figure	5.9.B)	
Interaction	 F	(2,	12)	=	0.4272	 0.6619	 ns	
Glucose	 F	(2,	12)	=	144.7	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	0.005771	 0.9407	 ns	
SW837	FH	foci	per	cell		
(Figure	5.9.C)	
Interaction	 F	(2,	12)	=	4.164	 0.0423	 *	
Glucose	 F	(2,	12)	=	34.76	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	2.649	 0.1296	 ns	
SW837	FH	area	per	cell		
(Figure	5.9.D)	
Interaction	 F	(2,	12)	=	11	 0.0019	 **	
Glucose	 F	(2,	12)	=	47.57	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	8.436	 0.0132	 *	
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Table	A.5.12.	Summary	of	Bonferroni	post	hoc	test	values	for	FH	foci	and	area	per	cell	
after	48	hours	treatment	with	20.9%	or	0.2%	O2.	Only	significant	values	shown.	See	also	
Figure	5.9.	
Measurement	 Conditions		 Bonferroni	post	
hoc	 value	
summary		
DLD1	 FH	 foci	 per	 cell		
(Figure	5.9.A)	
25mM	 20.9%	O2	 vs.	 0mM	 20.9%	
O2	
****	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 ****	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 ****	
25mM	0.2%	O2	vs.	0mM	0.2%	O2	 ****	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	 ****	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 ***	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	 ****	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 ***	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	 *	
DLD1	 FH	 area	 per	 cell		
(Figure	5.9.B)	
25mM	 20.9%	O2	 vs.	 0mM	 20.9%	
O2	
****	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 ****	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 ****	
25mM	0.2%	O2	vs.	0mM	0.2%	O2	 ****	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	 ****	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 ****	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	 ****	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 ****	
SW837	FH	foci	per	cell	
(Figure	5.9.C)	
25mM	 20.9%	O2	 vs.	 0mM	 20.9%	
O2	
*	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 ***	
25mM	0.2%	O2	vs.	0mM	0.2%	O2	 ***	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 ***	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 ***	
SW837	FH	area	per	cell		
(Figure	5.9.D)	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 ****	
25mM	0.2%	O2	vs.	0mM	0.2%	O2	 ****	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 ****	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 ****	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	 **	
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Table	A.5.13.	Summary	of	p	values	from	linear	regression	multivariate	analysis.	See	also	
Figure	5.11.		
	 p	value	 	
Gene	 ranked	 by	
glucose	p	value	
Glucose	 Oxygen		 Glucose	*	Oxygen	 R	 Squared	
value	
BAX	 0.01370		 0.19994	 0.11366		 0.608292	
CA9	 0.01723	 0.00958		 0.01723		 0.468597	
PDK1	 0.01900	 0.00864	 0.66805	 0.503016	
LDHA	 0.02906	 0.00836	 0.08518	 0.560577	
HK2	 0.05156	 0.00221	 0.35933	 0.487454	
HIF12a	 0.07798	 0.03318	 0.13318	 0.404661	
VEGF	 0.08164	 0.11080	 0.57847	 0.3938	
GLUT1	 0.14398	 0.00125	 0.35915	 0.489338	
VHL	 0.19989	 0.08781		 0.19838		 0.708561	
GAPDH	 0.22010	 0.22010	 0.13628		 0.741091	
GPX1	 0.22787	 0.21652	 0.22787	 0.70272	
HIF1b	 0.23631	 0.22897	 0.23631	 0.713115	
LONP1	 0.33639	 0.18453		 0.27880		 0.535988	
HIF-1α	 0.46743	 0.06651	 0.58087	 0.659095	
FH	 0.50686	 0.03717		 0.50686		 0.817944	
COX4I2	 0.55882	 0.02499	 0.55882	 0.494927	
GLUT4	 0.73180	 0.05227		 0.45613		 0.636521	
SOD2	 0.73899	 0.73899	 0.74647	 0.552914	
CASP9	 0.89299	 0.89299	 0.89299		 0.221554	
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Table	A.5.14.	Summary	of	normalised	values	for	RT-PCR	data	for	DLD1	cells	cultured	in	
25mM	glucose.	See	also	Figure	5.11.	
	 20.9%	O2	 0.2%	O2	
	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 5.63E-06	 5.55E-06	 1.03E-05	 4.32E-06	 3.84E-06	 6.66E-06	
GLUT4	 7.14E-09	 3.51E-08	 4.08E-08	 1.56E-08	 5.91E-05	 2.22E-08	
GAPDH	 5.43E-04	 1.22E-03	 1.19E-03	 3.69E-04	 8.50E-04	 8.13E-04	
LDHA	 1.67E-05	 1.00E-04	 7.98E-05	 9.30E-06	 7.64E-06	 4.73E-05	
HK2	 2.89E-07	 1.82E-06	 1.17E-06	 2.19E-07	 1.07E-06	 7.07E-07	
FH	 1.14E-06	 3.20E-06	 3.21E-06	 5.77E-07	 1.10E-06	 1.99E-06	
PDK1	 4.03E-07	 2.21E-06	 7.67E-07	 2.51E-07	 1.72E-06	 5.08E-07	
LONP1	 9.60E-06	 2.07E-05	 2.20E-05	 4.14E-06	 2.14E-05	 1.20E-05	
SOD2	 1.46E-06	 1.10E-05	 4.78E-06	 7.87E-07	 6.84E-06	 4.04E-06	
COX4I2	 2.03E-09	 5.34E-09	 9.33E-10	 4.80E-09	 2.11E-08	 5.60E-09	
HIF-1Α	 9.49E-07	 4.92E-06	 2.77E-06	 6.52E-07	 3.25E-06	 1.76E-06	
HIF1B	 6.90E-07	 5.68E-06	 2.62E-06	 3.84E-07	 2.67E-05	 1.69E-06	
HIF-2Α	 4.30E-07	 1.78E-06	 1.19E-06	 3.31E-07	 1.84E-06	 1.09E-06	
VHL	 1.52E-06	 3.89E-06	 3.35E-06	 5.32E-07	 1.89E-06	 1.96E-06	
CA9	 4.42E-08	 1.25E-07	 6.15E-08	 1.92E-08	 1.60E-07	 3.72E-08	
VEGF	 7.50E-07	 4.56E-06	 3.22E-06	 8.52E-07	 1.06E-05	 3.78E-06	
BAX	 3.27E-06	 1.54E-05	 1.08E-05	 2.78E-06	 3.49E-07	 6.49E-06	
CASP9	 1.81E-07	 1.21E-04	 5.88E-07	 1.05E-07	 8.50E-04	 4.05E-07	
GPX1	 2.06E-05	 6.30E-07	 5.30E-05	 1.23E-05	 1.65E-08	 3.29E-05	
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Table	A.5.15.	Summary	of	normalised	values	for	RT-PCR	data	for	DLD1	cells	cultured	in	
5mM	glucose.	See	also	Figure	5.11.	
	 20.9%	O2	 0.2%	O2	
	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 8.02E-06	 7.74E-06	 1.23E-05	 3.08E-05	 2.05E-05	 4.14E-05	
GLUT4	 6.38E-09	 3.78E-08	 2.70E-08	 1.15E-08	 8.26E-09	 5.83E-09	
GAPDH	 3.54E-04	 5.06E-04	 5.22E-04	 1.10E-03	 1.51E-03	 1.30E-03	
LDHA	 1.25E-05	 2.16E-05	 2.25E-05	 1.24E-04	 1.96E-04	 1.97E-04	
HK2	 4.13E-07	 1.92E-06	 1.51E-06	 2.08E-06	 2.14E-06	 2.23E-06	
PDK1	 5.80E-07	 1.74E-06	 7.34E-07	 2.70E-06	 4.24E-06	 2.23E-06	
FH	 5.17E-07	 8.60E-07	 1.17E-06	 8.74E-07	 5.74E-07	 7.57E-07	
LONP1	 1.24E-05	 1.11E-05	 2.04E-05	 1.36E-05	 1.56E-05	 2.40E-05	
SOD2	 1.81E-06	 7.39E-06	 3.30E-06	 1.62E-06	 2.99E-06	 1.74E-06	
COX4I2	 1.15E-09	 1.43E-09	 1.74E-09	 1.66E-09	 4.57E-09	 1.42E-09	
HIF-1Α	 1.37E-06	 1.71E-06	 2.57E-06	 1.60E-06	 1.07E-06	 2.00E-06	
HIF1B	 1.30E-06	 3.59E-06	 2.89E-06	 1.04E-06	 2.98E-06	 2.04E-06	
HIF-2Α	 1.08E-06	 1.85E-06	 1.22E-06	 1.52E-06	 2.63E-06	 2.62E-06	
VHL	 1.15E-06	 2.97E-06	 2.92E-06	 2.49E-06	 9.86E-07	 1.81E-06	
CA9	 1.64E-08	 2.42E-08	 9.81E-09	 4.62E-06	 1.23E-05	 4.92E-06	
VEGF	 1.62E-06	 6.15E-06	 8.45E-06	 6.53E-06	 1.75E-05	 2.38E-05	
BAX	 3.54E-06	 6.96E-06	 4.09E-06	 5.02E-06	 6.83E-06	 4.25E-06	
CASP9	 1.62E-07	 3.05E-05	 3.47E-07	 2.60E-07	 4.46E-05	 4.01E-07	
GPX1	 3.28E-05	 4.14E-07	 2.04E-05	 1.74E-05	 3.47E-07	 1.60E-05	
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Table	A.5.16.	Summary	of	normalised	values	for	RT-PCR	data	for	DLD1	cells	cultured	in	
0mM	glucose.	See	also	Figure	5.11.	
	 20.9%	O2	 0.2%	O2	
	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 6.55E-05	 5.27E-05	 1.42E-04	 9.03E-05	 4.43E-05	 9.11E-05	
GLUT4	 1.02E-08	 9.51E-09	 1.71E-09	 3.20E-09	 5.21E-09	 6.54E-09	
GAPDH	 1.50E-03	 1.62E-03	 1.82E-03	 1.05E-03	 1.13E-03	 1.06E-03	
GPX1	 2.32E-05	 3.09E-07	 1.33E-05	 1.49E-05	 3.33E-07	 1.42E-05	
LDHA	 1.61E-04	 2.23E-04	 2.21E-04	 9.58E-05	 1.24E-04	 2.09E-04	
PDK1	 2.87E-06	 4.95E-06	 3.45E-06	 2.08E-06	 0	 2.21E-06	
HK2	 1.64E-06	 4.97E-06	 4.59E-06	 6.64E-06	 1.28E-05	 9.25E-06	
FH	 6.56E-07	 6.22E-07	 5.53E-07	 5.60E-07	 3.20E-07	 6.29E-07	
LONP1	 8.73E-06	 5.03E-06	 2.08E-05	 1.55E-05	 4.55E-06	 1.15E-05	
SOD2	 1.81E-06	 6.62E-06	 1.50E-06	 1.84E-06	 1.37E-06	 3.28E-06	
COX4I2	 1.41E-08	 8.94E-09	 2.52E-09	 6.84E-10	 6.14E-10	 1.30E-09	
HIF-1Α	 2.18E-06	 1.74E-06	 2.25E-06	 2.52E-06	 3.81E-07	 2.13E-06	
HIF1B	 1.10E-06	 2.01E-06	 1.67E-06	 3.21E-06	 2.13E-06	 5.85E-06	
HIF-2Α	 9.70E-07	 9.92E-07	 1.63E-06	 5.01E-06	 3.31E-07	 1.92E-06	
VHL	 1.06E-06	 6.18E-07	 1.05E-06	 2.34E-06	 7.72E-07	 8.20E-07	
CA9	 1.94E-06	 2.80E-06	 3.41E-06	 1.20E-06	 2.23E-07	 1.17E-06	
VEGF	 6.16E-06	 1.55E-05	 4.22E-05	 2.23E-05	 1.73E-05	 4.50E-05	
CASP9	 2.05E-07	 3.72E-05	 3.68E-07	 3.08E-07	 1.61E-05	 4.12E-07	
BAX	 4.97E-06	 7.99E-06	 3.17E-06	 2.59E-06	 1.98E-06	 1.73E-06	
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Table	A.5.17.	Summary	of	normalised	values	for	RT-PCR	data	for	HT55	cells	cultured	in	
25mM	glucose.	See	also	Figure	5.11.	
	 20.9%	O2	 0.2%	O2	
	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 1.61E-01	 2.61E-01	 2.76E-01	 7.25E-01	 6.74E-01	 1.12E+00	
GLUT4	 2.09E-04	 2.83E-04	 4.75E-04	 9.98E-06	 2.46E-05	 4.33E-05	
GAPDH	 4.75E-01	 2.39E-02	 7.14E-01	 5.44E-01	 1.33E-01	 9.76E-01	
GPX1	 2.86E-01	 2.24E-01	 2.46E-01	 1.10E-01	 9.39E-02	 1.23E-01	
LDHA	 1.67E-01	 7.22E-02	 2.64E-01	 2.65E-01	 1.44E-01	 5.45E-01	
PDK1	 3.00E-03	 3.34E-03	 4.60E-03	 1.56E-02	 1.15E-02	 1.58E-02	
HK2	 7.04E-03	 9.15E-03	 1.28E-02	 2.66E-02	 1.46E-02	 3.69E-02	
FH	 3.14E-02	 3.30E-02	 4.89E-02	 2.07E-02	 1.28E-02	 1.85E-02	
LONP1	 4.54E-02	 2.68E-02	 3.13E-02	 2.76E-02	 2.78E-02	 2.31E-02	
SOD2	 4.05E-02	 3.25E-02	 3.74E-02	 2.13E-02	 1.93E-02	 1.84E-02	
COX4I2	 8.21E-06	 1.10E-05	 1.52E-06	 1.49E-05	 8.93E-06	 1.67E-05	
HIF-1Α	 1.07E-02	 1.40E-02	 3.36E-02	 7.77E-03	 5.86E-03	 1.02E-02	
HIF1B	 4.80E-03	 2.35E-03	 4.55E-03	 2.21E-03	 1.93E-03	 2.94E-03	
HIF-2Α	 6.25E-03	 7.91E-03	 6.24E-03	 1.79E-02	 2.35E-02	 1.99E-02	
VHL	 1.35E-02	 1.26E-02	 1.86E-02	 4.70E-03	 4.77E-03	 5.89E-03	
CA9	 4.97E-04	 4.19E-04	 4.64E-04	 7.86E-03	 4.99E-03	 5.18E-03	
VEGF	 1.38E-02	 7.20E-03	 1.96E-02	 3.65E-02	 4.28E-02	 7.53E-02	
CASP9	 7.92E-04	 5.38E-04	 9.44E-04	 5.70E-04	 5.81E-04	 1.08E-03	
BAX	 1.13E-02	 6.22E-03	 1.29E-02	 2.67E-03	 1.81E-03	 2.39E-03	
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Table	A.5.18.	Summary	of	normalised	values	for	RT-PCR	data	for	HT55	cells	cultured	in	
5mM	glucose.	See	also	Figure	5.11.	
	 20.9%	O2	 0.2%	O2	
	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 1.24E-01	 1.28E-01	 1.40E-01	 3.68E-01	 5.93E-01	 7.26E-01	
GLUT4	 2.69E-04	 3.71E-04	 2.73E-04	 1.21E-04	 1.58E-04	 1.97E-04	
GAPDH	 2.88E-01	 6.18E-02	 2.83E-01	 3.73E-01	 2.53E-01	 5.54E-01	
GPX1	 1.94E-01	 1.11E-01	 1.29E-01	 1.25E-01	 6.02E-02	 1.14E-01	
LDHA	 1.79E-01	 8.22E-02	 1.77E-01	 5.25E-01	 2.15E-01	 4.91E-01	
PDK1	 2.20E-03	 3.95E-03	 2.25E-03	 1.83E-02	 1.07E-02	 1.71E-02	
HK2	 6.28E-03	 3.60E-03	 8.86E-03	 9.65E-03	 1.94E-02	 2.82E-02	
FH	 2.94E-02	 2.98E-02	 3.35E-02	 2.32E-02	 1.35E-02	 2.03E-02	
LONP1	 2.39E-02	 1.95E-02	 1.52E-02	 2.95E-02	 1.53E-02	 2.07E-02	
SOD2	 2.72E-02	 2.82E-02	 2.51E-02	 2.75E-02	 1.88E-02	 1.84E-02	
COX4I2	 1.70E-05	 5.25E-06	 6.18E-06	 1.96E-05	 2.22E-05	 1.40E-05	
HIF-1Α	 1.48E-02	 1.11E-02	 1.70E-02	 8.99E-03	 5.78E-03	 9.06E-03	
HIF1B	 2.38E-03	 1.55E-03	 1.94E-03	 1.82E-03	 9.74E-04	 1.49E-03	
HIF-2Α	 4.90E-03	 7.54E-03	 3.67E-03	 1.56E-02	 1.61E-02	 1.20E-02	
VHL	 1.01E-02	 9.41E-03	 1.14E-02	 6.99E-03	 3.01E-03	 5.38E-03	
CA9	 1.47E-03	 1.45E-03	 8.79E-04	 2.69E-02	 2.79E-02	 1.85E-02	
VEGF	 4.85E-03	 5.76E-03	 5.00E-03	 2.39E-02	 2.71E-02	 2.43E-02	
CASP9	 5.13E-04	 5.20E-04	 4.18E-04	 5.34E-04	 4.18E-04	 5.46E-04	
BAX	 7.71E-03	 5.61E-03	 7.01E-03	 4.00E-03	 2.11E-03	 3.15E-03	
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Table	A.5.19.	Summary	of	normalised	values	for	RT-PCR	data	for	HT55	cells	cultured	in	
0mM	glucose.	See	also	Figure	5.11.	
	 20.9%	O2	 0.2%	O2	
	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 7.38E-02	 1.02E-01	 1.54E-01	 5.85E-01	 5.19E-01	 1.32E+00	
GLUT4	 1.23E-04	 3.34E-04	 3.63E-04	 1.42E-04	 1.59E-04	 4.27E-04	
GAPDH	 2.86E-01	 8.80E-02	 3.33E-01	 9.12E-01	 2.26E-01	 7.02E-01	
GPX1	 1.44E-01	 9.80E-02	 1.44E-01	 1.24E-01	 8.18E-02	 1.70E-01	
LDHA	 1.77E-01	 8.41E-02	 2.05E-01	 7.47E-01	 1.88E-01	 7.75E-01	
PDK1	 2.21E-03	 2.24E-03	 2.85E-03	 2.06E-02	 1.03E-02	 2.70E-02	
HK2	 3.32E-03	 3.00E-03	 5.29E-03	 1.71E-02	 8.35E-03	 3.50E-02	
FH	 2.64E-02	 2.80E-02	 4.20E-02	 2.45E-02	 1.55E-02	 4.42E-02	
LONP1	 2.34E-02	 1.67E-02	 2.18E-02	 4.19E-02	 2.48E-02	 3.73E-02	
SOD2	 2.92E-02	 2.94E-02	 3.16E-02	 3.12E-02	 1.80E-02	 3.00E-02	
COX4I2	 1.61E-05	 5.28E-06	 1.79E-05	 1.53E-05	 1.42E-05	 2.93E-05	
HIF-1Α	 1.25E-02	 1.23E-02	 1.86E-02	 9.57E-03	 4.48E-03	 1.47E-02	
HIF1B	 2.05E-03	 1.44E-03	 2.47E-03	 2.46E-03	 1.08E-03	 2.50E-03	
HIF-2Α	 3.89E-03	 4.88E-03	 4.94E-03	 2.08E-02	 1.81E-02	 2.18E-02	
VHL	 7.30E-03	 8.20E-03	 1.22E-02	 6.82E-03	 5.31E-03	 1.71E-02	
CA9	 4.88E-04	 5.51E-04	 6.49E-04	 2.11E-02	 1.61E-02	 3.85E-02	
VEGF	 6.42E-03	 5.28E-03	 7.90E-03	 4.92E-02	 2.57E-02	 3.80E-02	
CASP9	 4.76E-04	 5.71E-04	 7.24E-04	 7.62E-04	 5.41E-04	 1.11E-03	
BAX	 7.42E-03	 5.68E-03	 9.67E-03	 5.21E-03	 2.27E-03	 5.38E-03	
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Table	A.5.20.	Summary	of	normalised	values	for	RT-PCR	data	for	SW837	cells	cultured	
in	25mM	glucose.	See	also	Figure	5.11.	
	 20.9%	O2	 0.2%	O2	
	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 1.21E-01	 1.61E-01	 8.08E-02	 1.08E-01	 1.40E-01	 8.53E-02	
GLUT4	 7.23E-05	 7.37E-05	 5.99E-05	 5.78E-05	 1.35E-04	 3.24E-05	
GAPDH	 2.83E+00	 3.86E+00	 2.36E+00	 2.74E+00	 4.75E+00	 2.12E+00	
GPX1	 1.23E-01	 9.82E-04	 9.75E-02	 1.30E-01	 1.81E-03	 8.43E-02	
LDHA	 1.26E-01	 1.53E-01	 1.15E-01	 1.31E-01	 1.17E-01	 1.04E-01	
PDK1	 4.42E-03	 8.80E-04	 1.43E-03	 5.09E-03	 3.69E-03	 1.91E-03	
HK2	 1.69E-03	 1.89E-03	 1.50E-03	 2.20E-03	 2.77E-03	 1.32E-03	
FH	 8.85E-03	 1.43E-02	 7.82E-03	 7.83E-03	 1.69E-02	 7.04E-03	
LONP1	 1.07E-01	 1.75E-02	 4.74E-02	 1.11E-01	 7.03E-02	 5.53E-02	
SOD2	 5.13E-02	 8.01E-02	 7.44E-03	 4.92E-02	 7.08E-02	 4.54E-03	
COX4I2	 5.60E-06	 0.00E+00	 1.71E-07	 0.00E+00	 2.50E-05	 9.26E-07	
HIF-1Α	 1.41E-02	 1.33E-02	 9.93E-03	 1.37E-02	 1.09E-02	 1.06E-02	
HIF1B	 1.12E-02	 4.24E-03	 4.34E-03	 1.12E-02	 1.15E-02	 3.65E-03	
HIF-2Α	 2.37E-03	 3.54E-03	 1.24E-03	 6.17E-03	 5.51E-02	 2.43E-03	
VHL	 9.65E-03	 7.40E-03	 4.79E-03	 9.89E-03	 1.05E-02	 5.28E-03	
CA9	 6.07E-04	 1.46E-05	 2.28E-04	 1.34E-03	 1.98E-05	 3.33E-04	
VEGF	 3.44E-02	 5.11E-02	 8.71E-03	 2.63E-02	 1.53E-01	 5.72E-03	
CASP9	 1.06E-03	 7.40E-02	 9.43E-04	 9.50E-04	 8.59E-02	 7.74E-04	
BAX	 1.65E-01	 1.66E-01	 1.56E-01	 1.43E-01	 3.15E-01	 1.32E-01	
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Table	A.5.21.	Summary	of	normalised	values	for	RT-PCR	data	for	SW837	cells	cultured	
in	5mM	glucose.	See	also	Figure	5.11.	
	 20.9%	O2	 0.2%	O2	
	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 8.74E-02	 1.46E-01	 5.65E-02	 1.05E+00	 2.67E+00	 6.27E-01	
GLUT4	 5.50E-05	 1.06E-04	 6.56E-05	 9.50E-05	 9.56E-05	 6.28E-05	
GAPDH	 1.62E+00	 2.80E+00	 1.81E+00	 5.37E+00	 9.22E+00	 5.94E+00	
GPX1	 7.51E-02	 1.30E-03	 7.13E-02	 1.10E-01	 1.66E-03	 1.20E-01	
LDHA	 6.50E-02	 7.09E-02	 5.06E-02	 6.08E-01	 1.22E+00	 5.21E-01	
PDK1	 5.96E-03	 1.93E-03	 1.90E-03	 2.82E-02	 4.74E-06	 1.60E-02	
HK2	 1.94E-03	 1.72E-03	 1.37E-03	 1.48E-02	 1.51E-02	 9.14E-03	
FH	 5.54E-03	 6.58E-03	 4.48E-03	 4.16E-03	 9.59E-03	 5.02E-03	
LONP1	 7.34E-02	 3.05E-02	 3.29E-02	 1.29E-01	 2.51E-01	 8.90E-02	
SOD2	 4.66E-02	 5.19E-02	 3.69E-03	 3.28E-02	 5.73E-02	 5.14E-03	
COX4I2	 0.00E+00	 7.45E-06	 0.00E+00	 8.34E-06	 3.81E-05	 9.57E-07	
HIF-1Α	 1.15E-02	 5.33E-03	 1.11E-02	 1.38E-02	 2.41E-04	 8.42E-03	
HIF1B	 9.69E-03	 7.52E-03	 4.31E-03	 1.16E-02	 1.07E-02	 4.31E-03	
HIF-2Α	 5.58E-03	 2.83E-02	 8.26E-03	 1.02E-02	 4.06E-03	 1.24E-02	
VHL	 8.17E-03	 6.16E-03	 5.62E-03	 4.84E-03	 2.09E-03	 7.15E-03	
CA9	 2.13E-03	 3.91E-04	 7.64E-04	 9.44E-02	 2.88E-02	 5.02E-02	
VEGF	 3.09E-02	 5.77E-02	 7.80E-03	 1.52E-01	 1.96E-01	 6.08E-02	
CASP9	 4.89E-04	 4.88E-02	 1.05E-03	 7.96E-04	 1.34E-01	 1.16E-03	
BAX	 1.55E-01	 2.28E-01	 2.28E-01	 3.03E-02	 2.51E-02	 3.24E-02	
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Table	A.5.22.	Summary	of	normalised	values	for	RT-PCR	data	for	SW837	cells	cultured	
in	0mM	glucose.	See	also	Figure	5.11.	
	 20.9%	O2	 0.2%	O2	
	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 8.17E-01	 7.84E-01	 7.05E-01	 9.28E-01	 1.82E+00	 1.47E+00	
GLUT4	 2.77E-05	 9.45E-05	 3.91E-05	 5.83E-05	 3.27E-05	 5.07E-05	
GAPDH	 4.77E+00	 1.03E+01	 3.49E+00	 5.17E+00	 5.39E+00	 3.81E+00	
GPX1	 1.03E-01	 1.39E-03	 8.37E-02	 1.07E-01	 1.25E-03	 5.58E-02	
LDHA	 4.66E-01	 8.61E-01	 5.06E-01	 5.24E-01	 4.78E-01	 5.54E-01	
PDK1	 3.04E-02	 2.00E-02	 1.73E-02	 3.45E-02	 1.23E-02	 1.57E-02	
HK2	 1.25E-02	 2.55E-02	 1.19E-02	 2.95E-02	 4.87E-02	 5.72E-02	
FH	 2.80E-03	 6.81E-03	 4.06E-03	 4.16E-03	 2.49E-03	 3.59E-03	
LONP1	 6.76E-02	 3.23E-03	 7.12E-02	 9.17E-02	 1.51E-02	 2.45E-02	
SOD2	 3.36E-02	 4.22E-02	 8.23E-03	 2.46E-02	 6.07E-02	 1.29E-02	
COX4I2	 2.79E-06	 0.00E+00	 0.00E+00	 0.00E+00	 6.53E-06	 0.00E+00	
HIF-1Α	 9.14E-03	 2.08E-03	 1.46E-02	 1.17E-02	 6.40E-03	 1.32E-02	
HIF1B	 1.14E-02	 7.99E-03	 4.87E-03	 1.21E-02	 1.79E-02	 2.30E-02	
HIF-2Α	 2.82E-02	 1.24E-02	 1.57E-02	 2.62E-02	 1.44E-01	 9.28E-02	
VHL	 4.33E-03	 9.60E-04	 5.82E-03	 5.61E-03	 3.74E-03	 5.17E-03	
CA9	 3.30E-02	 4.29E-03	 4.08E-02	 2.39E-02	 5.85E-03	 1.16E-02	
VEGF	 2.29E-01	 2.55E-01	 8.48E-02	 1.59E-01	 8.79E-01	 3.23E-01	
CASP9	 3.16E-04	 1.97E-01	 7.12E-04	 7.13E-04	 5.71E-02	 1.28E-03	
BAX	 1.51E-02	 2.18E-02	 2.00E-02	 1.98E-02	 1.81E-02	 2.02E-02	
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Figure	 A.5.1.	 The	 normalised	 RT-PCR	 data	 for	 GLUT1,	 GLUT4,	 GADPH	 and	 GPX1	
expressed	as	fold	change	from	cells	cultured	in	25mM	glucose	at	20.9%	O2.	DLD1,	HT55,	
SW837	cells	were	cultured	in	25mM,	5mM	or	0mM	glucose	then	held	in	20.9%	or	0.2%	O2	
for	48	hours.	RNA	was	extracted	and	analysed	via	qPCR.	Mean	±	SEM	 in	Table	A.5.34,	
A.5.37,	A.5.40.	Two-way	ANOVA	was	performed	with	Bonferroni	post	hoc	test	*	p	<	0.1,	
**	p	<	0.01,	***	p	<	0.001	(A.5.35,	A.5.36,	A.5.38,	A.5.39,	A.5.41,	A.5.42).	See	also	Figure	
A.5.2,3,4,5	 and	 6.	 Glucose	 transporter	 1	 (GLUT1),	 glucose	 transporter	 4	 (GLUT4),	
glyceraldehyde	3-phosphate	dehydrogenase	(GAPDH),	glutathione	peroxidase	(GPX1).		
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Figure	A.5.2.	The	normalised	RT-PCR	data	for	LDHA,	PDX1,	and	HK2	expressed	as	fold	
change	from	cells	cultured	in	25mM	glucose	at	20.9%	O2.	DLD1,	HT55,	SW837	cells	were	
cultured	in	25mM,	5mM	or	0mM	glucose	then	held	in	20.9%	or	0.2%	O2	for	48	hours.	RNA	
was	extracted	and	analysed	via	qPCR.	Mean	±	SEM	in	Table	A.5.34,	A.5.37,	A.5.40.	Two-
way	ANOVA	was	performed	with	Bonferroni	post	hoc	test	*	p	<	0.1,	**	p	<	0.01,	***	p	<	
0.001	(A.5.35,	A.5.36,	A.5.38,	A.5.39,	A.5.41,	A.5.42).	See	also	Figure	A.5.1,3,4,5	and	6.	
Lactate	dehydrogenase	A	(LDHA),	pyruvate	dehydrogenase	kinase	1	(PDX1),	hexokinase	
(HK2).		
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Figure	A.5.3.	The	normalised	RT-PCR	data	for	FH,	LONP1,	SOD2	and	COX4I2	expressed	
as	 fold	change	from	cells	cultured	 in	25mM	glucose	at	20.9%	O2.	DLD1,	HT55,	SW837	
cells	were	cultured	in	25mM,	5mM	or	0mM	glucose	then	held	in	20.9%	or	0.2%	O2	for	48	
hours.	RNA	was	extracted	and	analysed	via	qPCR.	Mean	±	SEM	in	Table	A.5.34,	A.5.37,	
A.5.40.	Two-way	ANOVA	was	performed	with	Bonferroni	post	hoc	test	*	p	<	0.1,	**	p	<	
0.01,	 ***	 p	 <	 0.001	 (A.5.35,	 A.5.36,	 A.5.38,	 A.5.39,	 A.5.41,	 A.5.42).	 See	 also	 Figure	
A.5.1,2,4,5	 and	 6.	 Fumarate	 hydratase	 (FH),	 lon	 peptidase	 1	 (LONP1),	 superoxide	
dismutase	2	(SOD2),	cytochrome	c	oxidase	subunit	4	isoform	2	(COX4I2).		
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Figure	A.5.4.	The	normalised	RT-PCR	data	for	HIF-1α,	HIF-1ß	and	HIF-2α	expressed	as	
fold	change	from	cells	cultured	in	25mM	glucose	at	20.9%	O2.	DLD1,	HT55,	SW837	cells	
were	cultured	in	25mM,	5mM	or	0mM	glucose	then	held	in	20.9%	or	0.2%	O2	for	48	hours.	
RNA	was	extracted	and	analysed	via	qPCR.	Mean	±	SEM	in	Table	A.5.34,	A.5.37,	A.5.40.	
Two-way	ANOVA	was	performed	with	Bonferroni	post	hoc	test	*	p	<	0.1,	**	p	<	0.01,	***	
p	<	0.001	(A.5.35,	A.5.36,	A.5.38,	A.5.39,	A.5.41,	A.5.42).	See	also	Figure	A.5.1,2,3,5	and	
6.	Hypoxia	inducible	factor	1α	(HIF-1α),	hypoxia	inducible	factor	1ß	(HIF-1ß)	and	hypoxia	
inducible	factor	2α	(HIF-2α).	
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Figure	 A.5.5.	 The	 normalised	 RT-PCR	 data	 for	 VHL,	 CA9	 and	 VEGF	 expressed	 as	 fold	
change	from	cells	cultured	in	25mM	glucose	at	20.9%	O2.	DLD1,	HT55,	SW837	cells	were	
cultured	in	25mM,	5mM	or	0mM	glucose	then	held	in	20.9%	or	0.2%	O2	for	48	hours.	RNA	
was	extracted	and	analysed	via	qPCR.	Mean	±	SEM	in	Table	A.5.34,	A.5.37,	A.5.40.	Two-
way	ANOVA	was	performed	with	Bonferroni	post	hoc	test	*	p	<	0.1,	**	p	<	0.01,	***	p	<	
0.001	(A.5.35,	A.5.36,	A.5.38,	A.5.39,	A.5.41,	A.5.42).	See	also	Figure	A.5.1,2,3,4	and	6.	
Von	Hippel-Lindau	 (VHL),	 carbonic	 anhydrase	 9	 (CA9)	 and	 vascular	 endothelial	 growth	
factor	(VEGF).		
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Figure	A.5.6.	The	normalised	RT-PCR	data	for	CASP9	and	BAX	expressed	as	fold	change	
from	cells	cultured	in	25mM	glucose	at	20.9%	O2.	DLD1,	HT55,	SW837	cells	were	cultured	
in	25mM,	5mM	or	0mM	glucose	then	held	 in	20.9%	or	0.2%	O2	for	48	hours.	RNA	was	
extracted	and	analysed	via	qPCR.	Mean	±	SEM	in	Table	A.5.34,	A.5.37,	A.5.40.	Two-way	
ANOVA	was	performed	with	Bonferroni	post	hoc	test	*	p	<	0.1,	**	p	<	0.01,	***	p	<	0.001	
(A.5.35,	A.5.36,	A.5.38,	A.5.39,	A.5.41,	A.5.42).	See	also	Figure	A.5.1,2,3,4	and	5.	Caspase	
9	(CASP9),	Bcl-2	associated	X	protein	(BAX).		
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Table	A.5.23.	Summary	of	RT-PCR	DLD1	data.	Fold-change	from	25mM	glucose,	shown	
as	mean	±	SEM.	See	also	Figure	A.5.1,2,3,4	and	5.	
DLD1	 20.9%	
	 25mM		 5mM	 0mM	
GLUT1	 1.00±0.00	 1.34±0.07	 11.63±1.24	
GLUT4	 1.00±0.00	 0.88±0.12	 0.58±0.43	
GAPDH	 1.00±0.00	 0.50±0.08	 1.87±0.44	
GPX1	 1.00±0.00	 0.88±0.37	 0.62±0.26	
LDHA	 1.00±0.00	 0.42±0.17	 4.88±2.38	
PDX1	 1.00±0.00	 1.06±0.19	 4.62±0.40	
HK2	 1.00±0.00	 1.26±0.11	 4.11±0.85	
FH	 1.00±0.00	 0.36±0.05	 0.31±0.13	
LONP1	 1.00±0.00	 0.92±0.22	 0.70±0.23	
SOD2	 1.00±0.00	 0.87±0.19	 0.72±0.27	
COX4I2	 1.00±0.00	 0.90±0.49	 3.77±1.61	
HIF-1α	 1.00±0.00	 0.90±0.32	 1.15±0.59	
HIF-1ß	 1.00±0.00	 1.21±0.37	 0.86±0.37	
HIF-2α	 1.00±0.00	 1.53±0.49	 1.39±0.49	
VHL	 1.00±0.00	 0.80±0.04	 0.39±0.16	
CA9	 1.00±0.00	 0.24±0.07	 40.54±9.69	
VEGF	 1.00±0.00	 2.05±0.37	 8.23±2.80	
CASP9	 1.00±0.00	 0.58±0.19	 0.69±0.24	
BAX	 1.00±0.00	 0.64±0.22	 0.78±0.38	
	 0.2%	
	 25mM		 5mM	 0mM	
GLUT1	 0.88±0.21	 2.09±0.94	 0.74±0.06	
GLUT4	 0.49±0.03	 0.33±0.11	 2.51±1.00	
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GAPDH	 0.95±0.26	 2.16±0.88	 1.04±0.34	
GPX1	 0.95±0.36	 1.17±0.36	 1.24±0.16	
LDHA	 0.88±0.46	 5.96±2.93	 1.06±0.33	
PDX1	 1.02±0.30	 1.89±0.86	 0.67±0.40	
HK2	 0.84±0.24	 0.93±0.38	 1.61±0.70	
FH	 0.98±0.50	 0.64±0.02	 0.94±0.21	
LONP1	 1.30±0.53	 1.17±0.14	 0.67±0.12	
SOD2	 1.11±0.38	 0.68±0.22	 1.12±0.57	
COX4I2	 3.46±1.63	 1.57±0.82	 7.06±6.77	
HIF-1α	 0.97±0.03	 1.03±0.20	 0.81±0.30	
HIF-1ß	 1.09±0.36	 0.93±0.17	 1.63±0.95	
HIF-2α	 1.08±0.11	 1.43±0.42	 0.57±0.31	
VHL	 1.31±0.77	 0.47±0.08	 0.83±0.23	
CA9	 1.39±0.49	 336.438±168.23	 0.68±0.48	
VEGF	 1.46±0.44	 1.97±0.86	 0.82±0.27	
CASP9	 0.97±0.38	 1.08±0.25	 0.74±0.20	
BAX	 0.76±0.21	 0.91±0.10	 0.90±0.51	
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Table	A.5.24.	Summary	table	of	two-way	ANOVA	for	RT-PCR	DLD1	fold	change	data.	See	
also	Figure	A.5.1,2,3,4	and	5.	
	 ANOVA	table	 F	(DFn,	DFd)	 P	value	 P	value	summary	
GLUT1	
	
	
Interaction	 F	(2,	12)	=	51.21	 <0.0001	 ****	
Glucose		 F	(2,	12)	=	39.01	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	42.74	 <0.0001	 ****	
GLUT4	 Interaction	 F	(2,	12)	=	5.005	 0.0263	 *	
Glucose		 F	(2,	12)	=	2.557	 0.1188	 ns	
Oxygen	 F	(1,	12)	=	0.6377	 0.4401	 ns	
GAPDH	 Interaction	 F	(2,	12)	=	4.211	 0.0412	 *	
Glucose	 F	(2,	12)	=	0.6519	 0.5386	 ns	
Oxygen	 F	(1,	12)	=	0.5052	 0.4908	 ns	
GPX1	 Interaction	 F	(2,	12)	=	0.6723	 0.5287	 ns	
Glucose	 F	(2,	12)	=	0.05382	 0.9478	 ns	
Oxygen	 F	(1,	12)	=	1.493	 0.2452	 ns	
LDHA	 Interaction	 F	(2,	12)	=	4.56	 0.0337	 *	
	 Glucose	 F	(2,	12)	=	1.258	 0.3191	 ns	
	 Oxygen	 F	(1,	12)	=	0.1783	 0.6803	 ns	
PDK1	
	
Interaction	 F	(2,	12)	=	6.524	 0.0121	 *	
Glucose	 F	(2,	12)	=	2.838	 0.0979	 ns	
Oxygen	 F	(1,	12)	=	3.187	 0.0995	 ns	
HK2				 Interaction	 F	(2,	12)	=	3.539	 0.0619	 ns	
Glucose	 F	(2,	12)	=	9.632	 0.0032	 **	
Oxygen	 F	(1,	12)	=	6.208	 0.0284	 *	
FH		
	
Interaction	 F	(2,	12)	=	0.9929	 0.3990	 ns	
Glucose	 F	(2,	12)	=	2.431	 0.1299	 ns	
Oxygen	 F	(1,	12)	=	2.423	 0.1455	 ns	
LONP1	 Interaction	 F	(2,	12)	=	0.2237	 0.8028	 ns	
Glucose	
parameter	
F	(2,	12)	=	1.706	 0.2228	 ns	
Oxygen	 F	(1,	12)	=	0.6522	 0.4350	 ns	
SOD2	 Interaction	 F	(2,	12)	=	0.4144	 0.6698	 ns	
Glucose	 F	(2,	12)	=	0.3713	 0.6975	 ns	
Oxygen	 F	(1,	12)	=	0.1727	 0.6851	 ns	
COX4I2	 Interaction	 F	(2,	12)	=	0.1032	 0.9027	 ns	
Glucose	 F	(2,	12)	=	1.101	 0.3638	 ns	
Oxygen	 F	(1,	12)	=	0.7913	 0.3912	 ns	
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HIF-1α	 Interaction	 F	(2,	12)	=	0.2554	 0.7787	 ns	
Glucose	 F	(2,	12)	=	0.002182	 0.9978	 ns	
Oxygen	 F	(1,	12)	=	0.09108	 0.7680	 ns	
HIF-1ß	 Interaction	 F	(2,	12)	=	0.6335	 0.5476	 ns	
Glucose	 F	(2,	12)	=	0.1072	 0.8992	 ns	
Oxygen	 F	(1,	12)	=	0.2586	 0.6203	 ns	
HIF-2α	 Interaction	 F	(2,	12)	=	0.9099	 0.4286	 ns	
Glucose	 F	(2,	12)	=	1.145	 0.3508	 ns	
Oxygen	 F	(1,	12)	=	0.9285	 0.3543	 ns	
VHL				 Interaction	 F	(2,	12)	=	0.7323	 0.5011	 ns	
Glucose	 F	(2,	12)	=	1.659	 0.2312	 ns	
Oxygen	 F	(1,	12)	=	0.2547	 0.6229	 ns	
CA9	 Interaction	 F	(2,	12)	=	4.504	 0.0347	 *	
Glucose	 F	(2,	12)	=	3.531	 0.0622	 ns	
Oxygen	 F	(1,	12)	=	3.101	 0.1037	 ns	
VEGF	 Interaction	 F	(2,	12)	=	6.472	 0.0124	 *	
Glucose	
parameter	
F	(2,	12)	=	3.975	 0.0474	 *	
Oxygen	 F	(1,	12)	=	5.515	 0.0368	 *	
CASP9		
	
Interaction	 F	(2,	12)	=	0.7331	 0.5008	 ns	
Glucose	 F	(2,	12)	=	0.6441	 0.5424	 ns	
Oxygen	 F	(1,	12)	=	0.7848	 0.3931	 ns	
BAX	
	
Interaction	 F	(2,	12)	=	0.412	 0.6714	 ns	
Glucose	 F	(2,	12)	=	0.0667	 0.9358	 ns	
Oxygen	 F	(1,	12)	=	0.0474	 0.8313	 ns	
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Table	A.5.25.	Summary	table	for	Bonferroni	post	hoc	test	values	for	qPCR	on	the	DLD1	
cell	line.	See	also	Figure	A.5.1,2,3,4	and	5.	Only	significant	values	shown.		
	 	 P	value	 Summary	
GLUT1	 25mM	20.9%	O2	vs.	0mM	20.9%	
O2	
	
<0.0001	 ****	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 <0.0001	 ****	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
<0.0001	 ****	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
<0.0001	 ****	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	 <0.0001	 ****	
PDK1	
	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0293	 *	
HK2	 25mM	20.9%	O2	vs.	0mM	20.9%	
O2	
	
0.0111	 *	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 0.0074	 **	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0214	 *	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0093	 **	
VEGF	 25mM	20.9%	O2	vs.	0mM	20.9%	
O2	
	
0.0190	 *	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 0.0306	 *	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0569	 *	
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Table	A.5.26.	Summary	of	qPCR	for	the	HT55	cell	line.	Fold-change	from	25mM	glucose,	
shown	as	mean	±	SEM.	See	also	Figure	A.5.1,2,3,4	and	5.	
HT55	 20.9%	
	 25mM		 5mM	 0mM	
GLUT1	 1.00±0.00	 1.28±0.22	 2.18±0.22	
GLUT4	 1.00±0.00	 1.35±0.43	 1.29±0.25	
GAPDH	 1.00±0.00	 0.93±0.06	 1.90±0.20	
GPX1	 1.00±0.00	 1.12±0.13	 2.00±0.17	
LDHA	 1.00±0.00	 0.95±0.45	 1.03±0.13	
PDX1	 1.00±0.00	 1.18±0.30	 1.49±0.59	
HK2	 1.00±0.00	 1.59±0.20	 2.53±0.27	
FH	 1.00±0.00	 0.99±0.10	 1.18±0.01	
LONP1	 1.00±0.00	 0.96±0.14	 1.66±0.15	
SOD2	 1.00±0.00	 0.89±0.05	 1.22±0.08	
COX4I2	 1.00±0.00	 0.80±0.23	 13.42±13.17	
HIF-1α	 1.00±0.00	 1.00±0.09	 1.27±0.04	
HIF-1ß	 1.00±0.00	 1.01±0.11	 1.99±0.21	
HIF-2α	 1.00±0.00	 1.18±0.23	 1.50±0.12	
VHL	 1.00±0.00	 1.15±0.13	 1.64±0.11	
CA9	 1.00±0.00	 2.33±0.50	 0.83±0.09	
VEGF	 1.00±0.00	 0.83±0.14	 2.00±0.33	
CASP9	 1.00±0.00	 0.85±0.13	 1.30±0.21	
BAX	 1.00±0.00	 0.92±0.10	 1.32±0.12	
	 0.2%	
	 25mM		 5mM	 0mM	
GLUT1	 7.19±1.07	 5.17±0.33	 7.91±0.98	
GLUT4	 0.93±0.23	 0.67±0.16	 0.09±0.01	
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GAPDH	 2.65±0.44	 1.49±0.15	 2.42±0.42	
GPX1	 0.96±0.11	 0.76±0.07	 0.86±0.06	
LDHA	 3.42±0.60	 2.64±0.17	 1.96±0.36	
PDX1	 7.81±1.59	 6.36±1.03	 5.91±0.59	
HK2	 4.85±1.12	 4.90±1.05	 6.61±0.92	
FH	 0.84±0.15	 0.62±0.13	 0.56±0.11	
LONP1	 1.66±0.09	 1.04±0.11	 1.30±0.19	
SOD2	 0.88±0.14	 0.72±0.11	 0.66±0.04	
COX4I2	 1.76±0.50	 2.07±1.07	 1.91±0.98	
HIF-1α	 0.64±0.14	 0.56±0.08	 0.55±0.04	
HIF-1ß	 0.99±0.13	 0.72±0.09	 1.21±0.08	
HIF-2α	 4.48±0.47	 3.25±0.45	 4.48±0.24	
VHL	 0.99±0.22	 0.59±0.19	 0.57±0.05	
CA9	 38.16±11.54	 29.60±12.00	 31.94±14.94	
VEGF	 5.78±0.94	 3.98±0.61	 7.78±1.12	
CASP9	 1.36±0.21	 0.87±0.13	 1.23±0.14	
BAX	 0.55±0.09	 0.41±0.06	 0.31±0.03	
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Table	A.5.27.	Summary	table	of	two-way	ANOVA	data	for	the	HT55	cell	line	qPCR.	See	
also	Figure	A.5.1,2,3,4	and	5.	
	 ANOVA	table	 F	(DFn,	DFd)	 P	value	 P	value	summary	
GLUT1	 Interaction	 F	(2,	12)	=	1.936	 0.1868	 ns	
Glucose	
parameter	
F	(2,	12)	=	4.316	 0.0387	 *	
Oxygen	 F	(1,	12)	=	108.8	 <0.0001	 ****	
GLUT4	 Interaction	 F	(2,	12)	=	2.936	 0.0916	 ns	
Glucose	
parameter	
F	(2,	12)	=	1.115	 0.3598	 ns	
Oxygen	 F	(1,	12)	=	11.58	 0.0052	 **	
GAPDH	 Interaction	 F	(2,	6)	=	1.892	 0.2306	 ns	
Glucose	 F	(2,	6)	=	4.275	 0.0701	 ns	
Oxygen	 F	(1,	6)	=	11.26	 0.0153	 *	
GPX1	 Interaction	 F	(2,	12)	=	14.2	 0.0007	 ***	
Glucose	 F	(2,	12)	=	13.19	 0.0009	 ***	
Oxygen	 F	(1,	12)	=	35.69	 <0.0001	 ****	
LDHA	 Interaction	 F	(2,	12)	=	3.086	 0.0829	 ns	
Glucose	 F	(2,	12)	=	2.859	 0.0965	 ns	
Oxygen	 F	(1,	12)	=	46.99	 <0.0001	 ****	
PDK1	 Interaction	 F	(2,	12)	=	1.107	 0.3620	 ns	
Glucose	 F	(2,	12)	=	0.4465	 0.6501	 ns	
Oxygen	 F	(1,	12)	=	66.68	 <0.0001	 ****	
HK2				 Interaction	 F	(2,	12)	=	0.1384	 0.8721	 ns	
Glucose	 F	(2,	12)	=	2.735	 0.1050	 ns	
Oxygen	 F	(1,	12)	=	37.97	 <0.0001	 ****	
FH		 Interaction	 F	(2,	12)	=	2.563	 0.1184	 ns	
Glucose	 F	(2,	12)	=	0.6748	 0.5276	 ns	
Oxygen	 F	(1,	12)	=	21.19	 0.0006	 ***	
LONP1	 Interaction	 F	(2,	12)	=	8.121	 0.0059	 **	
Glucose	
parameter	
F	(2,	12)	=	7.381	 0.0081	 **	
Oxygen	 F	(1,	12)	=	1.524	 0.2406	 ns	
SOD2	 Interaction	 F	(2,	12)	=	4.156	 0.0425	 *	
Glucose	 F	(2,	12)	=	1.598	 0.2426	 ns	
Oxygen	 F	(1,	12)	=	17.44	 0.0013	 **	
COX4I2	 Interaction	 F	(2,	12)	=	0.8937	 0.4347	 ns	
Glucose	 F	(2,	12)	=	0.8916	 0.4355	 ns	
Oxygen	 F	(1,	12)	=	0.5119	 0.4880	 ns	
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HIF-1α	 Interaction	 F	(2,	12)	=	0.9084	 0.4292	 ns	
Glucose	 F	(2,	12)	=	0.4395	 0.6543	 ns	
Oxygen	 F	(1,	12)	=	19.79	 0.0008	 ***	
HIF-1ß	 Interaction	 F	(2,	12)	=	4.496	 0.0349	 *	
Glucose	 F	(2,	12)	=	19.24	 0.0002	 ***	
Oxygen	 F	(1,	12)	=	12.11	 0.0045	 **	
HIF-2α	 Interaction	 F	(2,	12)	=	2.802	 0.1003	 ns	
Glucose	 F	(2,	12)	=	3.384	 0.0683	 ns	
Oxygen	 F	(1,	12)	=	131.7	 <0.0001	 ****	
VHL				 Interaction	 F	(2,	12)	=	7.499	 0.0077	 **	
Glucose	 F	(2,	12)	=	1.446	 0.2738	 ns	
Oxygen	 F	(1,	12)	=	23.82	 0.0004	 ***	
CA9	 Interaction	 F	(2,	12)	=	0.1492	 0.8629	 ns	
Glucose	 F	(2,	12)	=	0.09377	 0.9112	 ns	
Oxygen	 F	(1,	12)	=	18.23	 0.0011	 **	
VEGF	 Interaction	 F	(2,	12)	=	1.983	 0.1802	 ns	
Glucose	
parameter	
F	(2,	12)	=	7.079	 0.0093	 **	
Oxygen	 F	(1,	12)	=	70.85	 <0.0001	 ****	
CASP9		 Interaction	 F	(2,	12)	=	1.077	 0.3712	 ns	
Glucose	 F	(2,	12)	=	3.851	 0.0511	 ns	
Oxygen	 F	(1,	12)	=	0.6507	 0.4356	 ns	
BAX	 Interaction	 F	(2,	12)	=	7.667	 0.0072	 **	
Glucose	 F	(2,	12)	=	1.923	 0.1885	 ns	
Oxygen	 F	(1,	12)	=	103.1	 <0.0001	 ****	
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Table	A.5.28.	Summary	table	for	Bonferroni	post	hoc	test	values	for	the	HT55	cell	line	
qPCR.	See	also	Figure	A.5.1,2,3,4	and	5.	Only	significant	values	shown.		
	 	 P	value	 Bonferroni	 post	
hoc	 test	 value	
summary	
GLUT1	 25mM	20.9%	O2	vs.	25mM	0.2%	O2	 0.0002	 ***	
25mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0069	 **	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 <0.0001	 ****	
25mM	0.2%	O2	vs.	5mM	20.9%	O2	 0.0003	 ***	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0014	 **	
5mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0120	 *	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
<0.0001	 ****	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0004	 ***	
GLUT4	 5mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0366	 *	
GPX1	 25mM	20.9%	O2vs.	0mM	20.9%	O2	
	
0.0003	 ***	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 0.0002	 ***	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0012	 **	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
<0.0001	 ****	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
<0.0001	 ****	
LDHA	 25mM	20.9%	O2	vs.	25mM	0.2%	O2	 0.0015	 **	
25mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0335	 *	
25mM	0.2%	O2	vs.	5mM	20.9%	O2	
	
0.0012	 **	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0017	 **	
5mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0272	 *	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0382	 *	
PDK1	 25mM	20.9%	O2	vs.	25mM	0.2%	O2	
	
0.0011	 **	
25mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0088	 **	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 0.0175	 *	
25mM	0.2%	O2	vs.	5mM	20.9%	O2	 0.0015	 **	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0022	 **	
5mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0116	 *	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 0.0232	 *	
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5mM	0.2%	O2	vs.	0mM	20.9%	O2	 0.0184	 *	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0373	 *	
HK2	
	
25mM	20.9%	O2	vs.	25mM	0.2%	O2	
	
0.0495	 *	
25mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0450	 *	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0027	 **	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0069	 **	
0mM	20.9%	O2vs.	0mM	0.2%	O2	
	
0.0333	 *	
FH	 5mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0315	 *	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0161	 *	
LONP1	 25mM	20.9%	O2	vs.	25mM	0.2%	O2	
	
0.0465	 *	
25mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0475	 *	
25mM	0.2%	O2	vs.	5mM	20.9%	O2	
	
0.0326	 *	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0333	 *	
SOD2	 5mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0184	 *	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0070	 **	
HIF-1ß	 25mM	20.9%	O2	vs.	0mM	20.9%	O2	 0.0021	 **	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0019	 **	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0023	 **	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0002	 ***	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.161	 *	
HIF-2α	 25mM	20.9%	O2	vs.	25mM	0.2%	O2	
	
<0.0001	 ****	
25mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0031	 **	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 <0.0001	 ****	
25mM	0.2%	O2	vs.	5mM	20.9%	O2	 <0.0001	 ****	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0002	 ***	
5mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0064	 **	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 <0.0001	 ****	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	 0.0228	 *	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	 0.0002	 ***	
VHL	 5mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0024	 **	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0020	 **	
VEGF	 25mM	20.9%	O2	vs.	25mM	0.2%	O2	
	
0.0040	 **	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 0.0002	 ***	
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25mM	0.2%	O2	vs.	5mM	20.9%	O2	 0.0030	 **	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
	
0.0254	 *	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	
	 	
	
0.0001	 ***	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 0.0247	 *	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	 0.0008	 ***	
BAX	 25mM	20.9%	O2	vs.	25mM	0.2%	O2	
	
0.0258	 *	
25mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0030	 **	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0007	 ***	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0003	 ***	
5mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0104	 *	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 0.0022	 **	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	 <0.0001	 ****	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
<0.0001	 ****	
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Table	A.5.29.	Summary	of	qPCR	SW837	cell	line	data.	Fold-change	from	25mM	glucose,	
shown	as	mean	±	SEM.	See	also	Figure	A.5.1,2,3,4	and	5.	
SW837	 20.9%	
	 25mM		 5mM	 0mM	
GLUT1	 1.00±0.00	 0.78±0.07	 6.78±1.11	
GLUT4	 1.00±0.00	 1.10±0.19	 0.77±0.27	
GAPDH	 1.00±0.00	 0.69±0.06	 1.94±0.36	
GPX1	 1.00±0.00	 0.89±0.22	 1.04±0.19	
LDHA	 1.00±0.00	 0.47±0.02	 4.58±0.57	
PDX1	 1.00±0.00	 1.62±0.28	 6.33±3.51	
HK2	 1.00±0.00	 0.99±0.08	 9.59±1.95	
FH	 1.00±0.00	 0.55±0.05	 0.44±0.06	
LONP1	 1.00±0.00	 1.04±0.35	 0.77±0.39	
SOD2	 1.00±0.00	 0.68±0.12	 0.76±0.18	
COX4I2	 1.00±0.00	 0±0	 0±0	
HIF-1α	 1.00±0.00	 0.78±0.21	 0.76±0.38	
HIF-1ß	 1.00±0.00	 1.21±0.28	 1.34±0.28	
HIF-2α	 1.00±0.00	 5.67±1.71	 9.56±2.93	
VHL	 1.00±0.00	 0.95±0.11	 0.60±0.32	
CA9	 1.00±0.00	 11.18±7.75	 175.47±68.92	
VEGF	 1.00±0.00	 0.97±0.08	 7.13±1.39	
CASP9	 1.00±0.00	 0.75±0.19	 1.24±0.73	
BAX	 1.00±0.00	 1.26±0.16	 0.12±0.012	
	 0.2%	
	 25mM		 5mM	 0mM	
GLUT1	 1.02±0.07	 9.82±5.29	 1.76±0.45	
GLUT4	 1.21±0.37	 0.81±0.11	 0.71±0.30	
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GAPDH	 1.05±0.10	 2.29±1.00	 0.85±0.17	
GPX1	 1.22±0.31	 1.21±0.29	 0.84±0.09	
LDHA	 0.88±0.06	 9.19±4.95	 0.85±0.16	
PDX1	 2.13±1.04	 2.88±2.77	 0±0	
HK2	 1.04±0.22	 5.20±2.61	 1.39±1.29	
FH	 1.07±0.09	 1.30±0.10	 0.64±0.15	
LONP1	 2.04±0.98	 3.83±2.28	 1.92±1.38	
SOD2	 0.85±0.13	 1.31±0.10	 1.46±0.06	
COX4I2	 0±0	 0±0	 0±0	
HIF-1α	 0.97±0.08	 0.54±0.25	 1.59±0.75	
HIF-1ß	 1.52±0.60	 1.09±0.18	 2.63±1.11	
HIF-2α	 5.98±4.82	 0.73±0.41	 6.19±3.03	
VHL	 1.16±0.13	 1.10±0.40	 1.85±1.02	
CA9	 1.09±0.32	 46.47±23.33	 1.01±0.36	
VEGF	 1.65±0.70	 3.80±2.20	 2.90±0.74	
CASP9	 1.03±0.11	 1.49±0.66	 0.84±0.48	
BAX	 1.30±0.31	 1.79±1.67	 0.87±0.07	
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Table	A.5.30.	Summary	table	of	two-way	ANOVA	summary	data	for	qPCR	on	the	SW837	
cell	line.	See	also	Figure	A.5.1,2,3,4	and	5.	
	 ANOVA	table	 F	(DFn,	DFd)	 P	value	 P	 value	
summary	
GLUT1	 Interaction	 F	(2,	12)	=	5.17	 0.0240	 *	
Glucose	
parameter	
F	(2,	12)	=	2.044	 0.1722	 ns	
Oxygen	 F	(1,	12)	=	0.5536	 0.4712	 ns	
GLUT4	 Interaction	 F	(2,	12)	=	0.5166	 0.6092	 ns	
Glucose	
parameter	
F	(2,	12)	=	1.145	 0.3507	 ns	
Oxygen	 F	(1,	12)	=	0.0591	 0.8120	 ns	
GAPDH	 Interaction	 F	(2,	12)	=	4.72	 0.0307	 *	
Glucose	 F	(2,	12)	=	0.6163	 0.5562	 ns	
Oxygen	 F	(1,	12)	=	0.2744	 0.6099	 ns	
GPX1	 Interaction	 F	(2,	12)	=	0.8283	 0.4603	 ns	
Glucose	 F	(2,	12)	=	0.322	 0.7308	 ns	
Oxygen	 F	(1,	12)	=	0.4368	 0.5211	 ns	
LDHA	 Interaction	 F	(2,	12)	=	4.938	 0.0272	 *	
Glucose	 F	(2,	12)	=	1.83	 0.2025	 ns	
Oxygen	 F	(1,	12)	=	0.9465	 0.3498	 ns	
PDK1	 Interaction	 F	(2,	11)	=	1.634	 0.2391	 ns	
Glucose	 F	(2,	11)	=	0.4935	 0.6234	 ns	
Oxygen	 F	(1,	11)	=	0.3724	 0.5541	 ns	
HK2				 Interaction	 F	(2,	12)	=	8.117	 0.0059	 **	
Glucose	 F	(2,	12)	=	6.073	 0.0151	 *	
Oxygen	 F	(1,	12)	=	0.712	 0.4153	 ns	
FH		 Interaction	 F	(2,	12)	=	8.491	 0.0050	 **	
Glucose	 F	(2,	12)	=	17.75	 0.0003	 ***	
Oxygen	 F	(1,	12)	=	22.92	 0.0004	 ***	
LONP1	 Interaction	 F	(2,	12)	=	0.3468	 0.7138	 ns	
Glucose	
parameter	
F	(2,	12)	=	0.494	 0.6220	 ns	
Oxygen	 F	(1,	12)	=	2.973	 0.1103	 ns	
SOD2	 Interaction	 F	(2,	12)	=	8.88	 0.0043	 **	
Glucose	 F	(2,	12)	=	1.426	 0.2782	 ns	
Oxygen	 F	(1,	12)	=	18.04	 0.0011	 **	
COX4I2	 Interaction	 n/a	
	
	
n/a	
	
n/a	
	
Glucose	 n/a	
	
n/a	
	
n/a	
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Oxygen	 n/a	
	
n/a	
	
n/a	
	
HIF-1α	 Interaction	 F	(2,	12)	=	1.173	 0.3426	 ns	
Glucose	 F	(2,	12)	=	0.9881	 0.4006	 ns	
Oxygen	 F	(1,	12)	=	0.3913	 0.5434	 ns	
HIF-1ß	 Interaction	 F	(2,	12)	=	0.8477	 0.4525	 ns	
Glucose	 F	(2,	12)	=	1.397	 0.2848	 ns	
Oxygen	 F	(1,	12)	=	1.597	 0.2303	 ns	
HIF-2α	 Interaction	 F	(2,	12)	=	1.902	 0.1916	 ns	
Glucose	 F	(2,	12)	=	1.785	 0.2096	 ns	
Oxygen	 F	(1,	12)	=	0.2222	 0.6458	 ns	
VHL				 Interaction	 F	(2,	12)	=	0.9011	 0.4319	 ns	
Glucose	 F	(2,	12)	=	0.09492	 0.9101	 ns	
Oxygen	 F	(1,	12)	=	1.835	 0.2004	 ns	
CA9	 Interaction	 F	(2,	12)	=	7.069	 0.0094	 **	
Glucose	 F	(2,	12)	=	4.447	 0.0359	 *	
Oxygen	 F	(1,	12)	=	3.613	 0.0816	 ns	
VEGF	 Interaction	 F	(2,	12)	=	5.012	 0.0262	 *	
Glucose	
parameter	
F	(2,	12)	=	5.538	 0.0198	 *	
Oxygen	 F	(1,	12)	=	0.0722	 0.7927	 ns	
CASP9		 Interaction	 F	(2,	12)	=	0.8151	 0.4657	 ns	
Glucose	 F	(2,	12)	=	0.02722	 0.9732	 ns	
Oxygen	 F	(1,	12)	=	0.1163	 0.7389	 ns	
BAX	 Interaction	 F	(2,	12)	=	0.05282	 0.9488	 ns	
Glucose	 F	(2,	12)	=	1.128	 0.3556	 ns	
Oxygen	 F	(1,	12)	=	0.8642	 0.3709	 ns	
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Table	A.5.31.	Summary	table	for	Bonferroni	post	hoc	test	values	for	the	SW837	cell	line	
qPCR.	Only	significant	values	shown.	See	also	Figure	A.5.1,2,3,4	and	5.	
	 Condition	 p	value	 Bonferroni	
post	 hoc	 test	
value	
summary	
HK2	 25mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0172	 *	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0178	 *	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0171	 *	
FH	 25mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0101	 *	
25mM	0.2%	O2	vs.	5mM	20.9%	O2	
	
0.0192	 *	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0038	 **	
5mM	20.9%	O2	vs.	5mM	0.2%	O2	
	
0.0008	 ***	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	 0.0002	 ***	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 0.0026	 **	
SOD2	 25mM	0.2%	O2	vs.	0mM	0.2%	O2	 0.0333	 *	
5mM	20.9%	O2	vs.	5mM	0.2%	O2	 0.0297	 *	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0055	 *	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0736	 *	
CA9	 25mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0209	 *	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	
	
0.0210	 *	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	 0.0323	 *	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	
	
0.0209	 *	
VEGF	 25mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0381	 *	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	
	
0.0370	 *	
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Table	A.5.32.	Summary	of	two-way	ANOVA	statistics	for	mitochondrial	foci	and	area	per	
cell.	See	also	Figure	5.14.		
Measurement		 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	 mitochondrial	 foci	
per	cell	(Figure	5.9.A)	
Interaction	 F	(2,	12)	=	19.68	 0.0002	 ***	
Glucose	 F	(2,	12)	=	86.35	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	8.261	 0.0140	 *	
DLD1	 mitochondrial	 area	
per	cell	(Figure	5.9.B)	
Interaction	 F	(2,	12)	=	7.364	 0.0082	 **	
Glucose	 F	(2,	12)	=	61.52	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	4.458	 0.0564	 ns	
SW837	 mitochondrial	 foci	
per	cell	(Figure	5.9.C)	
Interaction	 F	(2,	12)	=	0.518	 0.6084	 ns	
Glucose	 F	(2,	12)	=	17.27	 0.0003	 ***	
Oxygen	 F	(1,	12)	=	0.00	 0.9646	 ns	
SW837	 mitochondrial	 area	
per	cell	(Figure	5.9.D)	
Interaction	 F	(2,	12)	=	3.333	 0.0706	 ns	
Glucose	 F	(2,	12)	=	28.49	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	1.331	 0.2712	 ns	
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Table	A.5.33.	Bonferroni	post	hoc	test	values	for	mitochondrial	foci	and	area	per	cell.	
See	also	Figure	5.14.	Only	significant	values	shown.	
Measurement	 Conditions		 Bonferroni	 post	
hoc	 value	
summary		
DLD1	
mitochondrial	 foci	
per	 cell	 (Figure	
5.14.A)	
25mM	20.9%	O2	vs.	0mM	20.9%	O2	 ****	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 **	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 ****	
25mM	0.2%	O2	vs.	0mM	0.2%	O2	 **	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	 ****	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 **	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	 ****	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	 ***	
DLD1	
mitochondrial	 area	
per	 cell	 (Figure	
5.14.B)	
25mM	20.9%	O2	vs.	0mM	20.9%	O2	 ****	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 *	
25mM	0.2%	O2	vs.	0mM	20.9%	O2	 ****	
25mM	0.2%	O2	vs.	0mM	0.2%	O2	 *	
5mM	20.9%	O2	vs.	0mM	20.9%	O2	 ****	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 **	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	 ****	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 **	
0mM	20.9%	O2	vs.	0mM	0.2%	O2	 *	
SW837	
mitochondrial	 foci	
per	 cell	 (Figure	
5.14.C)	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 *	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	 *	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 **	
SW837	
mitochondrial	 area	
per	 cell	 (Figure	
5.14.D)	
25mM	20.9%	O2	vs.	0mM	0.2%	O2	 **	
25mM	0.2%	O2	vs.	0mM	0.2%	O2	 **	
5mM	20.9%	O2	vs.	0mM	0.2%	O2	 **	
5mM	0.2%	O2	vs.	0mM	20.9%	O2	 *	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 ***	
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Table	 A.5.34.	 Summary	 of	 two-way	 ANOVA	 statistics	 for	 percentage	 of	 total	 FH	 in	
mitochondria	and	cytoplasm	per	cell.	See	also	Figure	5.16.	
Measurement		 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	 value	
summary	
DLD1	–	FH	in	mitochondria	 Interaction	 F	(2,	12)	=	1.028	 0.3873	 ns	
Glucose	 F	(2,	12)	=	18.67	 0.0002	 ***	
Oxygen	 F	(1,	12)	=	6.511	 0.0254	 *	
DLD1	–	FH	in	cytoplasm	 Interaction	 F	(2,	12)	=	1.03	 0.3865	 ns	
Glucose	 F	(2,	12)	=	18.67	 0.0002	 ***	
Oxygen	 F	(1,	12)	=	6.516	 0.0253	 *	
SW837	 –	 FH	 in	
mitochondria	
Interaction	 F	(2,	12)	=	1.712	 0.2218	 ns	
Glucose	 F	(2,	12)	=	2.816	 0.0993	 ns	
Oxygen	 F	(1,	12)	=	3.117	 0.1029	 ns	
SW837	–	FH	in	cytoplasm	 Interaction	 F	(2,	12)	=	1.713	 0.2215	 ns	
Glucose	 F	(2,	12)	=	2.802	 0.1003	 ns	
Oxygen	 F	(1,	12)	=	3.109	 0.1033	 ns	
	
Table	A.5.35.	Bonferroni	post	hoc	test	values	for	percentage	of	total	FH	in	mitochondria	
and	cytoplasm	per	cell.	Only	significant	values	shown.	See	also	Figure	5.16.	
Measurement	 Conditions		 Bonferroni	
post	 hoc	
value	
summary		
DLD1	–	FH	in	mitochondria	 25mM	20.9%	O2	vs.	5mM	20.9%	O2	 *	
25mM	0.2%	O2	vs.	5mM	0.2%	O2	 **	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 **	
DLD1	–	FH	in	cytoplasm		 25mM	20.9%	O2	vs.	5mM	20.9%	O2	 *	
25mM	0.2%	O2	vs.	5mM	0.2%	O2	 **	
5mM	0.2%	O2	vs.	0mM	0.2%	O2	 **	
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Table	A.5.36.	Summary	of	unpaired	t-test	data	for	Seahorse	Mito	Stress	test.	See	also	
Figure	5.18.		
Cell	type		 Test	 Significant	tests	 P	value		 P	 value	
summary	
DLD1	 (Figure	
5.18.A)	
25mM	vs	0mM	 Spare	capacity	 0.0018	 **	
5mM	vs	0mM	 Spare	capacity	 0.0035	 **	
DLD1	 +	 25mM	
(Figure	5.18.B)	
25mM	vs	5mM		 Maximal	
respiration	
0.0027	 **	
25mM	vs	0mM	 Basal	respiration	 0.0029	 **	
Proton	leak	 0.0073	 **	
SW837	 (Figure	
5.18.C)	
25mM	vs	0mM	 Spare	capacity	 0.0004	 ***	
Maximal	
respiration	
0.0021	 **	
ATP	production	 0.0044	 **	
5mM	vs	0mM	 Spare	capacity	 0.0030	 **	
Maximal	
respiration	
0.0044	 **	
SW837	 +	
25mM	 (Figure	
5.18.D)	
25mM	vs	0mM	 Spare	capacity	 <0.0001	 ****	
5mM	vs	0mM	 0.0030	 **	
MEFs	 (Figure	
5.18.E)	
WT	vs	KO		 Spare	capacity	 <0.0001	 ****	
Maximal	
respiration	
0.0002	 ***	
Proton	leak	 0.0066	 **	
ATP	production	 0.0080	 **	
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Table	A.5.36b.	Summary	of	two-way	ANOVA	statistics	 for	seahorse	fold	change	data.	
See	also	Figure	5.18.		
Measurement		 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	(Figure	5.18b.A)	 Interaction	 F	(10,	34)	=	2.675	 0.0157	 *	
Glucose	 F	(5,	34)	=	2.775	 0.0331	 *	
Oxygen	 F	(2,	34)	=	30.07	 <0.0001	 ****	
DLD1	 +	 25mM	 (Figure	
5.18b.B)	
Interaction	 F	(10,	36)	=	4.416	 0.0004	 ***	
Glucose	 F	(5,	36)	=	7.318	 <0.0001	 ****	
Oxygen	 F	(2,	36)	=	11.5	 <0.0001	 ****	
SW837	(Figure	5.18b.C)	 Interaction	 F	(10,	34)	=	1.394	 0.2245	 ns	
Glucose	 F	(5,	34)	=	2.878	 0.0285	 *	
Oxygen	 F	(2,	34)	=	25.23	 <0.0001	 ****	
SW837	 +	 25mM	 (Figure	
5.18b.D)	
Interaction	 F	(10,	36)	=	13.29	 <0.0001	 ****	
Glucose	 F	(5,	36)	=	33.22	 <0.0001	 ****	
Oxygen	 F	(2,	36)	=	20.97	 <0.0001	 ****	
MEFs	(Figure	5.18b.E)	 Interaction	 F	(5,	24)	=	7.802	 0.0002	 ****	
Glucose	 F	(5,	24)	=	7.802	 0.0002	 ****	
Oxygen	 F	(1,	12)	=	2150	 <0.0001	 ****	
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Table	A.5.36c.	Bonferroni	post	hoc	test	values	for	Seahorse	data.	See	also	Figure	5.18.	
Only	significant	values	shown.	
Cell	type		 Test	 Significant	tests	 P	value		 P	 value	
summary	
DLD1	 (Figure	
5.18b.A)	
25mM	vs	0mM	 ATP	production	 0.0331	 *	
Max	resp.	 0.0005	 ***	
Spare	capacity	 <0.0001	 ****	
5mM	vs	0mM	 ATP	production	 0.0140	 *	
Maximal	resp.		 0.0011	 **	
Spare	capacity	 <0.0001	 ****	
DLD1	 +	 25mM	
(Figure	
5.18b.B)	
25mM	vs	0mM		 Proton	leak	 0.0082	 **	
Maximal	resp.	 <0.0001	 ****	
Spare	capacity		 0.0017	 **	
5mM	vs	0mM	 Maximal	resp.	 0.0373	 *	
Spare	capacity	 0.0017	 **	
25mM	vs	5mM	 Maximal	resp.	 0.0440	 *	
SW837	 (Figure	
5.18b.C)	
25mM	vs	0mM	 ATP	production	 0.0164	 *	
Maximal	resp.	 0.0061	 **	
Spare	capacity	 <0.0001	 ****	
5mM	vs	0mM		 Maximal	resp.	 0.0243	 *	
Spare	capacity	 0.0006	 ***	
SW837	 +	
25mM	 (Figure	
5.18b.D)	
25mM	vs	0mM	 ATP	production	 0.0140	 *	
Max	resp.	 0.0005	 ***	
Spare	capacity	 <0.0001	 ****	
5mM	vs	0mM	 Max	resp.	 <0.0001	 ****	
Spare	capacity	 0.0005	 ***	
25mM	vs	5mM	 Max	resp.	 0.0177	 *	
Non-mito	resp.	 0.0221	 *	
	 340	
MEFs	 (Figure	
5.18b.E)	
WT	vs	KO		 Basal	resp.		 <0.0001	 ****	
ATP	production	 <0.0001	 ****	
Proton	leak	 <0.0001	 ****	
Maximal	resp.		 <0.0001	 ****	
Spare	capacity	 <0.0001	 ****	
Non-mito	resp.		 <0.0001	 ****	
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